 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 1 of 324 CLINICAL STUDY PROTO COL  
STUDY NUMBER: SP848  
PHASE OF STUDY: 2  
AN OPEN -LABEL STUDY TO DETERMINE SAFETY,  TOLERABILITY, 
AND EFFICACY OF LONG -TERM ORAL LACOSAMID E (LCM) AS 
ADJUNCTIVE THERAPY IN CHILDREN WITH EPILEPSY  
EudraCT Number: 2011 -001559 -35 
Sponsor:  
UCB BIOSCIENCES, Inc  
8010 Arco Corporate Drive  
Raleigh, NC 27617  
United States  
Confidential Material  
All information supplied by Sponsor or the Sponsor’s affiliates to the Investigat ors or the Institution 
including, but not limited to, information contained in the Protocol, shall be deemed confidential and 
proprietary information of Sponsor (“Confidential Information”). Confidential Information shall not be 
used for any purpose other than that of the Study, shall be maintained in strict confidence and shall not be 
transferred or disclosed to any third party other than the Institution’s staff members involved in the Study.  
 
 
Protocol version: Final  
Date of  protocol: 02 Mar 2009  
Date of protocol amendment 1: 12 Nov 2009  
Date of protocol amendment 2: 13 Dec 2010  
Date of protocol amendment  3: 29 Jul 2011  
Date of protocol amendment  4: 09 Apr 2012  
Date of protocol amendment  5: 22  Jan 2013  
Date of protocol amendm ent 5.1 (Italy): 15  May  2014  
Date of protocol amendment 5.2 (Japan): 17  Jul 2014  
Date of protocol amendment 5.3 (Japan): 07  Aug 2014  
Date of protocol amendment 5.3.1 (Japan): 30  Oct 2017  
Date of protocol amendment 5.4 (China): 15  Dec 2015  
Date of protocol amendment 5.5 (China): 30  Nov 2016  
Date of protocol amendment 5.6 (China): 21  Dec 2016  
Date of protocol amendment 5.7 (China): 01  Feb 2017  Date of protocol amendment 6: 16 Nov 2016  
Date of protocol amendment 7: 06 Feb 2017  
Date of protocol amendment 8: 20 Oct 2020  
 
 
 
 
 
 
 
 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 2 of 324 Principal or Coordinating Investigator(s):  
Will be listed separately.  
Sponsor:  
Name:  UCB BIOSCIENCES, Inc.  
Address:  8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:  +1-866-724-2467 / +1 -919-767-2570  
Clinical Program Director:  
Name:    
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Project Manager:  
Name:   
Address:  UCB BIOSCIENCES, Inc  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone:    
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 3 of 324 Clinical Trial Biostatistician:  
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Medical Director (Medical Therapeutics) :  
Name:   
Address:  UCB BIOSCIENCES, GmbH  
Alfred -Nobel - Straße  10 
40789 Monheim am Rhein  
GERMANY   
Phone:    
E-mail:   
Safety Representative (Patient Safety) : 
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100  (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 4 of 324 SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  +32 2 386 24 21  
USA and Canada: +1 800 880 6949 or +1 866 890 3175  
Japan:  + 81 3 6864 7400  
Email  Europe and Rest of the World: DS_ICT@ucb.com or 
DSICT. -@ucb.com   
Japan: JDSO@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 5 of 324 TABLE OF CONTENTS  
LIST OF ABBREVIATION S ................................ ................................ ................................ .. 10 
1 SUMMARY  ................................ ................................ ................................ .....................  12 
2 BACKGROUND INFORMATI ON ................................ ................................ ................  13 
3 STUDY OBJECTIVES  ................................ ................................ ................................ .... 15 
4 STUDY DESIGN  ................................ ................................ ................................ .............  16 
4.1 Study description  ................................ ................................ ................................ .........  16 
4.1.1  Subjects enrolling from SP847 or other LCM pediatric clinical studies in 
epilepsy  ................................ ................................ ................................ ................  16 
4.1.2  Subjects enrolling directly into SP848  ................................ ................................  16 
4.2 Variables to be assessed  ................................ ................................ ...............................  17 
4.2.1  Safety variables  ................................ ................................ ................................ .... 17 
4.2.1.1  Primary safety variables  ................................ ................................ ............  17 
4.2.1.2  Other safety variables  ................................ ................................ ................  17 
4.2.2  PK variables  ................................ ................................ ................................ .........  18 
4.2.2.1  Primary PK variables  ................................ ................................ .................  18 
4.2.2.2  Other PK variables  ................................ ................................ ....................  18 
4.2.3  Efficacy variables  ................................ ................................ ................................  18 
4.2.3.1  Primary efficacy variables  ................................ ................................ .........  18 
4.2.3.2  Secondary efficacy variables  ................................ ................................ ..... 18 
4.2.3.3  Other efficacy variables  ................................ ................................ .............  18 
4.3 Selection and withdrawal of subjects  ................................ ................................ ...........  18 
4.3.1  Inclusion criteria  ................................ ................................ ................................ .. 18 
4.3.2  Exclusion criteria  ................................ ................................ ................................ . 19 
4.3.3  Criteria for withdrawal  ................................ ................................ ........................  21 
4.3.3.1  Potential drug -induced liver injury IMP discontinuation criteria ..............  23 
4.4 Study treatments ................................ ................................ ................................ ...........  24 
4.4.1  Treatments to be administered  ................................ ................................ .............  24 
4.4.1.1  Subjects enrolling from SP847 or other LCM pediatric clinical studies in 
epilepsy  ................................ ................................ ................................ ...... 24 
4.4.1.2  Subjects enrolling directly in to SP848  ................................ ......................  24 
4.4.1.3  All subjects  ................................ ................................ ................................  25 
4.4.1.4  Study completion  ................................ ................................ .......................  27 
4.4.2  Description of investigational medicinal product  ................................ ................  27 
4.4.3  Randomization  ................................ ................................ ................................ ..... 27 
4.5 Expected duration of the study  ................................ ................................ ....................  27 
4.6 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 28 
4.7 Procedures for monitoring subject compliance  ................................ ............................  28 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 6 of 324 5 TREATMENT PROCEDURES  BY VISIT  ................................ ................................ ..... 28 
5.1 Screening Visit  ................................ ................................ ................................ .............  29 
5.2 Titration Visit(s) (TV1, TV2, TV3, TV4, TV5, TV6)  ................................ .................  30 
5.3 Visit 1 (Week 0)  ................................ ................................ ................................ ...........  31 
5.4 Telephone contacts (Weeks 2, 6, 10, 16, 24, 32, 40, 48, 66, and  78) ..........................  33 
5.5 Visit 2 (Week 4)  ................................ ................................ ................................ ...........  33 
5.6 Visit 3 (Week 8)  ................................ ................................ ................................ ...........  35 
5.7 Visit 4 (Week 12)  ................................ ................................ ................................ .........  35 
5.8 Visit 5 (Week 20)  ................................ ................................ ................................ .........  36 
5.9 Visit 6 (Week 28)  ................................ ................................ ................................ .........  37 
5.10  Visit 7 (Week 36)  ................................ ................................ ................................ .........  37 
5.11  Visit 8 (Week 44)  ................................ ................................ ................................ .........  37 
5.12  Visit 9 (Week 52)  ................................ ................................ ................................ .........  37 
5.13  Visit  10 (Week 60)  ................................ ................................ ................................ ....... 37 
5.14  Visit 11 (Week 72)  ................................ ................................ ................................ ....... 37 
5.15  Visit 12 (Week 84)  ................................ ................................ ................................ ....... 38 
5.16  Visit 13/Termination Visit (Week 96)  ................................ ................................ .........  38 
5.17  Early Termination Visit  ................................ ................................ ...............................  39 
5.18  Unscheduled Visit(s)  ................................ ................................ ................................ .... 40 
5.19  Final Visit ................................ ................................ ................................ .....................  41 
5.20  Safety Follow -Up telephone contact  ................................ ................................ ............  42 
5.21  Study conduct due to coronavirus disease 2019 pandemic  ................................ ..........  42 
6 ASSESSMENT OF EFFICA CY ................................ ................................ ......................  43 
6.1 Seizure counts  ................................ ................................ ................................ ..............  43 
6.2 Global Imp ression of Change  ................................ ................................ ......................  43 
6.2.1  Clinical Global Impression of Change  ................................ ................................  43 
6.2.2  Caregiver Global Impression of Change  ................................ .............................  44 
6.3 Pediatric Quality of Life Inventory  ................................ ................................ ..............  44 
6.4 Health care resource use  ................................ ................................ ..............................  45 
7 ASSESSMENT OF PHARMA COKINETICS  ................................ ................................  45 
8 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  45 
8.1 Advers e events  ................................ ................................ ................................ .............  45 
8.1.1  Definition of AE  ................................ ................................ ................................ .. 45 
8.1.2  Procedures for reporting and recording AEs  ................................ .......................  46 
8.1.3  Description of AEs  ................................ ................................ ..............................  46 
8.1.4  Follow up on adverse events  ................................ ................................ ................  46 
8.1.5  Rule for repetition of an adverse event  ................................ ................................  46 
8.1.6  Pregnancy  ................................ ................................ ................................ ............  46 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 7 of 324 8.1.7  Suspected transmission of an infectious agent via a medicinal product  ..............  47 
8.1.8  Overdose of investigational medicinal product  ................................ ...................  47 
8.1.9  Safety signal detection in ongoing clinical studies and Data Monitoring 
Committees  ................................ ................................ ................................ ..........  47 
8.1.10  Occurrence of COVID -19 ................................ ................................ ....................  48 
8.2 Serious adverse events  ................................ ................................ ................................ . 48 
8.2.1  Definition of serious adverse event  ................................ ................................ ..... 48 
8.2.2  AEs of special interest  ................................ ................................ .........................  49 
8.2.3 Immediate reporting of AEs  ................................ ................................ ................  50 
8.2.4  Procedures for reporting serious adverse events  ................................ .................  50 
8.2.5  Follow up of serious adverse events  ................................ ................................ .... 50 
8.2.6  Anticipated serious adverse events  ................................ ................................ ...... 50 
8.3 Laboratory measurements  ................................ ................................ ............................  51 
8.3.1  Pregnancy testing  ................................ ................................ ................................ . 52 
8.3.2  Liver function tests and evaluation of PDILI  ................................ ......................  52 
8.3.2.1  Consultation with Medical Monitor and local hepatologist  ......................  56 
8.3.2.2  Immediate action: determination of IMP discontinuation  .........................  56 
8.3.2.3  Testing: identification/ex clusion of alternative etiology  ...........................  56 
8.3.2.4  Follow -up evaluation  ................................ ................................ .................  58 
8.4 Other measurements ................................ ................................ ................................ ..... 59 
8.4.1  Physical examination  ................................ ................................ ...........................  59 
8.4.1.1  Complete physical examination  ................................ ................................  59 
8.4.1.2  Brief physical examination  ................................ ................................ ........  59 
8.4.2  Neurological examination  ................................ ................................ ....................  59 
8.4.2.1  Complete neurological examination  ................................ ..........................  59 
8.4.2.2  Brief neurological examination  ................................ ................................ . 59 
8.4.3  Vital signs and body weight  ................................ ................................ ................  59 
8.4.4  12-lead ECG  ................................ ................................ ................................ ........  59 
8.4.4.1  Overall ECG interpretation  ................................ ................................ ....... 60 
8.4.4.2  Specific QTcB criteria  ................................ ................................ ...............  60 
8.4.5  Tanner Stage  ................................ ................................ ................................ ........  60 
8.4.6  Assessme nt of suicidality  ................................ ................................ ....................  60 
8.4.7  Achenbach CBCL  ................................ ................................ ................................  61 
8.4.8  Bayley Scales of Infant and Toddler Development, Third Edition  .....................  61 
8.4.9  Palatability and ease of use questionnaire for LCM  ................................ ............  62 
8.4.10  Behavior Rating Inventory of Executive Function  ................................ ..............  62 
9 MANUFACTURING, HANDL ING, AND ACCOUNTABIL ITY OF STUDY 
MEDICATION  ................................ ................................ ................................ ................  63 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 8 of 324 9.1 Manufacturing, packaging, and labeling  ................................ ................................ ...... 63 
9.2 Supply, handling, and storage  ................................ ................................ ......................  64 
9.3 Drug accountability procedures  ................................ ................................ ...................  64 
9.4 Retrieval/recall of study medication  ................................ ................................ ............  65 
9.5 Alternative study treatment supply due to COVID -19 pandemic  ................................  65 
10 DATA QUALITY CONTROL  AND QUALITY ASSURANCE  ................................ ... 65 
10.1  Site qualification  ................................ ................................ ................................ ..........  65 
10.2  Monitoring  ................................ ................................ ................................ ...................  65 
10.2.1  Definition of source data  ................................ ................................ .....................  65 
10.2.2  Source data verification  ................................ ................................ .......................  66 
10.3 Auditing  ................................ ................................ ................................ .......................  66 
11 DATA HANDLING AND RE CORD KEEPING  ................................ ...........................  66 
11.1  Case Report form completion  ................................ ................................ ......................  66 
11.2  Database entry and reconciliation  ................................ ................................ ................  67 
11.3  Subject Screening and Enrollment log/Subject Identification Code list  ......................  67 
11.4  Archiving and data retention  ................................ ................................ ........................  67 
11.5  Data management ................................ ................................ ................................ .........  67 
12 STATISTICS  ................................ ................................ ................................ ...................  67 
12.1  Description of statistical methods  ................................ ................................ ................  67 
12.1.1  Definition of analysis sets  ................................ ................................ ....................  68 
12.1.2  Statistical analysis of safety variables  ................................ ................................ . 68 
12.1.2.1  Primary safety variables  ................................ ................................ ............  68 
12.1.2.2  Other safety variables  ................................ ................................ ................  68 
12.1.3  Statistical analysis of PK variables  ................................ ................................ ...... 69 
12.1.3.1  Descriptive statistics  ................................ ................................ ..................  69 
12.1.3.2  Population PK analysis  ................................ ................................ ..............  69 
12.1.4  Statistical analysis of efficacy variables  ................................ ..............................  69 
12.1.4.1  Secondary efficacy variables  ................................ ................................ ..... 69 
12.1.4.2  Other efficacy variables  ................................ ................................ .............  70 
12.1.5  Handling of protocol violators, drop -outs, and missing values  ...........................  70 
12.1.6  Interim analysis  ................................ ................................ ................................ .... 70 
12.2  Determination of sample size  ................................ ................................ .......................  71 
13 ETHICS AND REGULATOR Y ................................ ................................ ......................  71 
13.1  Informed consent  ................................ ................................ ................................ .........  71 
13.2  Notification/submission to relevant regulatory authority(ies)  ................................ ..... 72 
13.3  Institutional Review Board/Independent Ethics Committee ................................ ........  72 
13.3.1  Reporting to ethics committee  ................................ ................................ .............  72 
13.4  Basic principles and appropriate national guidelines ................................ ...................  73 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 9 of 324 13.5  Subject privacy ................................ ................................ ................................ .............  73 
13.6  Protocol amendments and emergency deviations  ................................ ........................  73 
14 FINANCE, INSURANCE, AND PUBLICATION  ................................ .........................  73 
15 REFERENCES  ................................ ................................ ................................ ................  73 
16 SUPPLEMENTS  ................................ ................................ ................................ ..............  76 
16.1  Tabular schedule of study procedures ................................ ................................ ..........  76 
16.2  International Classification of Epileptic Seizures (1981)  ................................ ............  85 
17 APPENDICES  ................................ ................................ ................................ .................  86 
17.1  PROTOCOL AMENDMENT 1  ................................ ................................ ..................  86 
17.2  PROTOCOL AMENDMENT 2  ................................ ................................ ................  112 
17.3  PROTOCOL AMENDMENT  3 ................................ ................................ ................  144 
17.4  PROTOCOL AMENDMENT  4 ................................ ................................ ................  171 
17.5  PROTOCOL AMENDMENT  5 ................................ ................................ ................  226 
17.6  PROTOCOL AMENDMENT 6  ................................ ................................ ................  247 
17.7  PROTOCOL AMENDMENT 7  ................................ ................................ ................  292 
17.8  PROTOCOL AMENDMENT 8  ................................ ................................ ................  294 
18 DECLARATION AND SIGN ATURE OF INVESTIGATO R ................................ ..... 323 
19 SPONSOR DECLARATION  ................................ ................................ ........................  324 
 
LIST OF TABLES  
Table  8‒1:  Required investigations and follow up of PDILI  ................................ .............  54 
Table  8‒2:  PDILI laboratory measurements  ................................ ................................ ...... 57 
Table  8‒3:  PDILI information to be collected  ................................ ................................ ... 58 
Table  16‒1:  Schedule of study procedures  for SP848 (Year 1)  ................................ ...........  77 
Table  16‒2:  Schedule of study procedures for SP848 (Year 2)  ................................ ...........  80 
Table  16‒3:  Schedule of study procedures for SP848 (Screening Visit and Titration 
Visits, subjects enrolling directly into SP848)  ................................ .................  83 
 
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 10 of 324 LIST OF ABBREVIATIONS  
AE adverse event  
AED  antiepileptic drug  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AST  aspartate aminotransferase  
AV atrioventricular  
Bid twice daily  
BMI  body mass index  
BRIEF® Behavior Rating Inventory of Executive 
Function® 
BRIEF®-P Behavior Rating Inventory of Executive 
Function®-Preschool Version  
CBCL  Child Behavior Checklist  
CDMS  clinical data management system  
COVID -19 coronavirus dise ase 2019  
Cmax maximum plasma concentration  
CRO  Contract Research Organization  
C-SSRS  Columbia -Suicide Severity Rating Scale  
CV coefficient of variation  
ECG  electrocardiogram  
eCRF  electronic Case Report form  
EEG  electroencephalogram  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HRQoL  health -related quality of life  
ICH International Council for Harmonisation  
IEC Independent Ethic Committee  
IRB Institutional Review Board  
iv intravenous  
LCM  lacosamide  
LFT liver function test  
MAOI  monoamine oxidase inhibitor  
MedDRA® Medical Dictionary for Regulatory Activities  
n number of subjects  
PDILI  potential drug -induced liver injury  
PedsQL™  Pediatric Quality of Life Inventory  
PET polyethylene terephthalate  
PK pharmacokinetic(s)  
PKS Pharmacokinetic Set  
PS Patient Safety  
PT preferred term  
QTc corrected QT interval  
QTcB  corrected QT interval using the Bazett method  
RDC  remote data capture  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 11 of 324 SAE  serious adverse event  
SD standard deviation  
SOC  system organ class  
SOP standard operating procedure  
SPM 12809  O-desmethyl -LCM  
SS Safety Set  
TEAE  treatment -emergent adverse event  
TV Titration Visit  
ULN  upper limit of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 12 of 324 1 SUMMARY  
SP848 is an open -label study to obtain long -term safety, tolerability, and pharmacokinetic (PK) 
data in children with epilepsy (partial -onset seizures and other pediatric epilepsy syndromes) 
treated with lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy. In 
addition, the study is designed to obtain preliminary efficacy data on seizure frequency during 
long-term exposure. The study will also provide continued availability of LCM to subjects who 
have completed the SP847 epilepsy study and to subjects who have discontinued from SP847 
due to a dose reduction or status epilepticus , and who, in the investigator’s opinion, would 
benefit from long -term administration of LCM.  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to sub jects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. SP848 includes subjects ≥1 month to ≤18 years of age since subjects who complete 
SP847 or another applicable LCM pediatric epileps y study in subjects <18 years of age may have 
aged to 18 years old by the time they complete that study and enroll in SP848.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years t o ≤17  years of age with partial -onset seizures (deemed 
appropriate for treatment with adjunctive LCM) who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. Beginning with local Protocol 
Amendment 5.2 for sites in Japan, approximately 46  eligible pediatric subjects ≥4  years to 
≤17 years of age with partial -onset seizures who have not previously received LCM will directly 
enroll at approximately 9 sites in Japan. Beginning with local Protocol Amendment 5 .4 for sites 
in China, approximately 60 additional eligible pediatric subjects with partial -onset seizures aged 
≥4 years to ≤17  years, who have not previously participated in a LCM clinical study, will enroll 
directly into SP848. The purpose of enrolling t hese subjects directly into SP848 is to obtain 
sufficient long -term safety exposures in the age range of ≥4  years to ≤17  years of age; the 
long-term safety data will be included in planned regulatory submissions for LCM as adjunctive 
therapy for partial -onset seizures in pediatric subjects ≥4  years to ≤17  years of age with epilepsy.   
Protocol Amendment 6 allows up to approximately 75 additional eligible pediatric subjects with 
epilepsy who participated in EP0060 to enroll into SP848. Protocol Amendment 8 al lows an 
enrollment increase from 75 to 100 eligible pediatric subjects ≥1 month to ≤17  years of age with 
epilepsy who participated in EP0060 to enroll in SP848 in order to reflect EP0060’s inclusion of 
subjects down to 1 month of age. In addition, subjects  already enrolled in SP848 may participate 
in EP0060, if eligible, and then resume participation in SP848. These subjects may either 
voluntarily choose to have an iv LCM infusion even though they are capable of taking oral LCM 
or require iv LCM infusion du e to a medical reason or procedure (ie, unable to take oral LCM).  
Approximately 200  subjects who may participate in other LCM pediatric clinical studies in 
epilepsy will be eligible to participate in SP848. In total, up to approximately 400  subjects may 
be eligible to participate in SP848.  
Subjects who complete SP847 or another applicable LCM pediatric epilepsy study and choose to 
enter this open -label study will begin on the LCM dose they achieved in SP847 or their previous 
pediatric LCM study. Subjects wh o discontinued from SP847 due to a dose reduction or status 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 13 of 324 epilepticus, but for whom it is determined medically appropriate to enter this open -label study, 
will also begin on the LCM dose they achieved in SP847. Subjects who enroll from EP0060 will 
begin SP848 with an equivalent LCM dose as they last received in EP0060; however, the LCM 
dose may be further titrated/adjusted to a level to optimize tolerability and seizure control (up to 
a maximum level as described below). Subjects who meet eligibility requ irements and enroll 
directly into SP848 without previous participation in a LCM clinical study will initiate treatment 
with LCM, and the LCM dose will be titrated to a level to optimize tolerability and seizure 
control (up to a maximum level as described b elow).  
Subjects will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, 
investigators will be allowed to increase or decrease the dose of LCM and/or concomitant 
antiepileptic drugs (AEDs) to optimize tolerability and seizure red uction for each subject. The 
investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the corresponding 
dose levels for the tablet formulation) not to exceed 600mg/day based on body weight, even if 
the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in SP848 is 
12mg/kg/day or 600mg/day, whichever is lower. An increase in the LCM dose must occur only 
during office visits. If needed t o optimize tolerability and seizure reduction in selected subjects, 
concomitant AEDs may be carefully tapered and discontinued to achieve LCM monotherapy. 
New concomitant AEDs may be introduced as treatment if the medication has been approved by 
the Regula tory Authorities in the country in which the subject lives. New concomitant AEDs 
should be added only when the subject has not optimally or adequately responded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended th at LCM be 
tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day 
(tablets) for subjects who have achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or 
≥300mg/day (tablet) . A slower taper in weekly decrements of 2m g/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster 
taper is permitted after discussion with the medical monitor, whenever possible.  
The study variables to be assessed are defined i n Section  4.2.  
2 BACKGROUND INFORMATI ON 
Epilepsy is the second most prevalent neurological disorder in the world. It is estimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most 
patients with epilepsy require appropriate pharmacological therapy (Perucca, 19 96). In the past 
decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
The classification of epilepsies in children was described in 1989 by the Commission on 
Classificatio n and Terminology of the International League Against Epilepsy (1989; Aicardi, 
1994). Seizures are categorized based on whether the onset is focal or generalized and whether 
the disorder is idiopathic, symptomatic, or cryptogenic. Specific syndromes are fu rther classified 
according to a number of criteria including seizure type, cause, anatomy, precipitating factors, 
age of onset, and sometimes prognosis.  
The newer AEDs differ from older agents in several important ways, including mechanism of 
action, spect rum of activity, and PK characteristics (Herman and Pedley, 1998). However, more 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 14 of 324 than 30% of patients have inadequate seizure control on currently -available AEDs or experience 
significant adverse drug effects (CHMP/EWP/566/98, 2010). Therefore, a need rema ins for 
AEDs with improved effectiveness and tolerability (Sander, 1998).  
Among the newer AEDs, only 6 (gabapentin, lamotrigine, oxcarbazepine, topiramate, 
levetiracetam, and perampanel) have successfully demonstrated efficacy as adjunctive therapy in 
children with difficult to treat partial -onset seizures (Rheims and Ryvlin, 2013; Glauser et al, 
2006; Appleton et al, 1999; Duchowny et al, 1999; Elterman et al, 1999). Despite the availability 
of new AEDs, more than 25% of pediatric patients have inadequate seizure control on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
Lacosamide (LCM, Vimpat®, SPM 927, [R] -2-acetamido -N-benzyl -3-methoxypropionamide) 
belongs to a novel class of functionalized ami no acids. It has minimal protein binding and effect 
on cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and a half -life of approximately 13  hours (in adults), which allows a twice 
daily (bid) dose regimen. It also displays dose -proportional PK following administration over a 
range of doses up to 800mg in adults.  
Lacosamide (200mg/day to 400mg/day) is approved and indicated as adjunctive therapy in the 
treatment of partial -onset seizures with or  without secondary generalization in adult and 
adolescent (16 to 18 years of age) patients with epilepsy and was first approved in Aug 2008 by 
the European Commission. Lacosamide is available in tablet (50mg, 100mg, 150mg, and 200mg) 
and syrup (10mg/mL) or al formulations as well as solution for infusion (10mg/mL) formulation 
for use as temporary iv replacement when oral administration is not feasible. Lacosamide 
(200mg/day to 400mg/day) was approved in the US in Oct 2008 as adjunctive therapy and in 
Aug 201 4 as monotherapy in the treatment of partial -onset seizures in patients 17 years of age 
and older. Initiation of adjunctive LCM treatment with a single loading dose of LCM 200mg 
(oral tablets, syrup, or iv infusion) followed 12 hours later by a LCM 100mg t wice daily 
(200mg/day) maintenance dose regimen was also approved by the European Commission in Nov 
2012. Use of a LCM 200mg loading dose for initiation of initial LCM monotherapy, conversion 
to LCM monotherapy, or adjunctive therapy was approved in the US  in Aug 2014.  
The oral solution (syrup) is a formulation suitable for administration to children. Bioequivalence 
has been shown between the tablet and oral solution (syrup) formulations, comparing 2 tablets of 
LCM 100mg and the oral solution (syrup) conta ining LCM 200mg, after single -dose 
administration in healthy subjects. The PK of LCM and its major metabolite, SPM  12809 
(O-desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after single oral 
doses of LCM 200mg administered as tab lets or as oral solution (syrup).  
Three double -blind, placebo -controlled, multicenter studies (SP667, SP754, and SP755) in 
1308  adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive 
therapy (1 to 3 concomitant AEDs) in sub jects with difficult to control partial -onset seizures. In 
these studies, LCM was initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (200mg/day, 400mg/day, or 600mg/day) in 100mg/day per week increments.  
When oral LC M was administered as adjunctive therapy at doses up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent adverse events (TEAEs) were central ne rvous 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 15 of 324 system - and gastrointestinal -associated events. A dose relationship was seen for the most 
frequently reported common TEAEs, including dizziness, nausea, and diplopia. The nature and 
frequency of adverse events (AEs) were comparable to adjunctive ther apy with other marketed 
AEDs. Safety evaluations support the further development of LCM as an AED.  
SP847 was an open -label, dose -titration, safety, tolerability, and PK study to evaluate LCM as 
adjunctive therapy in children with uncontrolled partial -onset  seizures. The study completed on 
26 Aug 2014. Forty -seven  subjects (aged 1  month to 17 years) with uncontrolled partial -onset 
seizures on a stable dose regimen of at least 1 but no more than 3 AEDs were enrolled and 
treated during the study. The study con sisted of a Screening Phase, a Treatment Phase, and an 
End-of-Study Phase. The duration of treatment for an individual subject was up to approximately 
13 weeks.  
SP848 is an open -label study to obtain long -term safety, tolerability, and pharmacokinetic (PK ) 
data in children with epilepsy (partial -onset seizures and other pediatric epilepsy syndromes) 
treated with LCM oral solution (syrup) or LCM tablets as adjunctive therapy. In addition, the 
study is designed to obtain preliminary efficacy data on seizure frequency during long -term 
exposure. The study will also provide continued availability of LCM to subjects who have 
completed the SP847 epilepsy study and to subjects who have discontinued from SP847 due to a 
dose reduction or status epilepticus, and who, in the investigator’s opinion, would benefit from 
long-term administration of LCM.  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who p articipate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. In addition, at selected sites, beginning with Protocol Amendment  4, up to 
approximately 100  eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study will be permitted to enroll directly into SP848. Beginning 
with local Protocol Amendment 5.2 for sites in Japan, approximately 46  eligible pediatric 
subjects ≥4  years to ≤17  years of age with partial -onset seizures who have not previously 
received LCM will directly enroll at approximately 9 sites in Japan. Beginning with local 
Protocol Amendment 5.4 for sit es in China, approximately 60 additional eligible pediatric 
subjects with partial -onset seizures aged ≥4  years to ≤17  years, who have not previously 
participated in a LCM clinical study, will enroll directly into SP848. The purpose of enrolling 
these subje cts directly into SP848 is to obtain additional long -term safety exposures in the age 
range of ≥4  years to ≤17  years of age; the additional long -term safety data will be included in 
planned regulatory submissions for LCM as adjunctive therapy for partial -onset seizures.  
3 STUDY OBJECTIVES  
The objectives of this study are:  
• To obtain information about the safety, tolerability, and PK of LCM during long -term 
exposure  
• To obtain preliminary efficacy data on seizure frequency during long -term exposure  
• To allow subj ects who have participated in SP847 (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 16 of 324 • To allow subjects who have participated in other LCM pediatric clinical studies in epilepsy to 
continue receiving LCM  
• Beginn ing with Protocol Amendment 4, at selected sites, to allow up to approximately 
100 eligible pediatric subjects ≥4 years to ≤17 years of age who have not previously received 
LCM to begin receiving LCM  
4 STUDY DESIGN  
4.1 Study description  
4.1.1  Subjects enrolling from S P847 or other LCM pediatric clinical studies 
in epilepsy  
Subjects who complete SP847 (including discontinuation from SP847 due to a dose reduction or 
status epilepticus) or subjects from another applicable LCM pediatric clinical study in epilepsy 
and who c hoose to enter the open -label study, will begin with an equivalent LCM dose as they 
last received in the primary study. Subjects will be able to continue on LCM oral solution (syrup) 
or switch to LCM tablets. During the study, investigators will be allowed  to increase or decrease 
the dose of LCM and/or concomitant AEDs to optimize tolerability and seizure reduction for 
each subject. The investigator may titrate/adjust the LCM dose to a minimum of 2mg/kg/day 
(oral solution [syrup]) or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution 
[syrup]) or the corresponding dose levels for the tablet formulation), not to exceed 600mg/day 
based on body weight, even if the subject’s body weight exceeds 50kg. The maximum permitted 
LCM dose in SP848 is 12mg/kg/ day or 600mg/day, whichever is lower. Increases in the LCM 
dose must occur only during office visits. If needed to optimize tolerability and seizure reduction 
in selected subjects, concomitant AEDs may be carefully tapered and discontinued to achieve 
LCM m onotherapy. New concomitant AEDs may be introduced as treatment if the medication 
has been approved by the Regulatory Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or ade quately 
responded to a maximum tolerated dose of LCM. When subjects withdraw from the study, it is 
recommended that the study medication be tapered gradually in weekly decrements of 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who  have achieved a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . A slower taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if 
medically necessary. In case of an emergency, a faste r taper is permitted after discussion with the 
medical monitor, whenever possible.  
4.1.2  Subjects enrolling directly into SP848  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed appropriate 
for treatment with adjunctive LCM) who have not previously participated in a LCM clinical 
study will be permitted to enroll directly into SP848. Beginning with local Protocol Amendment 
5.2 for sites in Ja pan, approximately 46  eligible pediatric subjects ≥4  years to ≤17  years of age 
with partial -onset seizures who have not previously received LCM will directly enroll at 
approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 for sites in  China, 
approximately 60 additional eligible pediatric subjects with partial -onset seizures aged ≥4  years 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 17 of 324 to ≤17  years, who have not previously participated in a LCM clinical study, will enroll directly 
into SP848.  
Subjects who enroll directly into SP848 without previous participation in a LCM clinical study 
will undergo screening. Eligible subjects will initiate treatment with LCM, and the LCM dose 
will be titrated to a level to optimize tolerability and seizure control (see Section  4.4.1 ). Subjects 
will be able to receive LCM oral solution or LCM tablets for up to 2  years as determined 
appropriate by the investigator.  
SP848 includes subjects ≥1 month to ≤18 years of age since subjects who complete SP847 or 
another applicable LCM pediatric epilepsy study in subjects <18 years of age may have aged to 
18 years old by the time they complete that study and enroll in SP848.  
The same study conditions de scribed in Section  4.1.1  (eg, minimum and maximum LCM dose, 
required office visits for dose increases, concomitant AEDs, and study medication taper)  also 
apply.   
4.2 Variables to be assessed  
4.2.1  Safety variables  
4.2.1.1  Primary safety variables  
The primary safety variables are:  
• Incidence of TEAEs  
• Incidence of serious AEs (SAEs)  
• Subject withdrawal from the study due to TEAEs  
4.2.1.2  Other safety variables  
The other safety var iables are:  
• Hematology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body m ass index (BMI)  
• Tanner Stage (if applicable)  
• Achenbach Child Behavior Checklist (CBCL) at Baseline for children 18  months and older 
(CBCL/1½ -5 and CBCL/6 -18) assessing behavior  
• Bayley -III scales at Baseline for children <18  months of age at time of enrollm ent 
(applicable only to subjects enrolled in English -speaking countries)  
• Cognitive function assessments (Behavior Rating Inventory of Executive Function® 
[BRIEF®]/BRIEF®-Preschool Version [BRIEF®-P]) (if applicable)  
• LCM palatability and ease of use questio nnaire  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 18 of 324 4.2.2  PK variables  
4.2.2.1  Primary PK variables  
No primary PK variables are defined for this study.  
4.2.2.2  Other PK variables  
The other PK variables are:  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
4.2.3  Efficacy variables  
4.2.3.1  Primary efficacy variables  
No primary efficacy variables are defined for this study.  
4.2.3.2  Secondary efficacy variables  
The secondary efficacy variables, based on daily seizure diaries, are:  
• Percent change from Baseline in 28 -day partial -onset seizure frequency  
• ≥50% reduction i n 28-day partial -onset seizure frequency  
• ≥75% reduction in 28 -day partial -onset seizure frequency  
• Seizure days per 28 days (subjects with generalized seizures only)  
• Seizure -free status  
4.2.3.3  Other efficacy variables  
The other efficacy variables are:  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• Quality of life assessments (Pediatric Quality of Life Inventory [PedsQL™]) (if applicable)  
• Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations  not related to study, hospitalizations not related to study)   
• All seizure frequency analyses as described in the secondary efficacy variables (presented for 
the overall Treatment Period only) may be additionally presented by modal daily dose group, 
by sei zure type, by seizure classification subgroup, by time interval, by visit or time period, 
or by completer cohort  
4.3 Selection and withdrawal of subjects  
4.3.1  Inclusion criteria  
All subjects in SP848 must fulfill the following inclusion criteria:  
1. A signed informed consent form has been obtained from the parent/legal guardian and assent 
has been obtained from the subject (when possible or as required according to local 
Institutional Review Boards [IRBs]/Independent Ethics Committees [IECs]).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 19 of 324 4. Subject and caregiver (wh ich may be a parent, legal guardian, or other delegated caregiver) 
are willing and able to comply with all study requirements, including maintaining a daily 
seizure diary.  
Subjects who have participated in SP847 or other LCM pediatric clinical studies in 
epilepsy must fulfill the following inclusion criteria:  
2. Subject has completed SP847 (or the subject discontinued SP847 due to a dose reduction or 
status epilepticus) for the treatment of uncontrolled partial -onset seizures, or subject has 
participated in ot her LCM pediatric clinical studies in epilepsy.  
3. Subject is expected to benefit from participation, in the opinion of the investigator.  
Subjects who enroll directly into SP848 without previous participation in a LCM clinical 
study  must fulfill the following inclusion criteria:  
5. Subject is male or female and ≥4  years to ≤17  years of age.  
6. Subject has a diagnosis of epilepsy with partial -onset seizures.  
• The results of at least 1  prior electroencephalogram  (EEG) AND 1  prior magnetic 
resonance imaging/computerized tomography scan should be consistent with the above 
diagnosis.  
7. Subject has been observed to have uncontrolled partial -onset seizures after an adequate 
course of treatment (in the opinion of the investigator) with at least 2  AEDs (concurrently or 
sequentially).  
8. Subject has been observed to have at least 2 countable seizures in the 4 -week period prior to 
Screening.  
• In the case of simple partial seizures, only those with motor signs will be counted 
towards meeting the inclusion cr iteria (only partial seizures with a recognizable and 
countable manifestation).  
9. Subject is on a stable dosage regimen of 1 to 3 AEDs. The daily dosage regimen of 
concomitant AED therapy must be kept constant for a period of at least 1 week prior to 
Screeni ng. Vagal nerve stimulation is not counted as medical therapy; however, VNS settings 
must be kept constant for a period of at least 1  week prior to Screening.  
10. Subject is an acceptable candidate for venipuncture.  
4.3.2  Exclusion criteria  
Subjects are not permitte d to enroll in the study if any of the following criteria are met:  
1. Subject is receiving any investigational drugs or using any experimental devices in addition 
to LCM.  
3.  Subject ≥6  years of age has a lifetime history of suicide attempt (including an actu al attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6  months as 
indicated by a positive response (“Yes”) to either Question  4 or Question  5 of the 
Columbia -Suicide Severity Rating Scale (C -SSRS) at Screening.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 20 of 324 Subjects  who have participated in SP847 or other LCM pediatric clinical studies in 
epilepsy are not permitted to enroll in the study if any of the following criteria are met:  
2. Subject meets either of the following:  
a. Withdrawal criteria for the primary study (with  the exception of subjects who discontinued 
due to a dose reduction or status epilepticus). For subjects entering from EP0060, if the 
subject (or legal guardian) withdraws consent solely due to route of LCM administration (iv) 
or if the subject requires mo re than 10  iv LCM infusions, the subject may be allowed to 
participant in SP848 after discussion with and agreement from the Medical Monitor.  
b. Ongoing serious AE (SAE).  
Subjects who enroll directly into SP848 without previous participation in a LCM clinica l 
study  are not permitted to enroll in the study if any of the following criteria are met:  
4. Subject has ever received LCM.  
5. Subject has any medical or psychiatric condition that, in the opinion of the investigator, could 
jeopardize or would compromise the subject’s ability to participate in this study.  
6. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.  
7. Subject has a known hypersensitivity to any component of the investigational medicinal 
product.  
8. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of the study.  
• Medically acceptable contraceptive method includes oral or depot contraceptive 
treatment with at least 30μg ethinylestradiol per intake (or 50μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
oxcarbazepine]) which must be used in conjunction with a barrier method. Sexual 
abstinence is also  an acceptable method of contraception.  
• The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and undertake to inform the inves tigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.  
9. Subject has a creatinine clearance less than 30mL/min.  
10. Subject has a clinically relevant ECG abnormality, in the opini on of the principal investigator 
(ie, second or third degree heart block at rest or a QT prolongation greater than 450ms).  
11. Subject has hemodynamically significant heart disease (eg, heart failure).  
12. Subject has an arrhythmic heart condition requiring medica l therapy.  
13. Subject has a known history of severe anaphylactic reaction or serious blood dyscrasias.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 21 of 324 14. Subject has nonepileptic events, including psychogenic seizures, that could be confused with 
seizures. If both epileptic and nonepileptic events are present , epileptic events must be 
distinguished from nonepileptic phenomena.  
15. Subject has a history of primary generalized epilepsy.  
17. Subject is taking monoamine oxidase inhibitors -A (MAOI -A) or narcotic analgesics.  
18. Subject has epilepsy secondary to a progr essing cerebral disease or any other progressively 
neurodegenerative disease, such as Rasmussen syndrome.  
19. Subject has a known sodium channelopathy, such as Brugada syndrome.  
20. Subject has >2x upper limit of normal (ULN) of any of the following: alani ne 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractiona te bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elev ation must be 
understood and recorded in the electronic Case Report form (eCRF).  
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. T his includes re -screening.  
Subjects who were directly enrolled in EP0060 for iv LCM replacement therapy or to 
initiate LCM treatment are not permitted to enroll in the study if any of the following 
criteria are met:  
21. Subjects have previously participate d in a long -term, open -label LCM study.  
 
4.3.3  Criteria for withdrawal  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be followed until reso lution of the event or until the 
event is considered stable. The following criteria for subject withdrawal from SP848 are outlined 
below. Additional discontinuation criteria for potential drug -induced liver injury (PDILI) are 
presented in Section 4.3.3.1.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relevant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation in the study  
2.   T he request of the Sponsor or a Regulatory Agency  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 22 of 324 3.    Subject achieves menarche during the study and does not practice an acceptable method of 
contraception for the duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant, as evid enced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake or deve lops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is unwilling 
or unable to allow the subject to continue in the study.  
8.    Investigator’s decision that withdrawal from furt her participation would be in the subject’s 
best interest.  
9.    Subject experiences convulsive status epilepticus (if none had occurred prior to study entry) 
and is compliant with study treatment  
11.   For subject who did not complete a C -SSRS at Screenin g, subject has a lifetime history 
(prior to study entry or since study start) of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subject from the study and immediately refer the subject to a 
Mental Healthcare Professional.  
12. For all subjects ≥6  years of age, regardless of whether or not a C -SSRS was completed at 
Screening, subject has actual suicidal ideation as indicated by a positive respons e (“Yes”) to 
either Question  4 or Question  5 of the “since last visit” version of the C -SSRS. The subject 
should be referred immediately to a Mental Healthcare Professional and must be withdrawn 
from the study.  
Participation in this study may be discontinu ed for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
5.   For subject who did not complete a C -SSRS at  Screening, subject had actual suicidal ideation 
in the past 6  months as indicated by a positive response (“Yes”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental Hea lthcare Professional and use clinical judgment as to whether to 
withdraw the patient from the study.  
If a subject from SP848 enrolls in EP0060 and either withdraws consent solely due to route of 
LCM administration (iv) or if the subject requires more than 10 iv LCM infusions, the subject 
may be allowed to return to SP848 after discussion with and agreement from the Medical 
Monitor. If a subject from SP848 is advised to withdraw from the SP848 after participation in 
EP0060, the subject will be required to re turn to the SP848 to complete the required ETV and 
Safety Follow -up assessments.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 23 of 324 Investigators should attempt to obtain information on subjects in the case of withdrawal. For 
subjects considered as lost to follow up, the investigator should make efforts (a t least 1 phone 
call and 1 written message to the subject), and document his/her efforts (date and summary of the 
phone call and copy of the written message in the source documents), to complete the final 
evaluation. All results of these evaluations and ob servations, together with a narrative description 
of the reason(s) for removing the subject, must be recorded in the source documents. The eCRF 
must document the primary reason for withdrawal.  
Investigators should contact the Medical Monitor, whenever poss ible, to discuss the withdrawal 
of a subject in advance.  
4.3.3.1  Potential drug -induced liver injury IMP discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be immediately and permanently dis continued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued.  
The PDILI criteria below require immediate and permanent discontinuation of IMP:  
• Subjects with either of the followin g: 
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right 
upper  quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below requires discussion with the Medical Monitor to decide whether the 
subject is allowed to con tinue on IMP.  
• Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section  8.3.2 . If subjects are unable to 
comply with the applicable monitoring schedule, IMP must b e discontinued immediately.  
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring ar e complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuat ion. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 24 of 324 4.4 Study treatments  
4.4.1  Treatments to be administered  
4.4.1.1  Subjects enrolling from SP847 or other LCM pediatric clinical studies 
in epilepsy  
Subjects who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), 
who are eligible to partici pate in the open -label study SP848, and who choose to enter SP848, 
will begin SP848 on the LCM dose they achieved in the primary study.  
Subjects who enroll from EP0060 will begin SP848 with an equivalent dose to the last dose they 
received in EP0060; howev er, the LCM dose may be further titrated/adjusted to a level to 
optimize tolerability and seizure control (up to a maximum level as described in Section 4.4.1.3 ). 
For those subjects who initiated adjunctive LCM treatment in EP0060, the recommended LCM 
dose titration approach is outlined in Section 4.4.1.2 . 
4.4.1.2  Subjects enrolling directly into SP848  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be  permitted to enroll directly into SP848. Beginning with local Protocol 
Amendment 5.2 f or sites in Japan, approximately 46  eligible pediatric subjects ≥4  years to 
≤17 years of age with partial -onset seizures who have not previously received LCM will direct ly 
enroll at approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 f or sites 
in China, approximately 60 additional eligible pediatric subjects with partial -onset seizures aged 
≥4 years to ≤17  years, who have not previously participate d in a LCM clinical study, will enroll 
directly into SP848. After Screening, eligible subjects will initiate treatment with LCM (oral 
solution or tablet, as chosen by the investigator and subject/caregiver), and the LCM dose will be 
titrated to a level to optimize tolerability and seizure control.  
At the first Titration Visit (TV) (see Section  5.2), subjects who have enrolled directly into SP848 
will receive a single dose of LCM (1mg/kg [oral solution] or 50mg [tablet]) during the clinic 
visit. Over the following days, subjects will be administered LCM  1mg/kg  bid (oral solution) or 
LCM  50mg bid (tablet), and will begin titrating in weekly increments o f 2mg/kg/day (oral 
solution) or 100mg/day (tablet) up to a level to optimize tolerability and seizure control (not to 
exceed 12mg/kg/day [or 600mg/day based on body weight, whichever is lower]). Subjects must 
be on each LCM dose for at least 5  days before titrating up to the next dose.  
A total of up to 6  Titration Visits may be required (eg, for a subject whose dose is titrated to the 
maximum permitted dose of LCM  12mg/kg/day). However, based on tolerability and seizure 
control, a subject’s LCM dose may be titrated to a lower dose level; in such a case, fewer than 
6 Titration Visits would be required.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 25 of 324 The following table summarizes the recommended titration steps for the oral solution and tablet 
formulations:  
Recommended LCM dose titration for subjects enrol ling directly into SP848  
Formulation  Week 1  Week 2  Week 3  Week 4  Week 5 Week 6 
Oral solution 
(syrup)  2mg/kg/day  
(1mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  6mg/kg/day  
(3mg/kg bid)  8mg/kg/day  
(4mg/kg bid)  10mg/kg/day  
(5mg/kg bid)  12mg/kg/day  
(6mg/kg bid)  
Tablet  100mg/day  
(50mg bid)  200mg/day  
(100mg bid)  300mg/day  
(150mg bid)  400mg/day  
(200mg bid)  500mg/day  
(250mg bid)  600mg/day  
(300mg bid)  
bid=twice daily; LCM=lacosamide  
4.4.1.3  All subjects  
The investigator, together with the subject/caregiver (including parent/legal guardian), will be 
able to choose either the oral solution (syrup) formulation or the tablet formulation of LCM in 
this study. The study medication will be orally administered bid (at 12 -hour intervals, once in the 
morning and once in the evening) in equal ly divided doses. The oral solution (syrup) formulation 
will be measured and orally administered via a dosing syringe. The selection of doses, titration 
scheme, and rate of taper in SP847 were based on adult studies and were adjusted to a mg/kg 
basis plus 40% (ie, 600mg/day adult dose of LCM corresponds to [600mg/70kg]  x 1.4 = 
approximately 12mg/kg/day for a child). The selection of doses in this trial is based on the 
maximum recommended dose in SP847.  
The investigator may adjust the LCM dose to a minimum o f 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exce eds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower.  
The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 12mg/kg/day (o ral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever i s lower. The investigator may decrease the 
dose of LCM to a minimum of 2mg/kg/day (oral solution [syrup] or the corresponding dose level 
for the tablet formulation). Increases in the LCM dose must occur only during office visits. It 
should be noted, in cas es of incomplete doses (eg, subject spits out all or a portion of the syrup), 
missed doses, or administration of an erroneous volume of syrup, study medication should not be 
readministered and these subjects would remain at their assigned dose.  
Subjects en rolling from SP847 will have the option of remaining on the oral solution formulation 
of LCM or switching to the commercial tablet formulation, if feasible. Consideration of the 
current LCM milligram dose in the oral solution (syrup) should occur if/when t ransitioning to the 
tablet formulation. In cases where the LCM dose received with the oral solution (syrup) is not 
supported by the tablet strengths available in SP848 (50mg and 100mg), a clinical decision must 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 26 of 324 be made by the investigator or other study ph ysician to either increase or decrease the LCM dose 
to the next multiple of 100mg with a maximum permitted dose of 600mg/day.  
Subjects achieving a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) 
who withdraw during the study should t aper off study medication. It is recommended that the 
dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) (see tables below). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Recommended LCM dose reduction (taper) for oral solution (syrup) formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
12mg/kg/day  
(6mg/kg bid)  8mg/kg/day  
(4mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  0 
10mg/kg/day  
(5mg/kg bid)  6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 
8mg/kg/day  
(4mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  0 – 
6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 – 
4mg/kg/day  
(2mg/kg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
Recommended LCM dose reduction (taper) for tablet formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
600mg/day  
(300mg bid)  400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 
500mg/day  
(250mg bid)  300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 
400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 – 
300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 – 
200mg/day  
(100mg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 27 of 324 4.4.1.4  Study completion  
At the completion of the study, investigators  should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investi gator in consultation with the subject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not r equired for subjects 
who complete the study and who do not undergo taper of LCM. The Safety Follow -Up Visit and 
the Safety Follow -Up telephone contact are not required for subjects who participate in EP0151 
or EP0152.  
Subjects who complete the study and discontinue use of LCM (as determined by the investigator 
in consultation with the subject and/or parent/legal guardian) should taper LCM gradually as 
described in Section  4.4.1.3 . These subjects should complete Visit  13/Termination Visit, 
followed by the Final Visit which occurs 2  weeks after the final dose of study medication, and 
then the Safety Follow -Up telephone contact which occurs 28 to 35  days after the last dose of 
LCM.  
4.4.2  Description of investigational medicinal product  
Beginning with protocol Amendment  3, the oral solution formulation contains 10mg/mL of drug 
substance (formerly containing 15mg/mL of drug substance)  and is colorless to pale y ellow in 
appearance. The oral solution (syrup) will be packaged in amber polyethylene terephthalate 
(PET) bottles with a white, child -proof, polypropylene screw cap.  
The tablet formulation will be supplied in doses of 50mg and 100mg. The 50mg tablets are light 
pink, oval, film -coated tablets debossed with “SP” on 1 side and “50” on the other. The 100mg 
tablets are dark yellow, oval, film -coated tablets debossed with “SP” on one side and “100” on 
the other. The tablets will be packaged in high -density polye thylene bottles with a child -proof, 
polypropylene screw cap.  
4.4.3  Randomization  
This is an open -label study; subjects will not be randomized. Subjects who participated in SP847 
or other LCM pediatric clinical studies in epilepsy will keep the unique number assi gned in the 
primary study.  
Subjects enrolling directly into SP848 without participation in a previous LCM clinical study 
will be assigned unique numbers for the purpose of study and subject identification, as well as 
for subject confidentiality. At the Screening Visit, each subject will be assigned the unique 
identifying number for this study.  
4.5 Expected duration of the study  
The maximum duration of LCM administration for an individual subject will be approximately 
2 years or until approval of the marketin g application (for Japan only), whichever comes first.  
The start of the study is defined as the first visit of the first subject entering the study. The end of 
the study is defined as the date of the last visit of the last subject in the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 28 of 324 4.6 Concomitant  medication(s)/treatment(s)  
The following medications/therapies are prohibited during the course of this study:  
• Monoamine oxidase inhibitor -A compounds  
• Narcotic analgesics  
• Cannabidiols not approved or indicated for epilepsy by a local health authority  
All concomitant medications and treatments must be recorded in the appropriate study 
documents (eCRF and source document).  
Stable use of amphetamines and sedative antihistamines is allowed during the study. Also, 
stable, low doses of anxiolytics or hypnotics ( ie, diazepam 5mg/day) are allowed for nonepilepsy 
indications only.  
Therapy that becomes necessary, in the investigator’s opinion, during the course of the study 
must not be refused to a subject, even if described above as a therapy that is expressly not 
permitted. The subject's participation in this study may be discontinued in such a case.  
4.7 Procedures for monitoring subject compliance  
Subjects’ caregivers (including parent/legal guardian) will be instructed to return unused 
medication at each study visit. Returned medication will be reconciled by the investigator (or 
designee) in order to monitor the subject’s compliance with the medication schedule. Drug 
accountability must be done in the subject’s/caregiver’s presence in order to obtain explanations 
regar ding discrepancies in compliance with the dosing regimen.  
All findings will be documented on forms provided by UCB BIOSCIENCES. Subject’s 
noncompliance with regards to intake of LCM is defined as being less than 75% or more than 
125% compliant with the dos age schedule.  
If a subject is found to be noncompliant, a decision will be made by the investigator, in 
conjunction with UCB BIOSCIENCES, as to whether the subject should be withdrawn from the 
study.  
5 TREATMENT PROCEDURES BY VISIT  
For all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up 
telephone contact), a visit window of ±7 days relative to Visit  1 is applicable. The Safety 
Follow -Up telephone contact will be performed 28 -35 days after the last dose of LCM. The 
Safety F ollow -Up Visit and the Safety Follow -Up telephone contact are not required for subjects 
who participate in EP0151 or EP0152.   
Assessments will be done during monthly visits for the first 3 months, every 2 months for the 
remainder of Year 1, and every 3 mon ths for Year 2. A detailed tabular schedule of study 
procedures is provided in Section  16.1. For further details of the assessments and the required 
procedures and methods, please refer to Section  6, Section  7, and Section  8. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 29 of 324 5.1 Screening Visit  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848.  
At the Screening Visit, subjects entering d irectly into SP848 (ie, subjects who have not 
participated in SP847 or another applicable LCM pediatric clinical study in epilepsy) will be 
evaluated for their suitability for enrollment in SP848. The Screening Visit is not applicable for 
subjects who have  participated in SP847 or another applicable LCM pediatric clinical study in 
epilepsy; the first visit in SP848 for these subjects is Visit  1 (see Section  5.3). 
The Screening assessments will be conducted up to 14  days prior to the first administration of 
LCM. It is acceptable for the Screening assessments to be conducted on more than 1  day, 
although it should not be done over longer than 1  week. Prio r to the conduct of any study -related 
procedures, a complete explanation (both verbally and written) of the nature and purpose of the 
study will be given to the subject (when possible or as required according to local IRBs/IECs) 
and the subject’s parent/le gal guardian by the investigator (or designee). The subject’s 
parent/legal guardian will be requested to sign and date the IRB/IEC -approved Informed Consent 
Form. When possible, or as required by the local IRB/IEC, the subject will be requested to give 
assent to participate in the study. Each subject’s eligibility for the study will be determined on 
the basis of the inclusion/exclusion criteria and the results of the following pretreatment 
assessments (for further details of the assessments and the required  procedures and methods, 
please refer to Section  6, Section  7, and Section  8 of this protocol).  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Medical history assessment  
• Seizure history over the past 4 weeks (historical Baseline)  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight assess ment  
• Height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• C-SSRS  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 30 of 324 • Achenbach CBCL to be com pleted by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for children 6  years and 
older)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Adverse event reporting  
• Health care resource use  
• Dispense subject diary  
The subject will be scheduled to return for a clinic visit (TV) less than 14  days from the last 
Screening Visit assessment(s).  
5.2 Titrat ion Visit(s) (TV1, TV2, TV3, TV4, TV5, TV6)  
Eligible subjects who enter directly into SP848 (without prior participation in SP847 or another 
applicable LCM primary study) will initiate treatment with LCM at TV1, and the LCM dose will 
be titrated over the f ollowing week(s). Titration Visits are not applicable for subjects who have 
participated in SP847 or another LCM primary study; the first visit in SP848 for these subjects is 
Visit  1 (see Section  5.3). 
At TV1, subjects who have enrolled directly into SP848 will receive a single dose of LCM 
(1mg/kg [oral solution] or 50mg [tablet]) during the clinic visit. Over the following days, 
subjects will be adm inistered LCM  1mg/kg bid (oral solution) or LCM  50mg  bid (tablet), and 
will begin titrating in weekly increments of 2mg/kg/day (oral solution) or 100mg/day (tablet) up 
to a level to optimize tolerability and seizure control (not to exceed 12mg/kg/day [or 6 00mg/day 
based on body weight, whichever is lower]). Subjects must be on each LCM dose for at least 
5 days before titrating up to the next dose. It should be noted, in cases of incomplete doses (eg, 
subject spits out all or a portion of the syrup), missed doses, or administration of an erroneous 
volume of syrup, study medication should not be readministered and these cases would not be 
considered dose reductions. The LCM dose titration steps are summarized in Section  4.4.1.2 . 
A total of up to 6  Titration Visits may be required (eg, for a subject whose dose is titrated to the 
maximum permitted dose of LCM  12mg/kg/day). However, based on tolerability and seizure 
control, a subject’s LCM dose may be titrated to a lower dose level; in such a case, fewer than 
6 Titration Visits would be required.  
The following assessments are required for each TV:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 31 of 324 • Vital signs assessment (blood pressure and pulse)  
• Body wei ght 
• Blood sample for clinical chemistry, hematology, and endocrinology (TV4 only)  
• Urine sample for urinalysis (TV4 only)  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Health care resource use  
• Dispense subject  diary  
• Dispense LCM (as applicable)  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM 
maximum plasma concentration (C max) 1 week after an initial LCM dose increase to a LCM dose 
level that is ≥8mg/kg/day or a new co ncomitant AED is introduced. Subjects will be required to 
arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings 
appro ximately 20  to 30  minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
5.3 Visit 1 (Week 0)  
For subjects who completed SP847, Visit 1 for SP848 was the same as Day 2 of the second PK 
collection time period (which may include an overnight stay at a hospital or medical facility) in 
SP847 (Day  28 for Cohorts  1, 2, 3, and 5 with maximum recommended dose of 8mg/kg/day; 
Day 35 for Cohorts  2 to 5 with maximum recommended do se of 10mg/kg/day; and Day  42 for 
Cohorts  2 to 5 with maximum recommended dose of 12mg/kg/day). For subjects who 
discontinued SP847 due to a dose reduction or status epilepticus, Visit 1 was the Early 
Termination Visit in SP847. For subjects in SP847 who w ere titrated up to the maximum 
permitted dose of 600mg/day sooner than the study schedule would ordinarily indicate (based on 
body weight) and who enroll in SP848, the Early Termination Visit of SP847 also served as 
Visit  1 for SP848.  
For subjects who enro ll in SP848 after participation in other LCM pediatric clinical studies 
besides SP847 (ie, SP0966 and EP0060) in epilepsy, SP848 Visit  1 will be specified in the 
respective primary study protocol.  
For subjects who enter directly into SP848 (without prior p articipation in SP847 or other LCM 
pediatric clinic studies in epilepsy), the LCM dose will be titrated at weekly intervals as 
described in Section  4.4.1.2  and Section  5.2. These subjects will reach Visit  1 either (1) when the 
LCM dose is titrated to a level that, in the opinion of the investig ator, optimizes tolerability and 
seizure control, or (2) when the maximum permitted LCM dose is reached (12mg/kg/day [or 
600mg/day based on body weight, whichever is lower]). In the case of a subject who requires a 
dose reduction during the Titration Visit s, the subject’s LCM dose will be returned to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 32 of 324 previous dose level and the next clinic visit will be Visit  1 at the reduced level. Visit  1 should 
occur at least 5  days after the final TV. At Visit  1, the progress in SP848 for subjects who 
entered direct ly into SP848 and for subjects who have enrolled from SP847 or other LCM 
pediatric clinical studies in epilepsy will be aligned; subsequent regularly scheduled clinic visits 
for all subjects will be at 4 -week intervals as outlined in the following sections . 
The informed consent process for SP848 will be conducted at Visit  1 for subjects who have not 
previously been through the informed consent process at the Screening Visit (ie, subjects 
enrolling from SP847 or other LCM pediatric clinical studies in epilep sy for whom Visit  1 is the 
first study visit in SP848). Prior to the conduct of any study -related procedures, a complete 
explanation (both verbally and written) of the nature and purpose of the study will be given to 
the subject (when possible or as requir ed according to local IRBs/IECs) and the subject’s 
parent/legal guardian by the investigator (or designee). The subject’s parent/legal guardian will 
be requested to sign and date the IRB/IEC -approved Informed Consent Form. When possible, or 
as required by local IRB/IEC, the subject will be requested to give assent to participate in the 
study.  
Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments (applicable only for subjec ts for whom Visit  1 is the first 
clinic visit for SP848), and a complete medical history update will be obtained. If available, the 
data for the following assessments will be taken from the last assessment during SP847 (or other 
primary study, as applicabl e): 
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment but 30  minutes to 1 hour after the administration of LCM)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• C-SSRS  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 33 of 324 • Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for children 6  years and 
older) (subjects enrolling from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• Bayley -III scales for  children <18  months of age enrolled in English -speaking countries 
(subjects enrolling from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Adverse event reporting  
• Healt h care resource use  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to admini ster LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
5.4 Telephone contacts (Weeks 2, 6, 10, 16, 24, 32, 40, 48, 66, 
and 78) 
Between scheduled clinic visits, the investigator (or designee) should contact the subject’s 
caregiver (including parent/legal guardian) by telephone. The investigator (or designee) should 
remind the subject’s caregiver (including parent/legal guardian) to ensure the diary is completed 
and to bring unused LCM to the next clinic visit. The following sh ould be performed via 
telephone:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Adverse event reporting  
If an AE necessitates the subject’s withdrawal from the study, the subject should return for an 
Early Termination Visit ( Section  5.17) as soon as possible.  
Lacosamide is supplied so that the subject or caregiver (including parent/legal guardian) can 
immediately decrease their dose, if  needed, in consultation over the telephone with the 
investigator or subinvestigator. Thus, LCM can be continued at a decreased dose until a clinic 
visit can be scheduled.  
5.5 Visit 2 (Week 4)  
During Visit 2 (Week 4), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 34 of 324 • Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sa mple)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry and hematology  
• Blood samples for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine pregnancy test for female subjects of childbearing potential  
• LCM return/compliance. Subject’s caregivers will be instructed to return unused LCM at 
each study visit. Returned medication will be reconciled by the investigator (or designee) in 
order to monitor the sub ject’s compliance with the medication schedule. If a subject is found 
to be noncompliant, a decision will be made by the investigator, in conjunction with UCB 
BIOSCIENCES, as to whether the subject should be withdrawn from the study.  
• Subject diary assessme nt 
• C-SSRS  
• Adverse event reporting  
• Health care resource use  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parent/leg al guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increased to a LCM dose level that is ≥8 mg/kg/day or a new concomitant AED is introduced. 
The ECG should be performed after the increased dose of LCM or the new AED has reached 
steady -state. This ECG can be done at the next scheduled visit. When the ECG assessment is 
done, 2 interpretable record ings will be performed approximately 20 to 30  minutes apart 
prior to vital sign assessment and collection of blood samples (if applicable), but 30  minutes 
to 1 hour after the administration of LCM (if applicable).  
All subjects will be required to have an E CG (2 interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day . This ECG 
can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive 
at the clini c prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2 interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be perfo rmed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 35 of 324 5.6 Visit 3 (Week 8)  
During Visit 3 (Week 8), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Urine pregnancy test for female subjects of childbearing potential  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Health care resource use  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parents/legal guardians) will be i nstructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increased to a LCM level dose that is ≥8mg/kg/day or a new con comitant AED is introduced. 
The ECG should be performed after the increased dose of LCM or the new AED has reached 
steady -state. This ECG can be done at the next scheduled visit. When the ECG assessment is 
done, 2 interpretable recordings will be performed  approximately 20 to 30 minutes apart 
prior to vital sign assessment and collection of blood samples (if applicable), but 30  minutes 
to 1 hour after the  administration of LCM (if applicable).  
• All subjects will be required to have an ECG (2  interpretable re cordings) conducted at LCM 
Cmax 1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day . 
This ECG can be conducted at an Unscheduled Visit if necessary. These subjects will be 
required to arrive at the clinic prior to taking their  morning dose of LCM. Subjects will be 
administered their morning LCM dose by study personnel at the clinic so that an ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, at 
LCM steady state C max). 
5.7 Visit 4 (Week 12)  
Assessments for Visit 4 (Week 12) are the same as those described for Visit 3 (Week 8), in 
Section  5.6. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 36 of 324 5.8 Visit 5 (Week 20)  
During Visit 5 (Week 20), the following will be p erformed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Urine pregnancy test for female subjects of childbearing potential  
• Clinical Global Impres sion of Change  
• Caregiver Global Impression of Change  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for  children 6  years and 
older) (subjects enrolling from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries 
(subjects enrolling from SP847 or another ap plicable LCM pediatric clinical study in 
epilepsy)  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Adverse event reporting  
• Health care resource use  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AED s, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parents/legal guardians) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 37 of 324 A 12 -lead ECG (2 interpretable recordings)  is also required when the dose of LCM is increased 
to a LCM dose level that is ≥8mg/kg/day  or a new concomitant AED is introduced. The ECG 
should be performed after the increased dose of LCM or the new AED has reached steady -state. 
This ECG can be done at the next scheduled visit. When the ECG assessment is done, 2 
interpretable recordings will be performed approximately 20 to 30 minutes apart prior to vital 
sign assessment and collection of blood samples (if applicable), but 30  minutes to 1  hour after 
the administration of LCM (if applicable).  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day . This ECG 
can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive 
at the clinic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
5.9 Visit 6 (Week 28)  
Assessments for Visit 6 (Week 28) are th e same as those described for Visit 3 (Week 8) in 
Section  5.6, with the following exception: completion of the palatability and ease of use 
questio nnaire and a  12-lead ECG (2 interpretable recordings approximately 20 to 30  minutes 
apart prior to vital signs assessment and collection of blood sample) are conducted at Visit 6.  
5.10 Visit 7 (Week 36)  
Assessments for Visit 7 (Week 36) are the same as those de scribed for Visit 2 (Week 4), in 
Section  5.5, with the following exception: a 12 -lead ECG is not conducted at Visit 7.  
5.11 Visit 8 (Week 44)  
Assessments for Visit 8 (Week 44) are the same as those described for Visit 3 (Week 8), in 
Section  5.6, with the following exception: a Tanner Stage  assessment is conducted at Visit 8 (if 
applicable).  
5.12 Visit 9 (Week 52)  
Assessments for Visit 9 (Week 52) are the same as those described for Visit 5 (Week 20), in 
Section  5.8, with the following exception: completion of the palatability and ease of use 
questionnaire and a 12 -lead ECG (2 interpretable recordings approximately 20 to 30  minutes 
apart prior to vital signs assessment and collection of bloo d sample) are conducted at Visit 9.  
5.13 Visit 10 (Week 60)  
Assessments for Visit 10 (Week 60) are the same as those described for Visit 2 (Week 4), in 
Section  5.5, with the following exceptions: a 12 -lead ECG is not conducted at Visit 10 (all sites) 
and a PK sample is routinely drawn at sites in Japan (removed for all other sites) . 
5.14 Visit 11 (Week 72)  
Assessments for Visit 11 (Week 72) are the same as thos e described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions for all sites: brief physical and neurological exams are 
conducted  (instead of complete physical and neurological exams as indicated for Visit 5), the 
laboratory blood sample is collected only for clinical chemistry and hematology (ie, no 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 38 of 324 endocrinology), the palatability and ease of use questionnaire is completed,  and a 12-lead ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted. In addition to the noted differences, a PK sample is 
routinely drawn at sites in Japan (removed for a ll other sites) . 
5.15 Visit 12 (Week 84)  
Assessments for Visit 12 (Week 84) are the same as those described for Visit 2 (Week 4), in 
Section 5.5, with t he following exceptions for all sites: the laboratory blood sample is collected 
for endocrinology as well as clinical chemistry and hematology and a 12 -lead ECG is not 
conducted. In addition to the noted differences, a PK sample is routinely drawn at sites  in Japan 
(removed for all other sites) . 
5.16 Visit 13/Termination Visit (Week 96)  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investigator in consultation with the subject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper of LCM. The Safety Follow -Up Visit and 
the Safety Follow -Up telephone contact are not required for subjects who participate in EP0151 
or EP0152.  
Subjects who complete the study and discontinue use of LCM (as determined by the investigator 
in consultation with the subject and/or parent/legal guardian) should taper  LCM gradually as 
described in Section  4.4.1.3 . These subjects should complete Visit  13/Termination Visit, 
followed by the Final Visit which occurs 2 weeks after the final dose of study medication, and 
then the Safety Follow -Up telephone contact which occurs 28 to 35  days after the last dose of 
LCM . 
Assessments for Visit 13/Termination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following exceptions for all sites: the laboratory blood 
sample is collected only for clinical chemistry and hematolo gy (ie, no endocrinology), a 12-lead 
ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of blood sample) is conducted, a Tanner Stage assessment is 
conducted (if applicable), an Achenbach CBC L is conducted, Bayley -III scales are conducted, 
BRIEF -P/BRIEF and PedsQL scores are obtained, and the palatability and ease of use 
questionnaire is completed. In addition to the noted differences, a PK sample is routinely drawn 
at sites in Japan (removed for all other sites) . 
Lacosamide for taper will be dispensed only for subjects who achieve a dose of 
LCM  ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day  (oral solution [syrup]) or 
200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permi tted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible. Taper of LCM may not 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 39 of 324 be required for some subjects who complete the study depending on the treatment option sel ected 
by the investigator in consultation with the subject and/or parent/legal guardian.  
5.17 Early Termination Visit  
Subjects who withdraw from the study prematurely must complete an Early Termination Visit.  
At the time of withdrawal from the study, investigat ors should discuss treatment options with the 
subject and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM 
may not be required for some subjects who withdraw from the study prematurely, depending on 
the treatment option se lected by the investigator in consultation with the subject and/or 
parent/legal guardian. These subjects should complete the Early Termination Visit and then 
complete the Safety Follow -Up telephone contact 28 to 35  days after the Early Termination 
Visit. T he Final Visit is not required for subjects who withdraw from the study prematurely and 
who do not undergo taper of LCM.  
Subjects who withdraw from the study prematurely and discontinue use of LCM (as determined 
by the investigator in consultation with the  subject and/or parent/legal guardian) should taper 
LCM gradually as described in Section  4.4.1.3 . These subjects should complete the Early 
Termina tion Visit, followed by the Final Visit which occurs 2  weeks after the final dose of study 
medication, and then the Safety Follow -Up telephone contact.  
The following will be performed at the Early Termination Visit:  
• Concomitant medication assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment  (blood pressure and pulse)  
• Body weight and height  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
− Under any circumstance for an ETV durin g Year 1  
− If possible, if the early termination during Year 2 is due to a SAE and the event is 
ongoing  
• Urine sample for urinalysis  
• Serum pregnancy test for females of childbearing potential  
• Tanner Stage assessment (if applicable)  
• Clinical Global Impression of Change  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 40 of 324 • Caregiver Global Impression of Change  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for children 6  years and 
older)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Palatability and ease of use questionnaire  
• Adverse event reporting  
• Health c are resource use  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs)  
• Dispense LCM. Lacosamide for taper will be dispensed only for subjects who achieve a dose 
of LCM ≥6mg/kg/day (oral solution [syru p]) or ≥300mg/day (tablet). It is recommended that 
the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution 
[syrup]) or 200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, 
a faster taper is permitted after discussion with the medical monitor, whenever pos sible. 
Taper of LCM may not be required for some subjects who withdraw from the study 
prematurely, depending on the treatment option selected by the investigator in consultation 
with the subject and/or parent/legal guardian.  
5.18 Unscheduled Visit(s)  
An Unsched uled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, if an LCM dose increase is required at 
any time, or if a new concomitant AED is introduced, the subject must return for  an Unscheduled 
Visit. If an AE prompts a dose reduction, the reduction can be implemented immediately at the 
investigator’s discretion. However, the subject should return to the clinic as soon as possible for 
an Unscheduled Visit.  
The following assessment s are required:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 41 of 324 • 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS (only if Unscheduled Visit is conducted due to an AE)  
• Adverse event reporting  
• Health care r esource use  
• Dispense LCM (as applicable)  
• If possible, a blood sample for LCM and concomitant AED plasma concentrations (at any 
time post -dosing with LCM) if the unscheduled visit is due to a SAE  
Additional assessments can be performed at the investigator’s discretion.  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day  or after a 
new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if 
necessary. Subjects having a LCM dose increase to ≥8mg/kg/day will be required to arrive at the 
clinic prior to taking their morning dose of LCM. Subjects will be administered their morning 
LCM dose by study  personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
5.19 Final Visit  
Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication . The Final Visit is not required for subjects who participate i n EP0151 or EP0152.   
During the Final Visit, the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximate ly 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 42 of 324 • Urine sample f or urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Health care resource use  
5.20 Safety Follow -Up telephone contact  
The Safety Follow -Up telephone contac t is required for all subjects (those who complete the 
study as planned or have withdrawn prematurely from the study ) who do not participate in 
EP0151 or EP0152. For subjects who complete the study, this telephone contact will occur 28 to 
35 days after Vis it 13/Termination Visit (subjects who do not undergo taper of LCM) or 28 to 
35 days after the last dose of LCM (subjects who discontinue use of LCM [ie, taper]). For 
subjects who withdraw prematurely from the study, this telephone contact will occur 28 to 
35 days after the Early Termination Visit (subjects who do not undergo taper of LCM) or 28 to 
35 days after the last dose of LCM (subjects who discontinue use of LCM [ie, taper]). The Safety 
Follow -Up telephone contact is not required for subjects who part icipate in EP0151 or EP0152.  
The following should be performed via telephone:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Adverse event reporting. If an AE is reported at this telephone contact, the investigator will 
follow the AE until a definite outcome is achieved ( Section  8.1.2 ). 
5.21 Study conduct due to coronavirus disease 2019 pandemic  
The protocol -mandated visit schedule should be followed to the extent possible, considering the 
individual benefit -risk assessment by the investigator. If necessary, remote visits may be 
conducted and the subjects or caregivers will be contacted by telepho ne or videoconference. 
Remote follow -up, at minimum with a telephone call after 3 months, must be done (preferably 
more frequently and as needed to follow -up on participant safety assessments).  
Ad hoc subject contact may be warranted  to understand the cu rrent health status of the subjects, 
to follow up on AEs, and inform them of any protective measures taken by the clinical site as a 
result of the coronavirus disease 2019 (COVID -19) pandemic (eg, any measures that may limit 
access to the site or may requi re additional actions by the study participant prior to entry to the 
site).  
If a subject needs to be discontinued and cannot come into the clinic, then appropriate tapering 
instructions will be provided, and a visit will be scheduled to perform safety asse ssments as soon 
as possible.  
In situations where a subject is unable to return to the study site, investigators will assess and 
document the subject’s safety via telephone contact. Based on information gathered from the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 43 of 324 telephone contact, investigators wil l confirm whether the subject could continue the current 
study treatment based upon the outcome of the safety assessment. Subjects’ agreement to 
implement this procedure should be obtained and documented prior to implementing any 
changes. Changes in the st udy treatment supply in this situation are described in Section  9.5.  
If a subject visits another facility for a medical issue (or has to switch sites  for a COVID -19-
related reason), the investigator should request contact with the physician providing care to 
provide a detailed explanation of the subject’s condition and his/her participation in the clinical 
study. Subjects or caregivers shall be reminde d to completely collect and keep records of this 
visit.  
Deviations to data collection including inability to perform some assessments, such as ECG, 
blood collection for safety laboratory assessments and PK, or alternative methods of assessment, 
such as ph one calls, should be recorded in the source documentation and notated as “not done” in 
the eCRF.  
In cases where subjects cannot return to the clinic, and it will not be possible to dispense a new 
seizure diary, subjects will be instructed to continue recor ding of seizures in a manner that is 
mutually agreed with the investigator (eg, hand -written notes, recording on a smart device). Any 
recording of seizures in a manner outside of the study seizure diary must be carefully 
documented in the source medical re cords (copies/print -screen printouts of these recordings will 
be brought to and retained at the site).  
6 ASSESSMENT OF EFFICACY  
6.1 Seizure counts  
At Screening of SP847 (or other primary study as applicable) or at the Screening Visit of SP848 
(for subjects who e ntered directly into SP848) subjects/caregivers (including parents/legal 
guardians) will be asked how many seizures the subject has had in the previous 4  weeks; this will 
serve as a historical Baseline. After the subject is enrolled in the SP848 study, sei zure data will 
be collected in diaries provided to subjects/caregivers (including parents/legal guardians). Each 
subject/caregiver (including parent/legal guardian) will keep a diary to note daily seizure activity 
throughout the current study. The subject/ caregiver (including parent/legal guardian) should be 
reminded to bring the diary with them at each clinic visit. The following information will be 
recorded:  
• Seizure type  
• Seizure frequency  
6.2 Global Impression of Change  
6.2.1  Clinical Global Impression of Change  
The Clinical Global Impression of Change will be assessed at least once per year and be 
completed according to the tabular schedule of study procedures, Section  16.1. 
For the assessment of the Clinical Global Impression of Change, the investigator  should provide 
his/her assessment of the subject’s clinical status, compared to Baseline, including an evaluation 
of seizure frequency and intensity, the occurrence of AEs, and subject’s functional status. Visit  1 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 44 of 324 of SP847 (or other primary study as appli cable) will serve as Baseline; the Screening Visit of 
SP848 will serve as Baseline for those subjects entering directly into SP848.  
The investigator will be asked to check the number that best describes the subject’s condition 
over the past 4 weeks compare d to Baseline:  
1. Very much improved  
2. Much improved  
3. Minimally improved  
4. No Change  
5. Minimally worse  
6. Much worse  
7. Very much worse  
6.2.2  Caregiver Global Impression of Change  
The Caregiver Global Impression of Change will be assessed at least once per year and be 
completed  according to the tabular schedule of study procedures, Section  16.1. 
For the assessment of the Clinical Global Impression of Change, the caregiver  (including 
parent/legal guardian) should provide his/her assessment of the subject’s clinical status, 
compared to Baseline, including an evaluation of seizure frequency and intensity, the occurrence 
of AEs, and subject’s functional status. Visit 1 of SP847  (or other primary study as applicable) 
will serve as Baseline; the Screening Visit of SP848 will serve as Baseline for those subjects 
entering directly into SP848.  
The caregiver will be asked to check the number that best describes the subject’s condition  over 
the past 4 weeks compared to Baseline:  
1. Very much improved  
2. Much improved  
3. Minimally improved  
4. No Change  
5. Minimally worse  
6. Much worse  
7. Very much worse  
6.3 Pediatric Quality of Life Inventory  
The PedsQL is a validated instrument that consists of generic core sca les suitable for use with 
pediatric populations, including those with acute or chronic health conditions (Varni et al, 2001; 
Varni et al, 2011). The PedsQL will be completed up to two times per year and will be 
administered according to the tabular schedul e of study procedures, Section  16.1. 
The PedsQL Measurement Model consists of developmentally appropriate forms for pediatric 
subjects ≥1 month to ≤1 2 months; ≥13 months to ≤24 months; >2  years to ≤4  years, ≥5  years to 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 45 of 324 ≤7 years, ≥8  years to ≤12  years, and ≥13  years to ≤18 years of age. Self -report is measured for 
pediatric subjects ≥5  years to ≤18 years of age, and parent proxy report of child health -related 
quality of life (HRQoL) is measured for pediatric subjects ≥1 month to ≤18  years of age.  
The multidimensional PedsQL scale encompasses the essential core domains for pediatric 
HRQoL measurement: 1) Physical Functioning/Symptoms, 2) Emotional Functi oning, 3) Social 
Functioning, and 4) Cognitive/School Functioning. The PedsQL assessment is retrospective to 
the prior month, and individual items are scored using a 5 -point Likert scale (never, almost 
never, sometimes, often, or always). A total health su mmary score is calculated from the sum of 
the raw scores of the individual items, with higher scores indicating higher HRQoL.  
6.4 Health care resource use  
For health care resource use parameters, the following will be evaluated: concomitant AEDs, 
medical proce dures, health care provider consultations not related to study, and hospitalizations 
not related to study. Health care resource use parameters will be collected according to the 
tabular schedule of study procedures, Section  16.1. 
7 ASSESSMENT OF PHARMACOKINETICS  
Blood samples will be collected at selected visits for the assessment of LCM and concomitant 
AED plasma concentrations (for population PK analysis). These blood samples will be collected 
along with the clinical chemistry/hematology samples at any time afte r intake of study 
medication according to the tabular schedule of study procedures, Section  16.1. In each case, the 
exact time and dose (in mg) when  the subject took the most recent doses of LCM and 
concomitant AED(s), and the exact time of blood sampling must be recorded.  
Each blood sample drawn will be split into 2 duplicate samples. The samples will be centrifuged 
and stored at ≤ -20ºC until shippe d to a central laboratory. The central laboratory will store the 
plasma samples at -20ºC until analysis. Details of plasma sample collection and processing, 
sample labeling, and shipment will be provided in the laboratory manual.  
8 ASSESSMENT OF SAFETY  
8.1 Adver se events  
8.1.1  Definition of AE  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product which does not necessarily have a causal relationship 
with this treatment. An AE can therefore be any u nfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product.  
In order to ensur e complete safety data collection, all AEs occurring during the study (ie, after 
signature of the Informed Consent), including any Pretreatment and Posttreatment Periods 
required by the protocol, must be reported in the eCRF even if no investigational prod uct was 
taken but specific study procedures were conducted. These include all AEs not present prior to 
the initial visit and all AEs which recurred or worsened after the initial visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 46 of 324 Signs or symptoms of the condition/disease for which the investigation al product is being studied 
should be recorded as AEs only if their nature changes considerably or their frequency or 
intensity increases in a clinically significant manner as compared to the clinical profile known to 
the investigator from the subject’s hi story or the Baseline Period.  
8.1.2  Procedures for reporting and recording AEs  
The study participant will be given the opportunity to report AEs spontaneously. A general 
prompt will also be given to detect AEs, for example:  
“Did you notice anything unusual about  your health (since your last visit)?”  
In addition, the investigator should review any self -assessment procedures (eg, diary cards) 
employed in the study.  
8.1.3  Description of AEs  
When recording an AE, the investigator should use overall diagnosis or syndrome using standard 
medical terminology, rather than recording individual symptoms or signs. The eCRF and source 
documents should be consistent. Any discrepancies between the subject’s own words on his/her 
own records (eg, diary card) and the corresponding medi cal terminology should be clarified in 
the source documentation.  
Details for completion of the AE eCRF page (including judgment of relationship to trial 
medication) are described in the AE Completion Guideline in the eCRF.  
8.1.4  Follow up on adverse events  
If an AE is still ongoing at the end of the study for a subject, a follow -up report should be 
provided until resolution/stable level of sequelae, the investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow -up. If n o follow -up report is provided, 
the investigator must provide a justification. The follow -up will be usually continued for  30 days 
after the subject has completed the study.  
UCB BIOSCIENCES may request that the investigator perform or arrange for the cond uct of 
supplementary measurements and/or evaluations.  
8.1.5  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
• the outcome date of the first AE that is not related to the nat ural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”,  
• the AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the fir st one.  
8.1.6  Pregnancy  
Should a subject become pregnant after the first intake of any investigational medicinal product, 
UCB BIOSCIENCES should be informed immediately. The subject should be withdrawn from 
the study as soon as pregnancy is known and the follow ing should be completed:  
• The subject should return for an early discontinuation visit  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 47 of 324 • The subject should immediately stop the intake of the investigational medicinal product or be 
down -titrated as instructed at the early discontinuation visit  
• A Safety Follow -up visit should be scheduled 28 to 35 days after the subject has discontinued 
the investigational medicinal product.  
The investigator must inform the subject of information currently known about potential risks 
and about the available alternatives, eg, voluntary termination with medication (to be proposed 
on a study -specific basis).   
In cases where the partner of a male subject enrolled in a clinical trial becomes pregnant, UCB 
BIOSCIENCES will ask the investigator or designee to contact the subject  and his partner to 
request consent via the Partner Pregnancy Consent Form. If the partner agrees to provide 
additional information, the Pregnancy Report and Outcome Form will be forwarded to the 
subject’s partner for completion.  
The pregnancy will be docu mented on the Pregnancy Report and Outcome Form. The 
progression of the pregnancy and the eventual birth (if applicable) must be followed -up using the 
Pregnancy Report and Outcome form in which the investigator has to report on the health of the 
mother and  of the child. The health of the child must be followed for 30 days after birth for any 
significant medical issues.  
In certain circumstances, UCB BIOSCIENCES may request that follow -up is continued for a 
period longer than 30 days.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion, or 
anomaly/birth defect of the child. Those serious events must be additionally reported using the 
Investigator SAE Report Form.  
8.1.7  Suspected transmission of an infectious agent via a medicinal 
produc t 
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any or ganism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
8.1.8  Overdose of investigational medicinal product  
Excessive dosing (beyond that pres cribed per the protocol and including overdose) should be 
recorded in the source documents and eCRF module. Any SAE or non -serious AE associated 
with excessive dosing must be followed as any other serious or non -serious AE. These events 
may be symptomatic,  in that the excessive dosing results in clinical signs and symptoms, or the 
excessive intake may itself be a symptom.  
8.1.9  Safety signal detection in ongoing clinical studies and Data 
Monitoring Committees  
Selected data from this study will be reviewed periodi cally to detect as early as possible any 
safety concern(s) related to the investigational medicinal product so that investigators, clinical 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 48 of 324 study subjects, regulatory authorities, and IRBs/IECs will be informed appropriately and as early 
as possible.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the Patient Safety (PS) 
representative.  
As appropriate for the stage of development and accumula ted experience with the investigational 
medicinal product, medically qualified personnel at UCB may identify additional safety 
measures (examples: AEs, vital signs, laboratory or ECG results) for which data will be 
periodically reviewed during the course o f the study.  
8.1.10  Occurrence of COVID -19 
Occurrence of COVID -19 in subjects should be reported as either “suspected COVID -19” or 
“confirmed COVID -19” along with all available relevant data including diagnostic and 
laboratory data. For subjects where COVID -19 is still suspected despite a negative viral test, 
please report as “suspected COVID -19” and provide relevant data to support the diagnosis as 
well as the test results.  
8.2 Serious adverse events  
8.2.1  Definition of serious adverse event  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. A SAE must meet 1 or more of the following criteria:  
• Death  
• Life-threatening   
Life-threatening does not include a reaction that might have caused death had it occurred in a 
more sever e form.  
• Significant or persistent disability/incapacity  
• Congenital anomaly/birth defect (including that occurring in a fetus)  
• Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medic al or surgical intervention to prevent one of the other 
outcomes listed in the definition of serious  
(Important medical events include, but are not limited to, potential Hy’s Law [see 
Section  8.2.2 ], allergic bronchospasm requiring intensive treatment in an emergency room or 
at home, blood dyscrasias that do not result in inpatient hospitalization, or the development 
of drug dependency or drug abuse.)  
• Initial inpatient hospitalization or prolongation of hospitalization  
A patient admitted to a hospital, even if released on the same day, meets the criteria for the 
initial inpatient hospitalization. An emergency room visit that results in admission to the 
hospital would also qualify for the initial inpatient hospitalization criteria. However, 
emergency room visits that do not result in admission to the hospital would not qualify for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 49 of 324 this criteria and, instead, should be evaluated for one of the other criter ia in the definition of 
serious (eg, life -threatening adverse experience, important medical event).  
Hospitalizations for reasons not associated with the occurrence of an AE (eg, preplanned 
surgery or elective surgery for a pre -existing condition that has n ot worsened or manifested 
in an unusual or uncharacteristic manner) do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned 
surgery for this condition, it is not appropriate to record the surgery or hospitalization as an 
SAE since there is no AE upon which to assess the serious criterion. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as  an AE and, if necessary, the seriousness of the event would need 
to be determined.  
8.2.2  AEs of special interest  
An AE of special interest is any AE that a regulatory authority has mandated to be reported on an 
expedited basis, regardless of the seriousness, e xpectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
The following are the LCM AEs of special interest:  
• The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (second deg ree Type I and II and third degree), and marked bradycardia 
(<45beats/min)  
• Syncope or loss of consciousness (other than seizure related)  
• Serious suspected multiorgan hypersensitivity reactions  
Serious suspected multiorgan hypersensitivity cases may be iden tified and reported 
to the sponsor by the investigator using the following algorithm as agreed with the 
Food and Drug Administration:  
An AE or laboratory value (as defined below) suggestive of internal organ 
involvement (including but not limited to hepatitis, nephritis, pneumonitis, carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system 
involvement) combined  with at least one of the following: fever, rash, 
lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:  
• Eosinophils % ≥10%  
• Eosinophils absolute ≥0.5G/L  
• Neutrophils absolute <1.5G/L  
• Platelets ≤100G/L  
• ALT ≥2x ULN  
• AST ≥2x ULN  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 50 of 324 • Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnormality, mu st ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow -up 
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.  
8.2.3  Immediate reporting of AEs  
The following AEs must be reported immediately:  
• SAE: AEs that the investigator classifies as serious by the above definitions, regardless of 
causality.  
• Suspected transmission of an infectious agent via a medicinal product.  
• AEs of special interest (as defined in Section 8.2.2 ). 
8.2.4  Procedures for reporting serious adverse events  
If an SAE is report ed, UCB BIOSCIENCES must be informed within 24 hours of receipt of this 
information by the site (see contact details for SAE reporting listed in the Study Contact 
Information section). The investigator must forward to UCB BIOSCIENCES (or its 
representative ) a duly completed Investigator SAE Report form provided by UCB 
BIOSCIENCES, even if the data are incomplete, or if it is obvious that more data will be needed 
in order to draw any conclusions. Information recorded on this form will be entered into the 
global safety database.  
A copy of the Investigator SAE Report form will be provided to the investigator. The 
Investigator SAE Report form must be completed in English.  
Additional information (eg, autopsy or laboratory reports) received by the investigator mus t be 
provided within 24 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report form.  
The reference document for  the assessment of the expectedness of the SAEs is the Investigator 
Brochure.  
8.2.5  Follow up of serious adverse events  
A SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant , or the subject is lost to follow up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events are provided in Section 8.3.2.4 . 
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety database without limitation of time.  
8.2.6  Anticipated serious adverse events  
The following list of antici pated SAEs is anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. This list does not change the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 51 of 324 investigator’s obligation to report all SAEs (including anticipated SAEs) as detailed in 
Section 8.2.4 . 
Anticipated SAEs for the pediatric epilepsy population  
MedDRA SOC  MedDRA PT  
Congenital, familial and genetic disorders  Teratogenicity  
General disorders and administrative site 
conditions  Sudden unexplained death in epilepsy  
Nervous system disorders  Convulsion  
Incontinence  
Status epilepticus  
Pregnancy, puerperium and perinatal disorders  Abortion spontaneous  
Psychiatric disorders  Psychotic behavior  
Abnormal behavior  
Anxiety  
Sleep disorder  
Reproductive system and breast disorders  Menstrual disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; SOC=system organ 
class  
8.3 Laboratory measurements  
Blood and urine specimens (approximately 5 to 15mL each) for routine assay of hematology, 
clinical chemistry, endocrinology, and urinalysis testing will be collected according to the tabular 
schedule of study procedures, Section  16.1. For subjects aged 5 to 17  years, urine assessments 
will be based on the subject’s ability to void and staff’s ability to collect urine (in an appropriate 
container). A central laboratory will perform the routine analysis of blood and urine samples. 
The procedures for handling and shipping these specimens will be provided to the sites.  
The following laboratory tests will be performed:  
Urinalysis  Hematology  Clinical chemistry  Endocrinology  
Specific gravity  RBC  Total serum 
protein  Cholesterol  FSH 
pH WBC  Albumin  Triglycerides  LH 
Protein  Differential count  Calcium  Total bilirubin  Testosterone  
Glucose  Platelet count  Phosphorus  Alkaline 
phosphatase  TSH  
Ketone  Hemoglobin  Glucose  Creatinine  T3 (total and 
serum -free)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 52 of 324 Urinalysis  Hematology  Clinical chemistry  Endocrinology  
Microscopic exam 
for blood cells for 
casts/hpf  Hematocrit  Serum electrolytes 
(sodium, 
potassium, 
chloride, 
bicarbonate)  AST  
ALT  
GGT  T4 (total and 
serum -free)  
  Uric acid  BUN   
ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea nitrogen; FSH=follicle stimulating hormone; 
GGT=gamma  glutamyl transferase; hpf=high power field; LH=luteinizing hormone; RBC=red blood cells; T 3=triiodothyronine; 
T4=thyroxine; T SH=thyroid stimulating hormone; WBC=white blood cells  
8.3.1  Pregnancy testing  
Females of childbearing potential will have serum and urine pregnancy tests performed during 
the study according to the tabular schedule of study procedures, Section  16.1. 
8.3.2  Liver function tests and evaluation of PDILI  
The PDILI IMP discontinuation criteria for this study are provided in Section 4.3.3.1 with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor withi n 24 hours of learning 
of their occurrence. Any PDILI event that meets the criterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 8.2.2 ), and, if applicable, also reported as an 
SAE (see Section 8.2.1 ).  
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  8‒1 (specific tests dependent on laboratory results a nd corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 8.3.2.1 ). The local 
hepatologist is the e xpert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section  8.3.2.4 ).  
The results of all monitoring, including  laboratory testing and other testing, should be made 
available to the study site and sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whenever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative appro ach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laboratory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplemen ts that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose reduction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known t o be hepatotoxic to a suitable 
alternative.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 53 of 324 When IMP is stopped due to PDILI (as described in Section 4.3.3.1 ), IMP must be permanently 
discontinued.  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
The table below summarizes the approach to investigate PDILI.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 54 of 324 Table  8‒1: Required investigations and follow up of PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology consult.c 
Medical Monitor 
must be notified 
within 24  hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section  8.3.2.3 ); 
recommended to 
occur at the site 
with HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d 
 ≥5xULN  NA NA 
≥3xULN  NA Yes 
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  8.3.2.2 ). Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 55 of 324 Table  8‒1: Required investigations and follow up of PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥5xULN 
(and ≥2x 
Baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48  hours 
at the site with 
HCP (see 
Section  8.3.2.3 ) Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d 
 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms  include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophili a (>5%), 
rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medical Mon itor. 
.c Details provided in Section  8.3.2.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of potential  
hepatic disease. This would usually be a hepatol ogist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by the investigator and UCB responsible physician. Determination of stabi lization is at the discretio n of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 56 of 324 8.3.2.1  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discusse d with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined  necessary, this discussion should be followed by a full 
hepatology assessment (see Section 8.3.2.3 ) and SAE report (if applicable).  
8.3.2.2  Immediate action: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP ( followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 4.3.3.1  and Table  8‒1 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The investigator should also con sider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.  
8.3.2.3  Testing: identification/exclusion of alternative etiology  
The measure ments and additional information required for the assessment of PDILI events when 
there is a reasonable possibility  that they may have been caused by the IMP are detailed in 
Table  8‒2 (laboratory measurements) and Table  8‒3 (additional information). Results of the 
laboratory measurements and informatio n collected are to be submitted to the sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
assessments not included below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.  
The following measurements are to be assessed:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 57 of 324 Table  8‒2: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Hematocrit  
Hemoglobin  
Platelet count  
RBC count  
WBC count  
WBC differential count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
ALT  
AST  
ALP  
GGT  
Albumin  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 58 of 324 ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase; GGT=gamma -glutamyltransferase; HBcAb -IgM=hepatitis B core antibody -IgM; HBsAg=hepatitis 
B surface antigen; IgM=immunoglobulin M; INR=interna tional normalized ratio; LDH=lactate dehydrogenase; 
PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RBC=red blood cell; RNA=ribonucleic acid; 
ULN=upper limit of normal; WBC=white blood cell  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity sympto ms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
The following additional information is to be collected:  
Table  8‒3: PDILI information to b e collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
• History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver disease”)  
• Adverse reactions to drugs  
• Allergies  
• Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
• Recent travel  
• Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensiti vity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
 
8.3.2.4  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in  
Table  8‒1. Monitoring shoul d continue until liver chemistry values normalize, stabilize, or return 
to Baseline. Determination of stabilization is at the discretion of the investigator in consultation 
with the hepatologist (as applicable) and UCB responsible physician, as needed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 59 of 324 8.4 Other measurements  
8.4.1  Physical examination  
Physical examinations will be performed by medically qualified clinicians licensed to perform 
the examination according to the tabular schedule of study procedures, Section  16.1. Height will 
be measured without shoes ac cording to the tabular schedule of study procedures, Section  16.1. 
8.4.1.1  Complete physical examination  
The complete physical examination will include cardiac and respiratory function via 
auscultation, temperature, and review of all body systems.  
8.4.1.2  Brief physical examination  
The brief physical examination will includes a review of the following body systems:  
• Cardiovascular  
• Pulmonary  
• Abdominal (hepato -gastrointestinal)  
• Dermatologic  
8.4.2  Neurological examination  
The neurological examination will be performed according to the tabular schedule of study 
procedures, Section  16.1. The neurological examination should be conducted by a medically 
qualified clinician with documented training in the conduct of neurological examinations. If 
possible, the same clinician should conduct  all neurological examinations for the same subject 
during the study. The investigator or subinvestigator is responsible for confirming the diagnosis 
of partial -onset seizures or other epilepsy syndrome.  
8.4.2.1  Complete neurological examination  
The complete neuro logical examination will include selected assessment of mental status, 
sensory systems, motor functions, cranial nerves, reflexes, and coordination/cerebellar function.  
8.4.2.2  Brief neurological examination  
The brief neurological examination will include selected  assessment of mental status, cranial 
nerves, and coordination/cerebellar function.  
8.4.3  Vital signs and body weight  
Noninvasive blood pressure (systolic and diastolic) and pulse rate will be measured at all visits in 
a sitting position after at least 3 minutes  at rest. Body weight will be determined without shoes 
and wearing light clothing, according to the tabular schedule of study procedures, Section  16.1. 
8.4.4  12-lead ECG  
Standard 12 -lead ECGs will be performed according to the tabular schedule of study procedures, 
Section  16.1, and as described in Section  5. 
All subjects will be required to have a 12 -lead ECG (2  interpretable recordings approximately 
20 to 30  minutes apart) conducted at LCM C max 1 week after an initial LCM dose increase to a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 60 of 324 LCM dose level that is ≥8mg/kg/day or when a new concomitant AED is introduced. This ECG 
can be conducted at an Unscheduled Visit, if necessary. Subjects having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. 
Subjects will be administered their m orning LCM dose by study personnel at the clinic so that an 
ECG (2  interpretable recordings approximately 20  to 30  minutes apart prior to vital signs 
assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, at LCM 
steady state  Cmax). 
Care should be taken to assure proper lead placement and quality of ECG recording. Subjects 
should rest in a supine position at least 5  minutes prior to each recording and should be 
motionless during the recording.  
8.4.4.1  Overall ECG interpretation  
An imm ediate initial review of the ECGs will be conducted locally by the investigator, 
subinvestigator, or qualified designated reader. If this reading identifies abnormal ECG findings 
that are assessed by the investigator or subinvestigator to be clinically sig nificant, then the ECG 
should be repeated in 1  hour, unless circumstances require a more rapid assessment. If the 
clinically significant abnormality is confirmed by the repeat ECG or if the investigator feels it is 
medically necessary, then the subject mus t be withdrawn from the study (see Section  4.3.3 ). The 
investigator may consult with the cardiologist at the central ECG laboratory to confirm the 
presence of a clinically significant ECG abnormality. It remains the responsibility of the 
investigator to decide whether an ECG finding is of clinical significance on the basis of the 
complete clinical picture and whether this finding influences the subjec t’s participation in the 
study.  
8.4.4.2  Specific QTcB criteria  
The ECG recorder provides a corrected QT interval using the Bazett method (QTcB) for each 
QT interval measurement. The value of the QTcB is used to determine subject eligibility to enter 
and to continu e in the study (as noted in Section  4.3.2  and Section  4.3.3).  
8.4.5  Tanner Stage  
At selected visits for applicable subjects, the investigator or qualifie d designee will evaluate the 
subject’s sexual development using the 3 -item scale. The investigator should use clinical 
judgment in deciding which subjects are selected for evaluation of Tanner Stage (ie, those 
subjects who are pubescent at screening or tho se subjects who become pubescent during the 
course of the study).  
The evaluation of Tanner Stage for applicable subjects will be completed according to the tabular 
schedule of study procedures, Section  16.1. 
8.4.6  Assessment of suicidality  
Suicidality will be assessed by trained study personnel using the C -SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6  years of age, this scale will be used  for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C -SSRS will be 
completed according to the tabular schedule of study procedures, Section  16.1. 
Subjects enrolling directly who are ≥6 years of age will complete the “Baseline/Screening” 
version of the C -SSRS at Visit 1 and will complete the “Since Last Visit” version at subsequent 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 61 of 324 visits. If a subject becomes 6 years of age during the study, the “Already Enrolled” version of the 
C-SSRS should be used at the first visit at which the subject is 6 years of age and the “Since Last 
Visit” version used at subsequent visits.  
The C -SSRS is not validated  and will not be used for subjects <6  years of age. Subjects should 
be monitored for any changes in mood, ideas, or behavior for warning signs of depression. The 
investigator should be aware of common warning signs that might be a signal for risk of 
depres sion. For common signs and symptoms of depression in children younger than 6  years old, 
reference should be made to the current version of the Diagnostic and Statistical Manual of 
Mental Disorders. Parents and caregivers should also be advised accordingly and effort should be 
made at clinic visits to specifically assess potential depression.  
8.4.7  Achenbach CBCL  
The Achenbach CBCL is a widely used validated questionnaire to evaluate a child’s 
competencies and behavioral/emotional problems. Behavioral problems wil l be scored by the 
parent(s)/legal representative(s). Depending on the subject’s age, 2  versions of the CBCL will be 
used. The CBCL/1½ -5 checklist is intended for use in children 18  months to 5  years and 
11 months of age. For subjects ≥6  years to ≤17  years  of age, the CBCL/6 -18 version will be 
used.  
The Achenbach CBCL will be completed according to the tabular schedule of study procedures, 
Section  16.1. 
In both questionnaires, the occurrence of certain problems and behaviors (in the past 2 months 
for the CBCL/1½ -5 version and in the past 6 months for the CBCL/6 -18 version) will be scored 
on the following scale:  
• 0=not true (as far as known)  
• 1=somewhat or sometimes true  
• 2=very true or often true  
Syndrome scores will be calculated from these questions, which will in turn be summarized by 
2 composite scores. Additionally, for each syndrome and c omposite scores, categorizations based 
on a normative sample will be used to evaluate normal, borderline, or clinically relevant 
behavior.  
In addition, the Achenbach CBCL/6 -18 includes ratings related to performance in school, 
activities in leisure time, a nd special interests.  
8.4.8  Bayley Scales of Infant and Toddler Development, Third Edition  
The Bayley -III scales are recognized internationally as one of the most comprehensive 
developmental assessment instruments (Sattler and Hoge, 2006) used to examine the maj or 
facets of a young child’s development (Bayley, 2006). The Bayley Scales of Infant and Toddler 
Development, Third Edition (Bayley -III) are a standardized individually administered adaptive 
assessment that measures the developmental functioning of infants  and young children from 
1 month to 42  months of age (Bayley, 2006). The Bayley -III scales measure cognitive, language, 
motor, social -emotional, and adaptive development and are a revision of the predecessor, the 
Bayley Scales of Infant Development, Second  Edition (BSID -II) (Bayley, 1993). The Bayley -III 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 62 of 324 scales are a technically sound instrument, with strong internal consistency, as well as test -retest 
stability. The Bayley -III scales are validated only in English.  
This scale is validated as a tool for asse ssment of neurological development in young children 
and is therefore considered appropriate for SP848.  
The Bayley -III scales are an individually administered adaptive assessment that presents children 
with situations and tasks designed to produce an obser vable set of behavioral responses. They 
consist of a cognitive scale, a language composite scale with receptive and expressive language 
subscales, and a motor composite scale with fine and gross motor subscales to be completed by 
the Investigator or design ee, and of a social -emotional scale, comprising social emotional 
competence, and sensory processing, and an adaptive behavior scale, which assesses the 
attainment of skills necessary for the development of independence, to be completed by the 
child’s paren t or caregiver.  
The completion of the Bayley -III scales will require approximately 50  minutes for children who 
are 12  months old or younger and 90  minutes for children aged 13  months and older.  
The Bayley -III scales will be completed according to the tabu lar schedule of study procedures, 
Section  16.1. 
8.4.9  Palatability and ease of use questionnaire for LCM  
UCB BIOSCIENCES has created a palatability and ea se of use questionnaire to collect data from 
the subject or caregiver regarding different aspects of LCM and its administration. The 
questionnaire will assess the subject or caregiver’s response regarding the formulation of LCM 
the subject is receiving for  palatability items (eg, taste, smell, ability to swallow, aftertaste), 
mode of administration, and administration device as applicable.  
The questionnaire will be completed according to the tabular schedule of study procedures, 
Section  16.1. 
8.4.10  Behavior Rating Inventory of Executive Function  
The BRIEF -P and the BRIEF are validated tools that will be used for the evaluation of subjects 
≥2 years to <5  years of age and ≥5  years of age, respectively. The BRIEF -P/BRIEF will be 
administered according to the tabular schedule of study procedures, Section  16.1. 
The BRIEF -P and BRIEF include rating forms used by parents to assess subjects’ executive 
functioning. Executive functions broadly encompass a set of cognitive skills that are responsible 
for the planning, initiation, sequencing, and monitoring of compl ex goal -directed behavior.  
The BRIEF -P rating form consists of items that measure various aspects of executive 
functioning: Inhibit, Shift, Emotional Control, Working Memory, and Plan/Organize. The 
clinical scales form 3  broad indexes (Inhibitory Self -Cont rol, Flexibility, and Emergent 
Metacognition) and 1  composite score (Global Executive Composite).  
The BRIEF rating form consists of items that measure various aspects of executive functioning: 
Inhibit, Shift, Emotional Control, Initiate, Working Memory, Pl an/Organize, Organization of 
materials, and Monitor. These clinical scales form 2  broader Indexes: Behavioral Regulation 
(3 scales) and Metacognition (5  scales), as well as a Global Executive Composite score.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 63 of 324 Both the BRIEF -P and the BRIEF include validity  scales to measure negativity and 
inconsistency of responses.  
9 MANUFACTURING, HANDLING, AND ACCOUNTABILITY OF 
STUDY MEDICATION  
9.1 Manufacturing, packaging, and labeling  
Lacosamide is manufactured, packaged, and labeled according to Good Manufacturing Practice 
guidelines and applicable laws and regulations. It is suitably packaged, in such a way as to 
protect the product from deterioration during transport and storage.  
Description of packaging:  
Lacosamide oral solution (syrup) will be packaged in 200mL amber PET  bottles with a white, 
child -proof, polypropylene screw cap. Different volumes of LCM syrup will be taken to obtain 
the appropriate dose.  
Lacosamide tablets will be packaged in high-density polyethylene bottles with a child -proof, 
polypropylene screw cap.   
Contents of the labels:  
The labels for LCM will include the following information (not all information will appear on all 
labels):  
• Sponsor name, address, and telephone number  
• Statement “Caution: New drug – Limited by federal law to investigational use”  
• Statement “For clinical trial use only”  
• Study number  
• Kit number  
• Pharmaceutical dosage form  
• Name of drug  
• Route of administration  
• Directions for use  
• Date bottle opened  
• Do not use after (date)  
• Strength per unit  
• Quantity of dosage units  
• Batch number  
• Statement “ Keep out of reach of children”  
• Storage conditions  
• Expiry date  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 64 of 324 • Subject number  
• Visit number  
• Date dispensed  
• Name of investigator and telephone number  
• Statement “Return all empty, partially used, and unused product”  
• Statement “Class scheduling as a controlled  substance”  
9.2 Supply, handling, and storage  
Lacosamide (oral solution [syrup] and tablet) is stable at room temperature and is to be stored at 
temperatures not exceeding 25.4°C (77.7°F) or below 14.5°C (58.1°F). Lacosamide should not 
be frozen or refrigerate d. 
The investigator (or designee) is responsible for safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the label.  
Appropria te storage conditions must be ensured either by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time interval.  
In case an  out-of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
The investigator (or designee) will instruct the subject to store the IMP following the instructions 
on the label.  
9.3 Drug accountabi lity procedures  
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastag e), not used, partially used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to  review.  
The investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of LCM until returned or destroyed by a UCB representative.  
The investigator may assign some of the investigator’s duties for drug accounta bility at the study 
site to an appropriate pharmacist/designee.  
The investigator must ensure that LCM is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containe rs)/partially used, unused, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot  be used for any other 
purpose than that described in this protocol.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 65 of 324 9.4 Retrieval/recall of study medication  
Lacosamide being returned following study completion or due to product expiration or defect 
should be returned to UCB BIOSCIENCES or designee for final inventory using the provided 
forms. UCB BIOSCIENCES or designee will oversee destruction of returned drug after the 
clinical study report is completed.  
9.5 Alternative study treatment supply due to COVID -19 pandemic  
When a subject can no longer return t o the study site due to general circumstances but will 
continue in the study, the following methods may be used to provide study treatment:  
• Site to subject: In instances where site staff can ship study treatment dispensed from the site 
pharmacy supply dire ctly to the subject.  
• Depot to subject: In instances where it is not possible for the site staff to access study 
treatment in the site pharmacy and/or ship study treatment dispensed from the site pharmacy 
supply directly to the subject.  
10 DATA QUALITY CONTROL  AND QUALITY ASSURANCE  
10.1 Site qualification  
A site visit will be performed by UCB BIOSCIENCES or designee to discuss the protocol, to 
ensure the availability of appropriate study personnel, adequate resources, and to assess their 
ability to properly conduct the study according to International Council for Harmonisation -Good 
Clinical Practice (ICH -GCP) guidelines and local requirements. These procedures do not need to 
be repeated for this extension study (if a site needs to be added to SP848 that did not parti cipate 
in SP847, an assessment will be made to determine whether a site visit is required).  
10.2 Monitoring  
UCB BIOSCIENCES or designee will monitor the study to meet the Sponsor’s monitoring 
standard operating procedures (SOPs), ICH -GCP guideline, and applicab le regulatory 
requirements and to ensure that study initiation, conduct, and closure are adequate. Monitoring of 
the study may be delegated by UCB BIOSCIENCES to a CRO or a contract monitor.  
The investigator and his/her staff will be expected to cooperate with UCB BIOSCIENCES 
personnel or agents of UCB BIOSCIENCES and to be available during the monitoring visits to 
answer questions sufficiently and to provide any missing information.  
The investigator(s)/institution(s) will permit direct access to source dat a/documents for 
study -related monitoring, audits, IRB/IEC review, and regulatory inspections.  
10.2.1  Definition of source data  
All source documents must be accurate, legible, clear, unambiguous, permanent, and capable of 
being audited. They should be made using s ome permanent form of recording (ink, typing, 
printing, optical disc). They should not be obscured by correcting fluid or have temporary 
attachments (such as removable self -stick notes). Photocopies of CRF forms are not considered 
acceptable source documen ts. 
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/physician records, charts, diaries, x -rays, laboratory results, printouts, pharmacy 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 66 of 324 records, care records, ECG or other printouts, completed scales, or Quality of Life 
Questionnaires, for example. Source documents should be kept in a secure, limited access area.  
Source documents that are computer generated and stored electronically must be printed for 
review by the monitor (eg, ECG reports). On ce printed, these copies should be signed and dated 
by the investigator and become a permanent part of the subject’s source documents. The 
investigator will authorize the monitor to compare the content of the printout and the data stored 
in the computer to  ensure all data are consistent.  
Electronic data records, such as Holter monitor records or EEG records, must be saved and 
stored as instructed by UCB BIOSCIENCES (or designee).  
10.2.2  Source data verification  
Source data verification ensures accuracy and credibi lity of the data obtained. During monitoring 
visits, reported data are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg, subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory  notes). All data reported on the eCRF should be supported by source 
documents.  
10.3 Auditing  
The investigator will permit study -related audits mandated by UCB, and inspections by domestic 
or foreign regulatory authorities.  
The main purposes of an audit or insp ection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, that enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.  
The investigator will provide direct access to all study documents,  source records, and source 
data. If an inspection by a regulatory authority is announced, the investigator will immediately 
inform UCB (or designee).  
11 DATA HANDLING AND RECORD KEEPING  
The parent/legal guardian’s consent, subject’s assent, and enrollment in  the study must be 
recorded in the subject’s medical record. These data should identify the study and document the 
dates of the subject’s participation.  
11.1 Case Report form completion  
This study is performed using remote data capture (RDC); the investigator i s responsible for 
prompt reporting of accurate, complete, and legible data in the eCRFs and in all required reports. 
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change. Corrections made after the investigator’s  review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator. The investigator should 
maintain a list of personnel authorized to enter data into the eCRF. Detailed instructions will be 
provided in the eCRF Compl etion Guidelines.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 67 of 324 11.2 Database entry and reconciliation  
Electronic Case Report forms/external electronic data will be entered/loaded into a validated 
electronic database using a clinical data management system (CDMS). Computerized data 
cleaning checks will be used in addition to manual review to check for discrepancies and to 
ensure consistency of the data. This study is performed using RDC; the data are entered into the 
eCRFs once and are subsequently verified. An electronic audit trail system will be maintain ed 
within the CDMS to track all data changes in the database once the data have been saved initially 
into the system or electronically loaded. Regular backups of the electronic data will be 
performed.  
11.3 Subject Screening and Enrollment log/Subject Identifica tion 
Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
log.  
The investigator will keep a Subject Identification Code list. This list remains with the 
investigator and is used for unambiguous identifi cation of each subject.  
11.4 Archiving and data retention  
The investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, i nformation regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no p ending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applic able regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any s tudy records. The investigator will also notify UCB should he/she 
relocate or move the study -related files to a location other than that specified in the sponsor’s 
trial master file.  
11.5 Data management  
Details regarding data management will be elaborated in t he study -specific Data Management 
Manual.  
12 STATISTICS  
This study has an explorative, descriptive aim and does not intend to prove or disprove any 
statistical hypotheses. Hence, inferential statistical tests are not planned for the primary and 
secondary vari ables described below.  
12.1 Description of statistical methods  
Descriptive statistics will be used to provide an overview of the study results. For categorical 
parameters, these will consist of the number and percentage of subjects in each category. The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 68 of 324 denomin ator for percentages will be based on the number of subjects appropriate for the purpose 
of analysis. For continuous parameters, descriptive statistics will include the number of subjects 
(n), mean, standard deviation (SD), median, minimum, and maximum.  
Visit 1 of SP847 (or other primary study as applicable) or the Screening Visit of SP848 (for 
subjects who enter directly into SP848) will serve as Baseline values for safety and efficacy 
variables unless otherwise noted.  
Further statistical methods are presented below, and will be described in more detail in the 
Statistical Analysis Plan.  
12.1.1  Definition of analysis sets  
The Safety Set (SS), which is defined as all enrolled subjects who take at least 1  dose of LCM in 
this study. All safety analyses will be pe rformed on the SS.  
The Pharmacokinetic Per -Protocol Set (PK -PPS) will consist of all subjects from the SS having 
provided at least 1 measurable post -dose plasma sample (with recorded sampling time) on at 
least 1 visit with documented LCM intake times.  
The Full Analysis Set (FAS) will be used for the analysis of seizure data and will consist of all 
subjects in the SS, who have at least 1 completed post -Baseline seizure diary.  
12.1.2  Statistical analysis of safety variables  
12.1.2.1  Primary safety variables  
The primary vari ables, for assessment of safety and tolerability, are the incidence of TE AEs and 
the incidence of SAEs.  
12.1.2.1.1  AEs 
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®), and tabulated by system organ class and preferred te rm. 
Treatment -emergent AEs will be defined as those events which started on or after the date of first 
SP848 LCM administration, or whose severity worsened on or after the date of first SP848 LCM 
administration. Adverse events occurring within 30 days afte r last dose of LCM will be 
considered treatment -emergent. The incidence of TEAEs will be presented by system organ class 
and preferred term. Serious AEs will also be tabulated and listed.  
12.1.2.2  Other safety variables  
The other safety variables include changes in  laboratory parameters (ie, hematology, clinical 
chemistry, endocrinology, and urinalysis), 12 -lead ECG measurements, vital sign measurements 
(blood pressure and pulse rate), physical and neurological exam findings, body weight, height, 
calculated BMI, and  Tanner Stage (if applicable). The actual measurement and its change from 
Baseline (SP847 [or other primary study as applicable] Visit 1) or the Screening Visit (for 
subjects who entered directly into SP848) will be analyzed descriptively and presented by visit. 
In addition, shift tables may be used to evaluate the number and percentage of subjects having a 
different post -Baseline status when compared with their Baseline status.  
The shift from Baseline to the subject’s last visit at which a physical and/or neurological 
examination was performed post -Baseline will be summarized by category.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 69 of 324 Laboratory, ECG, and vital signs data outside of the respective reference ranges will be listed 
and highlighted.  
Changes in behavior and development from Baseline as measu red using the Achenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
children <18 months of age will be summarized descriptively and presented by visit. Changes in 
cognitive function as measured using the BRIEF -P/BRIEF will be summarized by descriptive 
statistics at each visit. Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy 
studies. Baseline values for subjects who enroll directly into SP848 will be taken from the 
Screening Visit.  
12.1.2.2.1  Palata bility and ease of use questionnaire  
Data from the palatability and ease of use questionnaire will be summarized descriptively at each 
visit where it is assessed.  
12.1.3  Statistical analysis of PK variables  
12.1.3.1  Descriptive statistics  
Descriptive summaries (n, mean, S D, coefficient of variation (CV), median, minimum, and 
maximum) for the LCM plasma concentration and the plasma concentrations for selected 
concomitant AEDs will be presented by visit and actual dose.  
12.1.3.2  Population PK analysis  
The plasma concentration data o f SP848 will be included in a population PK model of LCM, 
using the LCM plasma concentrations and dosing records, as well as demographic covariates and 
the presence of concomitant AEDs.  
Further details will be described in the Statistical Analysis Plan or in a separate Population PK 
analysis plan.  
12.1.4  Statistical analysis of efficacy variables  
12.1.4.1  Secondary efficacy variables  
12.1.4.1.1  Percent change from Baseline in 28 -day partial -onset seizure 
frequency  
Seizure frequency will be assessed using seizure diaries in order to evaluate the preliminary 
efficacy of LCM in this population. Seizure frequency per 28  days will be calculated as ([number 
of seizures over the specified time interval]) divided by [number of days in the interval]) 
multiplied by 28  and summarized descriptiv ely for the overall Treatment Period.  
12.1.4.1.2  ≥50% reduction in 28 -day partial -onset seizure frequency  
For subjects with POS, the number and percentage with ≥50% reduction in 28 -day partial -onset 
seizure frequency (≥50% responders) will be summarized for the overall Treatment Period.  
12.1.4.1.3  ≥75% reduction in 28 -day partial -onset seizure frequency  
For subjects wit h POS, the number and percentage with ≥75% reduction in 28 -day partial -onset 
seizure frequency (≥75% responders) will be summarized for the overall Treatment Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 70 of 324 12.1.4.1.4  Seizure days per 28 days (subjects with generalized seizures only)  
For subjects with gene ralized seizures, the number of seizure days per 28  days will be 
summarized descriptively for the overall Treatment Period . 
12.1.4.1.5  Seizure -free status  
The number and percentage of subjects achieving a seizure -free status for the overall Treatment 
Period will be p resented.  
12.1.4.2  Other efficacy variables  
12.1.4.2.1  Clinical Global Impression of Change and Caregiver Global 
Impression of Change  
The number and percentage of subjects with each Clinical Global Impression of Change and 
Caregiver Global Impression of Change value will be s ummarized at each visit in which they are 
assessed and grouped by dose.  
12.1.4.2.2  PedsQL  
The PedsQL score and change from Baseline scores will be analyzed in a descriptive manner. 
Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy studies. Base line values 
for subjects who enroll directly into SP848 will be taken from the Screening Visit.  
12.1.4.2.3  Health care resource use  
Descriptive statistics will be presented for the number of medical resources used (medications, 
consultations, procedures, hospitalizat ions, and length of hospital stays).  
12.1.4.2.4  Seizure frequency analyses  
All seizure frequency analyses as described in the secondary efficacy variables (Section  12.1.4.1 ) 
may be additionally presented by modal daily dose group, by seizure type, by seizure 
classification subgroup, by time interval, by visit or time period, or by completer cohort. 
Additional det ails will be provided in the Statistical Analysis Plan.  
12.1.5  Handling of protocol violators, drop -outs, and missing values  
All data will be used to their maximum possible extent, but without any imputations for missing 
data for any parameter. Important protocol  deviations will be reviewed as part of the ongoing 
data cleaning process and data evaluation. All important deviations will be identified and 
documented prior to database lock to confirm exclusion from analysis sets.  
Subjects who discontinue from the stud y prematurely will be evaluated based on the data 
collected at each visit attended.  
Protocol deviations (eg, missing assessments or visits) related to COVID -19 will be documented.  
12.1.6  Interim analysis  
No formal interim analysis is planned. However, data will b e reported prior to the completion of 
this study to support annual reports, regulatory submissions, and publications.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 71 of 324 12.2 Determination of sample size  
Approximately 42  subjects from the SP847 study will be eligible to enroll in this open -label 
study. Other sub jects will be eligible to enroll as other LCM pediatric clinical studies in epilepsy 
are undertaken.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age who have not previously participated 
in a LCM clinical study will be permitted to enroll directly into SP848. Beginning with local 
Protocol Amendment 5.2 for sites in Japan, approximately 46  eligible pediatric subjects ≥4  years 
to ≤17  years of age with partial -onset seizures who have not previously received LCM will 
directly enroll at approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 
for sites in China, approximately 60 additional eligible pediatric subjects with partial -onset 
seizures  aged ≥4  years to ≤17 years, who have not previously participated in a LCM clinical 
study, will enroll directly into SP848. The purpose of enrolling these subjects directly into SP848 
is to obtain additional long -term safety exposures in the age range from  which adequate PK data 
have already been obtained in SP847; the additional long -term safety data will be included in 
planned LCM marketing applications for subjects ≥4  years of age.  
Beginning with Protocol Amendment 6, up to 75 eligible pediatric subjects  ≥4 years to <17  years 
of age who have participated in EP0060 will be permitted to enroll into SP848. Protocol 
Amendment 8 allows an enrollment increase from 75 to 100 eligible pediatric subjects ≥1 month 
to ≤17  years of age with epilepsy who participated in EP0060 to enroll in SP848 in order to 
reflect EP0060’s inclusion of subjects down to 1 month of age.  
In total, up to approximately 400 subjects may be eligible to participate in SP848.  
13 ETHICS AND REGULATORY  
13.1 Informed consent  
Informed consent has to be obtained from the subject’s parent/legal guardian and documented in 
accordance with local regulations, ICH -GCP requirements, and the ethical principles that have 
their origin in the principles of the Declaration of Helsinki. When possible or as required 
according to local IRB/IEC, assent also has to be obtained from the subject.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject and/or the subject’s parent/legal guardian in both oral 
and written form by the investigator (or designee). Each subject and/or subject’s parent/legal 
guardian will have the opportunity to discuss the study and its alternatives with the investigator.  
Prior to participation in the study, the written  informed consent form should be signed and 
personally dated by the subject’s parent/legal guardian and by the person who conducted the 
informed consent discussion (investigator or designee). The subject’s parent/legal guardian must 
receive a copy of the s igned and dated informed consent form. As part of the consent process, 
each subject’s parent/legal guardian must consent to direct access to the subject’s medical 
records for study -related monitoring, auditing, IRB/IEC review, and regulatory inspection.  
The informed consent form should be updated or amended whenever new information becomes 
available that may be relevant to the subject. The subject’s parent/legal guardian should then sign 
the revised informed consent form.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 72 of 324 13.2 Notification/submission to relevant  regulatory authority(ies)  
UCB BIOSCIENCES in conjunction with the CRO is responsible for fulfilling all regulatory 
aspects of the study with regard to regulatory submissions/filings.  
13.3 Institutional Review Board/Independent Ethics Committee  
The study will b e conducted under the auspices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
The investigator/UCB BIOSCIENCES will ensure that an appropriately constituted IRB/IEC that 
complies with the requirements of the current ICH -GCP version or applicable country -specific 
regulations will be responsible for the initial and continuing review and approval of the clinical 
study. Prior to initiation of the study , the investigator/UCB BIOSCIENCES will forward copies 
of the protocol, informed consent form, investigator’s brochure, investigator’s curriculum vitae, 
advertisement (if applicable), and all other subject -related documents to be used for the study to 
the IRB/IEC for its review and approval.  
Before initiating a study, the investigator will have written, signed, and dated full approval from 
the responsible IRB/IEC for the protocol.  
The investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, and any protocol deviations, 
to eliminate immediate hazards to subjects.  
The investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, excep t where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the investigator to obtain an expedited review by the IRB/IEC as 
allowed.  
The investigator is specifically requested to collect and report to UCB BIOSCIENCES (or its 
representative) any SAEs (even if the investigator is certain that they are in no way associated 
with the investigational product), up to 30 day s from the end of the study for each subject, and to 
also inform participating subjects of the need to inform the investigator of any AE within this 
period. Adverse events that the investigator thinks may be associated with the investigational 
product must  be reported to UCB BIOSCIENCES regardless of the time between the event and 
the end of the study.  
As part of the IRB/IEC requirements for continuing review of approved studies, the investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC at intervals 
appropriate to the degree of subject risk involved but no less than once per year. The investigator 
should provide a final report to the IRB/IEC following study completion.  
13.3.1  Reporting to ethics committee  
The investigator is respo nsible for reporting to the IRB/IEC (eg, reporting of SAEs) in 
accordance with national or local requirements.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 73 of 324 13.4 Basic principles and appropriate national guidelines  
This protocol will be conducted under the current ICH E6 guideline commonly known as GCP, 
the applicable national requirements, and ethical principles that have their origins in the 
Declaration of Helsinki.  
13.5 Subject privacy  
UCB BIOSCIENCES staff or any designees affirm and uphold the subject’s confidentiality. 
Throughout this study, all data forwa rded to UCB BIOSCIENCES will be identified only by an 
identification number.  
The investigator agrees that representatives of UCB BIOSCIENCES, its designee, 
representatives of the relevant IRB/IEC, or representatives of regulatory authorities will be 
allowe d to review that portion of the subject’s primary medical records that directly concerns this 
study (including, but not limited to, laboratory test result reports, ECG reports, 
admission/discharge summaries for hospital admissions occurring during a subjec t’s study 
participation, and autopsy reports for deaths occurring during the study).  
13.6 Protocol amendments and emergency deviations  
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.  
Other than in an emergency, all items in the protocol and amendment(s) are to be followed 
exactly. If an amendment is required, this must be made in written form and receive appr oval 
according to the appropriate SOP. Protocol amendment(s) will be distributed to investigator(s) 
with instructions. All protocol amendments, except those with only logistical/administrative 
implications will be submitted to the IRB/IEC for review and ap proval prior to implementation 
and to regulatory authorities for approval/notification, as applicable.  
In the event that an emergency or other medical event occurs that requires a protocol deviation, 
the investigator (or designee) must contact UCB BIOSCIEN CES as soon as possible to decide 
whether the subject should continue with the study. The protocol deviation will be documented.  
14 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according to local requirements.  
Finance, insurance, and  publication rights are addressed in separate agreements as appropriate.  
15 REFERENCES  
Aicardi J. Syndromic classification in the management of childhood epilepsy. J Child Neurol. 
1994;9(Suppl 2):2S14 -18. 
Appleton R, Fichtner K, LaMoreaux L, Alexander J, Hals all G, Murray G, et al. Gabapentin as 
add-on therapy in children with refractory partial seizures: a 12 -week, multicentre, double -blind, 
placebo -controlled study: Gabapentin Pediatric Study Group. Epilepsia. 1999;40:1147 -54. 
Bayley N. Bayley Scales of Infa nt Development. 2nd ed. San Antonio: The Psychological 
Corporation; 1993.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 74 of 324 Bayley N. Bayley Scales of Infant and Toddler Development. 3rd ed. San Antonio: Pearson 
Education Inc; 2006.  
Columbia University Medical Center. Columbia -Suicide Severity Rating Scal e (2008). 
http://www.cssrs.columbia.edu/. Accessed 19  Jun 2011.  
Commission on Classification and Terminology of the International League Against Epilepsy. 
Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 
1989;30:389 -99. 
CHMP/EWP/566/98 Guideline on clinical investigation of medicinal products in the treatment of 
epileptic disorders (EMA) Rev 2, 20 Jan 2010.  
Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo -controlled 
trial of lamotrigine ad d-on therapy for partial seizures in children: Lamictal Pediatric Partial 
Seizure Study Group. Neurology. 1999;53:1724 -31. 
Elterman RD, Glauser TA, Wylie E, Reife R, Wu S -C, Pledger G, et al. A double -blind, 
randomized trial of topiramate as adjunctive the rapy for partial -onset seizures in children: 
Topiramate YP Study Group. Neurology. 1999;52:1338 -44. 
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Cent er for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
Food and Drug Administration. Guidance for Industry. Suicidality: Prospective assessment of 
occurrence in clinical trials. US Dept of Health and Human Services, Ce nter for Drug Evaluation 
and Research, 09/2010. Available upon request.  
Food and Drug Administration. Guidance for Industry and Investigators. Safety reporting 
requirements for INDs and BE/BA studies. US Dept of Health and Human Services, Center for 
Drug E valuation and Research, 09/2010. Available upon request.  
Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, et al. on behalf of 
the N159b Study Group. Double -blind placebo -controlled trial of adjunctive levetiracetam in 
pediatric partia l seizures. Neurology. 2006;66:1654 -60. 
Glauser TA, Nigro M, Sachdeo R, Pasteris LA, Weinstein S, Abou -Khalil B, et al. Adjunctive 
therapy with oxcarbazepine in children with partial seizures: the Oxcarbazepine Pediatric Study 
Group. Neurology. 2000;54:223 7-44. 
Hadjiloizou SM, Bourgeois BFD. Antiepileptic drug treatment in children. Expert Rev 
Neurother. 2007;7:179 -193. 
Herman ST, Pedley TA. New options for the treatment of epilepsy. JAMA. 1998;280:693 -4. 
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, S ander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta -analysis. Neurology. 2011; 77(10): 1005 –12. 
Perucca E. Established antiepileptic drugs. Baillieres Clin Neurol. 1996;5:693 -722. 
Rheims S, Ryvlin P. Profile of perampanel and its poten tial in the treatment of partial onset 
seizures. Neuropsychiatr Dis Treat. 2013;9:629 -37. 
Sander JW. New drugs for epilepsy. Curr Opin Neurol. 1998;11:141 -8. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 75 of 324 Sattler JM, Hoge RD. Assessment of children: behavioral, social, and clinical foundations. 5th 
ed. La Mesa: Jerome M Sattler; 2006.  
Varni JW, Limbers CA, Neighbors K, Schulz K, Lieu JE, Heffer RW, et al. The PedsQL™ 
Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants. 
Qual Life Res. 2011;20:45 -55. 
Varni  JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of 
Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 
2001;39:800 -12. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 76 of 324 16 SUPPLEMENTS  
16.1 Tabular schedule of study procedures  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 77 of 324 Table  16‒1: Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh, j  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh, j     X    X X  X  
Blood sample for LCM PKk Xh, j  X   X  X  X X    
Blood sample for concomitant AEDsk Xh, j  X   X  X  X X    
Urinalysis (subjects aged 5 to 17  years)  Xh, j     X    X X  X  
Pregnancy testl Xh, j, S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagem Xh, j        X  X    
Clinical GIC  Xh, j     X    X X    
Caregiver GIC  Xh, j     X    X X    
Palatability and ease of use 
questionnaire        X   X X    
Dispense LCM  X  X X X X X X X X Xn Xo   
LCM return/compliance    X X X X X X X X X Xo X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 78 of 324 Table  16‒1: Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
C-SSRSp Xh  X X X X X X X X X Xq X  
Achenbach CBCL  X     X    X X    
Bayley -III scales  X     X    X X    
BRIEF -P/BRIEF  X     X    X X    
PedsQL  X     X    X X    
AE reportingr Xh X X X X X X X X X X X X X 
Health care resource use  X  X X X X X X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; SAE= serious adverse event; U=urine; 
Unsch=Unscheduled; V=Visit  
Note: All subjects who directly enrolled into SP848 should follow the titration schedule in Table  16‒3.  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b For subjects  who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), Visit 1 is also the last visit of the p rimary study. At Visit 1, 
the informed consent will be signed (and assent, if applicable) and eligibility assessed, the medical hi story will be updated, body weight and height and 
concomitant medications including AEDs will be recorded, AEs will be assessed, and the subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be perf ormed at the investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between schedul ed clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be r ecorded at an Unscheduled Visit.  
f Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 
2 weeks after the final dose of study medication . The Final Visit is not required for subjects who participate in EP0151 or EP0152.  
g This TC occurs 28  to 35 days after the last dose of LCM. The Safety Follow -Up TC is not required for subjects who participate in EP0151 or EP0152.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 79 of 324 h For subjects enrolling from SP847 or other LCM  pediatric clinical studies in epilepsy, assessments may have been done as part of the last visit of the primary 
study. For subjects enrolling directly into SP848, these assessments should be completed at Visit 1.  
i All subjects will be required to have a 12-lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM 
dose level that is ≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjec ts having a 
LCM dose increase to ≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects  will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recording s approximately 20 to 30  minutes apart prior to vital signs 
assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
j For subjects enrolling from EP0060, these assessments should be completed at Vis it 1. 
k Blood samples may be drawn at any time post -dosing with LCM.  
l For female subjects of childbearing potential, serum pregnancy tests will be performed at Visit 1, the Early Termination Visi t, and the Final Visit. Urine 
pregnancy tests will be perfor med at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
m The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
n Lacosamide for taper will be dispensed only for subjects who achieve a  dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (t ablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted aft er 
discussion with the medical monitor, whenever possible.  
o As applicable.  
p For all subjects ≥6  years of age already enrolled, t he “already enrolled” version should be completed at the next clinic visit, and the “since last visit” version 
should be completed thereafter.  
q The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
r Ongoing AEs from the prim ary study will be followed, as well as recording of new AEs during the current study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 80 of 324 Table  16‒2: Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -
Up 
Visita V10 TCb V11 V12 V13/ 
TermV  ETVc Unsch 
Visitd Final 
Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam (complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PK  Xh  Xh Xh Xh Xi Xi   
Blood sample for concomitant 
AEDs       Xi Xi   
Urinalysis (subjects aged 5 to 
17 years)    X  X X  X  
Pregnancy testj XU  XU XU XU XS  XS  
Tanner  Stagek     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Palatability and ease of use 
questionnaire    X  X X    
Dispense LCM  X  X X Xl Xl Xm   
LCM return/compliance  X  X X X X Xm X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 81 of 324 Table  16‒2: Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -
Up 
Visita V10 TCb V11 V12 V13/ 
TermV  ETVc Unsch 
Visitd Final 
Visite TCf 
Weeks in study  60  72 84 96     
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
C-SSRSn X  X X X X Xo X  
Achenbach CBCL    X  X X    
Bayley -III scales    X  X X    
BRIEF -P/BRIEF    X  X X    
PedsQL    X  X X    
AE reporting X X X X X X X X X 
Health care resource use  X  X X X X X X  
AE=adverse event; AED=antiepileptic drug;  C-SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; TermV=Termination Visit;  U=urine; 
Unsch=Unscheduled; V= Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between schedul ed clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 
2 weeks after the final dose of study medication . The Final Visit is not required for s ubjects who participate in EP0151 or EP0152.  
f This TC occurs 28 -35 days after the last dose of LCM. The Safety Follow -Up TC is not required for subjects who participate in EP0151 or EP0152.  
g All subjects will be required to have a 12 -lead ECG (2  interpre table recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a  LCM 
dose level that is ≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects having a 
LCM dose in crease to ≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be ad ministered their 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 82 of 324 morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings approximately 20 to 3 0 minutes apart prior to vital signs 
assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
h Blood sample for LCM PK will be routinely collected for subjects enrolled at sites in Japan. Blood samp les may be drawn at any time post -dosing with LCM.  
i Blood samples for LCM and concomitant other AEDs may be collected at an Unscheduled Visit or Early Termination Visit if the v isit is related to an ongoing 
SAE.  
j For female subjects of childbearing poten tial, serum pregnancy tests will be performed at the Early Termination Visit and at the Final Visit. Urine pregnancy 
tests will be performed at Visits 10, 11, 12, and 13.  
k The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 o r who will enter puberty during the course of the study.  
l Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥30 0mg/day (tablet). It is 
recommended that the LCM dose be tapered gradual ly in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is permitted after  
discussion with the medical monitor, whenever possible.  
m As applicable.  
n For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version 
should be completed thereafter.  
o The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 83 of 324 Table  16‒3: Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling 
directly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
Informed Consent  X       
Inclusion/exclusion criteria  X       
Medical history  X       
Seizure history  X       
Concomitant medications  X X X X X X X 
Concomitant AEDs  X X X X X X X 
Physical exam (complete)  X       
Physical exam (brief)   X X X X X X 
Neurological exam  (complete)  X       
Neurological exam (brief)   X X X X X X 
12-lead ECGa X X X X X X X 
Blood pressure and pulse  X X X X X X X 
Body weight  X X X X X X X 
Height  X       
Clinical chemistry and hematology blood 
sample  X    X   
Endocrinology blood sample  X    X   
Urinalysis (subjects aged 5 to 17  years)  X    X   
Pregnancy testb X       
Tanner Stage  X       
Clinical GIC         
Caregiver GIC         
Dispense LCM   X X X X X X 
LCM return/compliance   X X X X X X 
Dispense diary  X X X X X X X 
Diary assessment   X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 84 of 324 Table  16‒3: Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling 
directly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
C-SSRSc X X X X X X X 
Achenbach CBCL  X       
Bayley -III scales  X       
BRIEF -P/BRIEF  X       
PedsQL  X       
AE reporting X X X X X X X 
Health care resource use  X X X X X X X 
AE=adverse event; AEDs=antiepileptic drugs; C max=maximum plasma concentration; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; GIC=Global Impression of Change; LCM=lacosamide  
a All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered their morning LCM dose by study  personnel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs asses sment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
b For female subjects of childbearing potential, serum pregnancy tests will be performed at the Screening Visit.  
c For all subjects ≥6  years of ag e already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since last visit” v ersion should be 
completed thereafter.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 85 of 324 16.2 International Classification of Epileptic Se izures (1981)  
Adapted from the International Classification of Epileptic Seizures (1981)  
I. Partial seizures (focal, local)  
A. Simple partial seizures (consciousness not impaired)  
1. With motor signs  
2. With somatosensory or special sensory symptoms (simple hallucinations, 
eg, tingling, light flashes, buzzing)  
3. With autonomic symptoms or signs (including epigastric sensation, pallor, sweating, 
flushing, piloerection, and pupillary dilatation)  
4. With psychic symptoms (disturbance of higher cerebral function). The se symptoms 
rarely occur without impairment of consciousness and are much more commonly 
experienced as complex partial seizures.  
B. Complex partial seizures (with impairment of consciousness: may sometimes  begin 
with simple symptomatology)  
C. Partial seizures ev olving to secondarily generalized seizures (this may be generalized 
tonic -clonic, tonic, or clonic)  
II. Generalized seizures (convulsive or non -convulsive)  
A. Absence seizures  
B. Myoclonic seizures - Myoclonic jerks (single or multiple)  
C. Clonic seizures  
D. Tonic seizure s 
E. Tonic -clonic seizures  
F. Atonic seizures - (Astatic)  
Unclassified epileptic seizures  
Includes all seizures that cannot be classified because of inadequate or incomplete data and some 
that defy classification in hitherto described categories. This includes some neonatal seizures, 
eg, rhythmic eye movements, chewing, and swimming movements.  
Status epilepticus  (prolonged partial or generalized seizures without recovery between attacks)  
Commission on Classification and Terminology of the International League Ag ainst Epilepsy. 
Proposal for revised clinical and electroencephalographic classification of epileptic seizures. 
Epilepsia. 1981; 22:489 -501. 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 86 of 324 17 APPENDICES  
17.1 PROTOCOL AMENDMENT 1  
Rationale for the Amendment  
The AEs of special interest were revised to reflect t he Sponsor’s current understanding of the 
potential risks of LCM based on a comprehensive review of the data from clinical trials and 
commitments to regulatory agencies.  
The LFT withdrawal criteria were revised to reflect the Sponsor’s current understandin g of the 
safety profile of LCM based on a comprehensive review of the data from clinical trials.  
The remainder of the changes in this amendment are administrative and are described in detail 
below.  
MODIFICATIONS/CHANGES  
• The title and contact information of  the Medical Director (Medical Therapeutics) and 
Associate Medical Director (Drug Safety) were updated.  
• For clarification, updated dose reduction wording as follows: the investigator may decrease 
the dose of LCM to a minimum of 2mg/kg/day (oral solution [s yrup]) or 100mg/day (tablet).  
• For clarification, text was added indicating that incomplete doses should not be 
readministered (Section 4.4.1 Treatments to be administered).  
• For Unscheduled Visits (Section 5.16) added text to discuss LCM dose increase betwe en 
scheduled visits.  
• For Unscheduled Visits (Section 5.16 Unscheduled Visit(s) and Section 16.1 [Tables 1 to 2]) 
in regards to dispensing LCM and LCM return/compliance, “as applicable” was added.  
• Revised text regarding safety signal detection (Section 8.1. 8 Safety signal detection in 
ongoing clinical studies and Data Monitoring Committees).  
• Revised text regarding AEs of special interest (Section 8.2.2 AEs of Special Interest) and 
immediate reporting of AEs (Section 8.2.3 Immediate reporting of AEs).  
• Revise d text on ability to collect and provide urine samples (Section 8.3 Laboratory 
measurements).  
• Revised text regarding liver function tests (Section 8.3.1 Liver function tests).  
• Text was revised to indicate that Tanner staging is performed for applicable sub jects at 
scheduled visits (Section  8.4.5 Tanner Stage).  
• The tabular schedules of trial procedures were updated to reflect the changes to the protocol.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 87 of 324 REFERENCE  
Clinical Trial Protocol, Contact information for the Senior Medical Director (Medical 
Therapeut ics) and Associate Medical Director (Drug Safety). Page 3. Original text:  
Senior Medical Director (Medical Therapeutics) : 
Name:   MD, PhD  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Associate Medical Director (Drug Safety) : 
Name:   MD 
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 88 of 324 Was revised as follows:  
Medical Director (Medical Therapeutics) : 
Name:  , MD  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Associate Medical Director (Drug Safety) : 
Name:  , MD  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
Clinical Trial Protocol, Section 1 (Summary). Page 10; paragraph 1 (third sentence) and 
paragraph 2 (second sentence). Original text:  
Paragraph 1:  
The study will also provide  continued availability of LCM to subjects who have completed the 
SP847 epilepsy study and to subjects who have discontinued from SP847 due to a second dose 
reduction or status epilepticus, and who, in the investigator’s opinion, would benefit from 
long-term administration of LCM.  
Paragraph 2:  
Subjects who discontinued from SP847 due to a second dose reduction or status epilepticus, but 
for whom it is determined medically appropriate to enter this open -label extension study, will 
also begin on the LCM dose they achieved in SP847.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 89 of 324 Was revised as follows:  
Paragraph 1:  
The study will also provide continued availability of LCM to subjects who have completed the 
SP847 epilepsy study and to subjects who have discontinued from SP847 due to a dose reduction 
or statu s epilepticus, and who, in the investigator’s opinion, would benefit from long -term 
administration of LCM.  
Paragraph 2:  
Subjects who discontinued from SP847 due to a dose reduction or status epilepticus, but for 
whom it is determined medically appropriate to enter this open -label extension study, will also 
begin on the LCM dose they achieved in SP847.  
Clinical Trial Protocol, Section 2 (Background Information). Page 12; paragraph 5 (second 
sentence) and paragraph 6 (last  sentence). Original text:  
Paragraph  5: 
A total of 30  children (aged 2 to 17 years) with uncontrolled partial -onset seizures after an 
adequate course of treatment with at least 2  AEDs (concurrently or sequentially) will be enrolled.  
Paragraph 6:  
The study will also provide continued availabi lity of LCM to subjects who have completed the 
SP847 epilepsy study (or discontinued SP847 due to a second dose reduction or status 
epilepticus), and who, in the investigator’s opinion, would benefit from long -term administration 
of LCM.  
Was revised as fol lows:  
Paragraph 5:  
Approximately 30  children (aged 2 to 17 years) with uncontrolled partial -onset seizures on a 
stable dose regimen of at least 1 but no more than 3 AEDs will be enrolled.  
Paragraph 6:  
The study will also provide continued availability of LCM to subjects who have completed the 
SP847 epilepsy study (or discontinued SP847 due to a dose reduction or status epilepticus), and 
who, in the investigator’s opinion, would benefit from long -term administration of LCM.  
Clinical Trial Protocol, Section 3 (Study Objectives). Page 13; last bullet point. Original text:  
• To allow subjects who have completed the SP847 study (or discontinued SP847 due to a 
second dose reduction or status epilepticus) to continue receiving LCM  
Was revised as follows:  
• To allow su bjects who have completed the SP847 study (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 90 of 324 Clinical Trial Protocol, Section 4.1 (Study description). Page 13; paragraph 1 (first sentence) 
Original text:  
Subject s who complete the SP847 study (or discontinue SP847 due to a second dose reduction or 
status epilepticus) and who choose to enter the open -label extension study, will begin on the 
LCM dose they achieved in SP847.  
Was revised as follows:  
Subjects who compl ete the SP847 study (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will begin on the LCM dose 
they achieved in SP847.  
Clinical Trial Protocol, Section 4.3.1 (Inclusion criteria).  Page 14; second bullet point.  
Original text:  
2.  Subject has completed SP847 (or the subject discontinued SP847 due to a second dose 
reduction or status epilepticus) for the treatment of uncontrolled partial -onset seizures.  
Was revised as follows:  
2.  Subject has completed SP847 (or the subject discontinued SP847 due to a dose reduction or 
status epilepticus) for the treatment of uncontrolled partial -onset seizures.  
Clinical Trial Protocol, Section 4.3.2 (Exclusion criteria). Page 14; second bullet point.   
Original text:  
2.  Subject meets the withdrawal criteria for the primary study (SP847) (with the exception of 
subjects who discontinued due to a second dose reduction or status epilepticus), or is 
experiencing an ongoing serious AE (SAE).  
Was revised as follows:  
2.  Subject meets the withdrawal criteria for the primary study (SP847) (with the exception of 
subjects who discontinued due to a dose reduction or status epilepticus), or is experiencing an 
ongoing serious AE (SAE).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 91 of 324 Clinical Trial Protocol, Secti on 4.3.3 (Criteria for withdrawal). Page 15; 10th bullet point.  
Original text:  
10th bullet point:  
10.  Liver function test (LFT) results are above the upper limit of normal (ULN), to the extent 
specified in the table below. Subjects with abnormal LFTs ar e to be followed as specified below.  
Abnormal liver function test results requiring discontinuation from the 
study  
Liver function test result  Action  
Transaminases (AST and/or ALT):  
≥3x to <5x ULN  
And 
Total bilirubin ≥2x ULN  Lacosamide to be discontinued immediately  
 
Liver function tests to be repeated as soon as possible (within 7 days) and 
thereafter as clinically indicated.  
Transaminases (AST and/or ALT):  
≥5x ULN  Lacosamide to be discontinued immediately.  
 
Liver function tests to be repeated as soon as  possible (within 7 days). 
Liver function test monitoring should continue until resolved.  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; ULN=upper limit of normal  
Participation in this study may be discontinued for any of the following reasons:  
1.  Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.  Subject requires a medication that  is not permitted by the protocol.  
3.  Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
4.  Liver function test results are above the ULN, to the extent specified in the table below. 
Subjects with abnormal LFTs are to be followed as specified below.  
Abnormal liver function test results that may require discontinuation from 
the study  
Liver function test result  Action  
Transaminases (AST and/or ALT):  
≥3x to <5x ULN  
And 
Total bilirubin within normal range  Lacosamide discontinuation at investigator discretion . 
 
Confirm results within a few days. If the repeat test confirms the 
abnormality, twice weekly LFT monitoring should continue unt il resolved.  
Transaminases (AST and/or ALT):  
≥3x ULN  Test subject for hepatitis A, B, and C.  
ALT=alanine aminostransferase; AST=aspartate aminotransferase; LFT=liver function test; ULN=upper limit of 
normal  
Was revised as follows:  
10th bullet point:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 92 of 324 10.  In the case of liver function test (LFT) results of transaminases (AST and/or ALT) ≥3x  ULN 
to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST and/or ALT) ≥5x ULN, the 
study medication must be immediately discontinued and the subject withdraw n from the 
study. The LFTs will be repeated as soon as possible, and in no case more than 1 week later.  
Participation in this study may be discontinued for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric conditi on (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the d iary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
Clinical Trial Protocol, Section 4.4.1 (Treatments to be administered). Pages 16; paragraph 1 
(first sentence) and paragraph 2. Original text:  
Paragraph 1:  
Subjects who complete the SP847 study (or discontinue SP847 due to a second dose reduction or 
status epilepticus) and choose to enter the open -label extension study will begin on the LCM 
dose they achieved in SP847.  
Paragraph 2:  
The investigator may increase  the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 8, 10, or 12mg/kg/day (oral solution [syrup]) or 
400, 500, or 600mg/day (tablet), depending on the maximum recommended dose in SP847. The 
investigator may decrease the dose of LCM by 2mg/kg/day (oral solution [syrup]) or 100mg/day 
(tablet) per week to a minimum of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet). 
Increases in the LCM dose must occur only during office visits.  
Was revised  as follows:  
Paragraph 1:  
Subjects who complete the SP847 study (or discontinue SP847 due to a dose reduction or status 
epilepticus) and choose to enter the open -label extension study will begin on the LCM dose they 
achieved in SP847.  
Paragraph 2:  
The inve stigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 8, 10, or 12mg/kg/day (oral solution [syrup]) or 
400, 500, or 600mg/day (tablet), depending on the maximum recommended do se in SP847. The 
investigator may decrease the dose of LCM to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet). Increases in the LCM dose must occur only during office visits. It should 
be noted, in cases of incomplete doses (eg subjec t spits out all or a portion of the syrup), missed 
doses, or administration of an erroneous volume of syrup, study medication should not be 
readministered and these subjects would remain at their assigned dose.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 93 of 324 Clinical Trial Protocol, Section 4.5 (Expecte d duration of study). Page 18; paragraph 1. 
Original text:  
The maximum duration of LCM administration will be approximately 2  years. The trial can be 
terminated by the Sponsor once LCM is commercially available. If LCM is not commercially 
available in a su bject’s country at the time the Sponsor closes the trial, access to LCM will be 
provided according to local laws.  
Was revised as follows:  
The maximum duration of LCM administration will be approximately 2  years.  
Clinical Trial Protocol, Section 4.7 (Proce dures for monitoring subject compliance). Page 19; 
paragraph 2 (removal of last sentence). Original text:  
All findings will be documented on forms provided by SCHWARZ BIOSCIENCES. Subject’s 
noncompliance with regards to intake of LCM is defined as being le ss than 75% or more than 
125% compliant with the dosage schedule. Compliance will be determined by assessment of the 
remaining volume of LCM using a graduated cylinder (oral solution [syrup]) or pill count 
(tablet).  
Was revised as follows:  
All findings wil l be documented on forms provided by SCHWARZ BIOSCIENCES. Subject’s 
noncompliance with regards to intake of LCM is defined as being less than 75% or more than 
125% compliant with the dosage schedule.  
Clinical Trial Protocol, Section 5.1 (Visit 1[Week 0]). Page 19; paragraph 1. Original text:  
For subjects who complete the SP847 study, Visit 1 is the second day of the second inpatient 
hospitalization in SP847 (Day  28 for Cohorts  1 to 3 with maximum recommended dose of 
8mg/kg/day; Day  35 for Cohorts  2 to 4 wit h maximum recommended dose of 10mg/kg/day; and 
Day 42 for Cohorts  2 to 4 with maximum recommended dose of 12mg/kg/day). For subjects who 
discontinue the SP847 study due to a second dose reduction or status epilepticus, Visit 1 is the 
Early Termination Visi t in SP847.  
Was revised as follows:  
For subjects who complete the SP847 study, Visit 1 is Day 2 of the second overnight stay at a 
hospital or medical facility in SP847 (Day  28 for Cohorts  1 to 3 with maximum recommended 
dose of 8mg/kg/day; Day  35 for Cohor ts 2 to 4 with maximum recommended dose of 
10mg/kg/day; and Day  42 for Cohorts  2 to 4 with maximum recommended dose of 
12mg/kg/day). For subjects who discontinue the SP847 study due to a dose reduction or status 
epilepticus, Visit 1 is the Early Terminatio n Visit in SP847.  
Clinical Trial Protocol, Section 5.2 (Telephone contacts [Week 2, 6, 10, 16, 24, 32, 40, 48, 66, 
and 78]); Page 20; last paragraph. Original text:  
Lacosamide is supplied so that the subject or caregiver (including parent/legal guardian) c an 
immediately decrease their dose by a step of 2mg/kg/day (oral solution [syrup]) or 100mg/day 
(tablet), if needed, in consultation over the telephone with the investigator or subinvestigator. 
Thus, LCM can be continued at a decreased dose until a clinic visit can be scheduled.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 94 of 324 Was revised as follows:  
Lacosamide is supplied so that the subject or caregiver (including parent/legal guardian) can 
immediately decrease their dose, if needed, in consultation over the telephone with the 
investigator or subinvesti gator. Thus, LCM can be continued at a decreased dose until a clinic 
visit can be scheduled.  
Clinical Trial Protocol, Section 5.16 (Unscheduled visit[s]); Page 25; first sentence and added 
bullet points 7 and 10. Original text:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, the subject must return for an 
Unscheduled Visit. The following assessments are required:  
• Concomitant medications assessment  
• Concomitant  AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Subject diary assessment  
• Adverse event reporting  
Additional assessments can be performed at the investigator’s discretion.  
Was revised as follows:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between  scheduled clinic visits due to an AE, or if a LCM dose increase is required 
between scheduled clinic visits, the subject must return for an Unscheduled Visit. The following 
assessments are required:  
• Concomitant medications assessment  
• Concomitant AEDs ass essment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 95 of 324 • Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
Clinical Trial Protocol, Section 8.1.7 (Overdose of investigational me dicinal product); Page 30; 
first sentence. Original text:  
Excessive dosing (beyond that prescribed per the protocol and including overdose) should be 
recorded in the Drug Accountability or Drug Dosing module.  
Was revised as follows:  
Excessive dosing (beyon d that prescribed per the protocol and including overdose) should be 
recorded in the source documents and Drug Accountability or Drug Dosing Log CRF module.  
Clinical Trial Protocol, Section 8.1.8 (Safety Signal detection in ongoing clinical studies and 
Data Monitoring Committees)); Page 30; replaced entire text. Original text:  
A regular monitoring of safety data collected during clinical studies will be performed as 
described in the Safety Signal Detection in Ongoing Clinical Trials Charter for lacosamide.  
This ongoing monitoring of safety data will be performed at the product level, possibly by an 
independent Data Monitoring Committee in some studies.  
Safety data, including SAEs, AEs, vital signs, laboratory results and ECG data (as applicable) 
will be per iodically reviewed by SCHWARZ BIOSCIENCES.  
The data from all studies with the same investigational medicinal product will be scrutinized to 
detect as early as possible any safety concern related to the investigational medicinal product so 
that the investig ators, the clinical study subjects, the regulatory authorities, and the ethics 
committees will be informed in the most appropriate manner.  
Was replaced as follows:  
Selected data from this study will be reviewed periodically to detect as early as possible a ny 
safety concern(s) related to the investigational medicinal product so that investigators, clinical 
study subjects, regulatory authorities, and IRBs/IECs will be informed appropriately and as early 
as possible.  
The Study Physician or medically qualified  designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the GCSP 
representative.  
As appropriate for the stage of development and accumulated experience with the investigational 
medicinal pro duct, medically qualified personnel at UCB may identify additional safety 
measures (examples: AEs, vital signs, laboratory or electrocardiogram results) for which data 
will be periodically reviewed during the course of the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 96 of 324 Clinical Trial Protocol, Section 8.2.2 (AEs of Special Interest); Page 31; replaced entire text. 
Original text:  
The following are AEs of special interest:   
• Any case of torsade de points  
• Any ECG abnormality accompanied by related clinical symptoms  
• Any case of discontinuation due t o any ECG abnormality or QTc prolongation  
Was replaced as follows:  
The following are AEs of special interest:  
• The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (2nd degree Type I and II and 3rd degre e), and marked bradycardia (<45beats/min)  
• Syncope or loss of consciousness (other than seizure related)  
• Serious suspected multiorgan hypersensitivity reactions  
Serious suspected multiorgan hypersensitivity cases may be identified and reported 
to the sponsor by the investigator using the following algorithm as agreed with the 
Food and Drug Administration:  
An AE or laboratory value (as defined below) suggestive of internal organ 
involvement (including but not limited to hepatitis, nephritis, pneumonitis , carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system 
involvement) combined  with at least one of the following: fever, rash, 
lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria sugge stive of internal organ 
involvement or eosinophilia:  
• Eosinophils % ≥10%  
• Eosinophils absolute ≥0.5G/L  
• Neutrophils absolute <1.5G/L  
• Platelets ≤100G/L  
• ALT ≥2x ULN  
• AST ≥2x ULN  
Clinical Trial Protocol, Section 8.2.3 (Immediate reporting of AEs); Page 31; replac ed entire 
text. Original text:  
The following AEs must be reported immediately:  
• SAE: AEs that the investigator classifies as serious by the above definitions regardless of 
causality.  
• Suspected transmission via a medicinal product of an infectious agent.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 97 of 324 • AEs of special interest:   
• Any case of torsade de points  
• Any ECG abnormality accompanied by related clinical symptoms  
• Any case of discontinuation due to any ECG abnormality or QTc prolongation  
Was replaced as follows:  
The following AEs must be reported immedi ately:  
• SAE: AEs that the investigator classifies as serious by the above definitions, regardless of 
causality.  
• Suspected transmission of an infectious agent via a medicinal product.  
• AEs of special interest (as defined in Section 8.2.2).  
Clinical Trial Prot ocol, Section 8.3 (Laboratory measurement); Page 32; first paragraph. 
Original text:  
Blood and urine specimens (approximately 5 to 15mL each) for routine assay of hematology, 
clinical chemistry, endocrinology, and urinalysis testing will be collected according to the tabular 
schedule of study procedures, Section  16.1. A central laboratory will perform the routine analysis 
of blood and urine samples. The procedures for handling and shipping these specimens will be 
provided to the sites.  
Was revised as f ollows:  
Blood and urine specimens (approximately 5 to 15mL each) for routine assay of hematology, 
clinical chemistry, endocrinology, and urinalysis testing will be collected according to the tabular 
schedule of study procedures, Section  16.1. For subjects aged 5 to 17  years, urine assessments 
will be based on the subject’s ability to void and staff’s ability to collect urine (in an appropriate 
container). A central laboratory will perform the routine analysis of blood and urine samples. 
The procedures for h andling and shipping these specimens will be provided to the sites.  
Clinical Trial Protocol, Section 8.3.1 (Liver function tests); Page 32, 33; replaced entire text. 
Original text:  
Transaminases (aspartate aminotransferase [AST], alanine aminotransferase [ ALT], or both) 
greater than or equal to 3  times but less than 5  times the ULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat test confirms the abnormality 
(ie, transaminases are greater than or equal to 3  times but less than 5  times the ULN with normal 
bilirubin) twice weekly monitoring of LFTs should continue until resolved. The investigator is to 
decide whether or not to stop the study medication.  
Transaminases (AST, ALT, or both) greater than or equal to 3  times but less than 5  times the 
ULN, in the presence of total bilirubin greater than or equal to 2  times the ULN, will result in 
immediate discontinuation of the study medication and withdrawal of the subject from the study. 
The LFTs will be repeated as soo n as possible, and in no case more than 7  days later and 
thereafter as clinically indicated.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 98 of 324 Transaminases (AST, ALT, or both) greater than or equal to 5  times the ULN will result in 
immediate discontinuation of the study medication and withdrawal of the s ubject from the study, 
regardless of the total bilirubin level. The LFTs will be repeated as soon as possible, and in no 
case more than 7  days later. Liver function test monitoring should continue until resolved.  
In all cases of transaminases (AST, ALT, or  both) greater than or equal to 3  times the ULN, 
testing for hepatitis A, B, and C will be done.  
All LFTs that meet the criteria above will be followed until resolution (ie, Baseline or stable 
condition).  
Referral to a specialist (ie, hepatologist or gastr oenterologist) is at the discretion of the 
investigator. This is recommended especially if the transaminase abnormalities greater than 
3 times the ULN persist after discontinuation of the study medication.  
Was replaced as follows:  
Transaminases (AST, ALT, or both) ≥3x ULN but <5x ULN, in the presence of total bilirubin 
≥2x ULN, or transaminases (AST, ALT, or both) ≥5x ULN will result in immediate 
discontinuation of LCM and withdrawal of the subject from the study. The LFTs will be repeated 
as soon as possib le, and in no case more than 1 week later (see Section 4.3.3).  
Clinical Trial Protocol, Section 8.4.5 (Tanner Stage); Page 35; first paragraph (first sentence). 
Original text:  
At each scheduled visit for selected patients, the investigator will evaluate th e subject’s sexual 
development using the 3 -item scale.  
Was replaced as follows:  
At selected visits for applicable subjects, the investigator or qualified designee will evaluate the 
subject’s sexual development using the 3 -item scale.  
Clinical Trial Protoco l, Section 12.1.2.2 (Other safety variables); Page 40; first paragraph 
(second sentence). Original text:  
The actual measurement and its change from Baseline (SP847 Visit 1) will be analyzed 
descriptively and presented by visit and day of collection.  
Was re vised as follows:  
The actual measurement and its change from Baseline (SP847 Visit 1) will be analyzed 
descriptively and presented by visit.  
Clinical Trial Protocol, Section 16.1 (Table 1 and 2); Pages 46 to 51). Original table:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical S tudy Protocol  SPM 927  SP848  
 
Page 99 of 324 Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -
Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion 
criteria  X              
Medical history 
update  X              
Concomitant 
medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam 
(complete)  Xh     X    X X  X  
Physical exam 
(brief)    X X X  X X X   X   
Neurological exam 
(complete)  Xh     X    X X  X  
Neurological exam 
(brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and 
pulse  Xh  X X X X X X X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical S tudy Protocol  SPM 927  SP848  
 
Page 100 of 324 Study SP848  Year 1  Safety 
Follow -
Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Body weight and 
height  Xh  X X X X X X X X X  X  
Clinical chemistry 
and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology 
blood sample  Xh     X    X X  X  
Blood sample for 
LCM PKj Xh  X   X  X  X X  X  
Blood sample for 
concomitant AEDsj Xh  X   X  X  X X  X  
Urinalysis  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X      
Clinical GIC       X    X X    
Caregiver GIC       X    X X    
Dispense LCM  X  X X X X X X X X Xm    
LCM return/ 
compliance    X X X X X X X X X  X  
Dispense  diary  X  X X X X X X X X X    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical S tudy Protocol  SPM 927  SP848  
 
Page 101 of 324 Study SP848  Year 1  Safety 
Follow -
Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Diary assessment    X X X X X X X X X X X  
AE reportingn Xh X X X X X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change ; LCM=lacosamide; 
PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b Visit 1 is also the last visit of the primary study (SP847). At Visit 1, the informed consent will be signed (and assent, if applicable) and eligibility assessed, 
the medical history will be updated, body weight and height and concom itant medications including AEDs will be recorded, AEs will be assessed, and the 
subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Vi sit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is decreased between visits due to an AE, the subject must return for an Unscheduled Visit.  
f A Final Visit should be performed 2 weeks after a subject has tapered off LCM.  
g This TC occurs 28 -35 days after the last dose of LCM.  
h Assessments should have been done as part of the last visit of the previous SP847 study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical S tudy Protocol  SPM 927  SP848  
 
Page 102 of 324 I An ECG is also required when the dose of LCM is increased or a new concomitant AED is introduced. The ECG should be performed  after the increased dose 
of LCM or the new AED has reached stea dy state. This ECG can be done at the next scheduled visit. When the ECG assessment is performed, 2 ECGs will be 
performed approximately 20 to 30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable), and prior to admin istration of 
LCM (if applicable).  
j Blood samples may be drawn at any time post -dosing with LCM.  
k For female subjects of childbearing potential (ie, females who have begun menstruating), serum pregnancy tests will be perfor med at Visit 1, the Early 
Termin ation Visit, and the Final Visit. Urine pregnancy tests will be performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥3 00mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syru p]) or 200mg/day (tablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is permitted after 
discussion with the medical monitor, whenever possible.  
n Ongoing aEs from the primary study (SP847) will be followed, as well as recording of new aEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 103 of 324 Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13 ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant 
medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam 
(complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam 
(brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and 
pulse  X  X X X X X X  
Body weight and 
height  X  X X X X  X  
Clinical chemistry and 
hematology blood 
sample  X  X X X X  X  
Endocrinology blood 
sample     X  X  X  
Blood sample for LCM 
PKh X  X X X X  X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 104 of 324 Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13 ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Blood sample for 
concomitant AEDsh X  X X X X  X  
Urinalysis    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Dispense LCM  X  X X Xk Xk    
LCM 
return/compliance  X  X X X X  X  
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
AE reporting X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change; LCM=lacosamide; 
PK=pharmacokinetics; S=serum; TC=telephone contact; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (wi th the exception of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is decreased between visits due to an AE, the subject must return for an Uns cheduled Visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 105 of 324 e A Final Visit should be performed 2 weeks after a subject has tapered off LCM.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g An ECG is also required when the dose of LCM is increased or a new concomitant AED is introduced. The  ECG should be performed after the increased dose 
of LCM or the new AED has reached steady state. This ECG can be done at the next scheduled visit. When the ECG assessment is performed, 2 ECGs will be 
performed approximately 20 to 30 minutes apart prior to  vital signs assessment, collection of blood samples (if applicable), and prior to administration of 
LCM (if applicable).  
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential (ie, females who have b egun menstruating), serum pregnancy tests will be performed at the Early Termination 
Visit and at the Final Visit. Urine pregnancy tests will be performed at Visits 10, 11, 12, and 13.  
j The Tanner Stage will be performed only for subjects who are pubescen t at Visit 1 or who will enter puberty during the course of the study.  
k Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥30 0mg/day (tablet). It is 
recommended that the LCM dose be t apered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is p ermitted after 
discussion with the medical monitor, whenever possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 106 of 324 Was revised as follows:  
Table 1.  Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X  X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X  X  
Blood sample for concomitant AEDsj Xh  X   X  X  X X  X  
Urinalysis  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC       X    X X    
Caregiver GIC       X    X X    
Dispense  LCM  X  X X X X X X X X Xm Xn   
LCM return/ compliance    X X X X X X X X X Xn X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 107 of 324 Table 1.  Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
AE reportingo Xh X X X X X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change; LCM=lacosamide; 
PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for al l scheduled visits and telephone contacts (with the exception of the Safety Follow -Up telephone contact).  
b Visit 1 is also the last visit of the primary study (SP847). At Visit 1, the informed consent will be signed (and assent, if applicable) and eligibi lity assessed, the medical history 
will be updated, body weight and height and concomitant medications including AEDs will be recorded, AEs will be assessed, an d the subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following w eeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Addit ional assessments can be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits , the subject must return for an Unschedule d Visit.  
f A Final Visit should be performed 2 weeks after a subject has tapered off LCM  
g This TC occurs 28 -35 days after the last dose of LCM.  
h Assessments should have been done as part of the last visit of the previous SP847 study.  
i An ECG is also req uired when the dose of LCM is increased or a new concomitant AED is introduced. The ECG should be performed after the increas ed dose of LCM or the 
new AED has reached steady state. This ECG can be done at the next scheduled visit. When the ECG assessment i s performed, 2 ECGs will be performed approximately 20 to 
30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable), and prior to administration of  LCM (if applicable).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 108 of 324 j Blood samples may be drawn at any time post -dosin g with LCM.  
k For female subjects of childbearing potential (ie, females who have begun menstruating), serum pregnancy tests will be perfor med at Visit 1, the Early Termination Visit, and 
the Final Visit. Urine pregnancy tests will be performed at Visits 2 , 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥ 6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower tape r of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussion with the medical monitor, whenever possible.  
n As applicable  
o Ongoing AEs from the primary study (SP847) will be followed, as well as recording of new AEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 109 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X  X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X  X  
Blood sample for 
concomitant AEDsh X  X X X X  X  
Urinalysis    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 110 of 324 Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
AE reporting X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change ; LCM=lacosamide; 
PK=pharmacokinetics; S=serum; TC=telephone contact; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up telephone 
conta ct). 
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the ass essments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If the LCM 
dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clini c visits , the subject must return for an 
Unscheduled Visit.  
e A Final Visit should be performed 2 weeks after a subject has tapered off LCM  
f This TC occurs 28 -35 days after the last dose of LCM.  
g An ECG is also required when the dose of LCM is increased or a new con comitant AED is introduced. The ECG should be performed after the increased dose of 
LCM or the new AED has reached steady state. This ECG can be done at the next scheduled visit. When the ECG assessment is per formed, 2 ECGs will be performed 
approximately 20 to 30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable), and prior to administrat ion of LCM (if applicable).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL   20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 111 of 324 h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing po tential (ie, females who have begun menstruating), serum pregnancy tests will be performed at the Early Termination Visit and  
at the Final Visit. Urine pregnancy tests will be performed at Visits 10, 11, 12, and 13.  
j The Tanner Stage will be performed onl y for subjects who are pubescent at Visit 1 or who will enter puberty during the course of the study.  
k Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥30 0mg/day (tablet). It is rec ommended 
that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A sl ower taper of 2mg/kg/day (oral 
solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an  emergency, a faster taper is permitted after discussion with the medical 
monitor, whenever possible.  
l As applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 112 of 324 Clinical Trial Protocol, Section 17.1. (Declarations and signatures of persons responsible for 
the study ) Page 53. Original text:  
Senior Medical Director  
(Medical Therapeutics)  
, MD, PhD  
Was revised as follows:  
Medical Director  
(Medical Therapeutics)  
, MD  
17.2 PROTOCOL AMENDMENT 2  
RATIONALE FOR THE AMENDMENT  
The primary purposes of this protocol amendment are to define an absolute maximum dose of 
LCM  600mg/day to be received by subjects in the study, to revise withdrawal criteria and 
follow -up recommendations for abnormal LFTs, and to specify that subjects who participate  in 
future studies (in addition to SP847) may participate in SP848. The rationales for these changes 
are described below.  
Based on the analysis of SP847 Cohort  1 (subjects aged 5  to 11  years) safety and PK data, the 
maximum permitted LCM dose in SP848 is 12mg/kg/day (for subjects weighing up to 50kg), or 
600mg/day (for subjects weighing >50kg).  
The decision to re -insert additional withdrawal criteria and follow -up recommendations for 
abnormal LFTs is based on the following:  
1) Newly adopted FDA Guidance on Drug -Induced Liver Injury (July 2009) and a 
recommendation from the FDA to re -insert previously included wording regarding additional 
withdrawal criteria and follow -up recommendations for abnormal LFTs in LCM protocols.  
2) Although no new liver -related saf ety issues with LCM have been identified, LFT 
abnormal has been added as a postmarketing adverse drug reaction in the LCM Company 
Core Data Sheet, and the EU Summary of Product Characteristics. Therefore, LCM protocols 
are being amended to reflect this add ition.  
With these revisions, liver -related safety signals will continue to be detected via protocol 
directed monitoring and additional follow -up in ongoing and future LCM clinical studies.  
In order to allow subjects who participate in other future LCM pedi atric clinical studies in 
epilepsy (ie, in addition to SP847) to continue receiving LCM treatment, these subjects will be 
provided the opportunity to participate in SP848.  
The remainder of the changes in this amendment were administrative in nature and are  described 
in detail below.  
MODIFICATIONS/CHANGES  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 113 of 324 • The contact information of the Clinical Project Manager, Clinical Pharmacokineticist, and 
Associate Medical Director (Global Clinical Safety and Pharmacovigilance) were updated.  
• Information was added to Sec tion 1 (Summary) and throughout the protocol to specify that 
subjects who participate in future studies (in addition to SP847) may participate in SP848.  
• Information was added to Section  1 (Summary) and throughout the protocol to indicate that 
the maximum p ermitted LCM dose in SP848 is 12mg/kg/day (for subjects weighing up to 
50kg), or 600mg/day (for subjects weighing >50kg).  
• The withdrawal criteria (Section  4.3.3) and follow -up recommendations for abnormal LFTs 
throughout the protocol were revised.  
• Information was added to Section  4.4.1 (Treatments to be administered) to clarify dosing for 
subjects who switch to the LCM tablet formulation.  
• The tabular schedules of trial procedures were updated to reflect the changes to the protocol.  
REFERENCE  
Clinica l Study Protocol, Contact information for the Clinical Project Manager, Clinical Trial 
Biostatistician, Clinical Pharmacokineticist, and Associate Medical Director (Global Clinical 
Safety and Pharmacovigilance), pages 2 and 3. Original text:  
Clinical Proje ct Manager:  
Name:  , BS 
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 114 of 324 Clinical Trial Biostatistician:  
Name:  , MPH  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Pharmacokineticist:  
Name:   
Address:  UCB S.A.  
Chemin du Foriest  
B-1420 Braine -l'Alleud  
Phone/Fax:   
E-mail:   
Associate Medical Director (Drug Safety) : 
Name:  , MD  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 115 of 324 Was revised as follows:  
Clinical Project Manager:  
Name:   
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Trial Biostatistician:  
Name:   MPH  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite  100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Pharmacokineticist:  
Name:   
Address:  UCB Celltech  
UCB Pharma  Ltd 
208 Bath Road  
Slough, Berkshire SL1 3WE, UK  
Phone/Fax:    
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 116 of 324 Associate Medical Director (Global Clinical Safety and Pharmacovigilance) : 
Name:   MD 
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
Clinical Study Protocol, List of Abbreviations, page 9. The following abbreviation was deleted:  
IRAE  immediately reportable adverse event  
 
Clinical Study Protocol, Section  1 (Summary), paragraphs 1 and 2. Original text:  
SP848 is an open -label extension study to obtain long -term safety , tolerability, and 
pharmacokinetic (PK) data in children with partial -onset seizures treated with lacosamide (LCM) 
oral solution (syrup) or LCM tablets as adjunctive therapy. In addition, the study is designed to 
obtain preliminary efficacy data on seizur e frequency during long -term exposure. The study will 
also provide continued availability of LCM to subjects who have completed the SP847 epilepsy 
study and to subjects who have discontinued from SP847 due to a dose reduction or status 
epilepticus, and who , in the investigator’s opinion, would benefit from long -term administration 
of LCM.  
Subjects who complete the SP847 study and choose to enter this open -label extension study will 
begin on the LCM dose they achieved in SP847. Subjects who discontinued from  SP847 due to a 
dose reduction or status epilepticus, but for whom it is determined medically appropriate to enter 
this open -label extension study, will also begin on the LCM dose they achieved in SP847. 
Subjects will be able to continue on LCM oral soluti on (syrup) or switch to LCM tablets. During 
the study, investigators will be allowed to increase or decrease the dose of LCM and/or 
concomitant antiepileptic drugs (AEDs) to optimize tolerability and seizure reduction for each 
subject. The investigator may  adjust the LCM dose to a minimum of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) and a maximum of 8, 10, or 12mg/kg/day (oral solution [syrup]) 
or 400, 500, or 600mg/day (tablet), depending on the maximum recommended dose in SP847. 
An increase  in the LCM dose must occur only during office visits. If needed to optimize 
tolerability and seizure reduction in selected subjects, concomitant AEDs may be carefully 
tapered and discontinued to achieve LCM monotherapy. New concomitant AEDs may be 
introdu ced as treatment if the medication has been approved by the Regulatory Authorities in the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 117 of 324 country in which the subject lives. New concomitant AEDs should be added only when the 
subject has not optimally or adequately responded to a maximum tolerated dose o f LCM. When 
subjects withdraw from the study, it is recommended that LCM be tapered gradually in weekly 
decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have 
achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup])  or ≥300mg/day (tablet) . A slower 
taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is 
permitted, if medically necessary. In case of an emergency, a faster taper is permitted after 
discussion with the medical monitor, w henever possible.  
Was revised as follows:  
SP848 is an open -label extension study to obtain long -term safety, tolerability, and 
pharmacokinetic (PK) data in children with partial -onset seizures treated with lacosamide (LCM) 
oral solution (syrup) or LCM tabl ets as adjunctive therapy. In addition, the study is designed to 
obtain preliminary efficacy data on seizure frequency during long -term exposure. The study will 
also provide continued availability of LCM to subjects who have completed the SP847 epilepsy 
study and to subjects who have discontinued from SP847 due to a dose reduction or status 
epilepticus, and who, in the investigator’s opinion, would benefit from long -term administration 
of LCM. SP848 will also be open to subjects who participate in other fut ure LCM pediatric 
clinical studies in epilepsy.  
Subjects who complete SP847 and choose to enter this open -label extension study will begin on 
the LCM dose they achieved in SP847. Subjects who discontinued from SP847 due to a dose 
reduction or status epilep ticus, but for whom it is determined medically appropriate to enter this 
open -label extension study, will also begin on the LCM dose they achieved in SP847. Subjects 
will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, invest igators 
will be allowed to increase or decrease the dose of LCM and/or concomitant antiepileptic drugs 
(AEDs) to optimize tolerability and seizure reduction for each subject. The investigator may 
adjust the LCM dose to a minimum of 2mg/kg/day (oral solutio n [syrup]) or 100mg/day (tablet) 
and a maximum of 12mg/kg/day (oral solution [syrup] or the corresponding dose levels for the 
tablet formulation) not to exceed 600mg/day based on body weight, even if the subject’s body 
weight exceeds 50kg. An increase in t he LCM dose must occur only during office visits. If 
needed to optimize tolerability and seizure reduction in selected subjects, concomitant AEDs 
may be carefully tapered and discontinued to achieve LCM monotherapy. New concomitant 
AEDs may be introduced a s treatment if the medication has been approved by the Regulatory 
Authorities in the country in which the subject lives. New concomitant AEDs should be added 
only when the subject has not optimally or adequately responded to a maximum tolerated dose of 
LCM . When subjects withdraw from the study, it is recommended that LCM be tapered 
gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for 
subjects who have achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥ 300mg/day 
(tablet) . A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenev er possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 118 of 324 Clinical Study Protocol, Section  2 (Background information). Original text:  
Epilepsy is the second most prevalent neurological disorder in the world. More than 40  million 
people suffer from epilepsy –about 1% of the world’s population (Dichek, 1999). Although some 
forms of epilepsy may respond to surgical treatment and others may not require any treatment at 
all, most patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996). In 
the past decade, several new options for t he medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
The classification of epilepsies in children was described in 1989 by the Commission on 
Classification and Terminology of the International League Agai nst Epilepsy (1989; Aicardi, 
1994). Seizures are categorized based on whether the onset is focal or generalized and whether 
the disorder is idiopathic, symptomatic, or cryptogenic. Specific syndromes are further classified 
according to a number of criteria  including seizure type, cause, anatomy, precipitating factors, 
age of onset, and sometimes prognosis.  
The newer AEDs differ from older agents in several important ways, including mechanism of 
action, spectrum of activity, and PK characteristics (Herman an d Pedley, 1998). However, more 
than 30% of patients have inadequate seizure control on currently -available AEDs or experience 
significant adverse drug effects (CPMP/EWP/566/98, 2000). Therefore, a need remains for 
AEDs with improved effectiveness and toler ability (Sander, 1998).  
Among the newer AEDs, only 5 (gabapentin, lamotrigine, oxcarbazepine, topiramate, and 
levetiracetam) have successfully demonstrated efficacy as adjunctive therapy in children with 
difficult to treat partial -onset seizures (Appleton et al, 1999; Duchowny et al, 1999; 
Elterman  et al, 1999; Glauser et al, 2000; Glauser et al, 2006). Despite the availability of new 
AEDs, more than 25% of pediatric patients have inadequate seizure control on currently -
available AEDs, or experience signifi cant adverse drug effects (Hadjiloizou and Bourgeois, 
2007). Therefore, a need remains for AEDs with improved effectiveness and tolerability.  
Lacosamide (LCM, Vimpat®, SPM 927, [R] -2-acetamido -N-benzyl -3-methoxypropionamide) 
belongs to a novel class of fu nctionalized amino acids. It has minimal protein binding and effect 
on cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and a half -life of approximately 13  hours (in adults), which allows a tw ice 
daily (bid) dose regimen. It also displays dose -proportional PK following administration over a 
range of doses up to 800mg in adults.  
Lacosamide has been approved as adjunctive therapy in the treatment of partial -onset seizures 
with or without secondar y generalization in patients 16 years of age and older in the European 
Union (oral tablets, oral solution [syrup], and solution for intravenous [iv] infusion) and in 
patients 17  years of age and older in the United States (oral tablets and solution for iv infusion). 
The oral solution (syrup) is a formulation suitable for administration to children. Bioequivalence 
has been shown between the tablet and oral solution (syrup) formulations, comparing 2 tablets of 
LCM 100mg and the oral solution (syrup) containin g LCM 200mg, after single -dose 
administration in healthy subjects. The PK of LCM and its major metabolite, SPM 12809 
(O-desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after single oral 
doses of LCM 200mg administered as tablets  or as oral solution (syrup).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 119 of 324 In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
400mg bid (800mg/day) were evaluated in approximately 700  unique volunteers who received 
LCM in Phase  1 studies. The safety and ef ficacy of LCM has also been evaluated in Phase  2/3 
studies as adjunctive oral therapy in over 1300  adult subjects with partial -onset seizures and as 
oral monotherapy in over 2200  adult subjects in other indications (eg, neuropathic pain, 
osteoarthritis, fi bromyalgia). In addition, LCM solution for infusion was evaluated as short -term 
replacement therapy in a subset of subjects with partial -onset seizures (199  patients) who were 
receiving adjunctive LCM tablets.  
Three double -blind, placebo -controlled, multic enter studies (SP667, SP754, and SP755) in 
1308  adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive 
therapy (1 to 3 concomitant AEDs) in subjects with difficult to control partial -onset seizures. In 
these studies, LCM wa s initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (200mg/day, 400mg/day, or 600mg/day) in 100mg/day per week increments.  
When oral LCM was administered as adjunctive therapy at doses up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastrointestinal -associated events. A dose relationship was seen f or the most frequently reported 
common TEAEs, including dizziness, headache, nausea, and diplopia. The nature and frequency 
of AEs were comparable to adjunctive therapy with other marketed AEDs. Safety evaluations 
support the further development of LCM as an AED.  
SP847, the primary study, is an open -label, dose -titration, safety, tolerability, and PK study to 
evaluate LCM as adjunctive therapy in children with uncontrolled partial -onset seizures. 
Approximately 30  children (aged 2 to 17 years) with uncontrol led partial -onset seizures on a 
stable dose regimen of at least 1 but no more than 3 AEDs will be enrolled. The study consists of 
a Screening Phase, a Treatment Phase, and an End -of-Study Phase. The duration of treatment for 
an individual subject may be up  to approximately 13 weeks.  
SP848 is an open -label extension study to obtain long -term safety, tolerability, and PK data in 
children with partial -onset seizures treated with LCM oral solution (syrup) or LCM tablets as 
adjunctive therapy. In addition, the s tudy is designed to obtain preliminary efficacy data on 
seizure frequency during long -term exposure. The study will also provide continued availability 
of LCM to subjects who have completed the SP847 epilepsy study (or discontinued SP847 due to 
a dose redu ction or status epilepticus), and who, in the investigator’s opinion, would benefit from 
long-term administration of LCM.  
Was revised as follows:  
Epilepsy is the second most prevalent neurological disorder in the world. More than 40  million 
people suffer f rom epilepsy –about 1% of the world’s population (Dichek, 1999). Although some 
forms of epilepsy may respond to surgical treatment and others may not require any treatment at 
all, most patients with epilepsy require appropriate pharmacological therapy (Peru cca, 1996). In 
the past decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
The classification of epilepsies in children was described in 1989 by the Commission on 
Classi fication and Terminology of the International League Against Epilepsy (1989; Aicardi, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 120 of 324 1994). Seizures are categorized based on whether the onset is focal or generalized and whether 
the disorder is idiopathic, symptomatic, or cryptogenic. Specific syndromes  are further classified 
according to a number of criteria including seizure type, cause, anatomy, precipitating factors, 
age of onset, and sometimes prognosis.  
The newer AEDs differ from older agents in several important ways, including mechanism of 
action , spectrum of activity, and PK characteristics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure control on currently -available AEDs or experience 
significant adverse drug effects (CHMP/EWP/566/98, 2010). Therefore, a ne ed remains for 
AEDs with improved effectiveness and tolerability (Sander, 1998).  
Among the newer AEDs, only 5 (gabapentin, lamotrigine, oxcarbazepine, topiramate, and 
levetiracetam) have successfully demonstrated efficacy as adjunctive therapy in children with 
difficult to treat partial -onset seizures (Appleton et al, 1999; Duchowny et al, 1999; 
Elterman  et al, 1999; Glauser et al, 2000; Glauser et al, 2006). Despite the availability of new 
AEDs, more than 25% of pediatric patients have inadequate seizure c ontrol on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
Lacosamide (LCM, Vimpat®, SPM 927, [R] -2-acetamido -N-benzyl -3-methoxypropionamide) 
belongs to a novel class of functionalized amino acids.  It has minimal protein binding and effect 
on cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and a half -life of approximately 13  hours (in adults), which allows a twice 
daily (bid) dose regi men. It also displays dose -proportional PK following administration over a 
range of doses up to 800mg in adults.  
Lacosamide has been approved as adjunctive therapy in the treatment of partial -onset seizures 
with or without secondary generalization in patie nts 16 years of age and older in the European 
Union (oral tablets, oral solution [syrup], and solution for intravenous [iv] infusion) and in 
patients 17  years of age and older in the United States (oral tablets, oral solution, and solution for 
iv infusion) . The oral solution (syrup) is a formulation suitable for administration to children. 
Bioequivalence has been shown between the tablet and oral solution (syrup) formulations, 
comparing 2 tablets of LCM 100mg and the oral solution (syrup) containing LCM 200 mg, after 
single -dose administration in healthy subjects. The PK of LCM and its major metabolite, 
SPM  12809 (O -desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after 
single oral doses of LCM 200mg administered as tablets or as or al solution (syrup).  
In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
400mg bid (800mg/day) were evaluated in approximately 700  unique volunteers who received 
LCM in Phase  1 studies. The safety and efficacy of  LCM has also been evaluated in Phase  2/3 
studies as adjunctive oral therapy in over 1300  adult subjects with partial -onset seizures and as 
oral monotherapy in over 2200  adult subjects in other indications (eg, neuropathic pain, 
osteoarthritis, fibromyalgi a, and migraine prophylaxis). In addition, LCM solution for infusion 
was evaluated as short -term replacement therapy in a subset of subjects with partial -onset 
seizures (199  patients) who were receiving adjunctive LCM tablets.  
Three double -blind, placebo -controlled, multicenter studies (SP667, SP754, and SP755) in 
1308  adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 121 of 324 therapy (1 to 3 concomitant AEDs) in subjects with difficult to control partial -onset seizures. In 
these studies, LCM was initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (200mg/day, 400mg/day, or 600mg/day) in 100mg/day per week increments.  
When oral LCM was administered as adjunctive therapy at doses up to 600mg/d ay in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastrointestinal -associated events. A dose relationship was seen for the most frequently reported 
common TEAEs, including dizziness, headache, nausea, and diplopia. The nature and frequency 
of AEs were comparable to adjunctive therapy with other marketed AEDs. Safety evaluations 
support the further development of LCM as an AED.  
SP847, the current primary study, is an open -label, dose -titration, safety, tolerability, and PK 
study to evaluate LCM as adjunctive therapy in children with uncontrolled partial -onset seizures. 
Approximately 42  children (aged 1  month to 17 years) with uncontrolled partial -onset seizures 
on a stable dose regimen of at least 1 but no more than 3 AEDs will be enrolled. The study 
consists of a Screening Phase, a Treatment Phase, and an End -of-Study Phase. The duration of 
treatment for an indi vidual subject may be up to approximately 13 weeks. Approximately 
300 additional subjects who may participate in other future LCM primary pediatric clinical 
studies in epilepsy will also be eligible to participate in SP848.  
SP848 is an open -label extension  study to obtain long -term safety, tolerability, and PK data in 
children with partial -onset seizures treated with LCM oral solution (syrup) or LCM tablets as 
adjunctive therapy. In addition, the study is designed to obtain preliminary efficacy data on 
seizure frequency during long -term exposure. The study will also provide continued availability 
of LCM to subjects who have completed the SP847 epilepsy study (or discontinued SP847 due to 
a dose reduction or status epilepticus), and who, in the investigator’s  opinion, would benefit from 
long-term administration of LCM. SP848 will also be open to subjects who participate in other 
future LCM pediatric clinical studies in epilepsy.  
Clinical Study Protocol, Section  3 (Objectives), third and objectives. Original te xt: 
• To allow subjects who have completed the SP847 study (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
Was revised as follows, and a fourth objective was added:  
• To allow subjects who have participated in SP847 (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
• To allow subjects who have participated in other future LCM pediatric clinical studies in 
epilepsy to continue receiving LCM  
Clinical Study Protocol, Sect ion 4 (Study description). Original text:  
Subjects who complete the SP847 study (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will begin on the LCM dose 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 122 of 324 they achieved in SP847. Subjects will be able to continue on LCM oral solution (syrup) or switch 
to LCM tablets. During the study, investigators will be allowed to increase or decrease the dose 
of LCM and/or concomitant AEDs to optimize tolerability and seizure reduction for each  
subject. The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) and a maximum of 8, 10, or 12mg/kg/day (oral solution [syrup]) 
or 400, 500, or 600mg/day (tablet), depending on the maximum recommen ded dose in SP847. 
Increases in the LCM dose must occur only during office visits. If needed to optimize tolerability 
and seizure reduction in selected subjects, concomitant AEDs may be carefully tapered and 
discontinued to achieve LCM monotherapy. New con comitant AEDs may be introduced as 
treatment if the medication has been approved by the Regulatory Authorities in the country in 
which the subject lives. New concomitant AEDs should be added only when the subject has not 
optimally or adequately responded t o a maximum tolerated dose of LCM. When subjects 
withdraw from the study, it is recommended that the study medication be tapered gradually in 
weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects 
who have achieved a do se of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . 
A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day 
(tablets) is permitted, if medically necessary. In case of an emergency, a faster taper is permitte d 
after discussion with the medical monitor, whenever possible.  
Was revised as follows:  
Subjects who complete SP847 (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will begin on the LCM dose 
they achieved in SP847. Subjects will be able to continue on LCM oral solution (syrup) or switch 
to LCM tablets. During the study, investigators will be allowed to increase or decrease the dose 
of LCM and/or concomitant AEDs to optimize tolera bility and seizure reduction for each 
subject. The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the 
corresponding dose levels for the t ablet formulation), not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. Increases in the LCM dose must occur 
only during office visits. If needed to optimize tolerability and seizure reduction in selected 
subjects,  concomitant AEDs may be carefully tapered and discontinued to achieve LCM 
monotherapy. New concomitant AEDs may be introduced as treatment if the medication has 
been approved by the Regulatory Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or adequately 
responded to a maximum tolerated dose of LCM. When subjects withdraw from the study, it is 
recommended that the study medication be tapered gradually in weekly decrements o f 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have achieved a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . A slower taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tab lets) is permitted, if 
medically necessary. In case of an emergency, a faster taper is permitted after discussion with the 
medical monitor, whenever possible.  
Clinical Study Protocol, Section  4.3.1 (Inclusion criteria), criterion 2. Original text:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 123 of 324 1. Subject has completed SP847 (or the subject discontinued SP847 due to a dose reduction or 
status epilepticus) for the treatment of uncontrolled partial -onset seizures.  
Was revised as follows:  
1. Subject has completed SP847 (or the subject discontinued SP847 due to a dose reduction or 
status epilepticus) for the treatment of uncontrolled partial -onset seizures, or subject has 
participated in other LCM pediatric clinical studies in epilepsy.  
Clinic al Study Protocol, Section  4.3.2 (Exclusion criteria), criterion 2. Original text:  
1. Subject meets the withdrawal criteria for the primary study (SP847) (with the exception of 
subjects who discontinued due to a dose reduction or status epilepticus), or is ex periencing 
an ongoing serious AE (SAE).  
Was revised as follows:  
1. Subject meets the withdrawal criteria for the primary study (with the exception of subjects 
who discontinued due to a dose reduction or status epilepticus), or is experiencing an 
ongoing serio us AE (SAE).  
Clinical Study Protocol, Section  4.3.3 (Criteria for withdrawal). Original text:  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be followed until resolution of the event or until the 
event is considered stable.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relevant abnormal laboratory findings t hat, in the 
opinion of the investigator, preclude further participation in the study  
2.   The request of the Sponsor or a Regulatory Agency  
3.    Subject achieves menarche during the study and does not practice an acceptable method of 
contraception for the  duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant, as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake or develops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is 
unwilling or unable to allow th e subject to continue in the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 124 of 324 8.    Investigator’s decision that withdrawal from further participation would be in the subject’s 
best interest.  
9.    Subject experiences status epilepticus  
10.  In the case of liver function test (LFT) results of tran saminases (AST and/or ALT) ≥3x  ULN 
to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST and/or ALT) ≥5x ULN, the 
study medication must be immediately discontinued and the subject withdrawn from the 
study. The LFTs will be repeated as soon as possib le, and in no case more than 1 week later.  
Participation in this study may be discontinued for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medicati on, in the opinion of the investigator.  
Was revised as follows:  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be followed until resolution of the event or until the 
event is considered stable.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relevant abnormal laboratory findings that, in the 
opinion of the  investigator, preclude further participation in the study  
2.   The request of the Sponsor or a Regulatory Agency  
3.    Subject achieves menarche during the study and does not practice an acceptable method of 
contraception for the duration of the study (un less sexually abstinent).  
4.    Subject becomes pregnant, as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develop s a second -degree atrioventricular (AV) block while awake or develops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is 
unwilling or unable to allow the subject to continue in t he study.  
8.    Investigator’s decision that withdrawal from further participation would be in the subject’s 
best interest.  
9.    Subject experiences status epilepticus  
10.  In the case of liver function test (LFT) results of transaminases (AST, ALT, or bo th) 
≥3x ULN to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST, ALT, or both) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 125 of 324 ≥5x ULN, the study medication must be immediately discontinued and the subject 
withdrawn from the study. The LFTs will be repeated as soon as possible, and in no case 
more than 1 week later.  
Participation in this study may be discontinued for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation  from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of th e investigator.  
4.   Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
(ie, transaminases are ≥3xULN to <5xULN with normal bilir ubin), then weekly monitoring 
of LFTs should continue until resolved (ie, <3xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.  
Clinical Study Protocol, Section  4.4.1 (Treatments to be administered). Origin al text:  
Subjects who complete the SP847 study (or discontinue SP847 due to a dose reduction or status 
epilepticus) and choose to enter the open -label extension study will begin on the LCM dose they 
achieved in SP847. The investigator, together with the subject/caregiver (including parent/legal 
guardian), will be able to choose either the oral solution (syrup) formulation or the tablet 
formulation of LCM in this study. The study medication will be orally administered bid (at 
12-hour intervals, once in the  morning and once in the evening) in equally divided doses. The 
oral solution (syrup) formulation will be measured and orally administered via a dosing syringe. 
The selection of doses, titration scheme, and rate of taper in SP847 were based on adult studie s 
and were adjusted to a mg/kg basis plus 40% (ie, 600mg/day adult dose of LCM corresponds to 
[600mg/70kg]  x 1.4 = approximately 12mg/kg/day for a child). The selection of doses in this 
trial is based on the maximum recommended dose in SP847.  
The investiga tor may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 8, 10, or 12mg/kg/day (oral solution [syrup]) 
or 400, 500, or 600mg/day (tablet), depending on the maximum recommended dose in  SP847. 
The investigator may decrease the dose of LCM to a minimum of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet). Increases in the LCM dose must occur only during office visits. 
It should be noted, in cases of incomplete doses (eg, subject sp its out all or a portion of the 
syrup), missed doses, or administration of an erroneous volume of syrup, study medication 
should not be readministered and these subjects would remain at their assigned dose.  
Subjects achieving a dose of LCM ≥6mg/kg/day (ora l solution [syrup]) or ≥300mg/day (tablet) 
who withdraw during the study should taper off study medication. It is recommended that the 
dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) (see tables be low). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 126 of 324 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Was revised as follows : 
Subjects who have participated in SP847 (or other future LCM pediatric clinical studies in 
epilepsy), who are eligible to participate in the open -label extension study SP848, and who 
choose to enter SP848, will begin SP848 on the LCM dose they achieved i n the primary study. 
The investigator, together with the subject/caregiver (including parent/legal guardian), will be 
able to choose either the oral solution (syrup) formulation or the tablet formulation of LCM in 
this study. The study medication will be o rally administered bid (at 12 -hour intervals, once in the 
morning and once in the evening) in equally divided doses. The oral solution (syrup) formulation 
will be measured and orally administered via a dosing syringe. The selection of doses, titration 
scheme, and rate of taper in SP847 were based on adult studies and were adjusted to a mg/kg 
basis plus 40% (ie, 600mg/day adult dose of LCM corresponds to [600mg/70kg]  x 1.4 = 
approximately 12mg/kg/day for a child). The selection of doses in this trial is base d on the 
maximum recommended dose in SP847.  
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the table t formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg  
The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 12mg /kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The investigator may decrease the dose 
of LCM to a minimum of 2mg/kg/d ay (oral solution [syrup] or the corresponding dose level for 
the tablet formulation). Increases in the LCM dose must occur only during office visits. It should 
be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the syrup), m issed 
doses, or administration of an erroneous volume of syrup, study medication should not be 
readministered and these subjects would remain at their assigned dose.  
Subjects enrolled in SP848 have the option of remaining on the oral solution formulation o f 
LCM or switching to the commercial tablet formulation, if feasible. Consideration of the current 
LCM milligram dose in the oral solution (syrup) should occur if/when transitioning to the tablet 
formulation. In cases where the LCM dose received with the o ral solution (syrup) is not 
supported by the tablet strengths available in SP848 (50mg and 100mg), a clinical decision must 
be made by the investigator or other study physician to either increase or decrease the LCM dose 
to the next multiple of 100mg with a maximum permitted dose of 600mg/day.  
Subjects achieving a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) 
who withdraw during the study should taper off study medication. It is recommended that the 
dose be tapered gradually in week ly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) (see tables below). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permit ted after discussion with the medical monitor, whenever possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 127 of 324 Clinical Study Protocol, Section  4.4.3 (Randomization). Original text:  
This is an open -label extension study; subjects will not be randomized. Subjects will keep the 
unique number assigned i n the SP847 study.  
Was revised as follows:  
This is an open -label extension study; subjects will not be randomized. Subjects will keep the 
unique number assigned in the primary study.  
Clinical Study Protocol, Section  5.1 (Visit  1 [Week  0]). Original text:  
For subjects who complete the SP847 study, Visit 1 is Day 2 of the second overnight stay at a 
hospital or medical facility in SP847 (Day  28 for Cohorts  1 to 3 with maximum recommended 
dose of 8mg/kg/day; Day  35 for Cohorts  2 to 4 with maximum recommended do se of 
10mg/kg/day; and Day  42 for Cohorts  2 to 4 with maximum recommended dose of 
12mg/kg/day). For subjects who discontinue the SP847 study due to a dose reduction or status 
epilepticus, Visit 1 is the Early Termination Visit in SP847.  
Prior to the conduc t of any study -related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by  the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC -approved Informed Consent Form. When possible, or as required by local IRB/IEC, 
the subject will be requested to give assent to participate in the study.  
Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments, and a complete medical history update will be obtained. 
The data for the following assessments will be taken from the last assessment during the SP847 
study:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior t o vital signs 
assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 128 of 324 • Tanner Stage assessment (if applicable)  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Was r evised as follows:  
For subjects who complete SP847, Visit 1 is Day 2 of the second PK collection time period 
(which may include an overnight stay at a hospital or medical facility) in SP847 (Day  28 for 
Cohorts  1, 2, 3, and 5 with maximum recommended dose o f 8mg/kg/day; Day  35 for Cohorts  2 
to 5 with maximum recommended dose of 10mg/kg/day; and Day  42 for Cohorts  2 to 5 with 
maximum recommended dose of 12mg/kg/day). For subjects who discontinue SP847 due to a 
dose reduction or status epilepticus, Visit 1 is the Early Termination Visit in SP847. For subjects 
in SP847 who are titrated up to the maximum permitted dose of 600mg/day sooner than the 
study schedule would ordinarily indicate (based on body weight) and who enroll in SP848, the 
Early Termination Visit of SP847 will also serve as Visit  1 for SP848.  
For subjects who enroll in SP848 after participation in future LCM pediatric clinical studies in 
epilepsy, SP848 Visit  1 will be specified in the respective primary study protocol.  
Prior to the conduct of any study -related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC -approved Informed Consent Form. When possible, or as required by local IRB/IEC, 
the subject will be requested to give assent to participate in the st udy. 
Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments, and a complete medical history update will be obtained. 
The data for the following assessments will be taken f rom the last assessment during SP847 (or 
other primary study as applicable):  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximate ly 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 129 of 324 • Blood sample fo r LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequen cy, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Clinical Study Protocol, Section  5.3 (Visit 2 [Week 4]), bullet 5. Original text:  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of blood sample)  
Was revised as follows:  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
Clinical Study Protocol, Section  5.4 (Visit 3 [Week 8), final paragraph. Original text:  
• A 12 -lead ECG is also requi red when the dose of LCM is increased or a new concomitant 
AED is introduced. The ECG should be performed after the increased dose of LCM or the 
new AED has reached steady -state. This ECG can be done at the next scheduled visit. When 
the ECG assessment is done, 2 ECGs will be performed approximately 20 to 30 minutes 
apart prior to vital sign assessment, collection of blood samples (if applicable), and prior to 
administration of LCM (if applicable).  
Was revised as follows:  
• A 12 -lead ECG is also required when  the dose of LCM is increased or a new concomitant 
AED is introduced. The ECG should be performed after the increased dose of LCM or the 
new AED has reached steady -state. This ECG can be done at the next scheduled visit. When 
the ECG assessment is done, 2 interpretable ECGs will be performed approximately 20 to 30 
minutes apart prior to vital sign assessment, collection of blood samples (if applicable), and 
prior to administration of LCM (if applicable).  
Clinical Study Protocol, Section  5.6 (Visit 5 [Week 2 0]), final paragraph. Original text:  
A 12 -lead ECG is also required when the dose of LCM is increased or a new concomitant AED 
is introduced. The ECG should be performed after the increased dose of LCM or the new AED 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 130 of 324 has reached steady -state. This ECG can be done at the next scheduled visit. When the ECG 
assessment is done, 2 ECGs will be performed approximately 20 to 30 minutes apart prior to 
vital sign assessment, collection of blood samples (if applicable), and prior to administration of 
LCM (if applicab le). 
Was revised as follows:  
A 12 -lead ECG is also required when the dose of LCM is increased or a new concomitant AED 
is introduced. The ECG should be performed after the increased dose of LCM or the new AED 
has reached steady -state. This ECG can be done at the next scheduled visit. When the ECG 
assessment is done, 2 interpretable ECGs will be performed approximately 20 to 30 minutes 
apart prior to vital sign assessment, collection of blood samples (if applicable), and prior to 
administration of LCM (if ap plicable).  
Clinical Study Protocol, Section  5.7 (Visit 6 [Week 28]). Original text:  
Assessments for Visit 6 (Week 28) are the same as those described for Visit 3 (Week 8) in 
Section  5.6, with the following exception: a  12-lead ECG (2 recordings approximately 20 to 
30 minutes apart prior to vital signs assessment and collection of blood sample) is conducted at 
Visit 6.  
Was revised as follows:  
Assessme nts for Visit 6 (Week 28) are the same as those described for Visit 3 (Week 8) in 
Section  5.6, with the following exception: a  12-lead ECG (2 inter pretable recordings 
approximately 20 to 30  minutes apart prior to vital signs assessment and collection of blood 
sample) is conducted at Visit 6.  
Clinical Study Protocol, Section  5.10 (Visit 9 [Week 52]). Original text:  
Assessments for Visit 9 (Week 52) ar e the same as those described for Visit 5 (Week 20), in 
Section  5.8, with the following exception: a 12 -lead ECG (2 recordings approximately 20 to 
30 minutes apart prior to vital signs assessment and collection of blood sample) is conducted at 
Visit 9.  
Was revised as follows:  
Assessments for Visit 9 (Week 52) are the same as those described for Visit 5 (Week 20), in 
Section  5.8, with the following exception: a 12 -lead ECG (2 interpretable recordings 
approximately 20 to 30  minutes apart prior to vital signs assessment and collection of blood 
sample) is conducted at Visit 9.  
Clinical Study Protocol, Section 5.12 (Visit 11 [Week 72]). Original text:  
Assessments for Visit 11 (Week 72) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: brief physical and neurological exams are conducted 
(instead of complete physical and neurological exams as indicated for Visit 5), the laboratory 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 131 of 324 blood sample is collected only for clinical chemistry and hematology (ie, no endocrinology), and 
a 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted . 
Was revised as f ollows:  
Assessments for Visit 11 (Week 72) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: bri ef physical and neurological exams are conducted 
(instead of complete physical and neurological exams as indicated for Visit 5), the laboratory 
blood sample is collected only for clinical chemistry and hematology (ie, no endocrinology), and 
a 12-lead ECG ( 2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample) is conducted . 
Clinical Study Protocol, Section  5.14 (Visit 13 [Week 96]). Original text:  
Assessments for Visit 13 (Week 96) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: the laboratory blood sample is collected only for  
clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG (2 recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment and collection of blood 
sample) is conducted, and a Tanner Stage assessment is conducted (if applica ble). 
Was revised as follows:  
Assessments for Visit 13 (Week 96) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: the laboratory blood sample is collected only for 
clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG (2 interpretable 
recordings approxima tely 20 to 30 minutes apart prior to vital signs assessment and collection of 
blood sample) is conducted, and a Tanner Stage assessment is conducted (if applicable) . 
Clinical Study Protocol, Section  5.15 (Early Termination Visit), bullet 5. Original text:  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of blood samples)  
Was revised as follows:  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs asses sment and collection of blood samples)  
Clinical Study Protocol, Section  5.16 (Unscheduled Visit[s]). Original text:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required 
between scheduled clinic visits, the subject must return for an Unscheduled Visit. The following 
assessments are required:  
• Concomitant medications assessment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 132 of 324 • Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• LCM return/compliance (as appli cable)  
• Subject diary assessment  
• Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
Was revised as follows:  
An Unscheduled Visit may be performed at the investigator’s discretion. I f the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if an LCM dose increase is required 
between scheduled clinic visits, the subject must return for an Unscheduled Visit. If an AE 
prompts a dose reduction, the reduction can be impl emented immediately at the investigator’s 
discretion. However, the subject should return to the clinic as soon as possible for an 
Unscheduled Visit.  
The following assessments are required:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 133 of 324 Clinical Study Protocol, Section  5.17 (Final Visit [2 weeks  after the last LCM dose]), bullet 5. 
Original text:  
• 12-lead ECG (2 recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of blood samples)  
Was revised as follows:  
• 12-lead ECG (2 interpretable recordings approximate ly 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
Clinical Study Protocol, Section  6.1 (Seizure counts). Original text:  
At Screening of the primary study, SP847, subjects/caregivers (including parents/legal 
guardian s) will be asked how many seizures the subject has had in the previous 4  weeks; this will 
serve as a historical Baseline. After the subject is enrolled in the SP848 study, seizure data will 
be collected in diaries provided to subjects/caregivers (including  parents/legal guardians). Each 
subject/caregiver (including parent/legal guardian) will keep a diary to note daily seizure activity 
throughout the current study. The subject/caregiver (including parent/legal guardian) should be 
reminded to bring the diary  with them at each clinic visit. The following information will be 
recorded:  
• Seizure type  
• Seizure frequency  
Was revised as follows:  
At Screening of SP847 (or other primary study as applicable) subjects/caregivers (including 
parents/legal guardians) will be  asked how many seizures the subject has had in the previous 
4 weeks; this will serve as a historical Baseline. After the subject is enrolled in the SP848 study, 
seizure data will be collected in diaries provided to subjects/caregivers (including parents/l egal 
guardians). Each subject/caregiver (including parent/legal guardian) will keep a diary to note 
daily seizure activity throughout the current study. The subject/caregiver (including parent/legal 
guardian) should be reminded to bring the diary with them  at each clinic visit. The following 
information will be recorded:  
• Seizure type  
• Seizure frequency  
Clinical Study Protocol, Section  6.2.1 (Clinical Global Impression of Change), paragraph 2. 
Original text:  
For the assessment of the Clinical Global Impressio n of Change, the investigator  should provide 
his/her assessment of the subject’s clinical status, compared to Baseline, including an evaluation 
of seizure frequency and intensity, the occurrence of AEs, and subject’s functional status. Visit  1 
of SP847 (pr imary study) will serve as Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 134 of 324 Was revised as follows:  
For the assessment of the Clinical Global Impression of Change, the investigator  should provide 
his/her assessment of the subject’s clinical status, compared to Baseline, including an evaluation 
of seizure frequency and intensity, the occurrence of AEs, and subject’s functional status. Visit  1 
of SP847 (or other primary study as applicable) will serve as Baseline.  
Clinical Study Protocol, Section  6.2.2 (Caregiver Global Impression of Change), para graph 2. 
Original text:  
For the assessment of the Clinical Global Impression of Change, the caregiver  (including 
parent/legal guardian) should provide his/her assessment of the subject’s clinical status, 
compared to Baseline, including an evaluation of sei zure frequency and intensity, the occurrence 
of AEs, and subject’s functional status. Visit 1 of SP847 (primary study) will serve as Baseline.  
Was revised as follows:  
For the assessment of the Clinical Global Impression of Change, the caregiver  (including 
parent/legal guardian) should provide his/her assessment of the subject’s clinical status, 
compared to Baseline, including an evaluation of seizure frequency and intensity, the occurrence 
of AEs, and subject’s functional status. Visit 1 of SP84 7 (or other primary study as applicable) 
will serve as Baseline.  
Clinical Study Protocol, Section  7 (Assessment of pharmacokinetics), paragraph 2. Original 
text: 
Each blood sample drawn will be split into 2 duplicate samples. The samples will be centrifuge d 
and stored at -20ºC until shipped to a central laboratory. The central laboratory will store the 
plasma samples at -70ºC until analysis. Details of plasma sample collection and processing, 
sample labeling, and shipment will be provided in the laboratory manual.  
Was revised as follows:  
Each blood sample drawn will be split into 2 duplicate samples. The samples will be centrifuged 
and stored at ≤ -20ºC until shipped to a central laboratory. The central laboratory will store the 
plasma samples at -20ºC until analysis. Details of plasma sample collection and processing, 
sample labeling, and shipment will be provided in the laboratory manual.  
Clinical Study Protocol, Section  8.2.2 (AEs of special interest), bullet 1. Original text:  
• The following arrhythmias: atr ial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (2nd degree Type I and II and 3rd degree), and marked bradycardia (<45beats/min)  
Was revised as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 135 of 324 • The following arrhythmias: atrial fibrillation/flutter, ventricular tachyca rdia or fibrillation, 
AV block (second degree Type I and II and third degree), and marked bradycardia 
(<45beats/min)  
Clinical Study Protocol, Section  8.3 (Laboratory measurements). The laboratory parameter:  
Acetone  
Was replaced with:  
Ketone  
Clinical Study Protocol, Section  8.3.1 (Liver function tests). Original text:  
Transaminases (AST, ALT, or both) ≥3x ULN but <5x ULN, in the presence of total bilirubin 
≥2x ULN, or transaminases (AST, ALT, or both) ≥5x ULN will result in immediate 
discontinuation of LCM a nd withdrawal of the subject from the study. The LFTs will be repeated 
as soon as possible, and in no case more than 1 week later (see  Section 4.3.3 ). 
Was revised as follows:  
Transaminases (AST, ALT, or both) ≥3x ULN but <5x ULN, in the presence of total bilirubin 
≥2x ULN, or transaminases (AST, ALT, or both) ≥5x ULN will result in immediate 
discontinuation of LCM and withdrawal of the subject from th e study. The LFTs will be repeated 
as soon as possible, and in no case more than 1 week later (see  Section 4.3.3 ). 
Transaminases (AST, ALT, or both)  ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality (ie, 
transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring of LFTs 
should continue until resolved (ie, <3xULN or stable condition). The investigator is to decide 
whether or not to stop the study medication.  
In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C will 
be done.  
Referral to a specialist (ie, hepatologist or gastroenterologist) is at the discretion of the 
investigator.  This is recommended especially if the transaminase abnormalities >3xULN persist 
after discontinuation of the study medication.  
Clinical Study Protocol, Section  9.1 (Manufac turing, packaging, and labeling). The following 
bullets were added:  
• Date bottle opened  
• Do not use after (date)  
Clinical Study Protocol, Section  10.2 (Monitoring), paragraph 1. Original text:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 136 of 324 SCHWARZ BIOSCIENCES or designee will monitor the study to meet th e Sponsor’s 
monitoring standard operating procedures (SOPs), ICH -GCP guideline, and applicable 
regulatory requirements and to ensure that study initiation, conduct, and closure are adequate.  
Was revised as follows:  
SCHWARZ BIOSCIENCES or designee will moni tor the study to meet the Sponsor’s 
monitoring standard operating procedures (SOPs), ICH -GCP guideline, and applicable 
regulatory requirements and to ensure that study initiation, conduct, and closure are adequate. 
Monitoring of the study may be delegated by SCHWARZ BIOSCIENCES to a CRO or a 
contract monitor.  
Clinical Study Protocol, Section  12.1 (Description of statistical methods), paragraph 2. Original 
text: 
Visit  1 of SP847 (primary study) will serve as Baseline values for safety and efficacy variables 
unless otherwise noted.  
Was revised as follows:  
Visit  1 of SP847 (or other primary study as applicable) will serve as Baseline values for safety 
and efficacy variables unless otherwise noted.  
Clinical Study Protocol, Section  12.1.2.2 (Other safety variables), paragraph 1. Original text:  
The other safety variables include changes in laboratory parameters (ie, hematology, clinical 
chemistry, and urinalysis), ECG measurements, vital sign measurements (blood pressure and 
pulse rate), body weight, height , calculated BMI, and Tanner Stage (if applicable). The actual 
measurement and its change from Baseline (SP847 Visit 1) will be analyzed descriptively and 
presented by visit. In addition, shift tables may be used to evaluate the number and percentage of 
subjects having a different postBaseline status when compared with their Baseline status.  
Was revised as follows:  
The other safety variables include changes in laboratory parameters (ie, hematology, clinical 
chemistry, and urinalysis), ECG measurements, vita l sign measurements (blood pressure and 
pulse rate), body weight, height, calculated BMI, and Tanner Stage (if applicable). The actual 
measurement and its change from Baseline (SP847 [or other primary study as applicable] Visit 
1) will be analyzed descript ively and presented by visit. In addition, shift tables may be used to 
evaluate the number and percentage of subjects having a different post -Baseline status when 
compared with their Baseline status.  
Clinical Study Protocol, Section  12.1.4.1 (Seizure frequ ency). Original text:  
Seizure frequency will be assessed using seizure diaries in order to evaluate the preliminary 
efficacy of LCM in this population. Seizure frequency per 7  days will be calculated as ([number 
of seizures over the specified time interval ]) divided by [number of days in the interval]) 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 137 of 324 multiplied by 7 and summarized descriptively and presented graphically at each visit and 
grouped by dose.  
Was revised as follows:  
Seizure frequency will be assessed using seizure diaries in order to evaluate  the preliminary 
efficacy of LCM in this population. Seizure frequency per 28  days will be calculated as ([number 
of seizures over the specified time interval]) divided by [number of days in the interval]) 
multiplied by 28  and summarized descriptively and presented graphically at each visit and 
grouped by dose.  
Clinical Study Protocol, Section  12.1.5 (Handling of protocol violators, drop -outs, and missing 
values), paragraph 1. Original text:  
All data will be used to their maximum possible extent, but witho ut any imputations for missing 
data for any parameter. Protocol deviations will be assessed during data review by a panel 
consisting of the study manager, the trial biostatistician, a representative of the monitoring team, 
and other appropriate study team members.  
Was revised as follows:  
All data will be used to their maximum possible extent, but without any imputations for missing 
data for any parameter. Protocol deviations will be assessed during data review by a panel 
consisting of the study manager, the  study biostatistician, a representative of the monitoring 
team, and other appropriate study team members.  
Clinical Study Protocol, Section  12.2 (Determination of sample size). Original text:  
Up to 30 subjects from the SP847 study will enroll in this open -label extension study.  
Was revised as follows:  
Approximately 42  subjects from the SP847 study will be eligible to enroll in this open -label 
extension study. Other subjects will be eligible to enroll as future LCM pediatric clinical studies 
in epilepsy are undertaken.  
Clinical Study Protocol, Section  15 (References). The following reference was updated:  
CHMP/EWP/566/98 Guideline on clinical investigation of medicinal products in the treatment of 
epileptic disorders (EMA) Rev 2, 20 Jan 2010.  
Clinical Study Pr otocol, Section  16.1 (Tabular schedule of study procedures) was updated to the 
following:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 138 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X  X  
Blood sample for concomitant AEDsj Xh  X   X  X  X X  X  
Urinalysis  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC       X    X X    
Caregiver GIC       X    X X    
Dispense LCM  X  X X X X X X X X Xm Xn   
LCM  return/ compliance    X X X X X X X X X Xn X  
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
AE reportingo Xh X X X X X X X X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 139 of 324 AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change; LCM=lacosamide; 
PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up telephone contact).  
b Visit 1 is also the last visit of the primary study. At Visit 1, the informed consent will be signed (and assent, if applicab le) and eligibility assessed, the medical history will b e 
updated, body weight and height and concomitant medications including AEDs will be recorded, AEs will be assessed, and the su bject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits , the subject must return for an Unscheduled Visit. 
Height will not be recorded at an Unscheduled Visit.  
f A Final Visit should be performed 2 weeks after a subject has tapered off LCM  
g This TC occurs 28  to 35 days after the last dose of LCM.  
h Assessments should have been done as part of the last visit of the primary study.  
i An ECG i s also required when the dose of LCM is increased or a new concomitant AED is introduced. The ECG should be performed after t he increased dose of LCM or the 
new AED has reached steady state. This ECG can be done at the next scheduled visit. When the ECG as sessment is performed, 2 interpretable ECGs will be performed 
approximately 20 to 30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable), and prior to administration of LCM (if applicable).  
j Blood samples may be draw n at any time post -dosing with LCM.  
k For female subjects of childbearing potential (ie, females who have begun menstruating), serum pregnancy tests will be perfor med at Visit 1, the Early Termination Visit, and 
the Final Visit. Urine pregnancy tests will be performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower tape r of 2mg/kg/day (oral  solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussio n with the medical monitor, whenever possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 140 of 324 n As applicable  
o Ongoing AEs from the primary study will be followed, as well as recording of new AEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 141 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X  X  
Blood sample for 
concomitant AEDsh X  X X X X  X  
Urinalysis    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
AE reporting X X X X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 142 of 324 AE=adverse event; AED=antiepileptic drug; ECG=electrocardiogram; ETV=Early Termination Visit; GIC=Global Impression of Change; LCM=lacosamide; 
PK=pharmacokinetics; S=serum; TC=telephone contact; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at the inv estigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is req uired between scheduled clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e A Final Visit should be performed 2 weeks after a subject has tapered off LCM.  
f This TC occurs 28 -35 days after  the last dose of LCM.  
g An ECG is also required when the dose of LCM is increased or a new concomitant AED is introduced. The ECG should be performed  after the increased dose 
of LCM or the new AED has reached steady state. This ECG can be done at the next  scheduled visit. When the ECG assessment is performed, 2 interpretable 
ECGs will be performed approximately 20 to 30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable), and prior to 
administration of LCM (if applica ble). 
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential (ie, females who have begun menstruating), serum pregnancy tests will be perfor med at the Early Termination 
Visit and at the Final Visit. U rine pregnancy tests will be performed at Visits 10, 11, 12, and 13.  
j The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
k Lacosamide for taper will be dispensed only  for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (t ablet). A slower taper of  
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is permitted after 
discussion with the medical monitor, whenever possible.  
l As applicable.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 143 of 324 Clinical Study Protocol, Section  16.3 (Declarations and signatures of persons responsible for 
the study). Original text:  
Clinical Project Manager  
, BS    _________________________________________  
      Date / Signature  
Clinical Trial Biostatistician  
 MPH     _________________________________________  
      Date / Signature  
Medical Director (Medical Therapeutics)  
, MD     _________________________________________  
      Date / Signature  
Associate Clinical Program Director  
, BS    _________________________________________  
      Date / Signature  
Was revised as follows:  
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in  this protocol and according to current Good Clinical Practice.  
Clinical Project Manager  
    _________________________________________  
      Date / Signature  
Clinical Trial Biostatistician  
, MPH     _______________________________ __________  
      Date / Signature  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 144 of 324 Medical Director (Medical Therapeutics)  
, MD     _________________________________________  
      Date / Signature  
Associate Clinical Program Director  
     _________________________________________  
      Date / Signature  
17.3 PROTOCOL AMENDMENT  3 
RATIONALE FOR THE AMENDMENT  
The sponsor’s name has been changed to UCB BIOSCIENCES, INC. Specific sponsor contact 
information has been updated.  
As recommended by the FDA, text has been added or modified to make i t clear that the 
maximum permitted LCM dose in SP848 is 12mg/kg/day or 600mg/day, whichever is lower.  
As recommended by the FDA, the C -SSRS has been added to evaluate and identify subjects at 
risk for suicide while participating in a clinical study of a drug with CNS activity (FDA, 
Guidance for Industry, 2010).  
Beginning with protocol Amendment  3, the oral solution (syrup) formulation of LCM to be used 
in this study contains 10mg/mL of drug substance (formerly containing 15mg/mL of drug 
substance).  
All su bjects will be required to have a 12 -lead ECG (2  interpretable recordings approximately 
20 to 30  minutes apart) conducted at LCM C max 1 week after an initial LCM dose increase. This 
ECG can be conducted at an Unscheduled Visit, if necessary. These subjects  will be required to 
arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20  to 30  minutes apart prior  to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
A list of anticipated SAEs has been included in this amendment in compliance with the recent 
US FDA guidance on safety reporti ng requirements for studies conducted under an open IND 
(effective 28 Mar 2011; FDA, Guidance for Industry and Investigators, 2010).  
Other changes made in this amendment are administrative in nature and are included in the 
specific changes below.  
MODIFICAT IONS/CHANGES  
• The name of the sponsor was changed from SCHWARZ BIOSCIENCES to UCB 
BIOSCIENCES throughout the text; each occurrence of this change is not included in 
Section REFERENCE.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 145 of 324 • The EudraCT number has been added to the cover page.  
• The name and contact  information for the Safety Physician (Global Clinical Safety and 
Pharmacovigilance) were updated.  
• Information was added to Section  1 (Summary) and throughout the protocol to indicate 
that the maximum permitted LCM dose in SP848 is 12mg/kg/day or 600mg/day , 
whichever is lower.  
• In Section  4.3.2  (Exclusion criteria), Section  4.3.3  (Criteria for withdrawal), and 
Section  8.4.6  (Assessment of suicidality), language was added to address the 
recommendations from the FDA to evaluate and identify subjects at risk for suicide while 
participating in a clinical study of a drug with CNS activity.  
• In Section  8.2.6  (Anticipated serious adverse events), a list of anticipated SAEs was 
added to follow the recent FDA guidance on safety reporting requirements for studies 
conducted under an open IND (effective 28 Mar 2011; FDA, Guidance for Industry and 
Investigators, 2010).  
• The tabular schedules of study procedures were updated to reflect the changes to the 
protocol.  
REFERENCE  
Clinical Study Protocol, cover page. The EudraCT number was added as follows:  
EudraCT Number: 2011 -001559 -35 
Clinical Study Protocol, Contact information for the Safety Physician (Global Clinical Safety 
and Pharmacovigilance). Original text:  
Associate Medical Director (Global Clinical Safety and Pharmacovigilance) : 
Name:  , MD  
Address:  SCHWARZ BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 146 of 324 Was revised as follows:  
Safety Physician (Global  Clinical Safety and Pharmacovigilance ) : 
Name:  , MB BCh BAO, MRCGP  
Address:  UCB Pharma S.A. Belgium  
Chemin du Foriest  
B-1420 Braine -L’Alleud, Belgium  
Phone/Fax:   
E-mail:   
Clinical Study Protocol, List of Abbreviations. The following abbreviations were added:  
C-SSRS  Columbia -Suicide Severity Rating Scale  
FDA  Food and Drug Administration  
PT preferred term  
SOC  system organ class  
 
Clinical Study Protocol, Section  1 (Summary), paragraph  2. Original text:  
Subjects who complete SP847 and choose to enter this open -label extension study will begin on 
the LCM dose they achieved in SP847. Subjects who discontinued from SP847 due to a dose 
reduction or status epilepticus, bu t for whom it is determined medically appropriate to enter this 
open -label extension study, will also begin on the LCM dose they achieved in SP847. Subjects 
will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, investigators 
will be allowed to increase or decrease the dose of LCM and/or concomitant antiepileptic drugs 
(AEDs) to optimize tolerability and seizure reduction for each subject. The investigator may 
adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup] ) or 100mg/day (tablet) 
and a maximum of 12mg/kg/day (oral solution [syrup] or the corresponding dose levels for the 
tablet formulation) not to exceed 600mg/day based on body weight, even if the subject’s body 
weight exceeds 50kg. An increase in the LCM do se must occur only during office visits. If 
needed to optimize tolerability and seizure reduction in selected subjects, concomitant AEDs 
may be carefully tapered and discontinued to achieve LCM monotherapy. New concomitant 
AEDs may be introduced as treatme nt if the medication has been approved by the Regulatory 
Authorities in the country in which the subject lives. New concomitant AEDs should be added 
only when the subject has not optimally or adequately responded to a maximum tolerated dose of 
LCM. When su bjects withdraw from the study, it is recommended that LCM be tapered 
gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for 
subjects who have achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 147 of 324 (tablet) . A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possib le. 
Was revised as follows:  
Subjects who complete SP847 and choose to enter this open -label extension study will begin on 
the LCM dose they achieved in SP847. Subjects who discontinued from SP847 due to a dose 
reduction or status epilepticus, but for whom it is determined medically appropriate to enter this 
open -label extension study, will also begin on the LCM dose they achieved in SP847. Subjects 
will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, investigators 
will be allo wed to increase or decrease the dose of LCM and/or concomitant antiepileptic drugs 
(AEDs) to optimize tolerability and seizure reduction for each subject. The investigator may 
adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 100mg/ day (tablet) 
and a maximum of 12mg/kg/day (oral solution [syrup] or the corresponding dose levels for the 
tablet formulation) not to exceed 600mg/day based on body weight, even if the subject’s body 
weight exceeds 50kg. The maximum permitted LCM dose in SP 848 is 12mg/kg/day or 
600mg/day, whichever is lower. An increase in the LCM dose must occur only during office 
visits. If needed to optimize tolerability and seizure reduction in selected subjects, concomitant 
AEDs may be carefully tapered and discontinued  to achieve LCM monotherapy. New 
concomitant AEDs may be introduced as treatment if the medication has been approved by the 
Regulatory Authorities in the country in which the subject lives. New concomitant AEDs should 
be added only when the subject has not  optimally or adequately responded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended that LCM be 
tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day 
(tablets) for subjects who  have achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or 
≥300mg/day (tablet) . A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster  
taper is permitted after discussion with the medical monitor, whenever possible.  
Clinical Study Protocol, Section  2 (Background information), paragraph  9. Original text:  
When oral LCM was administered as adjunctive therapy at doses up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastrointestinal -associated events. A dose relationship was seen f or the most frequently reported 
common TEAEs, including dizziness, headache, nausea, and diplopia. The nature and frequency 
of AEs were comparable to adjunctive therapy with other marketed AEDs. Safety evaluations 
support the further development of LCM as an AED.  
Was revised as follows:  
When oral LCM was administered as adjunctive therapy at doses up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastrointestinal -associated events. A dose relationship was seen for the most frequently reported 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 148 of 324 common TEAEs, including dizziness, nausea, and diplopia. The nature and frequency of AEs 
were comparable to  adjunctive therapy with other marketed AEDs. Safety evaluations support 
the further development of LCM as an AED.  
Clinical Study Protocol, Section  4.1 (Study description). Original text:  
Subjects who complete SP847 (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will begin on the LCM dose 
they achieved in SP847. Subjects will be able to continue on LCM oral soluti on (syrup) or switch 
to LCM tablets. During the study, investigators will be allowed to increase or decrease the dose 
of LCM and/or concomitant AEDs to optimize tolerability and seizure reduction for each subject. 
The investigator may adjust the LCM dose t o a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the 
corresponding dose levels for the tablet formulation), not to exceed 600mg/day based on body 
weight, even if the subject’s b ody weight exceeds 50kg. Increases in the LCM dose must occur 
only during office visits. If needed to optimize tolerability and seizure reduction in selected 
subjects, concomitant AEDs may be carefully tapered and discontinued to achieve LCM 
monotherapy. N ew concomitant AEDs may be introduced as treatment if the medication has 
been approved by the Regulatory Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or adequately 
respo nded to a maximum tolerated dose of LCM. When subjects withdraw from the study, it is 
recommended that the study medication be tapered gradually in weekly decrements of 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have achieve d a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . A slower taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if 
medically necessary. In case of an emergency, a faster taper is pe rmitted after discussion with the 
medical monitor, whenever possible.  
Was revised as follows:  
Subjects who complete SP847 (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will beg in on the LCM dose 
they achieved in SP847. Subjects will be able to continue on LCM oral solution (syrup) or switch 
to LCM tablets. During the study, investigators will be allowed to increase or decrease the dose 
of LCM and/or concomitant AEDs to optimize tolerability and seizure reduction for each subject. 
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the 
corresponding dose levels for  the tablet formulation), not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower. Increases in the LCM dose must occur 
only durin g office visits. If needed to optimize tolerability and seizure reduction in selected 
subjects, concomitant AEDs may be carefully tapered and discontinued to achieve LCM 
monotherapy. New concomitant AEDs may be introduced as treatment if the medication has  
been approved by the Regulatory Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or adequately 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 149 of 324 responded to a maximum tolerated dose of LCM. When subjects withdraw from the  study, it is 
recommended that the study medication be tapered gradually in weekly decrements of 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have achieved a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (table t). A slower taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if 
medically necessary. In case of an emergency, a faster taper is permitted after discussion with the 
medical monitor, whenever possible.  
Clinical Study Protocol, Section  4.3.2 (Exclusion criteria). Exclusion criterion  3 was newly 
added as follows:  
1. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation  in the past 6  months as indicated by a 
positive response (“Yes”) to either Question  4 or Question  5 of the Columbia -Suicide 
Severity Rating Scale (C -SSRS) at Screening.  
Clinical Study Protocol, Section  4.3.3 (Criteria for withdrawal). Original text:  
All s ubjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, t hese cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be followed until resolution of the event or until the 
event is considered stable.  
Participa tion in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relevant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation in the study  
2.   The reques t of the Sponsor or a Regulatory Agency  
3.    Subject achieves menarche during the study and does not practice an acceptable method of 
contraception for the duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant, as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake or develops a 
third-degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is unwilling 
or unable to allow the subject to continue in the study.  
8.    Investigator’s decision that withdrawal from further parti cipation would be in the subject’s 
best interest.  
9.    Subject experiences status epilepticus  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 150 of 324 10.  In the case of liver function test (LFT) results of transaminases (AST, ALT, or both) 
≥3x ULN to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST, ALT, or both) 
≥5x ULN, the study medication must be immediately discontinued and the subject 
withdrawn from the study. The LFTs will be repeated as soon as possible, and in no case 
more than 1 week later.  
Participation in this study may be discontinued fo r any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted  by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
4.   Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring 
of LFTs should continue until resolved (ie,  <3xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.  
Was revised as follows:  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be followed until resolution of the event or until the 
event is considered stable.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relev ant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation in the study  
2.   The request of the Sponsor or a Regulatory Agency  
3.    Subject achieves menarche during the study and does not practice an acceptab le method of 
contraception for the duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant, as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake or develops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is unwilling 
or unable to allow the subject to continue in the study.  
8.    Investigator’s decision that withdrawal from further participation would be in the subject’s 
best interest.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 151 of 324 9.    Subject experiences status epilepticus  
10.  In the case of liver f unction test (LFT) results of transaminases (AST, ALT, or both) 
≥3x ULN to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST, ALT, or both) 
≥5x ULN, the study medication must be immediately discontinued and the subject 
withdrawn from the study. The  LFTs will be repeated as soon as possible, and in no case 
more than 1 week later.  
11. For subject who did not complete a C -SSRS at Screening, subject has a lifetime history 
(prior to study entry or since study start) of suicide attempt (including an acti ve attempt, 
interrupted attempt, or aborted attempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subject from the study and immediately refer the subject to a 
Mental Healthcare Professional.  
12. For all subjects, regardless o f whether or not a C -SSRS was completed at Screening, subject 
has active suicidal ideation as indicated by a positive response (“Yes”) to either Question  4 
or Question  5 of the “since last visit” version of the C -SSRS. The subject should be referred 
immedi ately to a Mental Healthcare Professional and must be withdrawn from the study.  
Participation in this study may be discontinued for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant w ith study procedures or medication, in the opinion of the investigator.  
4.   Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring 
of LFTs should continue until resolved (ie, <3xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.  
5.   For subject who d id not complete a C -SSRS at Screening, subject had active suicidal ideation 
in the past 6  months as indicated by a positive response (“Yes”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental Healthcare Professional and use clinical judgment as to whether to 
withdraw the patient from the study.  
Clinical Study Protocol, Section  4.4.1 (Treatments to be administered), paragraph  2 and 
paragraph  3. Original text:  
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based  on body 
weight, even if the subject’s body weight exceeds 50kg  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 152 of 324 The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600 mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The investigator may decrease the dose 
of LCM to a minimum of 2mg/kg/day (oral solution [syrup] or the corresponding dose level for 
the tablet formulation). Increases in the LCM d ose must occur only during office visits. It should 
be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the syrup), missed 
doses, or administration of an erroneous volume of syrup, study medication should not be 
readministered  and these subjects would remain at their assigned dose.  
Was revised as follows:  
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower.  
The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower. The investigator may decrease the 
dose of LCM to a minimum of 2mg/kg/day (oral solution [syrup] or the correspo nding dose level 
for the tablet formulation). Increases in the LCM dose must occur only during office visits. It 
should be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the syrup), 
missed doses, or administration of an erro neous volume of syrup, study medication should not be 
readministered and these subjects would remain at their assigned dose.  
Clinical Study Protocol, Section  4.4.2 (Description of investigational product), paragraph  1. 
Original text:  
The oral solution (syr up) formulation contains 15mg/mL of drug substance and is colorless to 
pale yellow in appearance. The oral solution (syrup) will be packaged in amber polyethylene 
terephthalate (PET) bottles with a white, child -proof, polypropylene screw cap.  
Was revised as follows:  
Beginning with protocol Amendment  3, the oral solution formulation contains 10mg/mL of drug 
substance (formerly containing 15mg/mL of drug substance)  and is colorless to pale yellow in 
appearance. The oral solution (syrup) will be packaged in a mber polyethylene terephthalate 
(PET) bottles with a white, child -proof, polypropylene screw cap.  
Clinical Study Protocol, Section  5.1 (Visit  1 [Week  0]), list of assessments. Original text:  
• Concomitant medications assessment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 153 of 324 • Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potentia l 
• Tanner Stage assessment (if applicable)  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subjects and caregivers (including paren t/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Was revised as follows:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment but 30  minutes to 1  hour after the administration of LCM)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 154 of 324 • C-SSRS  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subjects and caregivers (including pa rent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Clinical Study Protocol, Section  5.3 (Visit  2 [Week  4]). Original text:  
During Visit 2 (Week 4), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collecti on of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry and hematology  
• Blood samples for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine pregnancy test for female subjects of childbearing potential  
• LCM return/compliance. Subject’s caregivers will be instructed to return unused LCM at 
each study visit. Returned medication will be reconciled by the investigator (or designee) in 
order to monitor the subject’s compliance with the medication schedule. If a subject is found 
to be noncompliant, a decision will be made by the investigator, in conjunction with 
SCHWARZ BIOSCIENCES, as to whether the subject should be withdrawn from the study.  
• Subject diary assessment  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 155 of 324 Was revised as follows:  
During Visit 2 (Week 4), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs ass essment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry and hematology  
• Blood samples for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine pregnancy test for female subjects of childbearing potential  
• LCM return/compliance. Subject’s caregivers will be instructed to return unused LCM at 
each study visit. Returned medication will be reconciled by the investigator (or designee) in 
order to monitor the subject’s compliance with the medication schedule. If a su bject is found 
to be noncompliant, a decision will be made by the investigator, in conjunction with UCB 
BIOSCIENCES, as to whether the subject should be withdrawn from the study.  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diar y (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour inter vals (once in the morning and once in the 
evening).  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increased or a new concomitant AED is introduced. The ECG should be performed after the 
increased dose of LCM or the new  AED has reached steady -state. This ECG can be done at 
the next scheduled visit. When the ECG assessment is done, 2 interpretable recordings will 
be performed approximately 20 to 30  minutes apart prior to vital sign assessment and 
collection of blood sampl es (if applicable), but 30  minutes to 1  hour after the administration 
of LCM (if applicable).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 156 of 324 • All subjects will be required to have an ECG (2 interpretable recordings) conducted at LCM 
Cmax 1 week after an initial LCM dose increase. This ECG can be conduct ed at an 
Unscheduled Visit, if necessary. These subjects will be required to arrive at the clinic prior to 
taking their morning dose of LCM. Subjects will be administered their morning LCM dose 
by study personnel at the clinic so that an ECG (2 interpretab le recordings approximately 20 
to 30 minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour 
after the administration of LCM (ie, at LCM steady state C max). 
Clinical Study Protocol, Section  5.4 (Visit  3 [Week  8]). Original text : 
During Visit 3 (Week 8), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Urine pregnancy test for female subjects of childbearing potential  
• LCM return/compliance  
• Subject diary assessment  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AE s until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parents/legal guardians) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening.  
• A 12 -lead ECG is also required wh en the dose of LCM is increased or a new concomitant 
AED is introduced. The ECG should be performed after the increased dose of LCM or the 
new AED has reached steady -state. This ECG can be done at the next scheduled visit. When 
the ECG assessment is done, 2 interpretable ECGs will be performed approximately 20 to 30 
minutes apart prior to vital sign assessment, collection of blood samples (if applicable), and 
prior to administration of LCM (if applicable).  
Was revised as follows:  
During Visit 3 (Week 8), th e following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 157 of 324 • Brief physical examination  
• Brief neurological examination  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Urine pregnancy test  for female subjects of childbearing potential  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including parents/legal guardians) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
• A 12 -lead ECG (2  interpretable recordings) is also requi red when the dose of LCM is 
increased or a new concomitant AED is introduced. The ECG should be performed after the 
increased dose of LCM or the new AED has reached steady -state. This ECG can be done at 
the next scheduled visit. When the ECG assessment is done, 2 interpretable recordings will 
be performed approximately 20 to 30 minutes apart prior to vital sign assessment and 
collection of blood samples (if applicable), but 30  minutes to 1  hour after the  administration 
of LCM (if applicable).  
• All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM 
Cmax 1 week after an initial LCM dose increase. This ECG can be conducted at an 
Unscheduled Visit if necessary. These subjects will be required to arrive at the clinic prior to 
taking their morning dose of LCM. Subjects will be administered their morning LCM dose 
by study personnel at the clinic so that an ECG (2 interpretable recordings approximately 20 
to 30 minutes apart prior to vital signs assessment) can be performed 30  minu tes to 1  hour 
after the administration of LCM (ie, at LCM steady state C max). 
Clinical Study Protocol, Section  5.6 (Visit  5 [Week  20]). Original text:  
During Visit 5 (Week 20), the following will be performed:  
• Concomitant medications assessment  
• Concomitant  AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 158 of 324 • Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and  concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Urine pregnancy test for female subjects of childbearing potential  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• LCM return/compliance  
• Subject diary assessment  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including pa rents/legal guardians) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
A 12 -lead ECG is also required when the dose of LCM is increased or a new concomitant AED 
is introduced. The ECG s hould be performed after the increased dose of LCM or the new AED 
has reached steady -state. This ECG can be done at the next scheduled visit. When the ECG 
assessment is done, 2 interpretable ECGs will be performed approximately 20 to 30 minutes 
apart prior  to vital sign assessment, collection of blood samples (if applicable), and prior to 
administration of LCM (if applicable).  
Was revised as follows:  
During Visit 5 (Week 20), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AE Ds assessment  
• Complete physical examination  
• Complete neurological examination  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 159 of 324 • Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Urine pregnancy test for female subjects of childbearing potential  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• LCM return/co mpliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs until the next clinic visit)  
• Dispense LCM. Subjects and caregivers (including pare nts/legal guardians) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
A 12 -lead ECG (2 interpretable recordings)  is also required when the dose of LCM is increased 
or a new concomitant A ED is introduced. The ECG should be performed after the increased dose 
of LCM or the new AED has reached steady -state. This ECG can be done at the next scheduled 
visit. When the ECG assessment is done, 2 interpretable recordings will be performed 
approxima tely 20 to 30 minutes apart prior to vital sign assessment and collection of blood 
samples (if applicable), but 30  minutes to 1  hour after the administration of LCM (if applicable).  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects will be administer ed their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM st eady state C max). 
Clinical Study Protocol, Section  5.14 (Visit  13 [Week  96]). Original text:  
Assessments for Visit 13 (Week 96) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: the laboratory blood sample is collected only for 
clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG (2 interpretable 
recordings approximately 20 to 30 minutes apart prior to vital signs assessment and collection of 
blood sample) is conducted, and a Tanner Stage assessment is conducted (if applicable) . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 160 of 324 Was revised as follows:  
Assessments for Visit 13 (Week 96) are the same as those described for Visit 5 ( Week 20), in 
Section 5.8, with the following exceptions: the laboratory blood sample is collected only for 
clinical chemistry and hematology (ie, no  endocrinology), a 12-lead ECG (2 interpretable 
recordings approximately 20 to 30 minutes apart prior to vital signs assessment and collection of 
blood sample) is conducted, and a Tanner Stage assessment is conducted (if applicable) . 
Lacosamide for taper w ill be dispensed only for subjects who achieve a dose of 
LCM  ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (table t) (Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Clinical Study Protocol, Section  5.15 (Early Termination Visit). The following assessment was 
added:  
• C-SSRS  
Clinical Study Protocol, Section  5.16 (Unschedu led Visit[s]). Original text:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if an LCM dose increase is required 
between scheduled clinic visits, the sub ject must return for an Unscheduled Visit. If an AE 
prompts a dose reduction, the reduction can be implemented immediately at the investigator’s 
discretion. However, the subject should return to the clinic as soon as possible for an 
Unscheduled Visit.  
The following assessments are required:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 161 of 324 • Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
Was revised as follows:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if an LCM dose increase is required 
between scheduled clinic visits, the subject must return for an Unscheduled Visit. If an AE 
prompts a dose reduction, the reduction can be implemented immediately at the investigator’s 
discretion. However, the subject should return to the clinic as soon as p ossible for an 
Unscheduled Visit.  
The following assessments are required:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense LCM ( as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 162 of 324 Clinical Study Protocol, Section  5.17 (Final Visit [2  weeks after the last LCM dose]). The 
following assessment was added:  
• C-SSRS  
Clinical Study Protocol, Section  8.2.6 (Anticipated serious adverse events), was newly added as 
follows:  
The following list of an ticipated SAEs has been identified as these events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug 
exposure. This original list will remain in effect for the duration of the protocol. This l ist does 
not change the investigator’s obligation to report all SAEs (including anticipated SAEs) as 
detailed in Section  8.2.4 . 
Anticipated SAEs for  the pediatric epilepsy population  
MedDRA SOC  MedDRA PT  
Congenital, familial and genetic disorders  Teratogenicity  
General disorders and administrative site 
conditions  Sudden unexplained death in epilepsy  
Nervous system disorders  Convulsion  
Incontinence  
Status epilepticus  
Pregnancy, puerperium and perinatal disorders  Abortion spontaneous  
Psychiatric disorders  Psychotic behavior  
Abnormal behavior  
Anxiety  
Sleep disorder  
Reproductive system and breast disorders  Menstrual disorder  
MedDRA=Medical Dictionary for Regulatory Activities; PT=preferred term; SAE=serious adverse event; SOC=system organ 
class  
Clinical Study Protocol, Section  8.3.2 (Pregnancy testing). Original text:  
Females of childbearing potential (ie, female subjects who  have begun menstruating) will have 
serum and urine pregnancy tests performed during the study according to the tabular schedule of 
study procedures, Section  16.1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 163 of 324 Was revised as follows:  
Females of childbearing potential will have serum and urine pregnancy tests performed during 
the study according to the tabular schedule of study procedures, Section  16.1. 
Clinical Study Protocol, Section  8.4.4 (12 -lead ECG). Original text:  
Standard 12 -lead ECGs will be performed according to the tabular schedule of study procedures, 
Section  16.1, and as described in Section  5. 
Care should be taken to assure proper lead placement and quality of ECG recording. Subjects 
should rest in a supin e position at least 5  minutes prior to each recording and should be 
motionless during the recording.  
Was revised as follows:  
Standard 12 -lead ECGs will be performed according to the tabular schedule of study procedures, 
Section  16.1, and as described in Section  5. 
Beginning with Protocol Amendment  3, all subjects will be required to have a 12 -lead ECG 
(2 interpretable recordings approximately 20  to 30 minutes apart) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects w ill be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approximately 20  to 30  minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of L CM 
(ie, at LCM steady state C max). 
Care should be taken to assure proper lead placement and quality of ECG recording. Subjects 
should rest in a supine position at least 5  minutes prior to each recording and should be 
motionless during the recording.  
Clinic al Study Protocol, Section  8.4.6 (Assessment of suicidality) was newly added as follows:  
Suicidality will be assessed by trained study personnel using the C -SSRS (Columbia University 
Medical Center, 2008). For subjects ≥6  years of age, this scale will be u sed for screening as well 
as to assess suicidal ideation and behavior that may occur during the study. The C -SSRS will be 
completed according to the tabular schedule of study procedures, Section  16.1. 
Clinical Study Protocol, Section  15 (References). The following references were added:  
Columbia University Medical Center. Columbia -Suicide Severity Rating Scale (2008). 
http://www.cssrs.columbia.edu/. Accessed 19  Jun 2011.  
Food and Drug Administration. Guidance for Industry. Suicidality: Prospective assessment of 
occurrence in clinical trials. US Dept of Health and Human Services, Center for Drug Evaluation 
and Research, 09/2010. Available upon request.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 164 of 324 Food and Drug Administration. Guidance for Industry and Investigators. Safety reporting 
requirements for INDs and BE/BA studies. US Dept of Health and Human Services, Center for 
Drug Evaluation and Research, 09/2010. Available upon request.  
Clinical Study  Protocol, Section  16.1 (Tabular schedule of study procedures) was updated to the 
following:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 165 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X  X  
Blood sample for concomitant AEDsj Xh  X   X  X  X X  X  
Urinalysis  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC       X    X X    
Caregiver GIC       X    X X    
Dispense LCM  X  X X X X X X X X Xm Xn   
LCM return/compliance    X X X X X X X X X Xn X  
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
C-SSRSo X  X X X X X X X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 166 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
AE reportingp Xh X X X X X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up telephone contact).  
b Visit 1 is also the last visit of the primary  study. At Visit 1, the informed consent will be signed (and assent, if applicable) and eligibility assessed, the medical hist ory will be 
updated, body weight and height and concomitant medications including AEDs will be recorded, AEs will be assessed, and  the subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits, the subject must return for an Unscheduled Visit. 
Height will not be recorded at an Unscheduled Visit.  
f A Final Visit should be performed 2 weeks after a subject has tapered off LCM  
g This TC occurs 28 to 35 days after the last dose of LCM.  
h Assessments should have been done as part of the last visit of the primary study.  
i An ECG (2  interpretable recordings) is also required when the dose of LCM is increased or a new concomitant AED is introduced. T he ECG should be performed after the 
increased dose of LCM or the new AED has reached steady state. This ECG can be done at the next scheduled visit. When the ECG  assessment is performed, 2 interpretable 
recordings will be performed approximately 20 to 30 minutes apart prior to vital signs assessment, collection of blood samples (if applicable),  but 30 minutes to 1 hour after 
the administration of LCM (if applicable).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 167 of 324  Beginning with Protocol Amendment  3, all subjects will be required to have a 12 -lead ECG (2 interpretable recordings) conducted at LCM C max 1 week after an initial LCM 
dose increase. This ECG can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive at the clinic prior to taking their morning dose of 
LCM . Subjects will be administered their morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart 
prior to vital signs assessment) can be performed 30  minutes to 1  hour after the adminis tration of LCM (ie, at LCM steady state C max). 
j Blood samples may be drawn at any time post -dosing with LCM.  
k For female subjects of childbearing potential, serum pregnancy tests will be performed at Visit 1, the Early Termination Visi t, and the Final Vi sit. Urine pregnancy tests will be 
performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is reco mmended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussio n with the medical monitor, whenever possible.  
n As applicable  
o For all sub jects ≥6  years of age already enrolled, the screening version should be completed at the next clinic visit, and the “since last visit”  version should be completed 
thereafter.  
p Ongoing AEs from the primary study will be followed, as well as recording of ne w AEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 168 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X  X  
Blood sample for 
concomitant AEDsh X  X X X X  X  
Urinalysis    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
C-SSRSm X  X X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 169 of 324 Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
AE reporting X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; U=urine; Unsch=Unschedul ed; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontin ue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if  a LCM dose increase is required between scheduled clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e A Final Visit should be performed 2 weeks after a subject has tapered off LCM.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g An ECG (2  interpretable recordings) is also required when the dose of LCM is increased or a new concomitant AED is introduced. The ECG should be 
performed after the increased dose of LCM or the new AED ha s reached steady state. This ECG can be done at the next scheduled visit. When the ECG 
assessment is performed, 2 interpretable recordings will be performed approximately 20 to 30 minutes apart prior to vital sig ns assessment, collection of 
blood samples ( if applicable), but 30  minutes to 1  hour after the administration of LCM (if applicable).  
 Beginning with Protocol Amendment  3, all subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after 
an initial L CM dose increase. This ECG can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive at the clinic prior to 
taking their morning dose of LCM. Subjects will be administered their morning LCM dose by study personnel at  the clinic so that an ECG (2  interpretable 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 170 of 324 recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, 
at LCM steady state C max). 
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential, serum pregnancy tests will be performed at the Early Termination Visit and at the Final Visit. Urine pregnancy 
tests will be performed at Visits 10, 11, 12, and 13.  
j The Ta nner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course of th e study.  
k Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) o r ≥300mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (t ablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if me dically necessary. In case of an emergency, a faster taper is permitted after 
discussion with the medical monitor, whenever possible.  
l As applicable.  
m For all subjects ≥6  years of age already enrolled, the screening version should be completed at the nex t clinic visit, and the “since last visit” version should be 
completed thereafter.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 171 of 324 17.4 PROTOCOL AMENDMENT  4 
RATIONALE FOR THE AMENDMENT  
The primary purpose of this protocol amendment is to permit (at selected sites) up to 
approximately 100  eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study to enroll directly into SP848. The pu rpose of enrolling these 
subjects directly into SP848 is to obtain sufficient long -term safety exposures in the age range of 
≥4 years to ≤17  years of age; the additional long -term safety data will be included in planned 
regulatory submissions for LCM as ad junctive therapy for partial -onset seizures in pediatric 
subjects ≥4  years to ≤17  years of age with epilepsy.  
In addition, based on regulatory agency recommendations, the Achenbach CBCL, Bayley -III 
scales, and a LCM palatability and ease of use questionnaire have been added as assessments in 
SP848.  
Other changes made in this amendment are administrative in nature and are included in the 
specific changes below.  
MODIFICATIONS/CHANGES  
• With this protocol amendment, approximately 100  eligible pediatri c subjects ≥4  years to 
≤17 years of age with partial -onset seizures (deemed appropriate for treatment with 
adjunctive LCM) who have not previously participated in a LCM clinical study will be 
permitted to enroll directly into SP848. Therefore, the study ti tle has been updated to reflect 
that SP848 is no longer exclusively an “extension study.”  
• Study contact information has been updated (eg, Clinical Program Director, Safety Physician, 
and SAE reporting).  
• Information was added to Section  1 (Summary) and thro ughout the protocol to indicate that 
approximately 100  eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study will be permitted to enroll directly into SP848. A 
Screening and Titration Visits have been added for subjects enrolling directly into SP848.  
• Information was added to Section  1 (Summary) and throughout the protocol to reflect the 
addition of the Achenbach CBCL, Bayley -III scales, and a LCM palatability and ease of use 
questionnaire as assessments in SP848.  
• Modifications were made to Section  4.3.1 (Inclusion criteria) and Section  4.3.2 (Exclusion 
criteria) in order to address subjects who have participated i n SP847 or other LCM pediatric 
clinical studies in epilepsy or who have enrolled directly into SP848 without previous 
participation in a LCM clinical study.  
• Information was added to Section  8.4.4 (12 -lead ECG) and throughout the protocol to clarify 
that al l subjects will be required to have a 12 -lead ECG (2  interpretable recordings 
approximately 20  to 30  minutes apart) conducted at LCM Cmax 1  week after an initial LCM 
dose increase to a LCM dose that is ≥8mg/kg/day or when a new concomitant AED is 
introduce d. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 172 of 324 REFERENCE  
Clinical Study Protocol, cover page, study title. Original text:  
AN OPEN -LABEL EXTENS ION STUDY TO DETERMI NE SAFETY, 
TOLERABILITY, AND EF FICACY OF LONG -TERM ORAL 
LACOSAMIDE  (LCM) AS ADJUNCTIVE THERAPY I N CHILDREN 
WITH  PARTIAL -ONSET S EIZURES  
Was revised as follows:  
AN OPEN -LABEL STUDY TO DETERMINE SAFETY,  TOLERABILITY, 
AND EFFICACY OF LONG -TERM ORAL LACOSAMID E (LCM) AS 
ADJUNCTIVE THERAPY I N CHILDREN WITH EPIL EPSY  
Clinical Study Protocol, cover page, sponsor information. The following text was del eted:  
A member of the UCB Group  
Clinical Study Protocol, Contact information for the Clinical Program Director and Safety 
Physician. Original text:  
Associate Clinical Program Director:  
Name:  , BS 
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 173 of 324 Safety Physician (Global Clinical Safety and Pharmacovigilance) : 
Name:  , MB BCh BAO, MRCGP  
Address:  UCB Pharma S.A. Belgium  
Chemin du Foriest  
B-1420 Braine -L’Alleud, Belgium  
Phone/Fax:   
E-mail:   
 
Was revised as follows:  
Clinical Program Director:  
Name:  , BS 
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
Safety Physician (Drug Safety) : 
Name:   MD 
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 174 of 324  
Clinical Study Protocol, Serious Adverse Event reporting contact information was added as 
follows:  
SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h), safety related issues,  
and emergency unblinding  
Fax Europe and Rest of the World (except Japan):  +32 2 386 24 21  
USA: +1 800 880 6949  
Canada:  +1 877 582 8842  
Japan: +81 3 5283 1869  
Email  Europe and Rest of the World (except Japan): GCSP@ucb.com  
Japan: JDSO@ucb.com  
 
Clinical Study Protocol, List of Abbreviations. The following abbreviations were added:  
Cmax maximum plasma concentration  
DS Drug Safety (formerly known as Global Clinical 
Safety and Pharmacovigilance)  
EEG  electroencephalogram  
GCSP  Global Clinical Safety and Pharmacovigilance  
MAO  monoamine oxidase  
TV Titration Visit  
 
Clinical Study Protocol, Section  1 (Summary). Original text:  
SP848 is an open -label extension study to obtain long -term safety, tolerability, and 
pharmacokinetic (PK) data in children with partial -onset seizures treated with lacosamide (LCM) 
oral solution (syrup) or LCM tablets as adjunctive therapy. In addition, th e study is designed to 
obtain preliminary efficacy data on seizure frequency during long -term exposure. The study will 
also provide continued availability of LCM to subjects who have completed the SP847 epilepsy 
study and to subjects who have discontinued from SP847 due to a dose reduction or status 
epilepticus, and who, in the investigator’s opinion, would benefit from long -term administration 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 175 of 324 of LCM. SP848 will also be open to subjects who participate in other future LCM pediatric 
clinical studies in epil epsy.  
Subjects who complete SP847 and choose to enter this open -label extension study will begin on 
the LCM dose they achieved in SP847. Subjects who discontinued from SP847 due to a dose 
reduction or status epilepticus, but for whom it is determined medically a ppropriate to enter this 
open -label extension study, will also begin on the LCM dose they achieved in SP847. Subjects 
will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, investigators 
will be allowed to increase or decrease the dose of LCM and/or concomitant antiepileptic drugs 
(AEDs) to optimize tolerability and seizure reduction for each subject. The investigator may 
adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) 
and a maximum o f 12mg/kg/day (oral solution [syrup] or the corresponding dose levels for the 
tablet formulation) not to exceed 600mg/day based on body weight, even if the subject’s body 
weight exceeds 50kg. The maximum permitted LCM dose in SP848 is 12mg/kg/day or 
600mg/ day, whichever is lower. An increase in the LCM dose must occur only during office 
visits. If needed to optimize tolerability and seizure reduction in selected subjects, concomitant 
AEDs may be carefully tapered and discontinued to achieve LCM monotherapy.  New 
concomitant AEDs may be introduced as treatment if the medication has been approved by the 
Regulatory Authorities in the country in which the subject lives. New concomitant AEDs should 
be added only when the subject has not optimally or adequately res ponded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended that LCM be 
tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day 
(tablets) for subjects who have achieved a dose of LCM  ≥6mg/kg/day (oral solution [syrup]) or 
≥300mg/day (tablet) . A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster 
taper is permitted after di scussion with the medical monitor, whenever possible.  
The primary variables for assessment of safety and tolerability are:  
• Adverse events (AEs) reported spontaneously by the subject and/or caregiver or observed by 
the investigator  
• Subject withdrawal due to  AEs 
• Hematology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body mass ind ex (BMI)  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
The secondary variables include seizure counts (assessed using seizure diaries in order to 
evaluate preliminary evidence of efficacy during long -term exposure in this p opulation), the 
Clinical Global Impression of Change, and the Caregiver Global Impression of Change.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 176 of 324 Was revised as follows:  
SP848 is an open -label study to obtain long -term safety, tolerability, and pharmacokinetic (PK) 
data in children with epilepsy (par tial-onset seizures and other pediatric epilepsy syndromes) 
treated with lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy. In 
addition, the study is designed to obtain preliminary efficacy data on seizure frequency during 
long-term exposure. The study will also provide continued availability of LCM to subjects who 
have completed the SP847 epilepsy study and to subjects who have discontinued from SP847 
due to a dose reduction or status epilepticus, and who, in the investigator’s op inion, would 
benefit from long -term administration of LCM.  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies in other epilepsy syndromes. In addition, at selected sites, 
beginning with Protocol Amendment  4, up to approximately 100  eligible pediatric subjects 
≥4 years to ≤17  years of age with partial -onset seizures (deemed appropriate fo r treatment with 
adjunctive LCM) who have not previously participated in a LCM clinical study will be permitted 
to enroll directly into SP848. The purpose of enrolling these subjects directly into SP848 is to 
obtain sufficient long -term safety exposures in  the age range of ≥4  years to ≤17  years of age; the 
long-term safety data will be included in planned regulatory submissions for LCM as adjunctive 
therapy for partial -onset seizures in pediatric subjects ≥4  years to ≤17  years of age with epilepsy. 
At selec ted sites, subjects may also be able to participate in a substudy without withdrawing from 
SP848.  
Subjects who complete SP847 or another applicable LCM pediatric epilepsy study and choose to 
enter this open -label study will begin on the LCM dose they achie ved in SP847 or their previous 
pediatric LCM study. Subjects who discontinued from SP847 due to a dose reduction or status 
epilepticus, but for whom it is determined medically appropriate to enter this open -label study, 
will also begin on the LCM dose they  achieved in SP847. Subjects who meet eligibility 
requirements and enroll directly into SP848 without previous participation in a LCM clinical 
study will initiate treatment with LCM, and the LCM dose will be titrated to a level to optimize 
tolerability and  seizure control (up to a maximum level as described below).  
Subjects will be able to receive LCM oral solution (syrup) or LCM tablets. During the study, 
investigators will be allowed to increase or decrease the dose of LCM and/or concomitant 
antiepileptic  drugs (AEDs) to optimize tolerability and seizure reduction for each subject. The 
investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the corr esponding 
dose levels for the tablet formulation) not to exceed 600mg/day based on body weight, even if 
the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in SP848 is 
12mg/kg/day or 600mg/day, whichever is lower. An increase in the LCM dose must occur only 
during office visits. If needed to optimize tolerability and seizure reduction in selected subjects, 
concomitant AEDs may be carefully tapered and discontinued to achieve LCM monotherapy. 
New concomitant AEDs may be introduced as treat ment if the medication has been approved by 
the Regulatory Authorities in the country in which the subject lives. New concomitant AEDs 
should be added only when the subject has not optimally or adequately responded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended that LCM be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 177 of 324 tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day 
(tablets) for subjects who have achieved a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or 
≥300mg/d ay (tablet) . A slower taper in weekly decrements of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster 
taper is permitted after discussion with the medical monitor, whenever poss ible. 
The primary variables for assessment of safety and tolerability are:  
• Adverse events (AEs) reported spontaneously by the subject and/or caregiver or observed by 
the investigator  
• Subject withdrawal due to AEs  
• Hematology, blood chemistry, endocrinology,  and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body mass index (BMI)  
• Plasma concentrations of LCM (for popul ation PK analysis) and concomitant AEDs  
• Achenbach CBCL for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) assessing 
behavior  
• Bayley -III scales for children <18  months of age at time of enrollment (applicable only to 
subjects enrolled in English -speaking countries)  
The secondary variables include seizure counts (assessed using seizure diaries in order to 
evaluate preliminary evidence of efficacy during long -term exposure in this population), the 
Clinical Global Impression of Change, the Caregiver Glo bal Impression of Change, and a LCM 
palatability and ease of use questionnaire.  
Clinical Study Protocol, Section  2 (Background information). Original text:  
Epilepsy is the second most prevalent neurological disorder in the world. More than 40  million 
people suffer from epilepsy –about 1% of the world’s population (Dichek, 1999). Although some 
forms of epilepsy may respond to surgical treatment and others may not require any treatment at 
all, most patients with epilepsy require appropriate pharmacologica l therapy (Perucca, 1996). In 
the past decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
The classification of epilepsies in children was described in 1989 by the Commi ssion on 
Classification and Terminology of the International League Against Epilepsy (1989; Aicardi, 
1994). Seizures are categorized based on whether the onset is focal or generalized and whether 
the disorder is idiopathic, symptomatic, or cryptogenic. Spe cific syndromes are further classified 
according to a number of criteria including seizure type, cause, anatomy, precipitating factors, 
age of onset, and sometimes prognosis.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 178 of 324 The newer AEDs differ from older agents in several important ways, including mech anism of 
action, spectrum of activity, and PK characteristics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure control on currently -available AEDs or experience 
significant adverse drug effects (CHMP/EWP/566/98, 2010). Therefore, a need remains for 
AEDs with improved effectiveness and tolerability (Sander, 1998).  
Among the newer AEDs, only 5 (gabapentin, lamotrigine, oxcarbazepine, topiramate, and 
levetiracetam) have successfully demonstrated efficacy as adjunctive thera py in children with 
difficult to treat partial -onset seizures (Appleton et al, 1999; Duchowny et al, 1999; 
Elterman  et al, 1999; Glauser et al, 2000; Glauser et al, 2006). Despite the availability of new 
AEDs, more than 25% of pediatric patients have inade quate seizure control on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
Lacosamide (LCM, Vimpat®, SPM 927, [R] -2-acetamido -N-benzyl -3-methoxypropionamide) 
belongs to a novel class of functionaliz ed amino acids. It has minimal protein binding and effect 
on cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and a half -life of approximately 13  hours (in adults), which allows a twice 
daily (bid) dose regimen. It also displays dose -proportional PK following administration over a 
range of doses up to 800mg in adults.  
Lacosamide has been approved as adjunctive therapy in the treatment of partial -onset seizures 
with or without secondary generali zation in patients 16 years of age and older in the European 
Union (oral tablets, oral solution [syrup], and solution for intravenous [iv] infusion) and in 
patients 17  years of age and older in the United States (oral tablets, oral solution, and solution f or 
iv infusion). The oral solution (syrup) is a formulation suitable for administration to children. 
Bioequivalence has been shown between the tablet and oral solution (syrup) formulations, 
comparing 2 tablets of LCM 100mg and the oral solution (syrup) con taining LCM 200mg, after 
single -dose administration in healthy subjects. The PK of LCM and its major metabolite, 
SPM  12809 (O -desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after 
single oral doses of LCM 200mg administered as t ablets or as oral solution (syrup).  
In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
400mg bid (800mg/day) were evaluated in approximately 700  unique volunteers who received 
LCM in Phase  1 studies. The safety and efficacy of LCM has also been evaluated in Phase  2/3 
studies as adjunctive oral therapy in over 1300  adult subjects with partial -onset seizures and as 
oral monotherapy in over 2200  adult subjects in other indications (eg, neuropathic pain, 
osteoarthrit is, fibromyalgia, and migraine prophylaxis). In addition, LCM solution for infusion 
was evaluated as short -term replacement therapy in a subset of subjects with partial -onset 
seizures (199  patients) who were receiving adjunctive LCM tablets.  
Three double -blind, placebo -controlled, multicenter studies (SP667, SP754, and SP755) in 
1308  adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive 
therapy (1 to 3 concomitant AEDs) in subjects with difficult to control partial -onset se izures. In 
these studies, LCM was initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (200mg/day, 400mg/day, or 600mg/day) in 100mg/day per week increments.  
When oral LCM was administered as adjunctive therapy at dose s up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 179 of 324 most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastrointestinal -associated events. A dos e relationship was seen for the most frequently reported 
common TEAEs, including dizziness, nausea, and diplopia. The nature and frequency of AEs 
were comparable to adjunctive therapy with other marketed AEDs. Safety evaluations support 
the further develop ment of LCM as an AED.  
SP847, the current primary study, is an open -label, dose -titration, safety, tolerability, and PK 
study to evaluate LCM as adjunctive therapy in children with uncontrolled partial -onset seizures. 
Approximately 42  children (aged 1  mont h to 17 years) with uncontrolled partial -onset seizures 
on a stable dose regimen of at least 1 but no more than 3 AEDs will be enrolled. The study 
consists of a Screening Phase, a Treatment Phase, and an End -of-Study Phase. The duration of 
treatment for an  individual subject may be up to approximately 13 weeks. Approximately 
300 additional subjects who may participate in other future LCM primary pediatric clinical 
studies in epilepsy will also be eligible to participate in SP848.  
SP848 is an open -label exte nsion study to obtain long -term safety, tolerability, and PK data in 
children with partial -onset seizures treated with LCM oral solution (syrup) or LCM tablets as 
adjunctive therapy. In addition, the study is designed to obtain preliminary efficacy data on  
seizure frequency during long -term exposure. The study will also provide continued availability 
of LCM to subjects who have completed the SP847 epilepsy study (or discontinued SP847 due to 
a dose reduction or status epilepticus), and who, in the investiga tor’s opinion, would benefit from 
long-term administration of LCM. SP848 will also be open to subjects who participate in other 
future LCM pediatric clinical studies in epilepsy.  
Was revised as follows:  
Epilepsy is the second most prevalent neurological di sorder in the world. More than 40  million 
people have epilepsy –about 1% of the world’s population (Dichek, 1999). Although some forms 
of epilepsy may respond to surgical treatment and others may not require any treatment at all, 
most patients with epilepsy  require appropriate pharmacological therapy (Perucca, 1996). In the 
past decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
The classification of epilepsies in children  was described in 1989 by the Commission on 
Classification and Terminology of the International League Against Epilepsy (1989; Aicardi, 
1994). Seizures are categorized based on whether the onset is focal or generalized and whether 
the disorder is idiopathi c, symptomatic, or cryptogenic. Specific syndromes are further classified 
according to a number of criteria including seizure type, cause, anatomy, precipitating factors, 
age of onset, and sometimes prognosis.  
The newer AEDs differ from older agents in sev eral important ways, including mechanism of 
action, spectrum of activity, and PK characteristics (Herman and Pedley, 1998). However, more 
than 30% of patients have inadequate seizure control on currently -available AEDs or experience 
significant adverse dru g effects (CHMP/EWP/566/98, 2010). Therefore, a need remains for 
AEDs with improved effectiveness and tolerability (Sander, 1998).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 180 of 324 Among the newer AEDs, only 5 (gabapentin, lamotrigine, oxcarbazepine, topiramate, and 
levetiracetam) have successfully demons trated efficacy as adjunctive therapy in children with 
difficult to treat partial -onset seizures (Appleton et al, 1999; Duchowny et al, 1999; 
Elterman  et al, 1999; Glauser et al, 2000; Glauser et al, 2006). Despite the availability of new 
AEDs, more than 2 5% of pediatric patients have inadequate seizure control on currently 
available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
Lacosamide (LCM, Vimpat®, SPM 927, [R] -2-acetamido -N-benzyl -3-methoxypropionamide) 
belon gs to a novel class of functionalized amino acids. It has minimal protein binding and effect 
on cytochrome P450 enzyme system function (reducing the risk of drug -drug interactions), high 
oral bioavailability, and a half -life of approximately 13  hours (in a dults), which allows a twice 
daily (bid) dose regimen. It also displays dose -proportional PK following administration over a 
range of doses up to 800mg in adults.  
Lacosamide has been approved as adjunctive therapy in the treatment of partial -onset seizures  
with or without secondary generalization in patients 16 years of age and older in the European 
Union (oral tablets, oral solution [syrup], and solution for intravenous [iv] infusion) and in 
patients 17  years of age and older in the United States (oral tab lets, oral solution, and solution for 
iv infusion). The oral solution (syrup) is a formulation suitable for administration to children. 
Bioequivalence has been shown between the tablet and oral solution (syrup) formulations, 
comparing 2 tablets of LCM 100m g and the oral solution (syrup) containing LCM 200mg, after 
single -dose administration in healthy subjects. The PK of LCM and its major metabolite, 
SPM  12809 (O -desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after 
single oral d oses of LCM 200mg administered as tablets or as oral solution (syrup).  
In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
400mg bid (800mg/day) were evaluated in approximately 700  unique volunteers who received 
LCM in Phase  1 studies. The safety and efficacy of LCM has also been evaluated in Phase  2/3 
studies as adjunctive oral therapy in over 1300  adult subjects with partial -onset seizures and as 
oral monotherapy in over 2200  adult subjects in other indications (eg, neuropathic pain, 
osteoarthritis, fibromyalgia, and migraine prophylaxis). In addition, LCM solution for infusion 
was evaluated as short -term replacement therapy in a subset of subjects with partial -onset 
seizures (199  patients) who were receiving adj unctive LCM tablets.  
Three double -blind, placebo -controlled, multicenter studies (SP667, SP754, and SP755) in 
1308  adult subjects, aged 16 to 70 years, established the efficacy of oral LCM as adjunctive 
therapy (1 to 3 concomitant AEDs) in subjects with di fficult to control partial -onset seizures. In 
these studies, LCM was initiated at a dose of 100mg/day (in 2 divided doses) and escalated to the 
randomized dose (200mg/day, 400mg/day, or 600mg/day) in 100mg/day per week increments.  
When oral LCM was adminis tered as adjunctive therapy at doses up to 600mg/day in the 
3 double -blind, placebo -controlled, multicenter studies in subjects with partial -onset seizures, the 
most frequently reported treatment -emergent AEs (TEAEs) were central nervous system - and 
gastro intestinal -associated events. A dose relationship was seen for the most frequently reported 
common TEAEs, including dizziness, nausea, and diplopia. The nature and frequency of AEs 
were comparable to adjunctive therapy with other marketed AEDs. Safety eval uations support 
the further development of LCM as an AED.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 181 of 324 SP847 is an open -label, dose -titration, safety, tolerability, and PK study to evaluate LCM as 
adjunctive therapy in children with uncontrolled partial -onset seizures. Approximately 
42 children (aged  1 month to 17 years) with uncontrolled partial -onset seizures on a stable dose 
regimen of at least 1 but no more than 3 AEDs will be enrolled. The study consists of a 
Screening Phase, a Treatment Phase, and an End -of-Study Phase. The duration of treatment  for 
an individual subject may be up to approximately 13 weeks. Approximately 200  additional 
subjects who may participate in other LCM pediatric clinical studies in epilepsy will also be 
eligible to participate in SP848.  
SP848 is an open -label study to obt ain long -term safety, tolerability, and pharmacokinetic (PK) 
data in children with epilepsy (partial -onset seizures and other pediatric epilepsy syndromes) 
treated with lacosamide (LCM) oral solution (syrup) or LCM tablets as adjunctive therapy. In 
additio n, the study is designed to obtain preliminary efficacy data on seizure frequency during 
long-term exposure. The study will also provide continued availability of LCM to subjects who 
have completed the SP847 epilepsy study and to subjects who have disconti nued from SP847 
due to a dose reduction or status epilepticus, and who, in the investigator’s opinion, would 
benefit from long -term administration of LCM.  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with p artial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies in other epilepsy syndromes. In addition, at selected sites, 
beginning with Protocol Amendment  4, up to approximately 100  eligible pe diatric subjects 
≥4 years to ≤17  years of age with partial -onset seizures (deemed appropriate for treatment with 
adjunctive LCM) who have not previously participated in a LCM clinical study will be permitted 
to enroll directly into SP848. The purpose of en rolling these subjects directly into SP848 is to 
obtain additional long -term safety exposures in the age range of ≥4  years to ≤17  years of age; the 
additional long -term safety data will be included in planned regulatory submissions for LCM as 
adjunctive th erapy for partial -onset seizures.  
Clinical Study Protocol, Section  3 (Study objectives). Original text:  
The objectives of this study are:  
• To obtain information about the safety, tolerability, and PK of LCM during long -term 
exposure  
• To obtain preliminary efficacy data on seizure frequency during long -term exposure  
• To allow subjects who have participated in SP847 (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
• To allow subjects who have participated in other f uture LCM pediatric clinical studies in 
epilepsy to continue receiving LCM  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 182 of 324 Was revised as follows:  
The objectives of this study are:  
• To obtain information about the safety, tolerability, and PK of LCM during long -term 
exposure  
• To obtain preliminary efficac y data on seizure frequency during long -term exposure  
• To allow subjects who have participated in SP847 (or discontinued SP847 due to a dose 
reduction or status epilepticus) to continue receiving LCM  
• To allow subjects who have participated in other LCM pedi atric clinical studies in epilepsy to 
continue receiving LCM  
• Beginning with Protocol Amendment  4, at selected sites, to allow up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age who have not previously received 
LCM to begin rec eiving LCM  
Clinical Study Protocol, Section  4.1 (Study description). Original text:  
Subjects who complete SP847 (or discontinue SP847 due to a dose reduction or status 
epilepticus) and who choose to enter the open -label extension study, will begin on the L CM dose 
they achieved in SP847. Subjects will be able to continue on LCM oral solution (syrup) or switch 
to LCM tablets. During the study, investigators will be allowed to increase or decrease the dose 
of LCM and/or concomitant AEDs to optimize tolerabilit y and seizure reduction for each subject. 
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the 
corresponding dose levels for the tablet  formulation), not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower. Increases in the LCM dose must occur 
only during office vi sits. If needed to optimize tolerability and seizure reduction in selected 
subjects, concomitant AEDs may be carefully tapered and discontinued to achieve LCM 
monotherapy. New concomitant AEDs may be introduced as treatment if the medication has 
been appro ved by the Regulatory Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or adequately 
responded to a maximum tolerated dose of LCM. When subjects withdraw from the study, it is 
recommended that the study medication be tapered gradually in weekly decrements of 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have achieved a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . A slowe r taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if 
medically necessary. In case of an emergency, a faster taper is permitted after discussion with the 
medical monitor, whenever possible.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 183 of 324 Was revised as follows (including additions of subsection headings 4.1.1 [Subjects enrolling 
from SP847 or other LCM pediatric clinical studies in epilepsy] and 4.1.2 [Subjects enrolling 
directly in SP848]):  
Subjects who complete SP847 (including discontinuation from SP847 due to a dose reduction or 
status epilepticus) or subjects from another applicable LCM pediatric clinical study in epilepsy 
and who choose to enter the open -label study, will begin on the LCM dose they achieved in the 
primary study. Subjects will be able to continue on LCM oral solution (syrup) or switch to LCM 
tablets. During the study, investigators will be allowed to increase or decrease the dose of LCM 
and/or concomitant AEDs to optimize tolerability and seizure reduction for each subject. The 
investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the corresponding 
dose levels for the tablet formulation), not to exceed 600mg/day based on b ody weight, even if 
the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in SP848 is 
12mg/kg/day or 600mg/day, whichever is lower. Increases in the LCM dose must occur only 
during office visits. If needed to optimize tolerability and seiz ure reduction in selected subjects, 
concomitant AEDs may be carefully tapered and discontinued to achieve LCM monotherapy. 
New concomitant AEDs may be introduced as treatment if the medication has been approved by 
the Regulatory Authorities in the country in which the subject lives. New concomitant AEDs 
should be added only when the subject has not optimally or adequately responded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended that the 
study medication be taper ed gradually in weekly decrements of 4mg/kg/day (oral solution 
[syrup]) or 200mg/day (tablets) for subjects who have achieved a dose of LCM ≥6mg/kg/day 
(oral solution [syrup]) or ≥300mg/day (tablet) . A slower taper in weekly decrements of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if medically necessary. In 
case of an emergency, a faster taper is permitted after discussion with the medical monitor, 
whenever possible.  
Beginning with Protocol Amendment  4, at selected sites, up to  approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed appropriate 
for treatment with adjunctive LCM) who have not previously participated in a LCM clinical 
study will be permitted to enroll directly  into SP848.  
Subjects who enroll directly into SP848 without previous participation in a LCM clinical study 
will undergo screening. Eligible subjects will initiate treatment with LCM, and the LCM dose 
will be titrated to a level to optimize tolerability an d seizure control (see Section  4.4.1 ). Subjects 
will be able to receive LCM oral solution or LCM tablets for up to 2  years as determined 
appropriate  by the investigator.  
The same study conditions described in Section  4.1.1  (eg, minimum and maximum LCM dose, 
required office visits for dose increa ses, concomitant AEDs, and study medication taper) also 
apply.  
Clinical Study Protocol, Section  4.2.1 (Primary variables). The following variables were added:  
• Achenbach CBCL at Baseline for children 18  months and older (CBCL/1½ -5 and 
CBCL/6 -18) assessing b ehavior  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 184 of 324 • Bayley -III scales at Baseline for children <18  months of age at time of enrollment 
(applicable only to subjects enrolled in English -speaking countries)  
Clinical Study Protocol, Section  4.2.2 (Secondary variables). Original text:  
Secondary efficacy variables include:  
• Seizure counts, which will be assessed using seizure diaries in order to evaluate preliminary 
evidence of efficacy during long -term exposure in this population  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
Was revised as follows:  
Secondary variables include:  
• Seizure counts, which will be assessed using seizure diaries in order to evaluate preliminary 
evidence of efficacy during long -term exposure in this population  
• Clinical Global Impression of Change  
• Caregi ver Global Impression of Change  
• LCM palatability and ease of use questionnaire  
Clinical Study Protocol, Section  4.3.1 (Inclusion criteria). Original text:  
Subjects must fulfill the following inclusion criteria:  
1. A signed informed consent form has been obtai ned from the parent/legal guardian and assent 
has been obtained from the subject (when possible or as required according to local 
Institutional Review Boards [IRBs]/Independent Ethics Committees [IECs]).  
2. Subject has completed SP847 (or the subject disconti nued SP847 due to a dose reduction or 
status epilepticus) for the treatment of uncontrolled partial -onset seizures, or subject has 
participated in other LCM pediatric clinical studies in epilepsy.  
3. Subject is expected to benefit from participation, in the opinion of the investigator.  
4. Subject and caregiver (which may be a parent, legal guardian, or other delegated caregiver) 
are willing and able to comply with all study requirements, including maintaining a daily 
seizure diary.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 185 of 324 Was revised as follows:  
All su bjects in SP848 must fulfill the following inclusion criteria:  
1. A signed informed consent form has been obtained from the parent/legal guardian and assent 
has been obtained from the subject (when possible or as required according to local 
Institutional Revi ew Boards [IRBs]/Independent Ethics Committees [IECs]).  
4. Subject and caregiver (which may be a parent, legal guardian, or other delegated caregiver) 
are willing and able to comply with all study requirements, including maintaining a daily 
seizure diary.  
Subjects who have participated in SP847 or other LCM pediatric clinical studies in epilepsy must 
fulfill the following inclusion criteria:  
2. Subject has completed SP847 (or the subject discontinued SP847 due to a dose reduction or 
status epilepticus) for the tr eatment of uncontrolled partial -onset seizures, or subject has 
participated in other LCM pediatric clinical studies in epilepsy.  
3. Subject is expected to benefit from participation, in the opinion of the investigator.  
Subjects who enroll directly into SP848  without previous participation in a LCM clinical study  
must fulfill the following inclusion criteria:  
5. Subject is male or female and ≥4  years to ≤17  years of age.  
6. Subject has a diagnosis of epilepsy with partial -onset seizures.  
a. The results of at least 1  prior electroencephalogram  (EEG) AND 1  prior magnetic 
resonance imaging/computerized tomography scan should be consistent with the above 
diagnosis.  
7. Subject has been observed to have uncontrolled partial -onset seizures after an adequate 
course of treatment (in the opinion of the investigator) with at least 1  AED (concurrently or 
sequentially).  
8. Subject has been observed to have at least 2 countable seizures in the 4 -week period prior to 
Screening.  
a. In the case of simple partial sei zures, only those with motor signs will be counted 
towards meeting the inclusion criteria (only partial seizures with a recognizable and 
countable manifestation).  
9. Subject is on a stable dosage regimen of 1 to 3 AEDs. The daily dosage regimen of 
concomitant  AED therapy must be kept constant for a period of at least 1 week prior to 
Screening. Vagal nerve stimulation is not counted as medical therapy; however, VNS settings 
must be kept constant for a period of at least 1  week prior to Screening.  
10. Subject is an acceptable candidate for venipuncture.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 186 of 324 Clinical Study Protocol, Section  4.3.2 (Exclusion criteria). Original text:  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Subject is receiving any investigational drugs or  using any experimental devices in addition 
to LCM.  
2. Subject meets the withdrawal criteria for the primary study (with the exception of subjects 
who discontinued due to a dose reduction or status epilepticus), or is experiencing an 
ongoing serious AE (SAE).  
3. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6  months as indicated by a 
positive response (“Yes”) to either Question  4 or Question  5 of the C olumbia -Suicide 
Severity Rating Scale (C -SSRS) at Screening.  
Was revised as follows:  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Subject is receiving any investigational drugs or using any experimental device s in addition 
to LCM.  
3. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6  months as indicated by a 
positive response (“Yes”) to either Question  4 or Question  5 of the Columbia -Suicide 
Severity Rating Scale (C -SSRS) at Screening.  
Subjects who have participated in SP847 or other LCM pediatric clinical studies in epilepsy are 
not permitted to enroll in the study if any of the following criteria are met:  
2. Subject meets the withdrawal criteria for the primary study (with the exception of subjects 
who discontinued due to a dose reduction or status epilepticus), or is experiencing an 
ongoing serious AE (SAE).  
Subjects who enroll directly into SP848 without pr evious participation in a LCM clinical study  
are not permitted to enroll in the study if any of the following criteria are met:  
4. Subject has ever received LCM.  
5. Subject has any medical or psychiatric condition that, in the opinion of the investigator, could 
jeopardize or would compromise the subject’s ability to participate in this study.  
6. Subject has a medical condition that could reasonably be expected to interfere with drug 
absorption, distribution, metabolism, or excretion.  
7. Subject has a known hypersensiti vity to any component of the investigational medicinal 
product.  
8. Subject is a female of childbearing potential and does not practice an acceptable method of 
contraception for the duration of the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 187 of 324 • Medically acceptable contraceptive method includes oral  or depot contraceptive 
treatment with at least 30μg ethinylestradiol per intake (or 50μg if associated with 
carbamazepine [or other strong enzyme inducers, eg, phenobarbital, primidone, 
oxcarbazepine]) which must be used in conjunction with a barrier meth od. Sexual 
abstinence is also an acceptable method of contraception.  
• The subject must understand the consequences and potential risks of inadequately 
protected sexual activity, be educated about and understand the proper use of 
contraceptive methods, and u ndertake to inform the investigator of any potential change 
in status. Females of childbearing potential must have a negative pregnancy test at the 
Screening Visit.  
9. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2  times the upper limit of normal (ULN), or creatinine 
clearance less than 50mL/min.  
10. Subject has a clinically relevant ECG abnormality, in the opinion of the principal investigator 
(ie, second or third degree heart b lock at rest or a QT prolongation greater than 450ms).  
11. Subject has hemodynamically significant heart disease (eg, heart failure).  
12. Subject has an arrhythmic heart condition requiring medical therapy.  
13. Subject has a known history of severe anaphylactic reacti on or serious blood dyscrasias.  
14. Subject has nonepileptic events, including psychogenic seizures, that could be confused with 
seizures. If both epileptic and nonepileptic events are present, epileptic events must be 
distinguished from nonepileptic phenomena . 
15. Subject has a history of primary generalized epilepsy.  
16. Subject has been treated with vigabatrin or felbamate for at least 12 months prior to entering 
the study and has experienced any toxicity issues with these treatments. Note: Any subject 
who is curren tly treated with vigabatrin or felbamate, and has received vigabatrin for a period 
of less than 12 months, is excluded from the study. Subjects who have received vigabatrin in 
the past must have documentation of an assessment for visual field defects after  completion 
of vigabatrin therapy.  
17. Subject is taking monoamine oxidase (MAO) inhibitors or narcotic analgesics.  
18. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively 
neurodegenerative disease, such as Rasmussen syndrom e. 
19. Subject has a known sodium channelopathy, such as Brugada syndrome.  
Clinical Study Protocol, Section  4.3.3 (Criteria for withdrawal), criterion  9. Original text:  
9.    Subject experiences status epilepticus  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 188 of 324 Was revised as follows:  
9.    Subject experiences convulsive status epilepticus (if none had occurred prior to study entry) 
and is compliant with study treatment  
Clinical Study Protocol, Section  4.4.1 (Treatments to be administered). Original text:  
Subjects who have participated in SP847 (or other future LCM pediatric clinical studies in 
epilepsy), who are eligible to participate in the open -label extension study SP848, and who 
choose to enter SP848, will begin SP848 on the LCM dose they achieved in the primary study. 
The investigator, togethe r with the subject/caregiver (including parent/legal guardian), will be 
able to choose either the oral solution (syrup) formulation or the tablet formulation of LCM in 
this study. The study medication will be orally administered bid (at 12 -hour intervals, once in the 
morning and once in the evening) in equally divided doses. The oral solution (syrup) formulation 
will be measured and orally administered via a dosing syringe. The selection of doses, titration 
scheme, and rate of taper in SP847 were based on a dult studies and were adjusted to a mg/kg 
basis plus 40% (ie, 600mg/day adult dose of LCM corresponds to [600mg/70kg]  x 1.4 = 
approximately 12mg/kg/day for a child). The selection of doses in this trial is based on the 
maximum recommended dose in SP847.  
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based o n body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower.  
The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg /day (tablet) per week to a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM d ose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower. The investigator may decrease the 
dose of LCM to a minimum of 2mg/kg/day (oral solution [syrup] or the corresponding dose level 
for the tablet formulation). Increases in the LCM dose must occur only during office visits. It 
should be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the syrup), 
missed doses, or administration of an erroneous volume of syrup, study medication should not be 
readministered and these subj ects would remain at their assigned dose.  
Subjects enrolled in SP848 have the option of remaining on the oral solution formulation of 
LCM or switching to the commercial tablet formulation, if feasible. Consideration of the current 
LCM milligram dose in the  oral solution (syrup) should occur if/when transitioning to the tablet 
formulation. In cases where the LCM dose received with the oral solution (syrup) is not 
supported by the tablet strengths available in SP848 (50mg and 100mg), a clinical decision must 
be made by the investigator or other study physician to either increase or decrease the LCM dose 
to the next multiple of 100mg with a maximum permitted dose of 600mg/day.  
Subjects achieving a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (t ablet) 
who withdraw during the study should taper off study medication. It is recommended that the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 189 of 324 dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) (see tables below). A slower taper of 2mg/kg/day ( oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Recommended LCM dose reduction (taper) for oral solution ( syrup) 
formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
12mg/kg/day  
(6mg/kg bid)  8mg/kg/day  
(4mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  0 
10mg/kg/day  
(5mg/kg bid)  6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 
8mg/kg/day  
(4mg/kg bid) 4mg/kg/day  
(2mg/kg bid)  0 – 
6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 – 
4mg/kg/day  
(2mg/kg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
Recommended LCM dose reduction (taper) for tablet formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
600mg/day  
(300mg bid)  400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 
500mg/day  
(250mg bid)  300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 
400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 – 
300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 – 
200mg/day  
(100mg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 190 of 324 Was revised as follows (including additions of subsection headings 4.4.1.1 [Subjects enrolling 
from SP847 or other LCM pediatric clinical studies in epilepsy], 4.4.1.2 [Subjects enrolling 
directly in SP848], 4.4.1.3 [All subjects], and 4.4.1.4 [Study completion]):  
Subjects who h ave participated in SP847 (or other LCM pediatric clinical studies in epilepsy), 
who are eligible to participate in the open -label study SP848, and who choose to enter SP848, 
will begin SP848 on the LCM dose they achieved in the primary study.  
Beginning wi th Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. After Screening, elig ible subjects 
will initiate treatment with LCM (oral solution or tablet, as chosen by the investigator and 
subject/caregiver), and the LCM dose will be titrated to a level to optimize tolerability and 
seizure control.  
At the first Titration Visit (TV) (see  Section  5.2), subjects who have enrolled directly into SP848 
will receive a single dose of LCM (1mg/kg [oral solution] or 50mg [tablet]) during the  clinic 
visit. Over the following days, subjects will be administered LCM  1mg/kg  bid (oral solution) or 
LCM  50mg bid (tablet), and will begin titrating in weekly increments of 2mg/kg/day (oral 
solution) or 100mg/day (tablet) up to a level to optimize toler ability and seizure control (not to 
exceed 12mg/kg/day [or 600mg/day based on body weight, whichever is lower]). Subjects must 
be on each LCM dose for at least 5  days before titrating up to the next dose.  
A total of up to 6  Titration Visits may be required  (eg, for a subject whose dose is titrated to the 
maximum permitted dose of LCM  12mg/kg/day). However, based on tolerability and seizure 
control, a subject’s LCM dose may be titrated to a lower dose level; in such a case, fewer than 
6 Titration Visits woul d be required.  
The following table summarizes the recommended titration steps for the oral solution and tablet 
formulations:  
Recommended LCM dose titration for subjects enrolling directly into SP848  
Formulation  Week 1  Week 2  Week 3  Week 4  Week 5 Week 6 
Oral solution 
(syrup)  2mg/kg/day  
(1mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  6mg/kg/day  
(3mg/kg bid)  8mg/kg/day  
(4mg/kg bid)  10mg/kg/day  
(5mg/kg bid)  12mg/kg/day  
(6mg/kg bid)  
Tablet  100mg/day  
(50mg bid)  200mg/day  
(100mg bid)  300mg/day  
(150mg bid)  400mg/day  
(200mg bid)  500mg/day  
(250mg bid)  600mg/day  
(300mg bid)  
bid=twice daily; LCM=lacosamide  
The investigator, together with the subject/caregiver (including parent/legal guardian), will be 
able to choose either the oral solution (syrup) formulation or the tablet formulation of LCM in 
this study. The study medication will be orally administered bid (at 12 -hour intervals, once in the 
morning and once in the evening) in equally divided doses. The oral solution (syrup) formulation 
will be measured and orally ad ministered via a dosing syringe. The selection of doses, titration 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 191 of 324 scheme, and rate of taper in SP847 were based on adult studies and were adjusted to a mg/kg 
basis plus 40% (ie, 600mg/day adult dose of LCM corresponds to [600mg/70kg]  x 1.4 = 
approximately  12mg/kg/day for a child). The selection of doses in this trial is based on the 
maximum recommended dose in SP847.  
The investigator may adjust the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) and a maximum of 12mg/kg/da y (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichev er is lower.  
The investigator may increase the dose of LCM no faster than 2mg/kg/day (oral solution [syrup]) 
or 100mg/day (tablet) per week to a maximum of 12mg/kg/day (oral solution [syrup] or the 
corresponding dose levels for the tablet formulation) not to exceed 600mg/day based on body 
weight, even if the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in 
SP848 is 12mg/kg/day or 600mg/day, whichever is lower. The investigator may decrease the 
dose of LCM to a minimum of 2mg/kg/day (ora l solution [syrup] or the corresponding dose level 
for the tablet formulation). Increases in the LCM dose must occur only during office visits. It 
should be noted, in cases of incomplete doses (eg, subject spits out all or a portion of the syrup), 
missed d oses, or administration of an erroneous volume of syrup, study medication should not be 
readministered and these subjects would remain at their assigned dose.  
Subjects enrolling from SP847 will have the option of remaining on the oral solution formulation 
of LCM or switching to the commercial tablet formulation, if feasible. Consideration of the 
current LCM milligram dose in the oral solution (syrup) should occur if/when transitioning to the 
tablet formulation. In cases where the LCM dose received with the oral solution (syrup) is not 
supported by the tablet strengths available in SP848 (50mg and 100mg), a clinical decision must 
be made by the investigator or other study physician to either increase or decrease the LCM dose 
to the next multiple of 100mg with  a maximum permitted dose of 600mg/day.  
Subjects achieving a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) 
who withdraw during the study should taper off study medication. It is recommended that the 
dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) (see tables below). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Recommended LCM dose reduction (taper) for oral solution (syrup) 
formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
12mg/kg/day  
(6mg/kg bid)  8mg/kg/day  
(4mg/kg  bid) 4mg/kg/day  
(2mg/kg bid)  0 
10mg/kg/day  
(5mg/kg bid)  6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 
8mg/kg/day  
(4mg/kg bid)  4mg/kg/day  
(2mg/kg bid)  0 – 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 192 of 324 Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
6mg/kg/day  
(3mg/kg bid)  2mg/kg/day  
(1mg/kg bid)  0 – 
4mg/kg/day  
(2mg/kg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
Recommended LCM dose reduction (taper) for tablet formulation  
Maximum LCM dose 
achieveda Taper schedule  
Week 1  Week 2  Week 3  
600mg/day  
(300mg bid)  400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 
500mg/day  
(250mg bid)  300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 
400mg/day  
(200mg bid)  200mg/day  
(100mg bid)  0 – 
300mg/day  
(150mg bid)  100mg/day  
(50mg bid)  0 – 
200mg/day  
(100mg bid)  0 – – 
bid=twice daily; LCM=lacosamide  
a     Maximum LCM dose achieved is based upon the maximum recommended dose in SP847.  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the  subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investigator in consultation with the subject and/or parent/legal guardian. These subjects 
should complete Visi t 13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper of LCM.  
Subjects who complete t he study and discontinue use of LCM (as determined by the investigator 
in consultation with the subject and/or parent/legal guardian) should taper LCM gradually as 
described in Section  4.4.1.3 . These subjects should complete Visit  13/Termination Visit, 
followed by the Final Visit which occurs 2  weeks after the final dose of study medication, and 
then the Safety Follow -Up telephone contact which occurs  28 to 35  days after the last dose of 
LCM.  
Clinical Study Protocol, Section  4.4.3. Original text:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 193 of 324 This is an open -label extension study; subjects will not be randomized. Subjects will keep the 
unique number assigned in the primary study.  
Was revised as fol lows:  
This is an open -label study; subjects will not be randomized. Subjects who participated in SP847 
or other LCM pediatric clinical studies in epilepsy will keep the unique number assigned in the 
primary study.  
Subjects enrolling directly into SP848 wit hout participation in a previous LCM clinical study 
will be assigned unique numbers for the purpose of study and subject identification, as well as 
for subject confidentiality. At the Screening Visit, each subject will be assigned the unique 
identifying nu mber for this study.  
Clinical Study Protocol, Section  4.5 (Expected duration of the study), first sentence. Original 
text: 
The maximum duration of LCM administration will be approximately 2  years.  
Was revised as follows:  
The maximum duration of LCM administration for an individual subject will be approximately 
2 years.  
Clinical Study Protocol, Section  5.1 (Screening Visit) was newly added as follows and 
subsequent section numbers were adjusted accordingly:  
Beginning with Protocol Amendment  4, at sele cted sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848.  
At the Screening Visit, subjects entering directly in to SP848 (ie, subjects who have not 
participated in SP847 or another applicable LCM pediatric clinical study in epilepsy) will be 
evaluated for their suitability for enrollment in SP848. The Screening Visit is not applicable for 
subjects who have participa ted in SP847 or another applicable LCM pediatric clinical study in 
epilepsy; the first visit in SP848 for these subjects is Visit  1 (see Section  5.3). 
The Screening assessments will be conducted up to 14  days prior to the first administration of 
LCM. It is acceptable for the Screening assessments to be conducted on more than 1  day, 
although it should not be done over longer than 1  week. Prior to the c onduct of any study -related 
procedures, a complete explanation (both verbally and written) of the nature and purpose of the 
study will be given to the subject (when possible or as required according to local IRBs/IECs) 
and the subject’s parent/legal guardi an by the investigator (or designee). The subject’s 
parent/legal guardian will be requested to sign and date the IRB/IEC -approved Informed Consent 
Form. When possible, or as required by the local IRB/IEC, the subject will be requested to give 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 194 of 324 assent to par ticipate in the study. Each subject’s eligibility for the study will be determined on 
the basis of the inclusion/exclusion criteria and the results of the following pretreatment 
assessments (for further details of the assessments and the required procedure s and methods, 
please refer to Section  6, Section  7, and Section  8 of this protocol).  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Medical history assessment  
• Seizure hi story over the past 4 weeks (historical Baseline)  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight assessment  
• Height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• C-SSRS  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months an d CBCL/6 -18 for children 6  years and 
older)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries  
• Adverse event reporting  
• Dispense subject diary  
The subject will be scheduled to return for a clinic visit (TV) less than 14 days from the last 
Screening Visit assessment(s).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 195 of 324 Clinical Study Protocol, Section  5.2 (Titration Visit[s] [TV1, TV2, TV3, TV4, TV5, TV6]) was 
newly added as follows and subsequent section numbers were adjusted accordingly:  
Eligible subjects who enter d irectly into SP848 (without prior participation in SP847 or another 
applicable LCM primary study) will initiate treatment with LCM at TV1, and the LCM dose will 
be titrated over the following week(s). Titration Visits are not applicable for subjects who ha ve 
participated in SP847 or another LCM primary study; the first visit in SP848 for these subjects is 
Visit  1 (see Section  5.3). 
At TV1, subjects wh o have enrolled directly into SP848 will receive a single dose of LCM 
(1mg/kg [oral solution] or 50mg [tablet]) during the clinic visit. Over the following days, 
subjects will be administered LCM  1mg/kg bid (oral solution) or LCM  50mg  bid (tablet), and 
will begin titrating in weekly increments of 2mg/kg/day (oral solution) or 100mg/day (tablet) up 
to a level to optimize tolerability and seizure control (not to exceed 12mg/kg/day [or 600mg/day 
based on body weight, whichever is lower]). Subjects must be on e ach LCM dose for at least 
5 days before titrating up to the next dose. It should be noted, in cases of incomplete doses (eg, 
subject spits out all or a portion of the syrup), missed doses, or administration of an erroneous 
volume of syrup, study medication  should not be readministered and these cases would not be 
considered dose reductions. The LCM dose titration steps are summarized in Section  4.4.1.2 . 
A total of up to 6  Titration Visits may be required (eg, for a subject whose dose is titrated to the 
maximum permitted dose of LCM  12mg/kg/day). However, based on tolerability and seizure 
control, a subject’s LCM dose may be titrated to a lower dose le vel; in such a case, fewer than 
6 Titration Visits would be required.  
The following assessments are required for each TV:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• Blood sample for clinical chemistry, hematology, and endocri nology (TV2 and TV4 only)  
• Urine sample for urinalysis (TV2 and TV4 only)  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diary  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 196 of 324 • Dispense LCM (as applicable)  
All subjects will be required to have  an ECG (2  interpretable recordings) conducted at LCM 
maximum plasma concentration (C max) 1 week after an initial LCM dose increase to a LCM dose 
level that is ≥8mg/day or a new concomitant AED is introduced. Subjects will be required to 
arrive at the clin ic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20  to 30  minutes apart prior to vital signs assessment) can be perf ormed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
Clinical Study Protocol, Section  5.3 (Visit  1 [Week  0]). Original text:  
For subjects who complete SP847, Visit 1 is Day 2 of the second PK collection time period 
(which may include an overnight stay at a hospital or medical facility) in SP847 (Day  28 for 
Cohorts  1, 2, 3, and 5 with maximum recommended dose of 8mg/kg/day; Day  35 for Cohorts  2 
to 5 with maximum recommended dose of 10mg/kg/day; and Day  42 for Cohorts  2 to 5 with 
maximum recommended dose of 12mg/kg/day). For subjects who discontinue SP847 due to a 
dose reduction or status epilepticus, Visit 1 is the Early Termination Visit in SP847. For subjects 
in SP847 who are titrated up to the maximum permitted dose of  600mg/day sooner than the 
study schedule would ordinarily indicate (based on body weight) and who enroll in SP848, the 
Early Termination Visit of SP847 will also serve as Visit  1 for SP848.  
For subjects who enroll in SP848 after participation in future LCM pediatric clinical studies in 
epilepsy, SP848 Visit  1 will be specified in the respective primary study protocol.  
Prior to the conduct of any study -related procedures, a complete explanation (both verbally and 
written) of the nature and purpose of the study will be given to the subject (when possible or as 
required according to local IRBs/IECs) and the subject’s parent/legal guardian by the 
investigator (or designee). The subject’s parent/legal guardian will be requested to sign and date 
the IRB/IEC -approved Informed Consent Form. When possible, or as required by local IRB/IEC, 
the subject will be requested to give assent to participate in the study.  
Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the re sults of the following assessments, and a complete medical history update will be obtained. 
The data for the following assessments will be taken from the last assessment during SP847 (or 
other primary study as applicable):  
• Concomitant medications assessmen t  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment but 30  minutes to 1  hour after the administration of  LCM)  
• Vital signs assessment (blood pressure and pulse)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 197 of 324 • Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sample for urinalysis  
• Serum pr egnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following  4 weeks)  
• Dispense LCM. Subjects and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Was revised as follows:  
For subjects who complete SP847 , Visit 1 for SP848 is the same as Day 2 of the second PK 
collection time period (which may include an overnight stay at a hospital or medical facility) in 
SP847 (Day  28 for Cohorts  1, 2, 3, and 5 with maximum recommended dose of 8mg/kg/day; 
Day 35 for Coh orts 2 to 5 with maximum recommended dose of 10mg/kg/day; and Day  42 for 
Cohorts  2 to 5 with maximum recommended dose of 12mg/kg/day). For subjects who 
discontinue SP847 due to a dose reduction or status epilepticus, Visit 1 is the Early Termination 
Visit in SP847. For subjects in SP847 who are titrated up to the maximum permitted dose of 
600mg/day sooner than the study schedule would ordinarily indicate (based on body weight) and 
who enroll in SP848, the Early Termination Visit of SP847 will also serve as Visit  1 for SP848.  
For subjects who enroll in SP848 after participation in other LCM pediatric clinical studies in 
epilepsy, SP848 Visit  1 will be specified in the respective primary study protocol.  
For subjects who enter directly into SP848 (without prior  participation in SP847 or other LCM 
pediatric clinic studies in epilepsy), the LCM dose will be titrated at weekly intervals as 
described in Section  4.4.1.2  and Section  5.2. These subjects will reach Visit  1 either (1) when the 
LCM dose is titrated to a level that, in the opinion of the invest igator, optimizes tolerability and 
seizure control, or (2) when the maximum permitted LCM dose is reached (12mg/kg/day [or 
600mg/day based on body weight, whichever is lower]). In the case of a subject who requires a 
dose reduction during the Titration Vis its, the subject’s LCM dose will be returned to the 
previous dose level and the next clinic visit will be Visit  1 at the reduced level. Visit  1 should 
occur at least 5  days after the final TV. At Visit  1, the progress in SP848 for subjects who 
entered dire ctly into SP848 and for subjects who have enrolled from SP847 or other LCM 
pediatric clinical studies in epilepsy will be aligned; subsequent regularly scheduled clinic visits 
for all subjects will be at 4 -week intervals as outlined in the following sectio ns. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 198 of 324 The informed consent process for SP848 will be conducted at Visit  1 for subjects who have not 
previously been through the informed consent process at the Screening Visit (ie, subjects 
enrolling from SP847 or other LCM pediatric clinical studies in epil epsy for whom Visit  1 is the 
first study visit in SP848). Prior to the conduct of any study -related procedures, a complete 
explanation (both verbally and written) of the nature and purpose of the study will be given to 
the subject (when possible or as requ ired according to local IRBs/IECs) and the subject’s 
parent/legal guardian by the investigator (or designee). The subject’s parent/legal guardian will 
be requested to sign and date the IRB/IEC -approved Informed Consent Form. When possible, or 
as required b y local IRB/IEC, the subject will be requested to give assent to participate in the 
study.  
Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments (applicable only for subj ects for whom Visit  1 is the first 
clinic visit for SP848), and a complete medical history update will be obtained. The data for the 
following assessments will be taken from the last assessment during SP847 (or other primary 
study as applicable):  
• Concomita nt medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment but 30  minutes to 1  hour after the administration of LCM)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations  
• Urine sam ple for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• Tanner Stage assessment (if applicable)  
• C-SSRS  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 1 1 months and CBCL/6 -18 for children 6  years and 
older) (subjects enrolling from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries 
(subjects enrollin g from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• Adverse event reporting  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 199 of 324 • Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs for the following 4 weeks)  
• Dispense LCM. Subje cts and caregivers (including parent/legal guardian) will be instructed 
to administer LCM at approximately 12 -hour intervals (once in the morning and once in the 
evening).  
Clinical Study Protocol, Section  5.5 (Visit  2 [Week  4]), final 2 paragraphs. Origina l text:  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increased or a new concomitant AED is introduced. The ECG should be performed after the 
increased dose of LCM or the new AED has reached steady -state. This ECG can be done at 
the next scheduled visit. When the ECG assessment is done, 2 interpretable recordings will 
be performed approximately 20 to 30  minutes apart prior to vital sign assessment and 
collection of blood samples (if applicable), but 30  minutes to 1  hour after the administration 
of LCM (if applicable).  
All subjects will be required to have an ECG (2 interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. Th ese subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2 interpretable recordings approximately 20 to 30 minutes  apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM steady state C max). 
Was revised as follows:  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increa sed to a LCM dose level that is ≥8mg/kg/day or a new concomitant AED is introduced. 
The ECG should be performed after the increased dose of LCM or the new AED has reached 
steady -state. This ECG can be done at the next scheduled visit. When the ECG assessme nt is 
done, 2 interpretable recordings will be performed approximately 20 to 30  minutes apart 
prior to vital sign assessment and collection of blood samples (if applicable), but 30  minutes 
to 1 hour after the administration of LCM (if applicable).  
All subj ects will be required to have an ECG (2 interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day . This ECG 
can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive 
at the clinic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2 interpretable recordings 
approximately 20 to 30 minutes apart prior to vi tal signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 200 of 324 Clinical Study Protocol, Section  5.6 (Visit  3 [Week  8]), final 2 paragraphs. Original text:  
• A 12 -lead ECG (2  interpretable recording s) is also required when the dose of LCM is 
increased or a new concomitant AED is introduced. The ECG should be performed after the 
increased dose of LCM or the new AED has reached steady -state. This ECG can be done at 
the next scheduled visit. When the EC G assessment is done, 2 interpretable recordings will 
be performed approximately 20 to 30  minutes apart prior to vital sign assessment and 
collection of blood samples (if applicable), but 30  minutes to 1  hour after the administration 
of LCM (if applicable) . 
All subjects will be required to have an ECG (2 interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the c linic prior to taking their morning 
dose of LCM. Subjects will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to 
vital signs assessment) can be p erformed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM steady state C max). 
Was revised as follows:  
• A 12 -lead ECG (2  interpretable recordings) is also required when the dose of LCM is 
increased to a LCM dose level that is ≥8mg/kg/day or a  new concomitant AED is introduced. 
The ECG should be performed after the increased dose of LCM or the new AED has reached 
steady -state. This ECG can be done at the next scheduled visit. When the ECG assessment is 
done, 2 interpretable recordings will be p erformed approximately 20 to 30  minutes apart 
prior to vital sign assessment and collection of blood samples (if applicable), but 30  minutes 
to 1 hour after the administration of LCM (if applicable).  
All subjects will be required to have an ECG (2 interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day . This ECG 
can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive 
at the clinic prio r to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2 interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
Clinical Study Protocol, Section  5.8 (Visit  5 [Week  20]), final 2 paragraphs. Original text:  
A 12 -lead ECG (2 interpretable recordings)  is also required when the dose of LC M is increased 
or a new concomitant AED is introduced. The ECG should be performed after the increased dose 
of LCM or the new AED has reached steady -state. This ECG can be done at the next scheduled 
visit. When the ECG assessment is done, 2 interpretable r ecordings will be performed 
approximately 20 to 30 minutes apart prior to vital sign assessment and collection of blood 
samples (if applicable), but 30  minutes to 1  hour after the administration of LCM (if applicable).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 201 of 324 All subjects will be required to have  an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM steady state C max). 
Was revised as follows:  
A 12 -lead ECG (2 interpretable recordings)  is also required when the dose of LCM is increased 
to a LCM dose level that is ≥8mg/kg/day  or a new concomitant AED is introduced. The ECG 
should be performed after the increased dose of LCM o r the new AED has reached steady -state. 
This ECG can be done at the next scheduled visit. When the ECG assessment is done, 2 
interpretable recordings will be performed approximately 20 to 30 minutes apart prior to vital 
sign assessment and collection of bl ood samples (if applicable), but 30  minutes to 1  hour after 
the administration of LCM (if applicable).  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose l evel that is ≥8mg/kg/day . This ECG 
can be conducted at an Unscheduled Visit, if necessary. These subjects will be required to arrive 
at the clinic prior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study pers onnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
Clinical Study Protoc ol, Section  5.9 (Visit  6 [Week  28]). Original text:  
Assessments for Visit 6 (Week 28) are the same as those described for Visit 3 (Week 8) in 
Section  5.6, with the following exception: a  12-lead ECG (2 interpretable recordings 
approximately 20 to 30  minutes apart prior to vital signs assessment and collection of blood 
sample) is conducted at Visit 6.  
Was revised as follows:  
Assessments for Visit 6 (W eek 28) are the same as those described for Visit 3 (Week 8) in 
Section  5.6, with the following exception: completion of the palatability and ease of use 
questionnaire and a  12-lead ECG (2 interpretable recordings approximately 20 to 30  minutes 
apart prior to vital signs assessment and collection of blood sample) are conducted at Visit 6.  
Clinical Study Protocol, Section  5.2 (Visit  9 [Week  52]). Orig inal text:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 202 of 324 Assessments for Visit 9 (Week 52) are the same as those described for Visit 5 (Week 20), in 
Section  5.8, with the following exception: a 12-lead ECG (2 interpretable recordings 
approximately 20 to 30  minutes apart prior to vital signs assessment and collection of blood 
sample) is conducted at Visit 9.  
Was revised as follows:  
Assessments for Visit 9 (Week 52) are the same as those described for Visit 5 (Week 20), in 
Section  5.8, with the following exception: completion of the palatability and ease of use 
questionnaire and a 12 -lead ECG  (2 interpretable recordings approximately 20 to 30  minutes 
apart prior to vital signs assessment and collection of blood sample) are conducted at Visit 9.  
Clinical Study Protocol, Section  5.14 (Visit  11 [Week 72]). Original text:  
Assessments for Visit 11 (Week 72) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: brief physi cal and neurological exams are conducted 
(instead of complete physical and neurological exams as indicated for Visit 5), the laboratory 
blood sample is collected only for clinical chemistry and hematology (ie, no endocrinology), and 
a 12-lead ECG (2 interp retable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood sample) is conducted . 
Was revised as follows:  
Assessments for Visit 11 (Week 72) are the same as those described for Visit 5 (Week 20), in 
Secti on 5.8, with the following exceptions: brief physical and neurological exams are conducted 
(instead of complete physical and neurological exams as i ndicated for Visit 5), the laboratory 
blood sample is collected only for clinical chemistry and hematology (ie, no endocrinology), the 
palatability and ease of use questionnaire is completed,  and a 12-lead ECG (2 interpretable 
recordings approximately 20 t o 30 minutes apart prior to vital signs assessment and collection of 
blood sample) is conducted . 
Clinical Study Protocol, Section  5.16 (Visit  13/Termination Visit [Week  96]). Original text:  
Assessments for Visit 13 (Week 96) are the same as those described  for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: the laboratory blood sample is collected only for 
clinical chemistry and hema tology (ie, no endocrinology), a 12-lead ECG (2 interpretable 
recordings approximately 20 to 30 minutes apart prior to vital signs assessment and collection of 
blood sample) is conducted, and a Tanner Stage assessment is conducted (if applicable) . 
Lacosami de for taper will be dispensed only for subjects who achieve a dose of 
LCM  ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 203 of 324 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible.  
Was revised as follows:  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/l egal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investigator in consultation with the subject and/or parent/legal guardian. The se subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper  of LCM.  
Subjects who complete the study and discontinue use of LCM (as determined by the investigator 
in consultation with the subject and/or parent/legal guardian) should taper LCM gradually as 
described in Section  4.4.1.3 . These subjects should complete Visit  13/Termination Visit, 
followed by the Final Visit which occurs 2  weeks after the final dose of study medication, and 
then the Safety Follow -Up telephone contact which occurs 28 to 35  days after the last dose of 
LCM . 
Assessments for Visit 13/Termination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following exceptions: the laboratory blood sample is 
collected only for clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG 
(2 interpretable recordings approxima tely 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted, a Tanner Stage assessment is conducted (if 
applicable), an Achenbach CBCL is conducted, Bayley -III scales are conducted, and the 
palatability and ease  of use questionnaire is completed . 
Lacosamide for taper will be dispensed only for subjects who achieve a dose of 
LCM  ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements  of 4mg/kg/day (oral solution [syrup]) or 
200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (ta blet) is permitted, if medically necessary. In case of an emergency, a faster taper is 
permitted after discussion with the medical monitor, whenever possible. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatm ent option selected 
by the investigator in consultation with the subject and/or parent/legal guardian.  
Clinical Study Protocol, Section  5.17 (Early Termination Visit). Original text:  
Subjects who withdraw from the study prematurely must complete an Early T ermination Visit.  
The following will be performed:  
• Concomitant medication assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 204 of 324 • Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart p rior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma conc entrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Serum pregnancy test for females of childbearing potential  
• Tanner Stage assessment (if applicable)  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs)  
• Dispense LCM. Lacosamide for taper will be dispensed only for subjects w ho achieve a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is recommended that 
the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution 
[syrup]) or 200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, 
a faster taper is permitt ed after discussion with the medical monitor, whenever possible.  
Was revised as follows:  
Subjects who withdraw from the study prematurely must complete an Early Termination Visit.  
At the time of withdrawal from the study, investigators should discuss treatment options with the 
subject and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM 
may not be required for some subjects who withdraw from the study prematurely, depending on 
the treatment option selected by the inves tigator in consultation with the subject and/or 
parent/legal guardian. These subjects should complete the Early Termination Visit and then 
complete the Safety Follow -Up telephone contact 28 to 35  days after the Early Termination 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 205 of 324 Visit. The Final Visit is n ot required for subjects who withdraw from the study prematurely and 
who do not undergo taper of LCM.  
Subjects who withdraw from the study prematurely and discontinue use of LCM (as determined 
by the investigator in consultation with the subject and/or par ent/legal guardian) should taper 
LCM gradually as described in Section  4.4.1.3 . These subjects should complete the Early 
Termination Visit, followed  by the Final Visit which occurs 2  weeks after the final dose of study 
medication, and then the Safety Follow -Up telephone contact.  
The following will be performed at the Early Termination Visit:  
• Concomitant medication assessment  
• Concomitant AEDs assessmen t 
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment (blood pressure and pulse ) 
• Body weight and height  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Serum pregnancy test for females of ch ildbearing potential  
• Tanner Stage assessment (if applicable)  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for children 6  years and 
older)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries  
• Palatability and ease of use questionnaire  
• Adverse event reporting  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 206 of 324 • Dispense subject diary (to assess seizure frequency, document the intake of concomitant 
AEDs, and record AEs)  
• Dispense LCM. Lacosamide for taper will be dispensed only for subjects who achieve a dose 
of LCM ≥6mg/kg/day (oral solution  [syrup]) or ≥300mg/day (tablet). It is recommended that 
the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution 
[syrup]) or 200mg/day (tablet) ( Section  4.4.1 ). A slower taper of 2mg/kg/day (oral solution 
[syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, 
a faster taper is permitted after discussion with the medical monitor, whenev er possible. 
Taper of LCM may not be required for some subjects who withdraw from the study 
prematurely, depending on the treatment option selected by the investigator in consultation 
with the subject and/or parent/legal guardian.  
Clinical Study Protocol, Section  5.18 (Unscheduled Visit[s]). Original text:  
An Unscheduled Visit may be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if an LCM dose increase is required 
between scheduled clinic visits, the subject must return for an Unscheduled Visit. If an AE 
prompts a dose reduction, the reduction can be implemented immediately at the investigator’s 
discretion. However, the subject should return to the clinic as soon as possible for an 
Unscheduled Visit.  
The following assessments are required:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart  prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the investigator’s discretion.  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 207 of 324 if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subjects will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approxi mately 20 to 30 minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration of LCM 
(ie, at LCM steady state C max). 
Was revised as follows:  
An Unscheduled Visit may be performed at the investigator’s discret ion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, if an LCM dose increase is required at 
any time, or if a new concomitant AED is introduced, the subject must return for an Unscheduled 
Visit. If an AE prompts a dose reduction,  the reduction can be implemented immediately at the 
investigator’s discretion. However, the subject should return to the clinic as soon as possible for 
an Unscheduled Visit.  
The following assessments are required:  
• Concomitant medications assessment  
• Conco mitant AEDs assessment  
• Brief physical examination  
• Brief neurological examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of any blood samples)  
• Vital signs assessment (blood  pressure and pulse)  
• Body weight  
• LCM return/compliance (as applicable)  
• Subject diary assessment  
• C-SSRS (only if Unscheduled Visit is conducted due to an AE)  
• Adverse event reporting  
• Dispense LCM (as applicable)  
Additional assessments can be performed at the  investigator’s discretion.  
All subjects will be required to have an ECG (2  interpretable recordings) conducted at LCM C max 
1 week after an initial LCM dose increase to a LCM dose level that is ≥8mg/kg/day  or after a 
new concomitant AED is introduced. This  ECG can be conducted at an Unscheduled Visit, if 
necessary. Subjects having a LCM dose increase to ≥8mg/kg/day will be required to arrive at the 
clinic prior to taking their morning dose of LCM. Subjects will be administered their morning 
LCM dose by stud y personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20 to 30 minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 208 of 324 Clinical Study Protocol, Section  5.19 (Final Visit). Original text:  
During the Final Visit (2 weeks after the last LCM dose), the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurologic al examination  
• 12-lead ECG (2 interpretable recordings approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment (blood pressure and pulse)  
• Body weight and height assessment  
• Blood sample fo r clinical chemistry, hematology, and endocrinology  
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• LCM return/ compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
Was revised as follows:  
Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the  final dose of study 
medication.  
During the Final Visit, the following will be performed:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Complete physical examination  
• Complete neurological examination  
• 12-lead ECG (2 interpretable recordings  approximately 20 to 30 minutes apart prior to vital 
signs assessment and collection of blood samples)  
• Vital signs assessment (blood pressure and pulse)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 209 of 324 • Body weight and height assessment  
• Blood sample for clinical chemistry, hematology, and endocrinology  
• Urine sample for urinalysis  
• Serum pregnancy test for female subjects of childbearing potential  
• LCM return/compliance  
• Subject diary assessment  
• C-SSRS  
• Adverse event reporting  
Clinical Study Protocol, Section  5.20 (Safety Follow -up telephone contact). Original text: 
The Safety Follow -Up telephone contact is required for all subjects (those who have withdrawn 
prematurely from the study or completed the study as planned). This telephone contact will occur 
28 to 35  days after the last dose of LCM. The following sho uld be performed via telephone:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Adverse event reporting. If an AE is reported at this telephone contact, the investigator will 
follow the AE until a definite outcome is achieved ( Section  8.1.2 ). 
Was revised as follows:  
The Safety Follow -Up telephone contact is required for all subjects (those who complete the 
study as planned or have with drawn prematurely from the study). For subjects who complete the 
study, this telephone contact will occur 28 to 35  days after Visit  13/Termination Visit (subjects 
who do not undergo taper of LCM) or 28 to 35  days after the last dose of LCM (subjects who 
discontinue use of LCM [ie, taper]). For subjects who withdraw prematurely from the study, this 
telephone contact will occur 28 to 35  days after the Early Termination Visit (subjects who do not 
undergo taper of LCM) or 28 to 35  days after the last dose of LC M (subjects who discontinue 
use of LCM [ie, taper]).  
The following should be performed via telephone:  
• Concomitant medications assessment  
• Concomitant AEDs assessment  
• Adverse event reporting. If an AE is reported at this telephone contact, the investigator w ill 
follow the AE until a definite outcome is achieved ( Section  8.1.2 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 210 of 324 Clinical Study Protocol, Section  6.1 (Seizure counts), first sentence. Orig inal text:  
At Screening of SP847 (or other primary study as applicable) subjects/caregivers (including 
parents/legal guardians) will be asked how many seizures the subject has had in the previous 
4 weeks; this will serve as a historical Baseline.  
Was revis ed as follows:  
At Screening of SP847 (or other primary study as applicable) or at the Screening Visit of SP848 
(for subjects who entered directly into SP848) subjects/caregivers (including parents/legal 
guardians) will be asked how many seizures the subjec t has had in the previous 4  weeks; this will 
serve as a historical Baseline.  
Clinical Study Protocol, Section  6.2.1 (Clinical Global Impression of Change), second 
paragraph. Original text:  
For the assessment of the Clinical Global Impression of Change, the investigator  should provide 
his/her assessment of the subject’s clinical status, compared to Baseline, including an evaluation 
of seizure frequency and intensity, the occurrence of AEs, an d subject’s functional status. Visit  1 
of SP847 (or other primary study as applicable) will serve as Baseline.  
Was revised as follows:  
For the assessment of the Clinical Global Impression of Change, the investigator  should provide 
his/her assessment of the  subject’s clinical status, compared to Baseline, including an evaluation 
of seizure frequency and intensity, the occurrence of AEs, and subject’s functional status. Visit  1 
of SP847 (or other primary study as applicable) will serve as Baseline; the Screen ing Visit of 
SP848 will serve as Baseline for those subjects entering directly into SP848.  
Clinical Study Protocol, Section 6.2.2 (Caregiver Global Impression of Change), second 
paragraph. Original text:  
For the assessment of the Clinical Global Impression  of Change, the caregiver  (including 
parent/legal guardian) should provide his/her assessment of the subject’s clinical status, 
compared to Baseline, including an evaluation of seizure frequency and intensity, the occurrence 
of AEs, and subject’s functiona l status. Visit 1 of SP847 (or other primary study as applicable) 
will serve as Baseline.  
Was revised as follows:  
For the assessment of the Clinical Global Impression of Change, the caregiver  (including 
parent/legal guardian) should provide his/her assessm ent of the subject’s clinical status, 
compared to Baseline, including an evaluation of seizure frequency and intensity, the occurrence 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 211 of 324 of AEs, and subject’s functional status. Visit 1 of SP847 (or other primary study as applicable) 
will serve as Baseline; the Screening Visit of SP848 will serve as Baseline for those subjects 
entering directly into SP848.  
Clinical Study Protocol, Section  8.1.8 (Safety signal detection in ongoing clinical studies and 
Data Monitoring Committees), second and third paragraphs. Original text:  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the GCSP 
representative.  
As appropriate for the stage of development and accu mulated experience with the investigational 
medicinal product, medically qualified personnel at UCB may identify additional safety 
measures (examples: AEs, vital signs, laboratory or electrocardiogram results) for which data 
will be periodically reviewed d uring the course of the study.  
Was revised as follows:  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the Drug Safety (DS) 
representative.  
As appropriate for the stage of development and accumulated experience with the investigational 
medicinal product, medically qualified personnel at UCB may identify additional safety 
measures (examples: AEs, vital signs, laboratory or ECG results) for whic h data will be 
periodically reviewed during the course of the study.  
Clinical Study Protocol, Section  8.2.4 (Procedures for reporting serious adverse events), first 
sentence. Original text:  
If an SAE is reported, UCB BIOSCIENCES must be informed within 24 hours of receipt of this 
information by the site (see contact numbers for SAE reporting listed in the Study Contact 
Information section).  
Was revised as follows:  
If an SAE is reported, UCB BIOSCIENCES must be informed within 24 hours of receipt of this 
information by the site (see contact details for SAE reporting listed in the Study Contact 
Information section).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 212 of 324 Clinical Study Protocol, Section  8.2.5 (Follow -up of serious adverse events), final sentence. 
Original text:  
Information on SAEs obtained after cl inical database lock will be captured through the Global 
Clinical Safety & Pharmacovigilance database without limitation of time.  
Was revised as follows:  
Information on SAEs obtained after clinical database lock will be captured through the Drug 
Safety dat abase without limitation of time.  
Clinical Study Protocol, Section  8.4.4 (12 -lead ECG), second paragraph. Original text:  
Beginning with Protocol Amendment  3, all subjects will be required to have a 12 -lead ECG 
(2 interpretable recordings approximately 20  to 30 minutes apart) conducted at LCM C max 
1 week after an initial LCM dose increase. This ECG can be conducted at an Unscheduled Visit, 
if necessary. These subjects will be required to arrive at the clinic prior to taking their morning 
dose of LCM. Subject s will be administered their morning LCM dose by study personnel at the 
clinic so that an ECG (2  interpretable recordings approximately 20  to 30  minutes apart prior to 
vital signs assessment) can be performed 30  minutes to 1  hour after the administration o f LCM 
(ie, at LCM steady state C max). 
Was revised as follows:  
All subjects will be required to have a 12 -lead ECG (2  interpretable recordings approximately 
20 to 30  minutes apart) conducted at LCM C max 1 week after an initial LCM dose increase or 
when a ne w concomitant AED is introduced. This ECG can be conducted at an Unscheduled 
Visit, if necessary. Subjects having a LCM dose increase to ≥8mg/kg/day will be required to 
arrive at the clinic prior to taking their morning dose of LCM. Subjects will be admini stered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings 
approximately 20  to 30  minutes apart prior to vital signs assessment) can be performed 
30 minutes to 1  hour after the administration of LCM (ie, at LC M steady state C max). 
Clinical Study Protocol, Section  8.4.7 (Achenbach CBCL) was newly added as follows and 
subsequent section numbers were adjusted accordingly:  
The Achenbach CBCL is a widely used validated questionnaire to evaluate a child’s 
competencie s and behavioral/emotional problems. Behavioral problems will be scored by the 
parent(s)/legal representative(s). Depending on the subject’s age, 2  versions of the CBCL will be 
used. The CBCL/1½ -5 checklist is intended for use in children 18  months to 5  years and 
11 months of age. For subjects ≥6  years to ≤17  years of age, the CBCL/6 -18 version will be 
used.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 213 of 324 The same scale will be completed at the Screening Visit (subjects enrolling directly into SP848), 
Visit  1 (subjects enrolling from SP847 or other pedia tric clinical studies in epilepsy), and 
Visit  13/Termination Visit (or Early Termination Visit) (all subjects) by the parent(s)/legal 
representative(s). The completion of the Achenbach CBCL will require approximately 
45 minutes.  
In both questionnaires, the occurrence of certain problems and behaviors in the past 6 months 
will be scored on the following scale:  
• 0=not true (as far as known)  
• 1=somewhat or sometimes true  
• 2=very true or often true  
Eight syndrome scores will be calculated from these questions, which will in turn be summarized 
by 2 composite scores. Additionally, for each score on the question, syndrome, and total level, 
categorizations based on a normative sample will be used to evaluate normal, borderline, or 
clinically relevant behavior.  
In ad dition, the Achenbach CBCL/6 -18 includes ratings related to performance in school, 
activities in leisure time, and special interests.  
Clinical Study Protocol, Section  8.4.8 (Bayley Scales of Infant and Toddler Development, Third 
Edition) was newly added as  follows and subsequent section numbers were adjusted 
accordingly:  
The Bayley -III scales are recognized internationally as one of the most comprehensive 
developmental assessment instruments (Sattler and Hoge, 2006) used to examine the major 
facets of a you ng child’s development (Bayley, 2006). The Bayley Scales of Infant and Toddler 
Development, Third Edition (Bayley -III) are a standardized individually administered adaptive 
assessment that measures the developmental functioning of infants and young childre n from 
1 month to 42  months of age (Bayley, 2006). The Bayley -III scales measure cognitive, language, 
motor, social -emotional, and adaptive development and are a revision of the predecessor, the 
Bayley Scales of Infant Development, Second Edition (BSID -II) (Bayley, 1993). The Bayley -III 
scales are a technically sound instrument, with strong internal consistency, as well as test -retest 
stability. The Bayley -III scales are validated only in English.  
This scale is validated as a tool for assessment of neurolog ical development in young children 
and is therefore considered appropriate for SP848.  
The Bayley -III scales are an individually administered adaptive assessment that presents children 
with situations and tasks designed to produce an observable set of behav ioral responses. They 
consist of a cognitive scale, a language composite scale with receptive and expressive language 
subscales, and a motor composite scale with fine and gross motor subscales to be completed by 
the Investigator or designee, and of a socia l-emotional scale, comprising social emotional 
competence, and sensory processing, and an adaptive behavior scale, which assesses the 
attainment of skills necessary for the development of independence, to be completed by the 
child’s parent or caregiver.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 214 of 324 The completion of the Bayley -III scales will require approximately 50  minutes for children who 
are 12  months old or younger and 90  minutes for children aged 13  months and older.  
The same scale will be completed at the Screening Visit (subjects enrolling dir ectly into SP848), 
Visit  1 (subjects enrolling from SP847 or other pediatric clinical studies in epilepsy), and 
Visit  13/Termination Visit (or Early Termination Visit) (all subjects) for children from 1  month 
to <18 months of age enrolled in English -speaki ng countries.  
Clinical Study Protocol, Section  8.4.9 (Palatability and ease of use questionnaire) was newly 
added as follows:  
UCB BIOSCIENCES has created a palatability and ease of use questionnaire to collect data from 
the subject or caregiver regarding d ifferent aspects of LCM and its administration. The 
questionnaire will assess the subject or caregiver’s response regarding the formulation of LCM 
the subject is receiving for palatability items (eg taste, smell, ability to swallow, aftertaste), mode 
of ad ministration, and administration device as applicable.  
Clinical Study Protocol, Section  10.1 (Site qualification), first sentence. Original text:  
A site visit will be performed by UCB BIOSCIENCES or designee prior to the start of the 
primary study (SP847) to discuss the protocol, to ensure the availability of appropriate study 
personnel, adequate resources, and to assess their ability to properly conduct the study according 
to International Conference on Harmonisation -Good Clinical Practice (ICH -GCP) guidel ines and 
local requirements.  
Was revised as follows:  
A site visit will be performed by UCB BIOSCIENCES or designee to discuss the protocol, to 
ensure the availability of appropriate study personnel, adequate resources, and to assess their 
ability to proper ly conduct the study according to International Conference on Harmonisation -
Good Clinical Practice (ICH -GCP) guidelines and local requirements.  
Clinical Study Protocol, Section  10.2.1 (Definition of source data), final sentence. Original text:  
Electronic d ata records, such as Holter monitor records or electroencephalogram records, must 
be saved and stored as instructed by UCB BIOSCIENCES (or designee).  
Was revised as follows:  
Electronic data records, such as Holter monitor records or EEG records, must be saved and 
stored as instructed by UCB BIOSCIENCES (or designee).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 215 of 324 Clinical Study Protocol, Section  12.1 (Description of statistical methods), second paragraph. 
Original text:  
Visit  1 of SP847 (or other primary study as applicable) will serve as Baseline val ues for safety 
and efficacy variables unless otherwise noted.  
Was revised as follows:  
Visit  1 of SP847 (or other primary study as applicable) or the Screening Visit of SP848 (for 
subjects who enter directly into SP848) will serve as Baseline values for saf ety and efficacy 
variables unless otherwise noted.  
Clinical Study Protocol, Section  12.1.1 (Definition of analysis sets), second sentence. Original 
text: 
All subjects from the SS with valid concentration data and the absence of major protocol 
deviations th at may have an influence on the concentration data will be included in the PK  Set 
(PKS).  
Was revised as follows:  
All subjects from the SS with valid concentration data and the absence of major protocol 
deviations that may have an influence on the concentration data will be included in the 
Pharmacokinetic Per -Protocol Set (PK -PPS).  
Clinical Study Protocol, Section  12.1.2.2 (Other safety variables). Original text:  
The other safety variables include changes in laboratory parameters (ie, hematology, cl inical 
chemistry, and urinalysis), ECG measurements, vital sign measurements (blood pressure and 
pulse rate), body weight, height, calculated BMI, and Tanner Stage (if applicable). The actual 
measurement and its change from Baseline (SP847 [or other primar y study as applicable] Visit 1) 
will be analyzed descriptively and presented by visit. In addition, shift tables may be used to 
evaluate the number and percentage of subjects having a different post -Baseline status when 
compared with their Baseline status.  
The shift from Baseline to the subject’s last visit at which a physical and/or neurological 
examination was performed post -Baseline will be summarized by category.  
Laboratory, ECG, and vital signs data outside of the respective reference ranges will be li sted 
and highlighted.  
Was revised as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 216 of 324 The other safety variables include changes in laboratory parameters (ie, hematology, clinical 
chemistry, and urinalysis), ECG measurements, vital sign measurements (blood pressure and 
pulse rate), body weight, height, calculated BMI, and Tanner Stage (if applicable). The actual 
measurement and its change from Baseline (SP847 [or other primary study as applicable] Visit 1) 
or the Screening Visit (for subjects who entered directly into SP848) will be analyzed 
descriptively and presented by visit. In addition, shift tables may be used to evaluate the number 
and percentage of subjects having a different post -Baseline status when compared with their 
Baseline status.  
The shift from Baseline to the subject’s last visit at which a physical and/or neurological 
examination was performed post -Baseline will be summarized by category.  
Laboratory, ECG, and vital signs data outside of the respective reference ranges will be listed 
and highlighted.  
Changes in behavior and develop ment from Baseline as measured using the Achenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
children <18 months of age will be summarized descriptively and presented by visit. Baseline is 
defined as Visit  1 for subjects from SP847 or other epilepsy studies. Baseline values for subjects 
who enroll directly into SP848 will be taken from the Screening Visit.  
Clinical Study Protocol, Section  12.1.4.3 (Palatability and ease of use questionnaire) was newly 
added as  follows:  
Data from the palatability and ease of use questionnaire will be summarized descriptively at each 
visit where it is assessed.  
Clinical Study Protocol, Section  12.2 (Determination of sample size). Original text:  
Approximately 42  subjects from the SP847 study will be eligible to enroll in this open -label 
extension study. Other subjects will be eligible to enroll as future LCM pediatric clinical studies 
in epilepsy are undertaken.  
Was revised as follows:  
Approximately 42  subjects from the SP847 study  will be eligible to enroll in this open -label 
study. Other subjects will be eligible to enroll as other LCM pediatric clinical studies in epilepsy 
are undertaken.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age who have not previously participated 
in a LCM clinical study will be permitted to enroll directly into SP848. The purpose of enrolling 
these subjects directly into SP848 is to obtain additional long -term safety exposures in the age 
range from which adequate PK data have already been obtained in SP847; the additional 
long-term safety data will be included in planned LCM marketing applications for subjects 
≥4 years of age.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 217 of 324 Clinical Study Protocol, Sect ion 15 (References). The following references were added:  
Sattler JM, Hoge RD. Assessment of children: behavioral, social, and clinical foundations. 5th 
ed. La Mesa: Jerome M Sattler; 2006.  
Bayley N. Bayley Scales of Infant Development. 2nd ed. San Antonio : The Psychological 
Corporation; 1993.  
Bayley N. Bayley Scales of Infant and Toddler Development. 3rd ed. San Antonio: Pearson 
Education Inc; 2006.  
Clinical Study Protocol, Section  16.1 (Tabular schedule of study procedures) was updated to the 
following (i ncluding the addition of Table  3). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 218 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X    
Blood sample for concomitant AEDsj Xh  X   X  X  X X    
Urinalysis (subjects aged 5 to 17  years)  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC       X    X X    
Caregiver GIC       X    X X    
Palatability and ease of use 
questionnaire        X   X X    
Dispense LCM  X  X X X X X X X X Xm Xn   
LCM return/compliance    X X X X X X X X X Xn X  
Dispense diary  X  X X X X X X X X X    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 219 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Diary assessment    X X X X X X X X X X X  
C-SSRSo Xh  X X X X X X X X X Xp X  
Achenbach CBCL  X          X    
Bayley -III scales  X          X    
AE reportingq Xh X X X X X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up telephone contact).  
b For subjects who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), Visit 1 is also the last v isit of the primary study. At Visit 1, the informed 
consent will be signed (and assent, if applicable) and e ligibility assessed, the medical history will be updated, body weight and height and concomitant medications including 
AEDs will be recorded, AEs will be assessed, and the subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the follo wing weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed.  Additional assessments can be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits , the subject must return for an Unsc heduled Visit. 
Height will not be recorded at an Unscheduled Visit.  
f Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 2  weeks after the final 
dose of study medication.  
g This TC occurs 28  to 35 days after the last dose of LCM.  
h Assessments should have been done as part of the last visit of the primary study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 220 of 324 i All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/kg/day will be requir ed to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered their morning LCM dose by  study personnel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs  assessment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
j Blood samples may be drawn at any time post -dosing with LCM.  
k For female subjects of childbearing potential, serum pregnancy tests will be  performed at Visit 1, the Early Termination Visit, and the Final Visit. Urine pregnancy tests will be 
performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter pub erty during the course of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥3 00mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrem ents of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussio n with th e medical monitor, whenever possible.  
n As applicable  
o For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version should be 
completed thereafter.  
p The C-SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
q Ongoing AEs from the primary study will be followed, as well as recording of new AEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study P rotocol  SPM 927  SP848  
 
Page 221 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X    
Blood sample for 
concomitant AEDsh X  X X X X    
Urinalysis (subjects aged 5 to 
17 years)    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Palatability and ease of use 
questionnaire    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
Dispense diary  X  X X X X    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study P rotocol  SPM 927  SP848  
 
Page 222 of 324 Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Diary assessment  X  X X X X X X  
C-SSRSm X  X X X X Xn X  
Achenbach CBCL      X X    
Bayley -III scales      X X    
AE reporting X X X X X X X X X 
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; TermV=Termination Visit;  U=urine; 
Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and tele phone contacts (with the exception of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely dis continue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE,  or if a LCM dose increase is required between scheduled clinic visits, the subject must return for 
an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e Subjects who complete the study or withdraw prematurely from the study, and who  discontinue use of LCM (ie, taper), should complete the Final Visit 
2 weeks after the final dose of study medication.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g All subjects will be required to have a 12 -lead ECG (2  interpretable recordings ) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/k g/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered their  morning LCM dose by study personnel at 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study P rotocol  SPM 927  SP848  
 
Page 223 of 324 the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential, serum pre gnancy tests will be performed at the Early Termination Visit and at the Final Visit. Urine pregnancy 
tests will be performed at Visits 10, 11, 12, and 13.  
j The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will ente r puberty during the course of the study.  
k Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥30 0mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly de crements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is permitted after 
discussion wit h the medical monitor, whenever possible.  
l As applicable.  
m For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version should be 
completed thereafter.  
n The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study P rotocol  SPM 927  SP848  
 
Page 224 of 324 Table 3.   Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling directly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
Informed Consent  X       
Inclusion/exclusion criteria  X       
Medical history  X       
Seizure history  X       
Concomitant  medications  X X X X X X X 
Concomitant AEDs  X X X X X X X 
Physical exam (complete)  X       
Physical exam (brief)   X X X X X X 
Neurological exam (complete)  X       
Neurological exam (brief)   X X X X X X 
12-lead ECGa X X X X X X X 
Blood pressure and pulse  X X X X X X X 
Body weight  X X X X X X X 
Height  X       
Clinical chemistry and hematology blood 
sample  X  X  X   
Endocrinology blood sample  X  X  X   
Urinalysis (subjects aged 5 to 17  years)  X  X  X   
Pregnancy testb X       
Tanner Stage  X       
Clinical GIC  X       
Caregiver GIC  X       
Dispense LCM   X X X X X X 
LCM return/compliance   X X X X X X 
Dispense diary  X X X X X X X 
Diary assessment   X X X X X X 
C-SSRSc X X X X X X X 
Achenbach CBCL  X       
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study P rotocol  SPM 927  SP848  
 
Page 225 of 324 Table 3.   Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling directly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
Bayley -III scales  X       
AE reporting X X X X X X X 
AE=adverse event; AEDs=antiepileptic drugs; C max=maximum plasma concentration; C -SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; GIC=Global Impression of Change; LCM=lacosamide  
a All subjects will be required to  have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary . Subjects having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered  their morning LCM dose by study personnel at 
the clinic so that an ECG (2  interpretable r ecordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
b For female subjects of childbearing potential, serum pregnancy tests wil l be performed at the Screening Visit.  
c For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version should be 
completed thereafter.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 226 of 324 17.5 PROTOCOL AMENDMENT  5 
RATIONALE FOR THE AMENDMENT  
In the FDA Division of Neurology Products’ 06  Aug 2012 Request for Information regarding 
SP847 protocol Amendment  5, the Agency recommended that UCB revise an inclusion criterion 
to require the use of more than 1  AED as monotherapy before initiat ing adjunctive LCM therapy 
in SP847. UCB has made this recommended change in the SP847 protocol (Amendment  6). In 
alignment with SP847, the primary purpose of this protocol amendment for SP848 is to modify 
inclusion criterion  7 to require that each subject  in SP848 has been observed to have 
uncontrolled partial -onset seizures after an adequate course of treatment (in the opinion of the 
investigator) with at least 2  AEDs (concurrently or sequentially) . Inclusion criterion  7 applies 
only to subjects who enrol l directly into SP848 without previous participation in a LCM clinical 
study.  
In addition, the BRIEF/BRIEF -P, PedsQL, and health care resource use have been added as 
assessments in SP848.  
Other changes made in this amendment are included in the specific ch anges below.  
MODIFICATIONS/CHANGES  
• Study contact information has been updated (eg, Clinical Project Manager, Safety Physician, 
and SAE reporting).  
• The List of Abbreviations was updated.  
• Information was added to Section  1 (Summary) and throughout the protoc ol as appropriate to 
reflect the addition of the BRIEF/BRIEF -P, the PedsQL, and assessment of health care 
resource use.  
• Inclusion criterion  7 (Section  4.3.1) was modified to require that each subject in SP848 has 
been observed to have uncontrolled partial -onset seizures after an adequate course of 
treatment (in the opinion of the investigator) with at least 2  AEDs (concurrently or 
sequentially) . Inclusion criterion  7 applies only to subjects who enroll directly into SP848 
without previous participation in a  LCM clinical study.  
• Information was added to Section  8.4.6 (Assessment of suicidality) to provide for monitoring 
for any changes in mood, ideas, or behavior for warning signs of depression in subjects 
<6 years of age for whom the C -SSRS is not used.  
REFER ENCE  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 227 of 324 Clinical Study Protocol, Contact information for the Clinical Project Manager and Safety 
Physician. Original text:  
Clinical Project Manager:  
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Safety Physician (Drug Safety) : 
Name:  , MD  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
Was revised as follows:  
Clinical Project Manager:  
Name:  , RN, MSN  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 228 of 324 Safety Physician (Drug Safety) : 
Name:  , MD  
Address:  UCB Pharma S.A. Belgium  
Chemin du Foriest  
B-1420 Braine -L’Alleud, Belgium  
 
Phone/Fax:   
E-mail:   
 
Clinical Study Protocol, Serious Adverse Event reporting contact information. Original text:  
SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h), safety related issues,  
and emergency unblinding  
Fax Europe and  Rest of the World (except Japan):  +32 2 386 24 21  
USA: +1 800 880 6949  
Canada:  +1 877 582 8842  
Japan: +81 3 5283 1869  
Email  Europe and Rest of the World (except Japan): GCSP@ucb.com  
Japan: JDSO@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 229 of 324 Was revised as follows:  
SERIOUS ADVERSE EVEN T REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World (except Japan):  +32 2 386 24 21  
USA: +1 800 880 6949  
Canada:  +1 877 582 8842  
Japan: +81 3 5283 1869  
Email  Global (except Japan): DS_ICT @ucb.com  
Japan: JDSO@ucb.com  
 
List of  Abbreviations. The following abbreviations were added:  
BRIEF® Behavior Rating Inventory of Executive 
Function® 
BRIEF®-P Behavior Rating Inventory of Executive 
Function®-Preschool Version  
CBCL  Child Behavior Checklist  
HRQoL  health -related quality of life 
PedsQL™  Pediatric Quality of Life Inventory  
 
Clinical Study Protocol, Section  1 (Summary). Original text:  
The primary variables for assessment of safety and tolerability are:  
• Adverse events (AEs) reported spontaneously by the subject and/or caregive r or observed by 
the investigator  
• Subject withdrawal due to AEs  
• Hematology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination  findings  
• Body weight, height, and calculated body mass index (BMI)  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 230 of 324 • Achenbach CBCL for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) assessing 
behavior  
Bayley -III scales for children <18  months of age at time of enrollment (applicable only to 
subjects enrolled in English -speaking countries)The secondary variables include seizure counts 
(assessed using seizure diaries in order to evaluate preliminary evidence of effi cacy during long -
term exposure in this population), the Clinical Global Impression of Change, the Caregiver 
Global Impression of Change, and a LCM palatability and ease of use questionnaire.  
 
Was revised as follows:  
The primary variables for assessment of safety and tolerability are:  
• Adverse events (AEs) reported spontaneously by the subject and/or caregiver or observed by 
the investigator  
• Subject withdrawal due to AEs  
• Hematology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead electrocard iograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body mass index (BMI)  
• Tanner stage (if applicable)  
• Plasma concentrations of LCM (for population PK analysis ) and concomitant AEDs  
• Achenbach Child Behavior Checklist (CBCL) for children 18  months and older (CBCL/1½ -5 
and CBCL/6 -18) assessing behavior  
• Bayley -III scales for children <18  months of age at time of enrollment (applicable only to 
subjects enrolled in E nglish -speaking countries)  
• Cognitive function assessments (Behavior Rating Inventory of Executive Function® 
[BRIEF®]/BRIEF®-Preschool Version [BRIEF®-P]) (if applicable)  
The secondary variables include seizure counts (assessed using seizure diaries in orde r to 
evaluate preliminary evidence of efficacy during long -term exposure in this population), the 
Clinical Global Impression of Change, the Caregiver Global Impression of Change, quality of 
life assessments (Pediatric Quality of Life Inventory [PedsQL™]), health care resource use, and 
a LCM palatability and ease of use questionnaire.  
 
Clinical Study Protocol, Section  4.2.1 (Primary variables). The following variable was added:  
• Cognitive function assessments (BRIEF -P/BRIEF) (if applicable)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 231 of 324 Clinical Study Pr otocol, Section  4.2.2 (Secondary variables). The following variables were 
added:  
• Quality of life assessments (PedsQL) (if applicable)  
• Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations not related to study, h ospitalizations not related to study)  
 
Clinical Study Protocol, Section  4.3.1 (Inclusion criteria). The following criterion:  
7. Subject has been observed to have uncontrolled partial -onset seizures after an adequate 
course of treatment (in the opinion of the investigator) with at least 1  AED (concurrently or 
sequentially).  
 
Was revised as follows:  
7. Subject has been observed to have uncontrolled partial -onset seizures after an adequate 
course of treatment (in the opinion of the investigator) with at least  2 AEDs (concurrently or 
sequentially).  
 
Clinical Study Protocol, Section  4.3.2 (Exclusion criteria). The following criterion:  
3. Subject has a lifetime history of suicide attempt (including an active attempt, interrupted 
attempt, or aborted attempt), or has suicidal ideation in the past 6  months as indicated by a 
positive response (“Yes”) to either Question  4 or Question  5 of the Columbia -Suicide 
Severity Rating Scale (C -SSRS) at Screening.  
 
Was revised as follows:  
3. Subject ≥6  years of age has a lifetime histo ry of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6  months as 
indicated by a positive response (“Yes”) to either Question  4 or Question  5 of the 
Columbia -Suicide Severity Rati ng Scale (C -SSRS) at Screening.  
 
Clinical Study Protocol, Section  4.3.3 (Criteria for withdrawal). The following criteria:  
11. For subject who did not complete a C -SSRS at Screening, subject has a lifetime history 
(prior to study entry or since study start ) of suicide attempt (including an active attempt, 
interrupted attempt, or aborted attempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subject from the study and immediately refer the subject to a 
Mental Healthcare Professio nal. 
12. For all subjects, regardless of whether or not a C -SSRS was completed at Screening, subject 
has active suicidal ideation as indicated by a positive response (“Yes”) to either Question  4 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 232 of 324 or Question  5 of the “since last visit” version of the C -SSRS . The subject should be referred 
immediately to a Mental Healthcare Professional and must be withdrawn from the study.  
5.   For subject who did not complete a C -SSRS at Screening, subject had active suicidal ideation 
in the past 6  months as indicated by a positive response (“Yes”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental Healthcare Professional and use clinical judgment as to whether to 
withdraw the patient fro m the study.  
 
Were revised as follows:  
11. For subject who did not complete a C -SSRS at Screening, subject has a lifetime history 
(prior to study entry or since study start) of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted a ttempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subject from the study and immediately refer the subject to a 
Mental Healthcare Professional.  
12. For all subjects ≥6  years of age, regardless of whether or not a C -SSRS was  completed at 
Screening, subject has actual suicidal ideation as indicated by a positive response (“Yes”) to 
either Question  4 or Question  5 of the “since last visit” version of the C -SSRS. The subject 
should be referred immediately to a Mental Healthcare Professional and must be withdrawn 
from the study.  
5.   For subject who did not complete a C -SSRS at Screening, subject had actual suicidal ideation 
in the past 6  months as indicated by a positive response (“Yes”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental Healthcare Professional and use clinical judgment as to whether to 
withdraw the patient from the study.  
 
Clinical Study Protocol, Section  5.1 (Screening Visit). The following assessments were added:  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Health care resource use  
 
Clinical Study Protocol, Section  5.2 (Titration Visit[s] [TV1, TV2, TV3, TV4, TV5, TV6]). The 
following assessments:  
• Blood sample for clinical chemistry, hematology, and endocrinology (TV2 and TV4 only)  
• Urine sample for urinalysis (TV2 and TV4 only)  
 
Were revised as follows:  
• Blood sample for clinical chemistry, hematology, and endocrinology (TV4 only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 233 of 324 • Urine sample for urin alysis (TV4 only)  
 
Clinical Study Protocol, Section  5.2 (Titration Visit[s] [TV1, TV2, TV3, TV4, TV5, TV6]). The 
following assessment was added:  
• Health care resource use  
 
Clinical Study Protocol, Section  5.3 (Visit  1 [Week  0]). The following assessments we re added:  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Health care resource use  
 
Clinical Study Protocol, Section  5.5 (Visit  2 [Week  4]). The following assessmen t was added:  
• Health care resource use  
 
Clinical Study Protocol, Section  5.6 (Visit  3 [Week  8]). The following assessment was added:  
• Health care resource use  
 
Clinical Study Protocol, Section  5.8 (Visit  5 [Week  20]). The following assessments were added:  
• Achenbach CBCL to be completed by the parent(s)/legal representative(s) (CBCL/1½ -5 for 
children from 18  months to 5  years 11  months and CBCL/6 -18 for children 6  years and 
older) (subjects enrolling from SP847 or another applicable LCM pediatric clinical st udy in 
epilepsy)  
• Bayley -III scales for children <18  months of age enrolled in English -speaking countries 
(subjects enrolling from SP847 or another applicable LCM pediatric clinical study in 
epilepsy)  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if app licable)  
• Health care resource use  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 234 of 324 Clinical Study Protocol, Section  5.16 (Visit  13/Termination Visit [Week  96]), third paragraph. 
Original text:  
Assessments for Visit 13/Termination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following exceptions: the laboratory blood sample is 
collected only for clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted, a Tanner Stage assessment is conducted (if 
applicable), an Achenbach CBCL is conducted, Bayley -III scales are conducted, and the 
palatability and ease of use questionnaire is completed . 
 
Was revised as follows:  
Assessments for Visit 13/Termination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following excepti ons: the laboratory blood sample is 
collected only for clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted, a Tanner Stage assessment is conducted (if 
applicable), an Achenbach CBCL is conducted, Bayley -III scales are conducted, 
BRIEF -P/BRIEF and PedsQL scores are obtained, and the palatability and ease of use 
questionnaire is completed . 
 
Clinical Study Protocol, Section 5.17 (Early Termination Visit). The following assessments were 
added:  
• BRIEF -P/BRIEF score (if applicable)  
• PedsQL score (if applicable)  
• Health care resource use  
 
Clinical Study Protocol, Section 5.18 (Unscheduled Visit[s]). The follo wing assessment was 
added:  
• Health care resource use  
 
Clinical Study Protocol, Section 5.19 (Final Visit). The following assessment was added:  
• Health care resource use  
 
Clinical Study Protocol, Section  6.3 (Pediatric Quality of Life Inventory) was newly add ed as 
follows:  
The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions (Varni et al, 2001; 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 235 of 324 Varni et al, 2011). The PedsQL will be administered according to the tabular schedule of study 
procedures, Section  16.1. 
The PedsQL Measurement Model  consists of developmentally appropriate forms for pediatric 
subjects ≥1 month to ≤12 months; ≥13 months to ≤24 months; >2  years to ≤4  years, ≥5  years to 
≤7 years, ≥8  years to ≤12  years, and ≥13  years to ≤18 years of age. Self -report is measured for 
pediat ric subjects ≥5  years to ≤18 years of age, and parent proxy report of child health -related 
quality of life (HRQoL) is measured for pediatric subjects ≥1 month to ≤18  years of age.  
The multidimensional PedsQL scale encompasses the essential core domains fo r pediatric 
HRQoL measurement: 1) Physical Functioning/Symptoms, 2) Emotional Functioning, 3) Social 
Functioning, and 4) Cognitive/School Functioning. The PedsQL assessment is retrospective to 
the prior month, and individual items are scored using a 5 -point Likert scale (never, almost 
never, sometimes, often, or always). A total health summary score is calculated from the sum of 
the raw scores of the individual items, with higher scores indicating higher HRQoL.  
 
Clinical Study Protocol, Section  6.4 (Health care resource use) was newly added as follows:  
For health care resource use parameters, the following will be evaluated: concomitant AEDs, 
medical procedures, health care provider consultations not related to study, and hospitalizations 
not related to stud y. Health care resource use parameters will be collected according to the 
tabular schedule of study procedures, Section  16.1. 
 
Clinical Study Protoc ol, Section  8.4 section heading. Original text:  
Other safety measurements  
 
Was revised as follows:  
Other measurements  
 
Clinical Study Protocol, Section  8.4.2 (Neurological examination), final sentence. Original text:  
The investigator or subinvestigator is responsible for confirming the diagnosis of partial -onset 
seizures.  
 
Was revised as follows:  
The investigator or subinvestigator is responsible for confirming the diagnosis of partial -onset 
seizures or other epilepsy syndrome.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 236 of 324 Clinical Study Protocol, Sec tion 8.4.6 (Assessment of suicidality), the following paragraph was 
added:  
The C -SSRS is not validated and will not be used for subjects <6  years of age. Subjects should 
be monitored for any changes in mood, ideas, or behavior for warning signs of depressi on. The 
investigator should be aware of common warning signs that might be a signal for risk of 
depression. For common signs and symptoms of depression in children younger than 6  years old, 
reference should be made to the current version of the Diagnostic and Statistical Manual of 
Mental Disorders. Parents and caregivers should also be advised accordingly and effort should be 
made at clinic visits to specifically assess potential depression.  
 
Clinical Study Protocol, Section  8.4.10 (Behavior Rating Inventor y of Executive Function) was 
newly added as follows:  
The BRIEF -P and the BRIEF are validated tools that will be used for the evaluation of subjects 
≥2 years to <5  years of age and ≥5  years of age, respectively. The BRIEF -P/BRIEF will be 
administered accord ing to the tabular schedule of study procedures, Section  16.1. 
The BRIEF -P and BRIEF include rating forms used by parents to assess subjects’ execu tive 
functioning. Executive functions broadly encompass a set of cognitive skills that are responsible 
for the planning, initiation, sequencing, and monitoring of complex goal -directed behavior.  
The BRIEF -P rating form consists of items that measure variou s aspects of executive 
functioning: Inhibit, Shift, Emotional Control, Working Memory, and Plan/Organize. The 
clinical scales form 3  broad indexes (Inhibitory Self -Control, Flexibility, and Emergent 
Metacognition) and 1  composite score (Global Executive Co mposite).  
The BRIEF rating form contains items in nonoverlapping clinical scales. These theoretically and 
statistically derived scales form 2  broader Indexes: Behavioral Regulation (3  scales) and 
Metacognition (5  scales), as well as a Global Executive Comp osite score.  
Both the BRIEF -P and the BRIEF include validity scales to measure negativity and 
inconsistency of responses.  
 
Clinical Study Protocol, Section  12.1.2.2 (Other safety variables), final paragraph. Original 
text: 
Changes in behavior and development from Baseline as measured using the Achenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
children <18 months of age will be summarized descriptively and presented by visit. Baseline is 
defined as V isit 1 for subjects from SP847 or other epilepsy studies. Baseline values for subjects 
who enroll directly into SP848 will be taken from the Screening Visit.  
 
Was revised as follows:  
Changes in behavior and development from Baseline as measured using the A chenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 237 of 324 children <18 months of age will be summarized descriptively and presented by visit. Changes in 
cognitive function as measured using the BRIEF -P/BRIEF will be  summarized by descriptive 
statistics at each visit. Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy 
studies. Baseline values for subjects who enroll directly into SP848 will be taken from the 
Screening Visit.  
 
Clinical Study Proto col, Section 12.1.4.4 (PedsQL) was newly added as follows:  
The PedsQL score and change from Baseline scores will be analyzed in a descriptive manner. 
Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy studies. Baseline values 
for subj ects who enroll directly into SP848 will be taken from the Screening Visit.  
 
Clinical Study Protocol, Section  12.1.4.5 (Health care resource use) was newly added as 
follows:  
Descriptive statistics will be presented for the number of medical resources used (medications, 
consultations, procedures, hospitalizations, and length of hospital stays).  
 
Clinical Study Protocol, Section  15 (References). The following references were added:  
Varni JW, Limbers CA, Neighbors K, Schulz K, Lieu JE, Heffer RW, et al. The Pe dsQL™ 
Infant Scales: feasibility, internal consistency reliability, and validity in healthy and ill infants. 
Qual Life Res. 2011;20:45 -55. 
Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of 
Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 
2001;39:800 -12. 
 
Clinical Study Protocol, Section  16.1 (Tabular schedule of study procedures) was updated to the 
following:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 238 of 324  
Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X    
Blood sample for concomitant AEDsj Xh  X   X  X  X X    
Urinalysis (subjects aged 5 to 17  years)  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC  Xh     X    X X    
Caregiver GIC  Xh     X    X X    
Palatability and ease of use 
questionnaire        X   X X    
Dispense LCM  X  X X X X X X X X Xm Xn   
LCM return/compliance    X X X X X X X X X Xn X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 239 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
C-SSRSo Xh  X X X X X X X X X Xp X  
Achenbach CBCL  X     X    X X    
Bayley -III scales  X     X    X X    
BRIEF -P/BRIEF  X     X    X X    
PedsQL  X     X    X X    
AE reportingq Xh X X X X X X X X X X X X X 
Health care resource use  X  X X X X X X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up telephone contact).  
b For subjects who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), Visit 1 is also the last v isit of the primary study. At Visit 1, the informed 
consent will be signed (and assent , if applicable) and eligibility assessed, the medical history will be updated, body weight and height and concomitant medica tions including 
AEDs will be recorded, AEs will be assessed, and the subject diary and LCM dispensed.  
c Telephone contacts are sche duled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits , the subject  must return for an Unscheduled Visit. 
Height will not be recorded at an Unscheduled Visit.  
f Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 2  weeks after the final 
dose of study medication.  
g This TC occurs 28  to 35 days after the last dose of LCM.  
h For subjects enrolling from SP847 or other LCM pediatric clinical studies in epilepsy, assessments should have been done as p art of the last visit of the prima ry study. For 
subjects enrolling directly into SP848, these asssessments should be completed at Visit 1.  
i All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a  LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their m orning dose of LCM. Subjects will be administered their morning LCM dose by study personnel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 240 of 324 j Blood samples may be drawn at any time post -dosing with LCM.  
k For female subjects of childbearing potential, serum pregnancy tests will be performed at Visit 1, the Early Termination Visi t, and the Final Visit. Urine pregnancy tests will be 
performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (t ablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200m g/day (tablet). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussio n with the medical monitor, whenever possible.  
n As applica ble  
o For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version should be 
completed thereafter.  
p The C -SSRS assessment should be completed if the Uns cheduled Visit is due to an AE.  
q Ongoing AEs from the primary study will be followed, as well as recording of new AEs during the current study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 241 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X    
Blood sample for 
concomitant AEDsh X  X X X X    
Urinalysis (subjects aged 5 to 
17 years)    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Palatability and ease of use 
questionnaire    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
Dispense diary  X  X X X X    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 242 of 324 Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Diary assessment  X  X X X X X X  
C-SSRSm X  X X X X Xn X  
Achenbach CBCL    X  X X    
Bayley -III scales    X  X X    
BRIEF -P/BRIEF    X  X X    
PedsQL    X  X X    
AE reporting X X X X X X X X X 
Health care resource use  X  X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; TermV=Termination Visit;  U=urine; 
Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Vis it 1 is applicable for all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at t he investigator’s discretion. If 
the LCM dose is d ecreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between scheduled clinic visits,  the subject must return for 
an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e Subjects who complete the  study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should complete the Final Visit 
2 weeks after the final dose of study medication.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g All subjects will be requ ired to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if ne cessary. Subjects having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects will be administered  their morning LCM dose by study personnel at 
the clinic so that an ECG (2  interpre table recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential, serum pregnancy tests will be performed at the Early Termination Visit and at th e Final Visit. Urine pregnancy 
tests will be performed at Visits 10, 11, 12, and 13.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 243 of 324 j The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course of the study.  
k Lacosamide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥30 0mg/day (tablet). It is 
recommend ed that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A  slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emerg ency, a faster taper is permitted after 
discussion with the medical monitor, whenever possible.  
l As applicable.  
m For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since last visit” version should be 
completed thereafter.  
n The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 244 of 324 Table 3.   Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling dir ectly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
Informed Consent  X       
Inclusion/exclusion criteria  X       
Medical history  X       
Seizure history  X       
Concomitant medications  X X X X X X X 
Concomitant AEDs  X X X X X X X 
Physical exam (complete)  X       
Physical exam (brief)   X X X X X X 
Neurological exam (complete)  X       
Neurological exam (brief)   X X X X X X 
12-lead ECGa X X X X X X X 
Blood pressure and pulse  X X X X X X X 
Body weight  X X X X X X X 
Height  X       
Clinical chemistry and hematology blood 
sample  X    X   
Endocrinology blood sample  X    X   
Urinalysis (subjects aged 5 to 17 years)  X    X   
Pregnancy testb X       
Tanner Stage  X       
Clinical GIC         
Caregiver GIC         
Dispense LCM   X X X X X X 
LCM return/compliance   X X X X X X 
Dispense diary  X X X X X X X 
Diary assessment   X X X X X X 
C-SSRSc X X X X X X X 
Achenbach CBCL  X       
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 245 of 324 Table 3.   Schedule of study procedures for SP848 (Screening Visit and Titration Visits, subjects enrolling dir ectly into SP848)  
Study SP848  Screening  Titration Visits  
Visit Screening Visit  Titration 
Visit  1 Titration 
Visit  2 Titration 
Visit  3 Titration 
Visit  4 Titration 
Visit  5 Titration 
Visit  6 
Bayley -III scales  X       
BRIEF -P/BRIEF  X       
PedsQL  X       
AE reporting X X X X X X X 
Health care resource use  X X X X X X X 
AE=adverse event; AEDs=antiepileptic drugs; C max=maximum plasma concentration; C-SSRS=Columbia -Suicide Severity Rating Scale; 
ECG=electrocardiogram; GIC=Global Impression of Change; LCM=lacosamide  
a All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to t aking their morning dose of LCM. Subjects will be administered their morning LCM dose by study personnel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minu tes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
b For female subjects of childbearing potential, serum pregnancy tests will be performed at the Screening Visit.  
c For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since last visit” version should be 
completed thereafter.  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 246 of 324 Clinical Study Protocol, Section  16.3 (Declaration and signatures of person responsi ble for the 
study). The signature block for the Clinical Project Manager was updated as follows:  
 
Clinical Project Manager  
, RN, MSN    _________________________________________  
      Date / Signature  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 247 of 324 17.6 PROTOCOL AMENDMENT 6  
RATIONALE FOR THE AMENDMENT  
The primary purpose of this protocol amendment is to permit enrollment of up to approximately 
75 eligible pediatric subjects ≥4 years to <17 years of age with partial -onset seizures (deemed 
appropriate for treatment with LCM) who previously parti cipated in the iv LCM clinical study, 
EP0060. The purpose of enrolling these subjects is to obtain additional long -term safety 
exposures in the age range of ≥4 years to <17 years of age; the additional long -term safety data 
will be included in planned regu latory submissions for LCM as adjunctive therapy for 
partial -onset seizures in pediatric subjects ≥4 years to ≤17 years of age with epilepsy.  
In addition, Sponsor language for monitoring of PDILI events was added to increase clarity for 
the sites and to al ign across programs. Addition of this language is to align with FDA guidance 
regarding monitoring of PDILI events and does not reflect a change in the liver safety signal for 
LCM.  
Furthermore, administrative changes, including the update of the study team and minor 
corrections (ie, CRF to eCRF and Drug Safety to Patient Safety), incorporation of updated 
protocol template language, and update of the Sponsor Declaration for electronic signature, have 
been made.  
MODIFICATIONS/CHANGES  
• The name and contact infor mation for the Clinical Project Manager, Medical Director 
(Medical Therapeutics), and Safety Representative (Patient Safety) were updated. Update to 
Sponsor site fax number to other contacts is not detailed below.  
• Serious AE reporting number was updated fo r Canada and was removed for Japan (falls 
under global number)  
• Clarifications were added that SP847 is a completed study and that new subjects enrolling 
into SP848 either  enroll directly or from other pediatric studies of LCM.  
• Text added to clarify that u p to 75 subjects may enroll in SP848 from EP0060.  
• Background information was updated for current status of LCM clinical development 
program  
• Exclusion Criterion 2 was revised to potentially allow subjects from EP0060 who either 
withdrew consent for the sole  reason of route of LCM administration or who required more 
than 10 infusions to participate in SP848 pending discussion with and agreement from the 
Medical Monitor.  
• Exclusion Criterion 9 was modified to update creatinine clearance exclusion to <30mL/min 
to align with the rest of the LCM program. The liver function requirements from Exclusion 
Criterion 9 were moved to a new exclusion criterion (19).  
• Exclusion Criterion 16, which excluded use of vigabatrin or felbamate, was removed.  
• Exclusion Criterion 17 and the list of prohibited medications were updated to exclude use of 
MAOI -A inhibitors and cannabidiols.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 248 of 324 • Exclusion Criterion 20 was added such that subjects who initiated treatment in EP0060 could 
not enter SP848 if they had previously participated in a l ong-term open -label study.  
• Clarification was added to withdrawal criteria for subjects transitioning to SP848 from 
EP0060.  
• Sponsor language for monitoring of PDILI events was added to increase clarity for the sites 
and to align across programs .  
• Clarificat ion was added for prohibited concomitant medications.  
• Routine blood samples for LCM PK analysis during Year 2 will be collected for subjects 
enrolled at sites in Japan. Across all sites, a blood sample for LCM PK analysis may be 
collected if the subject ha s an Unscheduled Visit due to a SAE.  
• Blood samples for concomitant AED PK analysis were removed from Year 2 visits; however, 
a sample may be collected if the subject has an Unscheduled Visit due to a SAE.  
• Updates to the CRF language were incorporated to ac commodate use of an eCRF. Minor 
edits to change CRF to eCRF in Section 8 are not itemized below.  
• Updated protocol template language was incorporated regarding suspected transmission of 
infectious agent, AEs of special interest, drug supply, drug accountabi lity, auditing, and data 
handling and record keeping.  
• Schedules of Assessments were updated to reflect changes above and to indicate which 
Visit  1 assessments would need to be performed for subjects enrolling from EP0060.  
• The Sponsor Declaration has been u pdated for electronic signature.  
REFERENCE  
Clinical Study Protocol, Contact information for the Clinical Project Manager, Medical 
Director (Medical Therapeutics), and Safety Representative (Patient Safety) were updated. 
Original text:  
Clinical Project Manager:  
Name:  , RN, MSN  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 249 of 324 Medical Director (Medical Therapeutics) : 
Name:   MD 
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Safety Physician (Drug Safety) : 
Name:  , MD  
Address:  UCB Pharma S.A. Belgium  
Chemin du Foriest  
B-1420 Braine -L’Alleud, Belgium  
Phone/Fax:   
E-mail:   
Were revised as follows:  
Clinical Project Manager:  
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Medical Director (Medical Therapeutics) : 
Name:  , MD  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 250 of 324 Safety Representative (Patient Safety) : 
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco  Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
 
Clinical Study Protocol, Serious Adverse Event Reporting details were updated. Original text:  
SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World (except Japan):  +32 2 386 24 21  
USA: +1 800 880 6949  
Canada:  +1 877 582 8842  
Japan: +81 3 5283 1869  
Email  Global (except Japan): DS_ICT @ucb.com  
Japan: JDSO@ucb.com   
Was revised as follows:  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  +32 2 386 24 21  
USA and Canada: +1 800 880 6949 or +1 866 890 3175  
Email  Global: DS_ICT @ucb.com  
 
List of  Abbreviations:  
The abbreviations of ALP, CDMS, PDILI, and RDC were added. The abbreviation eCRF and PS 
replaced the terms CRF and DS, respectively. The term MAO was clarified to MAOI, and the 
definition of ICH was updated to reflect the recent name change . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 251 of 324  
Clinical Study Protocol, Section 1 (Summary, Original text, second and third paragraphs:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subj ects who participate in 
other LCM pediatric clinical studies in other epilepsy syndromes. In addition, at selected sites, 
beginning with Protocol Amendment  4, up to approximately 100  eligible pediatric subjects 
≥4 years to ≤17  years of age with partial -onset seizures (deemed appropriate for treatment with 
adjunctive LCM) who have not previously participated in a LCM clinical study will be permitted 
to enroll directly into SP848. The purpose of enrolling these subjects directly into SP848 is to 
obtain suffic ient long -term safety exposures in the age range of ≥4  years to ≤17  years of age; the 
long-term safety data will be included in planned regulatory submissions for LCM as adjunctive 
therapy for partial -onset seizures in pediatric subjects ≥4  years to ≤17  years of age with epilepsy. 
At selected sites, subjects may also be able to participate in a substudy without withdrawing from 
SP848.  
Subjects who complete SP847 or another applicable LCM pediatric epilepsy study and choose to 
enter this open -label study wil l begin on the LCM dose they achieved in SP847 or their previous 
pediatric LCM study. Subjects who discontinued from SP847 due to a dose reduction or status 
epilepticus, but for whom it is determined medically appropriate to enter this open -label study, 
will also begin on the LCM dose they achieved in SP847. Subjects who meet eligibility 
requirements and enroll directly into SP848 without previous participation in a LCM clinical 
study will initiate treatment with LCM, and the LCM dose will be titrated to a level to optimize 
tolerability and seizure control (up to a maximum level as described below).  
Was revised as follows:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now  amended to be open to subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible p ediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed 
appropriate for treatment with adjunctive LCM) who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. The purpose of e nrolling these 
subjects directly into SP848 is to obtain sufficient long -term safety exposures in the age range of 
≥4 years to ≤17  years of age; the long -term safety data will be included in planned regulatory 
submissions for LCM as adjunctive therapy for partial -onset seizures in pediatric subjects 
≥4 years to ≤17  years of age with epilepsy.   
Protocol Amendment 6 allows up to approximately 75 additional eligible pediatric subjects with 
epilepsy who participated in EP0060 to enroll into SP848. In addition, subjects already enrolled 
in SP848 may participate in EP0060, if eligible, and then resume participation in SP848. These 
subjects may either voluntarily choose to have an iv LCM infusion even though they are capable 
of taking oral LCM or require iv LCM inf usion due to a medical reason or procedure (ie, unable 
to take oral LCM).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 252 of 324 Subjects who complete SP847 or another applicable LCM pediatric epilepsy study and choose to 
enter this open -label study will begin on the LCM dose they achieved in SP847 or their previous 
pediatric LCM study. Subjects who discontinued from SP847 due to a dose reduction or status 
epilepticus, but for whom it is determined medically appropriate to enter this open -label study, 
will also begin on the LCM dose they achieved in SP847. Su bjects who enroll from EP0060 will 
begin SP848 with an equivalent LCM dose as they last received in EP0060; however, the LCM 
dose may be further titrated/adjusted to a level to optimize tolerability and seizure control (up to 
a maximum level as described b elow). Subjects who meet eligibility requirements and enroll 
directly into SP848 without previous participation in a LCM clinical study will initiate treatment 
with LCM, and the LCM dose will be titrated to a level to optimize tolerability and seizure 
control (up to a maximum level as described below).  
 
Clinical Study Protocol, Section 2 (Background information). Original text, first paragraph:  
Epilepsy is the second most prevalent neurological disorder in the world. More than 40  million 
people have epileps y–about 1% of the world’s population (Dichek, 1999). Although some forms 
of epilepsy may respond to surgical treatment and others may not require any treatment at all, 
most patients with epilepsy require appropriate pharmacological therapy (Perucca, 1996).  In the 
past decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
Was revised as follows:  
Epilepsy is the second most prevalent neurological disorder in the world. It is e stimated that 
almost 70 million people suffer from epilepsy (Ngugi et al, 2011). Although some forms of 
epilepsy may respond to surgical treatment and others may not require any treatment at all, most 
patients with epilepsy require appropriate pharmacologi cal therapy (Perucca, 1996). In the past 
decade, several new options for the medical treatment of epilepsy have been introduced, 
including novel AEDs and vagus nerve stimulation.  
 
Clinical Study Protocol, Section 2 (Background information). Original text, fourth paragraph:  
Among the newer AEDs, only 5 (gabapentin, lamotrigine, oxcarbazepine, topiramate, and 
levetiracetam) have successfully demonstrated efficacy as adjunctive therapy in children with 
difficult to treat partial -onset seizures (Appleton et al,  1999; Duchowny et al, 1999; 
Elterman  et al, 1999; Glauser et al, 2000; Glauser et al, 2006). Despite the availability of new 
AEDs, more than 25% of pediatric patients have inadequate seizure control on currently 
available AEDs, or experience significant a dverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
Was revised as follows:  
Among the newer AEDs, only 6 (gabapentin, lamotrigine, oxcarbazepine, topiramate, 
levetiracetam, and perampanel) have successfully demonstrated efficacy as adjunctive therapy in  
children with difficult to treat partial -onset seizures (Rheims and Ryvlin, 2013; Glauser et al, 
2006; Appleton et al, 1999; Duchowny et al, 1999; Elterman et al, 1999). Despite the availability 
of new AEDs, more than 25% of pediatric patients have inadeq uate seizure control on currently 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 253 of 324 available AEDs, or experience significant adverse drug effects (Hadjiloizou and Bourgeois, 
2007).  
 
Clinical Study Protocol, Section 2 (Background information). Original text, sixth and seventh 
paragraphs:  
Lacosamide has be en approved as adjunctive therapy in the treatment of partial -onset seizures 
with or without secondary generalization in patients 16 years of age and older in the European 
Union (oral tablets, oral solution [syrup], and solution for intravenous [iv] infusi on) and in 
patients 17 years of age and older in the United States (oral tablets, oral solution, and solution for 
iv infusion). The oral solution (syrup) is a formulation suitable for administration to children. 
Bioequivalence has been shown between the ta blet and oral solution (syrup) formulations, 
comparing 2 tablets of LCM 100mg and the oral solution (syrup) containing LCM 200mg, after 
single -dose administration in healthy subjects. The PK of LCM and its major metabolite, SPM 
12809 (O -desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after 
single oral doses of LCM 200mg administered as tablets or as oral solution (syrup).  
In the clinical development program for LCM, safety and tolerability of multiple doses of up to 
400mg bid (80 0mg/day) were evaluated in approximately 700  unique volunteers who received 
LCM in Phase  1 studies. The safety and efficacy of LCM has also been evaluated in Phase  2/3 
studies as adjunctive oral therapy in over 1300  adult subjects with partial -onset seizur es and as 
oral monotherapy in over 2200  adult subjects in other indications (eg, neuropathic pain, 
osteoarthritis, fibromyalgia, and migraine prophylaxis). In addition, LCM solution for infusion 
was evaluated as short -term replacement therapy in a subset o f subjects with partial -onset 
seizures (199  patients) who were receiving adjunctive LCM tablets.  
Were revised as follows:  
Lacosamide (200mg/day to 400mg/day) is approved and indicated as adjunctive therapy in the 
treatment of partial -onset seizures with or  without secondary generalization in adult and 
adolescent (16 to 18 years of age) patients with epilepsy and was first approved in Aug 2008 by 
the European Commission. Lacosamide is available in tablet (50mg, 100mg, 150mg, and 200mg) 
and syrup (10mg/mL) or al formulations as well as solution for infusion (10mg/mL) formulation 
for use as temporary iv replacement when oral administration is not feasible. Lacosamide 
(200mg/day to 400mg/day) was approved in the US in Oct 2008 as adjunctive therapy and in 
Aug 201 4 as monotherapy in the treatment of partial -onset seizures in patients 17 years of age 
and older. Initiation of adjunctive LCM treatment with a single loading dose of LCM 200mg 
(oral tablets, syrup, or iv infusion) followed 12 hours later by a LCM 100mg t wice daily 
(200mg/day) maintenance dose regimen was also approved by the European Commission in Nov 
2012. Use of a LCM 200mg loading dose for initiation of initial LCM monotherapy, conversion 
to LCM monotherapy, or adjunctive therapy was approved in the US  in Aug 2014.  
The oral solution (syrup) is a formulation suitable for administration to children. Bioequivalence 
has been shown between the tablet and oral solution (syrup) formulations, comparing 2 tablets of 
LCM 100mg and the oral solution (syrup) conta ining LCM 200mg, after single -dose 
administration in healthy subjects. The PK of LCM and its major metabolite, SPM  12809 
(O-desmethyl -LCM), in plasma, urine, and saliva were identical or very similar after single oral 
doses of LCM 200mg administered as tab lets or as oral solution (syrup).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 254 of 324  
Clinical Study Protocol, Section 2 (Background information). Original text, tenth paragraph:  
SP847 is an open -label, dose -titration, safety, tolerability, and PK study to evaluate LCM as 
adjunctive therapy in children wit h uncontrolled partial -onset seizures. Approximately 
42 children (aged 1 month to 17 years) with uncontrolled partial -onset seizures on a stable dose 
regimen of at least 1 but no more than 3 AEDs will be enrolled. The study consists of a 
Screening Phase, a  Treatment Phase, and an End -of-Study Phase. The duration of treatment for 
an individual subject may be up to approximately 13 weeks. Approximately 200 additional 
subjects who may participate in other LCM pediatric clinical studies in epilepsy will also be  
eligible to participate in SP848.  
Was revised as follows:  
SP847 was an open -label, dose -titration, safety, tolerability, and PK study to evaluate LCM as 
adjunctive therapy in children with uncontrolled partial -onset seizures. The study completed on 
26 Aug  2014. Forty -seven  subjects (aged 1  month to 17 years) with uncontrolled partial -onset 
seizures on a stable dose regimen of at least 1 but no more than 3 AEDs were enrolled and 
treated during the study. The study consisted of a Screening Phase, a Treatment  Phase, and an 
End-of-Study Phase. The duration of treatment for an individual subject was up to approximately 
13 weeks.  
 
Clinical Study Protocol, Section 2 (Background information). Original text, last paragraph:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies in other epilepsy syndromes. In addition, at selected sites, 
beginning wi th Protocol Amendment  4, up to approximately 100  eligible pediatric subjects 
≥4 years to ≤17  years of age with partial -onset seizures (deemed appropriate for treatment with 
adjunctive LCM) who have not previously participated in a LCM clinical study will b e permitted 
to enroll directly into SP848. The purpose of enrolling these subjects directly into SP848 is to 
obtain additional long -term safety exposures in the age range of ≥4  years to ≤17  years of age; the 
additional long -term safety data will be include d in planned regulatory submissions for LCM as 
adjunctive therapy for partial -onset seizures.  
Was revised as follows:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. In addition, at selected sites, beginning with Protocol Amendment  4, up to 
approximately 100  eligible ped iatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study will be permitted to enroll directly into SP848. The purpose 
of enr olling these subjects directly into SP848 is to obtain additional long -term safety exposures 
in the age range of ≥4  years to ≤17  years of age; the additional long -term safety data will be 
included in planned regulatory submissions for LCM as adjunctive the rapy for partial -onset 
seizures.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 255 of 324  
Clinical Study Protocol, Section 4.1.1 (Subjects enrolling from SP847 or other LCM pediatric 
clinical studies in epilepsy). Original text:  
Subjects who complete SP847 (including discontinuation from SP847 due to a dose reduction or 
status epilepticus) or subjects from another applicable LCM pediatric clinical study in epilepsy 
and who choose to enter the open -label study, will begin on the LCM dose they achieved in the 
primary study. Subjects will be able to continue on LCM oral solution (syrup) or switch to LCM 
tablets. During the study, investigators will be allowed to increase or decrease the dose of LCM 
and/or concomitant AEDs to optimize tolerability and seizure reduction for each subject. The 
investigator may adjust  the LCM dose to a minimum of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution [syrup]) or the corresponding 
dose levels for the tablet formulation), not to exceed 600mg/day based on body weight, even if 
the subject’s body weight exceeds 50kg. The maximum permitted LCM dose in SP848 is 
12mg/kg/day or 600mg/day, whichever is lower. Increases in the LCM dose must occur only 
during office visits. If needed to optimize tolerability and seizure reduction in sel ected subjects, 
concomitant AEDs may be carefully tapered and discontinued to achieve LCM monotherapy. 
New concomitant AEDs may be introduced as treatment if the medication has been approved by 
the Regulatory Authorities in the country in which the subject  lives. New concomitant AEDs 
should be added only when the subject has not optimally or adequately responded to a maximum 
tolerated dose of LCM. When subjects withdraw from the study, it is recommended that the 
study medication be tapered gradually in week ly decrements of 4mg/kg/day (oral solution 
[syrup]) or 200mg/day (tablets) for subjects who have achieved a dose of LCM ≥6mg/kg/day 
(oral solution [syrup]) or ≥300mg/day (tablet). A slower taper in weekly decrements of 
2mg/kg/day (oral solution [syrup]) or  100mg/day (tablets) is permitted, if medically necessary. In 
case of an emergency, a faster taper is permitted after discussion with the medical monitor, 
whenever possible.  
Was revised as follows:  
Subjects who complete SP847 (including discontinuation fro m SP847 due to a dose reduction or 
status epilepticus) or subjects from another applicable LCM pediatric clinical study in epilepsy 
and who choose to enter the open -label study, will begin with an equivalent LCM dose as they 
last received in the primary st udy. Subjects will be able to continue on LCM oral solution (syrup) 
or switch to LCM tablets. During the study, investigators will be allowed to increase or decrease 
the dose of LCM and/or concomitant AEDs to optimize tolerability and seizure reduction for  
each subject. The investigator may titrate/adjust the LCM dose to a minimum of 2mg/kg/day 
(oral solution [syrup]) or 100mg/day (tablet) and a maximum of 12mg/kg/day (oral solution 
[syrup]) or the corresponding dose levels for the tablet formulation), not to exceed 600mg/day 
based on body weight, even if the subject’s body weight exceeds 50kg. The maximum permitted 
LCM dose in SP848 is 12mg/kg/day or 600mg/day, whichever is lower. Increases in the LCM 
dose must occur only during office visits. If needed to optimize tolerability and seizure reduction 
in selected subjects, concomitant AEDs may be carefully tapered and discontinued to achieve 
LCM monotherapy. New concomitant AEDs may be introduced as treatment if the medication 
has been approved by the Regulato ry Authorities in the country in which the subject lives. New 
concomitant AEDs should be added only when the subject has not optimally or adequately 
responded to a maximum tolerated dose of LCM. When subjects withdraw from the study, it is 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 256 of 324 recommended that  the study medication be tapered gradually in weekly decrements of 
4mg/kg/day (oral solution [syrup]) or 200mg/day (tablets) for subjects who have achieved a dose 
of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet) . A slower taper in weekly 
decrements of 2mg/kg/day (oral solution [syrup]) or 100mg/day (tablets) is permitted, if 
medically necessary. In case of an emergency, a faster taper is permitted after discussion with the 
medical monitor, whenever possible.  
 
Clinical Study Protocol, Sectio n 4.3.2 (Exclusion criteria). Original text:  
2. Subject meets the withdrawal criteria for the primary study (with the exception of subjects 
who discontinued due to a dose reduction or status epilepticus), or is experiencing an 
ongoing serious AE (SAE).  
9. Subject has an alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total 
bilirubin level greater than or equal to 2  times the upper limit of normal (ULN), or creatinine 
clearance less than 50mL/min.  
16. Subject has been treated with vigaba trin or felbamate for at least 12 months prior to entering 
the study and has experienced any toxicity issues with these treatments. Note: Any subject 
who is currently treated with vigabatrin or felbamate, and has received vigabatrin for a period 
of less th an 12 months, is excluded from the study. Subjects who have received vigabatrin in 
the past must have documentation of an assessment for visual field defects after completion 
of vigabatrin therapy.  
17. Subject is taking monoamine oxidase (MAO) inhibitors o r narcotic analgesics.  
Were revised as follows:  
2. Subject meets either of the following:  
b. Withdrawal criteria for the primary study (with the exception of subjects who discontinued 
due to a dose reduction or status epilepticus).  For subjects entering from  EP0060, if the 
subject (or legal guardian) withdraws consent solely due to route of LCM administration (iv) 
or if the subject requires more than 10  iv LCM infusions, the subject may be allowed to 
participant in SP848 after discussion with and agreement fr om the Medical Monitor.  
c. Ongoing serious AE (SAE).  
9. Subject has a creatinine clearance less than 30mL/min.  
16. Subject is taking monoamine oxidase inhibitors -A (MAOI -A) or narcotic analgesics.  
19. Subject has >2x upper limit of normal (ULN) of any of the  following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1 .5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinicall y meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 257 of 324 If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no  further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once fo r confirmation. This includes re -screening.  
Subjects who were directly enrolled in EP0060 for iv LCM replacement therapy or to 
initiate LCM treatment are not permitted to enroll in the study if any of the following 
criteria are met:  
20. Subjects have previousl y participated in a long -term, open -label LCM study.  
 
Clinical Study Protocol, Section 4.3.3 (Criteria for withdrawal). Original text:  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All sub jects who 
withdraw from the study due to an AE must be followed until resolution of the event or until the 
event is considered stable.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinic ally relevant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation in the study  
2.   The request of the Sponsor or a Regulatory Agency  
3.    Subject achieves menarche during the study and does not practice a n acceptable method of 
contraception for the duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant, as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake or develops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal  guardian is unwilling 
or unable to allow the subject to continue in the study.  
8.    Investigator’s decision that withdrawal from further participation would be in the subject’s 
best interest.  
9.    Subject experiences convulsive status epilepticus (if no ne had occurred prior to study entry) 
and is compliant with study treatment  
10.  In the case of liver function test (LFT) results of transaminases (AST, ALT, or both) 
≥3x ULN to <5x ULN and total bilirubin ≥2x ULN or transaminases (AST, ALT, or both) 
≥5x U LN, the study medication must be immediately discontinued and the subject 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 258 of 324 withdrawn from the study. The LFTs will be repeated as soon as possible, and in no case 
more than 1 week later.  
11. For subject who did not complete a C -SSRS at Screening, subject h as a lifetime history 
(prior to study entry or since study start) of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subject from the study an d immediately refer the subject to a 
Mental Healthcare Professional.  
12. For all subjects ≥6  years of age, regardless of whether or not a C -SSRS was completed at 
Screening, subject has actual suicidal ideation as indicated by a positive response (“Yes”) to  
either Question  4 or Question  5 of the “since last visit” version of the C -SSRS. The subject 
should be referred immediately to a Mental Healthcare Professional and must be withdrawn 
from the study.  
Participation in this study may be discontinued for any o f the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the  protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
4.   Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the p resence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality 
(ie, transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly monitoring 
of LFTs should continue until resolved (ie, <3xULN or stable condition). The investigator is 
to decide whether or not to stop the study medication.  
5.   For subject who did not complete a C -SSRS at Screening, subject had actual suicidal ideation 
in the past 6  months as indicated by a positive response (“Ye s”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental Healthcare Professional and use clinical judgment as to whether to 
withdraw the patient from the study.  
Was revis ed as follows:  
All subjects discontinuing treatment with study medication for any reason should taper off 
medication as described in Section  4.4.1 . Whenever possible, these cases should be discussed 
with the medical monitor prior to withdrawing the subject from the study. All subjects who 
withdraw from the study due to an AE must be fol lowed until resolution of the event or until the 
event is considered stable. The following criteria for subject withdrawal from SP848 are outlined 
below. Additional discontinuation criteria for potential drug -induced liver injury are presented in 
Section 4 .3.3.1.  
Participation in this study must  be discontinued for any of the following reasons:  
1.   Intolerable AEs, including clinically relevant abnormal laboratory findings that, in the 
opinion of the investigator, preclude further participation in the stud y 
2.   The request of the Sponsor or a Regulatory Agency  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 259 of 324 3.    Subject achieves menarche during the study and does not practice an acceptable method of 
contraception for the duration of the study (unless sexually abstinent).  
4.    Subject becomes pregnant,  as evidenced by a positive pregnancy test.  
5.    Subject has a corrected QT interval (QTc) of greater than or equal to 500ms as confirmed by 
a cardiologist overread on any ECG.  
6.    Subject develops a second -degree atrioventricular (AV) block while awake  or develops a 
third -degree AV block at any time.  
7.    Subject is unwilling or unable to continue, or the caregiver/parent/legal guardian is unwilling 
or unable to allow the subject to continue in the study.  
8.    Investigator’s decision that withdrawal f rom further participation would be in the subject’s 
best interest.  
9.    Subject experiences convulsive status epilepticus (if none had occurred prior to study entry) 
and is compliant with study treatment  
11.   For subject who did not complete a C -SSRS at Screening, subject has a lifetime history 
(prior to study entry or since study start) of suicide attempt (including an actual attempt, 
interrupted attempt, or aborted attempt) of the screening version of the C -SSRS. The 
investigator must withdraw the subje ct from the study and immediately refer the subject to a 
Mental Healthcare Professional.  
12. For all subjects ≥6  years of age, regardless of whether or not a C -SSRS was completed at 
Screening, subject has actual suicidal ideation as indicated by a positive  response (“Yes”) to 
either Question  4 or Question  5 of the “since last visit” version of the C -SSRS. The subject 
should be referred immediately to a Mental Healthcare Professional and must be withdrawn 
from the study.  
Participation in this study may be di scontinued for any of the following reasons:  
1.   Any clinically relevant change in medical or psychiatric condition (if in the opinion of the 
investigator, the condition warrants discontinuation from the study).  
2.   Subject requires a medication that is not permitted by the protocol.  
3.   Subject and/or delegated caregiver is unable to manage the completion of the diary or is 
noncompliant with study procedures or medication, in the opinion of the investigator.  
5.   For subject who did not complete a C -SSRS at Screening, subject had actual suicidal ideation 
in the past 6  months as indicated by a positive response (“Yes”) to either Question  4 or 
Question  5 of the screening version of the C -SSRS. The investigator must immediately refer 
the subject to a Mental  Healthcare Professional and use clinical judgment as to whether to 
withdraw the patient from the study.  
If a subject from SP848 enrolls in EP0060 and either withdraws consent solely due to route of 
LCM administration (iv) or if the subject requires more t han 10  iv LCM infusions, the subject 
may be allowed to return to SP848 after discussion with and agreement from the Medical 
Monitor. If a subject from SP848 is advised to withdraw from the SP848 after participation in 
EP0060, the subject will be required t o return to the SP848 to complete the required ETV and 
Safety Follow -up assessments.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 260 of 324 Investigators should attempt to obtain information on subjects in the case of withdrawal. For 
subjects considered as lost to follow up, the investigator should make effort s (at least 1 phone 
call and 1 written message to the subject), and document his/her efforts (date and summary of the 
phone call and copy of the written message in the source documents), to complete the final 
evaluation. All results of these evaluations an d observations, together with a narrative description 
of the reason(s) for removing the subject, must be recorded in the source documents. The eCRF 
must document the primary reason for withdrawal.  
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.  
4.3.3.1  Potential drug -induced liver injury IMP discontinuation criteria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDILI cr iteria below require immediate and permanent discontinuation of IMP:  
• Subjects with either of the following:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requires immediate discontinuation of IMP:  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without cle ar 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.  
• Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no e osinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section  8.3.2 . If subjects are unable to 
comply with the applicable monitoring schedule, IMP must be discontinued immediately.  
Investigators should attempt to obtain information on subjects in the case of IM P discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IMP discontinuat ion and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 261 of 324 Clinical Study Protocol, Section 4.4.1.1 (Subjects enrolling from SP847 or other LCM pediatric 
clinica l studies in epilepsy).  
The following text was added as a last paragraph:  
Subjects who enroll from EP0060 will begin SP848 with an equivalent dose to the last dose they 
received in EP0060; however, the LCM dose may be further titrated/adjusted to a level  to 
optimize tolerability and seizure control (up to a maximum level as described in Section 4.4.1.3 ). 
For those subjects who initiated adjunctive L CM treatment in EP0060, the recommended LCM 
dose titration approach is outlined in Section 4.4.1.2 . 
 
Clinical Study Protocol, Section 4.6 (Concomita nt medication[s]/treatment[s]). Original text, 
through second paragraph:  
The following medications/therapies are prohibited during the course of this study:  
• Monoamine oxidase inhibitors  
• Narcotic analgesics  
All concomitant medications and treatments must be  recorded in the appropriate study 
documents (case report form [CRF] and source document).  
Was revised as follows:  
The following medications/therapies are prohibited during the course of this study:  
• Monoamine oxidase inhibitor -A compounds  
• Narcotic analgesics  
• Cannabidiols not approved or indicated for epilepsy by a local health authority  
All concomitant medications and treatments must be recorded in the appropriate study 
documents (eCRF and source document).  
 
Clinical Study Protocol, Section 5.3 (Vis it 1[Week 0]). Original text, first, second, and fifth 
paragraphs:  
For subjects who complete SP847, Visit 1 for SP848 is the same as Day 2 of the second PK 
collection time period (which may include an overnight stay at a hospital or medical facility) in 
SP847 (Day 28 for Cohorts 1, 2, 3, and 5 with maximum recommended dose of 8mg/kg/day; 
Day 35 for Cohorts 2 to 5 with maximum recommended dose of 10mg/kg/day; and Day 42 for 
Cohorts 2 to 5 with maximum recommended dose of 12mg/kg/day). For subjects who 
discon tinue SP847 due to a dose reduction or status epilepticus, Visit 1 is the Early Termination 
Visit in SP847. For subjects in SP847 who are titrated up to the maximum permitted dose of 
600mg/day sooner than the study schedule would ordinarily indicate (based  on body weight) and 
who enroll in SP848, the Early Termination Visit of SP847 will also serve as Visit 1 for SP848.  
For subjects who enroll in SP848 after participation in other LCM pediatric clinical studies in 
epilepsy, SP848 Visit 1 will be specified i n the respective primary study protocol.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 262 of 324 Each subject’s eligibility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments (applicable only for subjects for whom Visit 1 is the first 
clinic visit fo r SP848), and a complete medical history update will be obtained. The data for the 
following assessments will be taken from the last assessment during SP847 (or other primary 
study as applicable):  
Were revised as follows:  
For subjects who completed SP847, Visit 1 for SP848 was the same as Day 2 of the second PK 
collection time period (which may include an overnight stay at a hospital or medical facility) in 
SP847 (Day  28 for Cohorts  1, 2, 3, and 5 with maximum recommended dose of 8mg/kg/day; 
Day 35 for Coho rts 2 to 5 with maximum recommended dose of 10mg/kg/day; and Day  42 for 
Cohorts  2 to 5 with maximum recommended dose of 12mg/kg/day). For subjects who 
discontinued SP847 due to a dose reduction or status epilepticus, Visit 1 was the Early 
Termination Visit  in SP847. For subjects in SP847 who were titrated up to the maximum 
permitted dose of 600mg/day sooner than the study schedule would ordinarily indicate (based on 
body weight) and who enroll in SP848, the Early Termination Visit of SP847 also served as 
Visit 1 for SP848.  
For subjects who enroll in SP848 after participation in other LCM pediatric clinical studies 
besides SP847 (ie, SP0966 and EP0060) in epilepsy, SP848 Visit  1 will be specified in the 
respective primary study protocol.  
Each subject’s eligib ility will be determined on the basis of the inclusion/exclusion criteria and 
the results of the following assessments (applicable only for subjects for whom Visit  1 is the first 
clinic visit for SP848), and a complete medical history update will be obtain ed. If available, the 
data for the following assessments will be taken from the last assessment during SP847 (or other 
primary study, as applicable):  
 
Clinical Study Protocol, Section 5.13 (Visit 10 [Week 60]). Original text:  
Assessments for Visit 10 (Week  60) are the same as those described for Visit 2 (Week 4), in 
Section  5.5, with the following exception: a 12 -lead ECG is not conducted at Visit 10 . 
Was revised as follows:  
Assessments for Visit 10 (Week 60) are the same as those described for Visit 2 (Week 4), in 
Section  5.5, with the followi ng exceptions: a 12 -lead ECG is not conducted at Visit 10 (all sites) 
and a PK sample is routinely drawn at sites in Japan (removed for all other sites) . 
 
Clinical Study Protocol, Section 5.14 (Visit 11 [Week 72]). Original text:  
Assessments for Visit 11 ( Week 72) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions: brief physical and neurological exams are conducted 
(instead of complete physical and neurological exams as indicated for Visit 5), the laboratory 
blood sample  is collected only for clinical chemistry and hematology (ie, no endocrinology), the 
palatability and ease of use questionnaire is completed,  and a 12-lead ECG (2 interpretable 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 263 of 324 recordings approximately 20 to 30 minutes apart prior to vital signs assessment  and collection of 
blood sample) is conducted . 
Was revised as follows:  
Assessments for Visit 11 (Week 72) are the same as those described for Visit 5 (Week 20), in 
Section 5.8, with the following exceptions for all sites: brief physical and neurological exams are 
conducted (instead of complete physical and neurological exams as indicated for Visit 5), the 
laboratory blood sample is collected only for  clinical chemistry and hematology (ie, no 
endocrinology), the palatability and ease of use questionnaire is completed,  and a 12-lead ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blo od sample) is conducted. In addition to the noted differences, a PK sample is 
routinely drawn at sites in Japan (removed for all other sites) . 
 
Clinical Study Protocol, Section 5.15 (Visit 12 [Week 84]). Original text:  
Assessments for Visit 12 (Week 84) ar e the same as those described for Visit 2 (Week 4), in 
Section 5.5, with the following exceptions: the laboratory blood sample is collected for 
endo crinology as well as clinical chemistry and hematology and a 12 -lead ECG is not conducted.  
Was revised as follows:  
Assessments for Visit 12 (Week 84) are the same as those described for Visit 2 (Week 4), in 
Section 5.5, with the following exceptions for all sites: the laboratory blood sample is collected 
for endocrinology as well as clinical chemistry and hematology and a 12 -lead ECG is not 
conducted.  In addition to the noted differences, a PK sample is routinely drawn at sites in Japan 
(removed for all other sites) . 
 
Clinical Study Protocol, Section 5.16 (Visit 13/Termination Visit [Week 96]). Original text, third 
paragraph:  
Assessments for Visit 13/T ermination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following exceptions: the laboratory blood sample is 
collected only for clinical chemistry and hematology (ie, no endocrinology), a 12-lead ECG 
(2 interpretable recordings approximately 20 to 30 minutes apart prior to vital signs assessment 
and collection of blood sample) is conducted, a Tanner Stage assessment is conducted (if 
applicable), an Achenbach CBCL is conducted, Bayley -III scales are conducted, 
BRIEF -P/BRIEF and PedsQL scores are obtained, and the palatability and ease of use 
questionna ire is completed . 
Was revised as follows:  
Assessments for Visit 13/Termination Visit (Week 96) are the same as those described for 
Visit  5 (Week 20), in Section 5.8, with the following exceptions for all sites: the laboratory blood 
sample is collected only for clinical chemistry and hematology (ie, no endocrinology), a 12-lead 
ECG (2  interpretable recordings approximately 20 to 30 minutes apart prior to vital signs 
assessment and collection of blood sample) is conducted, a Tanner Stage assessment is 
conducted (if applicable), an Achenbach CBCL is conducted, Bayley -III scales are conducted, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 264 of 324 BRIEF -P/BRIEF and PedsQL scores are obtained, and the palatabil ity and ease of use 
questionnaire is completed. In addition to the noted differences, a PK sample is routinely drawn 
at sites in Japan (removed for all other sites) . 
 
Clinical Study Protocol, Section 5.17 (Early Termination Visit). Original text, ninth bul let: 
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
Was revised as follows:  
• Blood sample for LCM and concomitant AED plasma concentrations (at any time 
post-dosing with LCM)  
− Under any circumstance for an  ETV during Year 1  
− If possible, if the early termination during Year 2 is due to a SAE and the event is 
ongoing  
 
Clinical Study Protocol, Section 5.18 (Unscheduled Visit[s]). The final bullet point was added:  
• If possible, a blood sample for LCM and concomi tant AED plasma concentrations (at any 
time post -dosing with LCM) if the unscheduled visit is due to a SAE  
 
Clinical Study Protocol, Section 8.1.7 (Suspected transmission of an infectious agent via a 
medicinal product). Was added to align with new protoco l template and subsequent sections 
were renumbered as a result:  
8.1.7  Suspected transmission of an infectious agent via a medicinal product  
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and followed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), patho genic or 
nonpathogenic, is considered an infectious agent.  
 
Clinical Study Protocol, Section 8.2.1 (Definition of serious adverse event). Original text, fifth 
bullet point:  
• Important medical event that, based upon appropriate medical judgment, may jeopardi ze the 
patient or subject and may require medical or surgical intervention to prevent one of the other 
outcomes listed in the definition of serious  
Important medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or  at home or blood dyscrasias that do not result in inpatient hospitalization, 
or the development of drug dependency or drug abuse.  
Was revised as follows:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 265 of 324 • Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or  subject and may require medical or surgical intervention to prevent one of the other 
outcomes listed in the definition of serious  
(Important medical events include, but are not limited to, potential Hy’s Law [see 
Section  8.2.2 ], allergic bronchospasm requiring intensive treatment in an emergency room or 
at home, blood dyscrasias that do not result in inpatient hospitalization, or the development 
of drug dependency or drug abuse.)  
 
Clinical Study Protocol, Section 8.2.2 (AEs of special interest). Original text:  
The following are AEs of special interest:  
• The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (second degree Type I and II and third degree), and marked bradycardia 
(<45beats/min)  
• Syncope or loss of consciousness (other than seizure related)  
• Serious suspected multiorgan hypersensitivity reactions  
Serious suspected multiorgan hypersensitivit y cases may be identified and reported 
to the sponsor by the investigator using the following algorithm as agreed with the 
Food and Drug Administration:  
An AE or laboratory value (as defined below) suggestive of internal organ 
involvement (including but no t limited to hepatitis, nephritis, pneumonitis, carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system 
involvement) combined  with at least one of the following: fever, rash, 
lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:  
• Eosinophils % ≥10%  
• Eosinophils absolute ≥0.5G/L  
• Neutrophils absolute <1.5G/L  
• Platelets ≤100G/L  
• ALT ≥2x ULN  
• AST ≥2x ULN  
Was revised as follows:   
An AE of special interest is any AE that a regulatory authority has mandated to be reported on an 
expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
The following are the LCM AEs o f special interest:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 266 of 324 • The following arrhythmias: atrial fibrillation/flutter, ventricular tachycardia or fibrillation, 
AV block (second degree Type I and II and third degree), and marked bradycardia 
(<45beats/min)  
• Syncope or loss of consciousness (other tha n seizure related)  
• Serious suspected multiorgan hypersensitivity reactions  
Serious suspected multiorgan hypersensitivity cases may be identified and reported 
to the sponsor by the investigator using the following algorithm as agreed with the 
Food and Drug Administration:  
An AE or laboratory value (as defined below) suggestive of internal organ 
involvement (including but not limited to hepatitis, nephritis, pneumonitis, carditis, 
colitis, encephalitis, pancreatitis, myositis, arthritis, or hematologic system  
involvement) combined  with at least one of the following: fever, rash, 
lymphadenopathy, or eosinophilia.  
Treatment -emergent abnormal laboratory value criteria suggestive of internal organ 
involvement or eosinophilia:  
• Eosinophils % ≥10%  
• Eosinophils absolut e ≥0.5G/L  
• Neutrophils absolute <1.5G/L  
• Platelets ≤100G/L  
• ALT ≥2x ULN  
• AST ≥2x ULN  
• Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total 
bilirubin in the absence of ≥2xULN ALP, with no alternative explanation for the biochemical 
abnor mality, must ALWAYS be reported to UCB as an AE of special interest (ie, without 
waiting for any additional etiologic investigations to have been concluded). Follow -up 
information should then be reported if an alternative etiology is identified during 
investigation and monitoring of the subject.  
 
Clinical Study Protocol, Section 8.2.5 (Follow up of serious adverse events). Original text:  
A SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow -up.  
Information on SAEs obtained after clinical database lock will be captured  through the Drug 
Safety database without limitation of time.  
Was revised as follows:   
A SAE should be followed until it has resolved, has a stable sequelae, the investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 267 of 324 follow -up requirement applies to AEs, SAEs, and AEs of special interes t; further details 
regarding follow up of PDILI events are provided in Section 8.3.2.4 . 
Information on SAEs obtained after clinical database lock wi ll be captured through the Patient 
Safety database without limitation of time.  
 
Clinical Study Protocol, Section 8.2.6 (Anticipated serious adverse events). Original text, first 
paragraph:  
The following list of anticipated SAEs has been identified as these  events are anticipated to 
occur in the population studied in this protocol at some frequency that is independent of drug 
exposure. This original list will remain in effect for the duration of the protocol. This list does 
not change the investigator’s obli gation to report all SAEs (including anticipated SAEs) as 
detailed in Section  8.2.4 . 
Was revised as follows:   
The following list of anticipated SAE s is anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure. This list does not change the 
investigator’s obligation to report all SAEs (including anticipated SAEs) as detailed in 
Section  8.2.4 . 
 
Clinical Study Protocol, Section 8.3.1 (Liver function tests). Original text:  
8.3.1  Liver function tests  
Transaminases (AST, ALT, or both) ≥3x  ULN but <5x ULN, in the presence of total bilirubin 
≥2x ULN, or transaminases (AST, ALT, or both) ≥5x ULN will result in immediate 
discontinuation of LCM and withdrawal of the subject from the study. The LFTs will be repeated 
as soon as possible, and in n o case more than 1 week later (see  Section 4.3.3 ). 
Transaminases (AST, ALT, or both) ≥3xULN to <5xULN, in the presence of normal total 
bilirubin, will be repeated within a few days. If the repeat testing confirms the abnormality (ie, 
transaminases are ≥3xULN to <5xULN with normal bilirubin), then weekly mo nitoring of LFTs 
should continue until resolved (ie, <3xULN or stable condition). The investigator is to decide 
whether or not to stop the study medication.  
In all cases of transaminases (AST, ALT, or both) ≥3xULN, testing for hepatitis A, B, and C will 
be done.  
Referral to a specialist (ie, hepatologist or gastroenterologist) is at the discretion of the 
investigator.  This is recommended especially if the transaminase abnormalities >3xULN persist 
after discontinuation of the study medication.  
Was revised as follows:   
8.3.2  Liver function tests and evaluation of PDILI  
The PDILI IMP discontinuation criteria for this study are provided in Section 4.3.3.1  with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and sponsor within 24 hours of learning 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL    20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 268 of 324 of their occurrence. Any PDILI event that meets the c riterion for potential Hy’s Law must be 
reported as an AE of special interest (see Section 8.2.2 ), and, if applicable, also reported as an 
SAE (see Section 8.2.1 ).  
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  8‒1 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section 8.3.2.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section  8.3.2.4 ).  
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and sponsor.  
All initial tests resulting in abnormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory wh enever possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 2 
laboratory tests are significantly different. Data from the local and central labo ratory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the investigator should also 
consider dose re duction for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as described in Section 4.3.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings.  
Rechallenge with a substance potentially causin g drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
The table below summarizes the approach to investigate PDILI.   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 269 of 324 Table  8-1: Required investigations and follow up of PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology  consult.c 
Medical Monitor 
must be notified 
within 24  hours 
(eg, by laboratory 
alert) and subject 
discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must 
have repeat liver 
chemistry values 
and additional 
testing completed 
ASAP (see 
Section  8.3.2.3 ); 
recommended to 
occur at the site 
with HCP.  Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d 
 ≥5xULN  NA NA 
≥3xULN  NA Yes Immediate, 
temporary or 
permanent, IMP 
discontinuation.  
≥3xULN 
(and ≥2x 
Baseline) 
and 
<5xULN  <2xULN  No Discussion with 
Medical Monitor 
required if the 
criterion that allows 
for IMP continuation 
is met.  Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  8.3.2.2). Not required 
unless otherwise 
medically 
indicated (at 
discretion of 
investigator).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
Page 270 of 324 Table  8-1: Required investigations and follow up of PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis or 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥5xULN 
(and ≥2x 
Baseline)  <2xULN  No Discussion with 
Medical Monitor 
required.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Every 
attempt must be 
made to have 
repeat liver 
chemistry values 
and additional 
testing completed 
within 48  hours 
at the site with 
HCP (see 
Section  8.3.2.3 ) Monitoring of liver chemistry 
values at least twice per week 
until values normalize, stabilize, 
or return to within Baseline 
values.d 
 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitioner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternative cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.  
.c Details provided in Section  8.3.2.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and ma nagement of potential 
hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by the investigator and UCB res ponsible physician. Determination of stabilization is at the discretion of the 
investigator in consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 271 of 324 8.3.2.1  Consultation with Medical Monitor  and local hepatologist  
Potential drug -induced liver injury events require notification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subje ct must also be discussed with the local hepatologist. The 
local hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroent erologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section 8.3.2.3 ) and SAE report (if appli cable).  
8.3.2.2  Immediate action: determination of IMP discontinuation  
All PDILI events require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and permanent discontinuation (see Section 4.3.3.1  and Table  8‒1 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The in vestigator should also consider dose 
reduction for medically necessary concomitant medication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.  
8.3.2.3  Testing: identification/exclusion o f alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility that they may have been caused by the IMP are detailed in 
Table  8‒2 (laboratory measurements) and Table  8‒3 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
assessments not included below , these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.  
The followi ng measurements are to be assessed:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 272 of 324 Table  8-2: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tendernes s; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
The following additional information is to be collected:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 273 of 324 Table  8-3: PDILI information to be collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
• History of liver disease (eg, autoimmune hepatitis, nonalcoholic steato hepatitis or other “fatty 
liver disease”)  
• Adverse reactions to drugs  
• Allergies  
• Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
• Recent travel  
• Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by itself, 
should not be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quad rant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy , if done  
Results of any specialist or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
 
8.3.2.4  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in  
Table  8‒1. Monitoring should continue until liver chemistry val ues normalize, stabilize, or return 
to Baseline. Determination of stabilization is at the discretion of the investigator in consultation 
with the hepatologist (as applicable) and UCB responsible physician, as needed.  
 
Clinical Study Protocol, Section 8.3.2  (Pregnancy testing). Number revised to Section 8.3.1.  
 
Clinical Study Protocol, Section 9.1 (Manufacturing, packaging, and labeling). Original text, 
first paragraph:  
Lacosamide oral solution (syrup) and tablets are manufactured and supplied by UCB 
BIOSCIENCES GmbH, Monheim am Rhein, Germany. Lacosamide is manufactured, packaged, 
and labeled according to Good Manufacturing Practice guidelines and applicable laws and 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 274 of 324 regulations. It is suitably packaged, in such a way as to protect the product from deterioration 
during transport and storage.  
Was revised as follows:   
Lacosamide is manufactured, packaged, and labeled according to Good Manufacturing Practice 
guidelines and a pplicable laws and regulations. It is suitably packaged, in such a way as to 
protect the product from deterioration during transport and storage.  
 
Clinical Study Protocol, Section 9.2 (Supply, handling, and storage). Original text:  
Lacosamide (oral solutio n [syrup] and tablet) is stable at room temperature and is to be stored at 
temperatures not exceeding 25°C (77°F). Lacosamide should not be frozen.  
The investigator (or designee) is responsible for safe and proper storage of LCM at the site. 
Lacosamide sto red by the investigator is to be kept in a secured area with limited access.  
Was revised as follows:   
Lacosamide (oral solution [syrup] and tablet) is stable at room temperature and is to be stored at 
temperatures not exceeding 25°C (77°F). Lacosamide shou ld not be frozen.  
The investigator (or designee) is responsible for safe and proper storage of LCM at the site. 
Lacosamide stored by the investigator is to be kept in a secured area with limited access 
according to the storage conditions mentioned on the l abel.  
Appropriate storage conditions must be ensured either by controlling the temperature and by 
completion of a temperature log in accordance with local requirements on a regular basis, 
showing minimum and maximum temperatures reached over the time inter val. 
In case an out -of-range temperature is noted, it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
The investigator (or designee) will instruct the subject to store the IMP following the instructions 
on the label.  
 
Clinical Study Protocol, Section 9.3 (Drug accountability procedures). Original text:  
Responsibility for drug accountability at the study site rests with the investigator.  
The investigator may assign some of the investigator’s duties for drug accountabili ty at the study 
site to an appropriate pharmacist/designee.  
The investigator must ensure that the LCM is used only in accordance with the protocol.  
The investigator (or designee) is expected to collect and retain all used, unused, and partially 
used contai ners of LCM until collection.  
The investigator should maintain records that document the drug’s delivery to the study site, the 
inventory at the site, the use by each subject, and return to UCB BIOSCIENCES or alternative. 
These records include dates, quant ities, batch numbers, expiry dates, and the unique code 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 275 of 324 numbers assigned to the LCM and study subjects. The investigator (or designee) should maintain 
records that document adequately that the subjects were provided the doses specified by the 
protocol and reconcile all LCM received from UCB BIOSCIENCES.  
Completed accountability records and all used/unused dosing containers will be returned to UCB 
BIOSCIENCES or Contract Research Organization (CRO) at completion of the study.  
Was revised as follows:   
A Drug Accountability form will be used to record LCM dispensing and return information on a 
by-subject basis and will serve as source documentation during the course of the study. Details of 
any LCM lost, damaged (due to breakage or wastage), not used, partially  used, disposed of at the 
study site, or returned to the sponsor or designee must also be recorded on the appropriate forms. 
All supplies and pharmacy documentation must be made available throughout the study for UCB 
(or designee) to review.  
The investigat or (or designee) is responsible for retaining all used, unused, and partially used 
containers of LCM until returned or destroyed by a UCB representative.  
The investigator may assign some of the investigator’s duties for drug accountability at the study 
site to an appropriate pharmacist/designee.  
The investigator must ensure that LCM is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unu sed, damaged, and/or expired LCM must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB SOPs or returned to UCB (or 
designee). Investigational medicinal product intended for the study cannot be used for any other 
purpose than that described in this protocol.  
 
Clinical Study Protocol, Section 10.3 (Auditing). Original text:  
As a quality assurance measure, UCB BIOSCIENCES or regulatory authorities may undertake 
audits before, during, and after the study.  
Regulatory a uthorities and representatives of the relevant IRB/IEC must be allowed to conduct 
inspections at the site.  
The investigator should notify UCB BIOSCIENCES if regulatory authorities contact them to 
schedule an inspection.  
Was revised as follows:   
The investi gator will permit study -related audits mandated by UCB, and inspections by domestic 
or foreign regulatory authorities.  
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, t hat enrolled subjects (ie, signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
IMP have been processed and reported in compliance with the planned arrangements, the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 276 of 324 protocol, investigational site, and IRB/IEC SOPs, ICH GCP, and applicable regulatory 
requirements.  
The investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the inves tigator will immediately 
inform UCB (or designee).  
 
Clinical Study Protocol, Section 11.1 (Data handling) and Section 11.2 (Record keeping). 
Original text:  
11.1 Data handling  
The investigator is responsible for prompt reporting of accurate, complete, and l egible data in the 
CRFs and in all required reports.  
Any change or correction to the CRF should be dated, initialed, and explained (if necessary) and 
should not obscure the original entry. Use of correction fluid is not permitted.  
Corrections made after th e investigator’s review and signature of the completed CRF will be 
re-signed and dated by the investigator.  
The investigator should maintain a list of personnel authorized to enter data into the CRF.  
The investigator will keep a list containing all subjects enrolled into the study. This list remains 
with the investigator and is used for unambiguous identification of each subject. The list contains 
the subject identification number, full name, date of birth, date of enrollment in the study, and 
the ho spital number or National Health Security number, if applicable.  
The parent/legal guardian’s consent, subject’s assent, and enrollment in the study must be 
recorded in the subject’s medical record. These data should identify the study and document the 
dates of the subject’s participation.  
11.2 Record keeping  
To comply with international regulations, the investigator will arrange for the retention of 
essential study documents as described in the ICH -GCP guideline. The guideline requires that 
the documents be  retained at least 2 years after the last approval of a marketing application in an 
ICH region when there are no pending or contemplated marketing applications in an ICH region 
or at least 2 years after the formal discontinuation of clinical development of  LCM. However, 
UCB BIOSCIENCES requires the documents be retained at least 15  years after completion of the 
study. The documents should be retained for a longer period if required by the applicable 
regulatory authorities. UCB BIOSCIENCES will inform the in vestigator/institution when 
records no longer need to be retained.  
The investigator should take measures to prevent accidental or premature destruction of records. 
If archiving can no longer be maintained at the site, the investigator will notify the Spons or. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 277 of 324 Were revised as follows:  
The parent/legal guardian’s consent, subject’s assent, and enrollment in the study must be 
recorded in the subject’s medical record. These data should identify the study and document the 
dates of the subject’s participation.  
11.1 Case Report form completion  
This study is performed using remote data capture (RDC); the investigator is responsible for 
prompt reporting of accurate, complete, and legible data in the eCRFs and in all required reports. 
Any change or correction to the  eCRF after saving must be accompanied by a reason for the 
change. Corrections made after the investigator’s review and approval (by means of a 
password/electronic signature) will be reapproved by the investigator. The investigator should 
maintain a list o f personnel authorized to enter data into the eCRF. Detailed instructions will be 
provided in the eCRF Completion Guidelines.  
11.2 Database entry and reconciliation  
Electronic Case Report forms/external electronic data will be entered/loaded into a validat ed 
electronic database using a clinical data management system (CDMS). Computerized data 
cleaning checks will be used in addition to manual review to check for discrepancies and to 
ensure consistency of the data. This study is performed using RDC; the data  are entered into the 
eCRFs once and are subsequently verified. An electronic audit trail system will be maintained 
within the CDMS to track all data changes in the database once the data have been saved initially 
into the system or electronically loaded. Regular backups of the electronic data will be 
performed.  
11.3 Subject Screening and Enrollment log/Subject Identification Code list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
log.  
The investigator will  keep a Subject Identification Code list. This list remains with the 
investigator and is used for unambiguous identification of each subject.  
11.4 Archiving and data retention  
The investigator will maintain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the inves tigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (CPMP/ICH/135/95, 2002 [Section 4.9.5]). The investigator will contact 
UCB  for authorization prior to the destruction of any study records or in the event of accidental 
loss or destruction of any study records. The investigator will also notify UCB should he/she 
relocate or move the study -related files to a location other than t hat specified in the sponsor’s 
trial master file.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 278 of 324  
Clinical Study Protocol, Section 11.3 (Data Management) is now numbered Section 11.5.  
 
Clinical Study Protocol, Section 12.1.1 (Definition of analysis sets). Original text:  
The primary analysis set will be  the Safety Set (SS), which is defined as all subjects who meet 
the inclusion/exclusion criteria, sign an informed consent form, and take at least 1  dose of LCM.  
All subjects from the SS with valid concentration data and the absence of major protocol 
devia tions that may have an influence on the concentration data will be included in the 
Pharmacokinetic Per -Protocol Set (PK -PPS). The validity of concentration data will be 
determined by the responsible UCB BIOSCIENCES study team including the responsible 
clinical pharmacokineticist and bioanalytic personnel.  
Was revised as follows:  
The Safety Set (SS), which is defined as all enrolled subjects who take at least 1  dose of LCM in 
this study. All safety analyses will be performed on the SS.  
The Pharmacokinetic P er-Protocol Set (PK -PPS) will consist of all subjects from the SS having 
provided at least 1 measurable post -dose plasma sample (with recorded sampling time) on at 
least 1 visit with documented LCM intake times.  
The full -analysis set will be used for the analysis of seizure data and will consist of all subjects in 
the SS, who have at least 1 completed post -Baseline seizure diary.  
 
Clinical Study Protocol, Section 12.1.5 (Handling of protocol violators, drop -outs, and missing 
values). Original text, first p aragraph:  
All data will be used to their maximum possible extent, but without any imputations for missing 
data for any parameter. Protocol deviations will be assessed during data review by a panel 
consisting of the study manager, the study biostatistician,  a representative of the monitoring 
team, and other appropriate study team members.  
Was revised as follows:  
All data will be used to their maximum possible extent, but without any imputations for missing 
data for any parameter. Important protocol deviatio ns will be reviewed as part of the ongoing 
data cleaning process and data evaluation. All important deviations will be identified and 
documented prior to database lock to confirm exclusion from analysis sets.  
 
Clinical Study Protocol, Section 12.2 (Determi nation of sample size). The following final 
paragraph was added:  
Beginning with Protocol Amendment 6, up to 75 eligible pediatric subjects ≥4  years to <17  years 
of age who have participated in EP0060 will be permitted to enroll into SP848.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                          SPM 927  SP848  
   
 
Page 279 of 324 Clinical Study Protocol, Section  15 (References). The following references were added:  
Clinical Global Impression of Change, the Caregiver Global Impression of Change, quality of 
life assessments (Pediatric Quality of Life Inventory [PedsQL™]). 
http://www.pedsql.org/Peds QL-CostStructure.pdf and http://plaza.umin.ac.jp/qol -research/. 
Accessed on 10 July 2014.  
Cognitive function assessments (Behavior Rating Inventory of Executive Function® 
[BRIEF®]/BRIEF® Preschool Version [BRIEF® P]. 
http://www4.parinc.com/Products/PermsLicensing.aspx?id=6 and 
http://www4.parinc.com/products/PermsLicensing.aspx?id=8. Accessed 10 July 2014.  
Food and Drug Administration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evalua tion. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
Kyoto International; Social Welfare Exchange Centre (KISWEC). Achenbach Child Behavior 
Checklist (CBCL) for childre n 18 months and older.  
http://www.kiswec.com/aseba%20 -%20order.html. Accessed 10 July 2014.  
Ngugi AK, Kariuki SM, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Incidence of 
epilepsy: A systematic review and meta -analysis. Neurology. 2011; 77(10): 1005 –12. 
Rheims S, Ryvlin P. Profile of perampanel and its potential in the treatment of partial onset 
seizures. Neuropsychiatr Dis Treat. 2013;9:629 -37. 
 
And the following reference was deleted:  
Dichek B. Epilepsy: an ancient ailment that still eludes a cure.  Scrip Magazine. 1999;Feb:9 -11. 
 
Clinical Study Protocol, Section 16.1(Table 1 Schedule of study procedures for SP848 [Year  1]). 
Original table:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 280 of 324  
Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh  X X X X X X X X X X X  
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh     X    X X  X  
Blood sample for LCM PKj Xh  X   X  X  X X    
Blood sample for concomitant AEDsj Xh  X   X  X  X X    
Urinalysis (subjects aged 5 to 17  years)  Xh     X    X X  X  
Pregnancy testk Xh,S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagel Xh        X  X    
Clinical GIC  Xh     X    X X    
Caregiver GIC  Xh     X    X X    
Palatability and ease of use 
questionnaire        X   X X    
Dispense LCM  X  X X X X X X X X Xm Xn   
LCM return/compliance    X X X X X X X X X Xn X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 281 of 324 Table 1.   Schedule of study procedures for SP848 (Year 1)  
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
C-SSRSo Xh  X X X X X X X X X Xp X  
Achenbach CBCL  X     X    X X    
Bayley -III scales  X     X    X X    
BRIEF -P/BRIEF  X     X    X X    
PedsQL  X     X    X X    
AE reportingq Xh X X X X X X X X X X X X X 
Health care resource use  X  X X X X X X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; U=urine; Unsch=Unschedul ed; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up telephone contact).  
b For subjects who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), Visit 1 is also the last v isit of the primary study. At Visit 1, the inf ormed 
consent will be signed (and assent, if applicable) and eligibility assessed, the medical history will be updated, body weight  and height and concomitant medications including 
AEDs will be recorded, AEs will be assessed, and the subject diary and LCM dispensed.  
c Telephone contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, then the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If the LCM dose is 
decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required betwee n scheduled clinic visits, the subject must return for an Unscheduled Visit. 
Height will not be recorded at an Unscheduled Visit.  
f Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should c omplete the Final Visit 2  weeks after the final 
dose of study medication.  
g This TC occurs 28  to 35 days after the last dose of LCM.  
h For subjects enrolling from SP847 or other LCM pediatric clinical studies in epilepsy, assessments should have been done as part of the last visit of the primary study. For 
subjects enrolling directly into SP848, these asssessments should be completed at Visit 1.  
i All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week a fter an initial LCM dose increase to a LCM dose level that is 
≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects  having a LCM dose increase to 
≥8mg/kg/day will be required to arrive  at the clinic prior to taking their morning dose of LCM. Subjects will be administered their morning LCM dose by study person nel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs assessment)  can be performed 30  minutes to 1  hour after the 
administration of LCM (ie, at LCM steady state C max). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 282 of 324 j Blood samples may be drawn at any time post -dosing with LCM.  
k For female subjects of childbearing potential, serum pregnancy tests will be performed a t Visit 1, the Early Termination Visit, and the Final Visit. Urine pregnancy tests will be 
performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
l The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course of the study.  
m Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥3 00mg/day (tablet). It is recommended that the 
LCM dose be tapered gradually in weekly decrements of 4mg/ kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 2mg/kg/day (oral solution [syrup]) or 
100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is permitted after discussio n with the medical mo nitor, whenever possible.  
n As applicable  
o For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version should be 
completed thereafter.  
p The C -SSRS ass essment should be completed if the Unscheduled Visit is due to an AE.  
q Ongoing AEs from the primary study will be followed, as well as recording of new AEs during the current study.  
 
Was revised to:  
Table  16-1: Schedule of study procedures for SP848 (Year  1) 
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Informed Consent  X              
Inclusion/exclusion criteria  X              
Medical history update  X              
Concomitant medications  Xh X X X X X X X X X X X X X 
Concomitant AEDs  Xh X X X X X X X X X X X X X 
Physical exam (complete)  Xh     X    X X  X  
Physical exam (brief)    X X X  X X X   X   
Neurological exam (complete)  Xh     X    X X  X  
Neurological exam (brief)    X X X  X X X   X   
12-lead ECGi Xh  X    X   X X X X  
Blood pressure and pulse  Xh  X X X X X X X X X X X  
Body weight and height  Xh, j  X X X X X X X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 283 of 324 Table  16-1: Schedule of study procedures for SP848 (Year  1) 
Study SP848  Year 1  Safety 
Follow -Up 
Visita V1b TCc V2 V3 V4 V5 V6 V7 V8 V9 ETVd Unsch 
Visite Final 
Visitf TCg 
Weeks in study  0  4 8 12 20 28 36 44 52     
Clinical chemistry and hematology 
blood sample  Xh  X   X  X  X X  X  
Endocrinology blood sample  Xh, j     X    X X  X  
Blood sample for LCM PKk Xh, j  X   X  X  X X    
Blood sample for concomitant AEDsk Xh, j  X   X  X  X X    
Urinalysis (subjects aged 5 to 17  years)  Xh, j     X    X X  X  
Pregnancy testl Xh, j, S  XU XU XU XU XU XU XU XU XS  XS  
Tanner Stagem Xh, j        X  X    
Clinical GIC  Xh, j     X    X X    
Caregiver GIC  Xh, j     X    X X    
Palatability and ease of use 
questionnaire        X   X X    
Dispense LCM  X  X X X X X X X X Xn Xo   
LCM  return/compliance    X X X X X X X X X Xo X  
Dispense diary  X  X X X X X X X X X    
Diary assessment    X X X X X X X X X X X  
C-SSRSp Xh  X X X X X X X X X Xq X  
Achenbach CBCL  X     X    X X    
Bayley -III scales  X     X    X X    
BRIEF -P/BRIEF  X     X    X X    
PedsQL  X     X    X X    
AE reportingr Xh X X X X X X X X X X X X X 
Health care resource use  X  X X X X X X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; TC=telephone contact; S=serum; SAE= serious adverse eve nt; U=urine; 
Unsch=Unscheduled; V=Visit  
Note: All subjects who directly enrolled into SP848 should fol low the titration schedule in Table  16‒3.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 284 of 324 a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up 
telephone contact).  
b For subjects who have participated in SP847 (or other LCM pediatric clinical studies in epilepsy), Visit 1 is also the last v isit of the primary study. At Visit 1, 
the informed consent will be signed (and assent, if applicable) and eligibility assessed, the medical history will be updated, body weight and height a nd 
concomitant medications including AEDs will be recorded, AEs will be assessed, and the subject diary and LCM dispensed.  
c Teleph one contacts are scheduled during the following weeks during Year 1: Weeks 2, 6, 10, 16, 24, 32, 40, and 48.  
d An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
e If an Unscheduled Visit is needed, th en the assessments noted will be performed. Additional assessments can be performed at the investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between schedul ed clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
f Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final V isit 
2 weeks after the final dose of study medication.  
g This TC occurs 28  to 35 days after the last dose of LCM.  
h For subjects enrolling from SP847 or other LCM pediatric clinical studies in epilepsy, assessments may have been done as part  of the last vi sit of the primary 
study. For subjects enrolling directly into SP848, these assessments should be completed at Visit 1.  
i All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dos e increase to a LCM 
dose level that is ≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects having a 
LCM dose increase to ≥8mg/kg/day will be required to arrive at the clinic prior to  taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs 
assessment) can be performed 30  minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
j For subjects enrolling from EP0060, these assessments should be completed at Visit 1.  
k Blood samples may be drawn at any time post -dosing with LCM.  
l For female subjects of childbearing potential, serum pregnancy tests will be performed at Visit 1, the Early Termination Visit, and the Final Visit.  Urine 
pregnancy tests will be performed at Visits 2, 3, 4, 5, 6, 7, 8, and  9. 
m The Tanner Stage will be performed only for subjec ts who are pubescent at Visit 1 or who will enter puberty during the course of the study.  
n Lacosamide for taper will be dispensed only for subjects who achieve a dose of  LCM ≥6mg/kg/day (oral solution [syrup]) or ≥3 00mg/day (tablet). It is 
recommended th at the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slow er taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency,  a faster taper is permitted after 
discussion with the medical monitor, whenever possible.  
o As applicable  
p For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since last visit” version 
should be completed thereafter.  
q The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
r Ongoing AEs from the primary study will be followed, as well as recording of new AEs during the current study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
Page 285 of 324 Clinical Study Protocol, Section 16.1 (Table 2 Schedule of study procedures for SP848 
[Year  2]). Original table:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 286 of 324  
Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam 
(complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
Blood sample for LCM PKh X  X X X X    
Blood sample for 
concomitant AEDsh X  X X X X    
Urinalysis (subjects aged 5 to 
17 years)    X  X X  X  
Pregnancy testi XU  XU XU XU XS  XS  
Tanner Stagej     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Palatability and ease of use 
questionnaire    X  X X    
Dispense LCM  X  X X Xk Xk Xl   
LCM return/compliance  X  X X X X Xl X  
Dispense diary  X  X X X X    
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 287 of 324 Table 2.  Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -Up 
Visita V10 TCb V11 V12 V13/TermV  ETVc Unsch Visitd Final Visite TCf 
Weeks in study  60  72 84 96     
Diary assessment  X  X X X X X X  
C-SSRSm X  X X X X Xn X  
Achenbach CBCL    X  X X    
Bayley -III scales    X  X X    
BRIEF -P/BRIEF    X  X X    
PedsQL    X  X X    
AE reporting X X X X X X X X X 
Health care resource use  X  X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; TermV=Termination Visit; U=urine; 
Unsch=Unscheduled; V=Visit  
a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visit is needed, then the assessments noted will be per formed. Additional assessments can be performed at the investigator’s discretion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between schedul ed clinic visits, the subject must return for 
an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 
2 weeks after the final dose of  study medication.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial LCM dose increase to a LCM dose level that is 
≥8mg/k g/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects havin g a LCM dose increase to 
≥8mg/kg/day will be required to arrive at the clinic prior to taking their morning dose of LCM. Subjects w ill be administered their morning LCM dose by study personnel at 
the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs assessment) can be performed 30  minutes to 1  hour after the 
administration of L CM (ie, at LCM steady state C max). 
h Blood samples may be drawn at any time post -dosing with LCM.  
i For female subjects of childbearing potential, serum pregnancy tests will be performed at the Early Termination Visit and at the Final Visit. Urine pregnanc y 
tests will be performed at Visits 10, 11, 12, and 13.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 288 of 324 j The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
k Lacosamide for taper will be dispensed only for subjects  who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/day (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (t ablet). A slower taper of 
2mg/kg/day ( oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a faster taper is  permitted after 
discussion with the medical monitor, whenever possible.  
l As applicable.  
m For all subjects ≥6  years of age alread y enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since last visit” version s hould be 
completed thereafter.  
n The C -SSRS assessment should be completed if the Unscheduled Visit is due to an AE.  
 
Was revised t o: 
Table  16-2: Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -
Up 
Visita V10 TCb V11 V12 V13/ 
TermV  ETVc Unsch 
Visitd Final 
Visite TCf 
Weeks in study  60  72 84 96     
Concomitant medications  X X X X X X X X X 
Concomitant AEDs  X X X X X X X X X 
Physical exam (complete)      X X  X  
Physical exam (brief)  X  X X   X   
Neurological exam (complete)      X X  X  
Neurological exam (brief)  X  X X   X   
12-lead ECGg   X  X X X X  
Blood pressure and pulse  X  X X X X X X  
Body weight and height  X  X X X X X X  
Clinical chemistry and 
hematology blood sample  X  X X X X  X  
Endocrinology blood sample     X  X  X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 289 of 324 Table  16-2: Schedule of study procedures for SP848 (Year 2)  
Study SP848  Year 2  Safety 
Follow -
Up 
Visita V10 TCb V11 V12 V13/ 
TermV  ETVc Unsch 
Visitd Final 
Visite TCf 
Weeks in study  60  72 84 96     
Blood sample for LCM PK  Xh  Xh Xh Xh Xi Xi   
Blood sample for concomitant 
AEDs       Xi Xi   
Urinalysis (subjects aged 5 to 
17 years)    X  X X  X  
Pregnancy testj XU  XU XU XU XS  XS  
Tanner Stagek     X X    
Clinical GIC    X  X X    
Caregiver GIC    X  X X    
Palatability and ease of use 
questionnaire    X  X X    
Dispense LCM  X  X X Xl Xl Xm   
LCM return/compliance  X  X X X X Xm X  
Dispense diary  X  X X X X    
Diary assessment  X  X X X X X X  
C-SSRSn X  X X X X Xo X  
Achenbach CBCL    X  X X    
Bayley -III scales    X  X X    
BRIEF -P/BRIEF    X  X X    
PedsQL    X  X X    
AE reporting X X X X X X X X X 
Health care resource use  X  X X X X X X  
AE=adverse event; AED=antiepileptic drug; C -SSRS=Columbia -Suicide Severity Rating Scale; ECG=electrocardiogram; ETV=Early Termination Visit; 
GIC=Global Impression of Change; LCM=lacosamide; PK=pharmacokinetics; S=serum; TC=telephone contact; TermV=Termination Visit; U=urine; 
Unsch=Unscheduled; V=Visit  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol  SPM 927  SP848  
 
 Page 290 of 324 a A time window of ±7 days relative to Visit 1 is applicable for all scheduled visits and telephone contacts (with the exceptio n of the Safety Follow -Up 
telephone contact).  
b Telephone contacts are scheduled during the following weeks during Year 2: Weeks 66 and 78.  
c An Early Termination Visit must be completed for all subjects who prematurely discontinue from the study.  
d If an Unscheduled Visi t is needed, then the assessments noted will be performed. Additional assessments can be performed at the investigator’s disc retion. If 
the LCM dose is decreased between scheduled clinic visits due to an AE, or if a LCM dose increase is required between sc heduled clinic visits, the subject 
must return for an Unscheduled Visit. Height will not be recorded at an Unscheduled Visit.  
e Subjects who complete the study or withdraw prematurely from the study, and who discontinue use of LCM (ie, taper), should co mplete the Final Visit 
2 weeks after the final dose of study medication.  
f This TC occurs 28 -35 days after the last dose of LCM.  
g All subjects will be required to have a 12 -lead ECG (2  interpretable recordings) conducted at LCM C max 1 week after an initial L CM dose increase to a LCM 
dose level that is ≥8mg/kg/day or a new concomitant AED is introduced. This ECG can be conducted at an Unscheduled Visit, if necessary. Subjects having a 
LCM dose increase to ≥8mg/kg/day will be required to arrive at the clinic pr ior to taking their morning dose of LCM. Subjects will be administered their 
morning LCM dose by study personnel at the clinic so that an ECG (2  interpretable recordings approximately 20 to 30  minutes apart prior to vital signs 
assessment) can be performed  30 minutes to 1  hour after the administration of LCM (ie, at LCM steady state C max). 
h Blood sample for LCM PK will be routinely collected for subjects enrolled at sites in Japan. Blood samples may be drawn at an y time post -dosing with LCM.  
i Blood sample s for LCM and concomitant other AEDs may be collected at an Unscheduled Visit or Early Termination Visit if the visit is rela ted to an ongoing 
SAE.  
j For female subjects of childbearing potential, serum pregnancy tests will be performed at the Early Termin ation Visit and at the Final Visit. Urine pregnancy 
tests will be performed at Visits 10, 11, 12, and 13.  
k The Tanner Stage will be performed only for subjects who are pubescent at Visit 1 or who will enter puberty during the course  of the study.  
l Lacosa mide for taper will be dispensed only for subjects who achieve a dose of LCM ≥6mg/kg/day (oral solution [syrup]) or ≥300mg/da y (tablet). It is 
recommended that the LCM dose be tapered gradually in weekly decrements of 4mg/kg/day (oral solution [syrup]) or 200mg/day (tablet). A slower taper of 
2mg/kg/day (oral solution [syrup]) or 100mg/day (tablet) is permitted, if medically necessary. In case of an emergency, a fas ter taper is permitted after 
discussion with the medical monitor, whenever possible.  
m As app licable.  
n For all subjects ≥6  years of age already enrolled, the “already enrolled” version should be completed at the next clinic visit, and the “since la st visit” version 
should be completed thereafter.  
o The C -SSRS assessment should be completed if the  Unscheduled Visit is due to an AE.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 291 of 324 
  
Clinical Study Protocol, Section 16.3 (Declarations and signatures of persons responsible for 
study) and Section 16.4 (Declaration and signature of investigator) were moved to new 
Section 18 (Declaration and signature of investigator) and new Section 19 (Sponsor 
declaration), respectively.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 292 of 324 
 17.7 PROTOCOL AMENDMENT 7  
RATIONALE FOR THE AMENDMENT  
This administrative amendment is to fix the numbering of exclusion criteria. During Protocol 
Amendme nt 6, Exclusion Criterion 16 was deleted. The remaining criteria should have been 
numbered 17 through 21, inclusive, to align with the CRF.  
The rationale for removal of Exclusion Criterion 16 during Protocol Amendment 6 was to allow 
physicians to have thes e medications as options for treatment during the open -label study.  
MODIFICATIONS/CHANGES  
• Exclusion Criteria 16 through 20, inclusive, were mistakenly misnumbered.  
. 
REFERENCE  
Clinical Study Protocol, Section  4.3.2 (Exclusion criteria). Original text:  
16. Subject is taking monoamine oxidase inhibitors -A (MAOI -A) or narcotic analgesics.  
17. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively 
neurodegenerative disease, such as Rasmussen syndrome.  
18. Subject has a known  sodium channelopathy, such as Brugada syndrome.  
19. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject has 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a Base line result >ULN for ALT, AST, ALP, or total bilirubin, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).  
If subject has >ULN ALT, AST, or ALP that does n ot meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medi cal Monitor.  
Tests that result in ALT, AST, or ALP up to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re -screening.  
Subjects who were directly enrolled in EP0060 for iv LCM replacement therapy or to 
initiate LCM treatment are not permitted to enroll in the study if any of the following 
criteria are met:  
20. Subjects have previously participated in a long -term, open -label LCM study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 293 of 324 
 Were revised as follows:  
17. Subject is taking monoamine oxidase inhibitors -A (MAO I-A) or narcotic analgesics.  
18. Subject has epilepsy secondary to a progressing cerebral disease or any other progressively 
neurodegenerative disease, such as Rasmussen syndrome.  
19. Subject has a known sodium channelopathy, such as Brugada syndrome.  
20. Subject has >2x upper limit of normal (ULN) of any of the following: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or 
>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome). If subject ha s 
elevations only in total bilirubin that are >ULN and <1.5xULN, fractionate bilirubin to 
identify possible undiagnosed Gilbert’s syndrome (ie, direct bilirubin <35%).  
For randomized subjects with a Baseline result >ULN for ALT, AST, ALP, or total bilirubi n, 
a Baseline diagnosis and/or the cause of any clinically meaningful elevation must be 
understood and recorded in the electronic Case Report form (eCRF).  
If subject has >ULN ALT, AST, or ALP that does not meet the exclusion limit at screening, 
repeat the tests, if possible, prior to dosing to ensure there is no further ongoing clinically 
relevant increase. In case of a clinically relevant increase, inclusion of the subject must be 
discussed with the Medical Monitor.  
Tests that result in ALT, AST, or ALP up  to 25% above the exclusion limit may be repeated 
once for confirmation. This includes re -screening.  
Subjects who were directly enrolled in EP0060 for iv LCM replacement therapy or to 
initiate LCM treatment are not permitted to enroll in the study if any o f the following 
criteria are met:  
21. Subjects have previously participated in a long -term, open -label LCM study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 294 of 324 
 17.8 PROTOCOL AMENDMENT 8  
RATIONALE FOR THE AMENDMENT  
The primary purpose of this protocol amendment is to align with modifications made to the 
Paediatric Investigation Plan. The primary changes include:  
• A new categorization for main primary and secondary endpoints key binding element was 
proposed in order to ensure reporting compliance with registries (EudraCT, 
clinicaltrials.gov). This categoriza tion does not affect the type or processing of data collected 
and reported in the study report as they will be assessed as initially planned.  
• UCB also took the occasion to provide further clarification to the study duration as well as 
the primary, secondary, and other variables wording and categorization.  
In addition, language specifying applicable study conduct modifications due to the COVID -19 
pandemic has been added.  
Furthermore, minor administrative changes have been done, including the update of the study 
team and minor editorial corrections to correct typographical errors and to update document 
abbreviations.  
MODIFICATIONS/CHANGES  
• The name and contact information for the Clinical Program Director, Clinical Project 
Manager, Clinical Trial Bios tatistician, and  Medical Director (Medical Therapeutics) were 
updated.  
• Reorganization and clarification of the study variables and corresponding statistical analyses 
sections was completed.  
• Text added to allow 100 subjects to enroll in SP848 from EP0060.  
• Text added to identify the subjects directly enrolling from sites in Japan and China.  
• Text added to clarify study conduct due the COVID -19 pandemic.  
• Text updated to clarify the study duration.  
• Text updated to clarify that the Safety Follow -Up Visit or the  Safety Follow -Up telephone 
contact is not required for subjects who participate in EP0151 or EP0152.  
REFERENCE  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 295 of 324 
 Contact information for the Clinical Program Director, Clinical Project Manager, Clinical Trial 
Biostatistician, and Medical Director (Medical T herapeutics) were updated. Original text:  
Clinical Program Director:  
Name:  , BS 
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Project Manager:  
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Trial Biostatistician:  
Name:   MPH  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 296 of 324 
 Medical Director (Medical Therapeutics):  
Name:  , MD  
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Were revised as follows:  
Clinical Program Director:  
Name:    
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Clinical Project Manager:  
Name:   
Address:  UCB BIOSCIENCES, Inc  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone:    
E-mail:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 297 of 324 
 Clinical Trial Biostatistician:  
Name:   
Address:  UCB BIOSCIENCES, Inc.  
8010 Arco Corporate Drive, Suite 100 (courier)  
Raleigh, NC 27617, USA  
PO Box 110167 (mail)  
Research Triangle Park, NC 27709, USA  
Phone/Fax:   
E-mail:   
Medical Director (Medical Therapeutics) :  
Name:   MD 
Address:  UCB BIOSCIENCES, GmbH  
Alfred -Nobel - Straße  10 
40789 Monheim am Rhein  
GERMANY   
Phone:    
E-mail:   
Serious Adverse Event Reporting phone numbers and emails were updated. Original text:  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  +32 2 386 24 21  
USA and Canada: +1 800 880 6949 or +1 866 890 3175  
Email  Global: DS_ICT @ucb.com  
 
Were revised as follows:  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World:  +32 2 386 24 21  
USA and Canada: +1 800 880 6949 or +1 866 890 3175  
Japan:  + 81 3 6864 7400  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 298 of 324 
 Email  Europe and Rest of the World:  DS_ICT @ucb.com or 
DSICT. -@ucb.com   
Japan: JDSO@ucb.com  
 
Clinical Study Protocol, Section 1 (Summary). Original text, second, third, and fourth 
paragraphs:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed 
appropriate for treatment with adjunctive LCM) who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. The purpose of enrolling these 
subjects directly into SP848 is to obtain sufficient long -term safety exposures in the age range of 
≥4 years to ≤17  years of age; the long -term safety data will be included in planned regulatory 
submissio ns for LCM as adjunctive therapy for partial -onset seizures in pediatric subjects 
≥4 years to ≤17  years of age with epilepsy.   
Protocol Amendment 6 allows up to approximately 75 additional eligible pediatric subjects with 
epilepsy who participated in EP006 0 to enroll into SP848. In addition, subjects already enrolled 
in SP848 may participate in EP0060, if eligible, and then resume participation in SP848. These 
subjects may either voluntarily choose to have an iv LCM infusion even though they are capable 
of taking oral LCM or require iv LCM infusion due to a medical reason or procedure (ie, unable 
to take oral LCM).  
Were revised as follows:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizu res. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. SP848 includes subjects ≥1 month to ≤18 years of age since subjects who complete 
SP847 or another applicable LCM pediatric epilepsy study in subjects <18 years of age may have 
aged to 18 years old by the time they complete that study and enroll in SP848.  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately  
100 eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed 
appropriate for treatment with adjunctive LCM) who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. B eginning with local Protocol 
Amendment 5.2 for sites in Japan, approximately 46  eligible pediatric subjects ≥4  years to 
≤17 years of age with partial -onset seizures who have not previously received LCM will directly 
enroll at approximately 9 sites in Japan . Beginning with local Protocol Amendment 5.4 for sites 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 299 of 324 
 in China, approximately 60 additional eligible pediatric subjects with partial -onset seizures aged 
≥4 years to ≤17  years, who have not previously participated in a LCM clinical study, will enroll 
directly into SP848. The purpose of enrolling these subjects directly into SP848 is to obtain 
sufficient long -term safety exposures in the age range of ≥4  years to ≤17  years of age; the 
long-term safety data will be included in planned regulatory submissions f or LCM as adjunctive 
therapy for partial -onset seizures in pediatric subjects ≥4  years to ≤17  years of age with epilepsy.   
Protocol Amendment 6 allows up to approximately 75 additional eligible pediatric subjects with 
epilepsy who participated in EP0060 to  enroll into SP848. Protocol Amendment 8 allows an 
enrollment increase from 75 to 100 eligible pediatric subjects ≥1 month to ≤17 years of age with 
epilepsy who participated in EP0060 to enroll in SP848 in order to reflect EP0060’s inclusion of 
subjects do wn to 1 month of age. In addition, subjects already enrolled in SP848 may participate 
in EP0060, if eligible, and then resume participation in SP848. These subjects may either 
voluntarily choose to have an iv LCM infusion even though they are capable of ta king oral LCM 
or require iv LCM infusion due to a medical reason or procedure (ie, unable to take oral LCM).  
Approximately 200  subjects who may participate in other LCM pediatric clinical studies in 
epilepsy will be eligible to participate in SP848. In to tal, up to approximately 400  subjects may 
be eligible to participate in SP848.  
 
Clinical Study Protocol, Section 1 (Summary). Original text, seventh and eighth paragraphs:  
The primary variables for assessment of safety and tolerability are:  
• Adverse events (AEs) reported spontaneously by the subject and/or caregiver or observed by 
the investigator  
• Subject withdrawal due to AEs  
• Hematology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (bloo d pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body mass index (BMI)  
• Tanner stage (if applicable)  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
• Achenbach Child Behav ior Checklist (CBCL) for children 18  months and older (CBCL/1½ -5 
and CBCL/6 -18) assessing behavior  
• Bayley -III scales for children <18  months of age at time of enrollment (applicable only to 
subjects enrolled in English -speaking countries)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 300 of 324 
 • Cognitive functio n assessments (Behavior Rating Inventory of Executive Function® 
[BRIEF®]/BRIEF®-Preschool Version [BRIEF®-P]) (if applicable)  
The secondary variables include seizure counts (assessed using seizure diaries in order to 
evaluate preliminary evidence of effica cy during long -term exposure in this population), the 
Clinical Global Impression of Change, the Caregiver Global Impression of Change, quality of 
life assessments (Pediatric Quality of Life Inventory [PedsQL™]), health care resource use, and 
a LCM palatabi lity and ease of use questionnaire.  
Were revised as follows:  
The study variables to be assessed are defined in Section  4.2.  
 
Clinical Study Protocol, Section 2 (Background Information). Original text, final paragraph:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open to subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. In addition, at selected sites, beginning with Protocol Amendmen t 4, up to 
approximately 100  eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study will be permitted to enrol l directly into SP848. The purpose 
of enrolling these subjects directly into SP848 is to obtain additional long -term safety exposures 
in the age range of ≥4  years to ≤17  years of age; the additional long -term safety data will be 
included in planned regulat ory submissions for LCM as adjunctive therapy for partial -onset 
seizures.  
Was revised as follows:  
SP848 was originally designed as an open -label extension study for pediatric subjects in SP847 
with partial -onset seizures. SP848 is now amended to be open t o subjects who participate in 
other LCM pediatric clinical studies, including partial -onset seizures and other epilepsy 
syndromes. In addition, at selected sites, beginning with Protocol Amendment  4, up to 
approximately 100  eligible pediatric subjects ≥4  years to ≤17  years of age with partial -onset 
seizures (deemed appropriate for treatment with adjunctive LCM) who have not previously 
participated in a LCM clinical study will be permitted to enroll directly into SP848. Beginning 
with local Protocol Amendmen t 5.2 for sites in Japan, approximately 46  eligible pediatric 
subjects ≥4  years to ≤17  years of age with partial -onset seizures who have not previously 
received LCM will directly enroll at approximately 9 sites in Japan. Beginning with local 
Protocol Amend ment 5.4 for sites in China, approximately 60 additional eligible pediatric 
subjects with partial -onset seizures aged ≥4  years to ≤17  years, who have not previously 
participated in a LCM clinical study, will enroll directly into SP848. The purpose of enrol ling 
these subjects directly into SP848 is to obtain additional long -term safety exposures in the age 
range of ≥4  years to ≤17  years of age; the additional long -term safety data will be included in 
planned regulatory submissions for LCM as adjunctive thera py for partial -onset seizures.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 301 of 324 
 Clinical Study Protocol, Section 4.1.2 (Subjects enrolling directly into SP848). Original text, 
first and second paragraph, new third paragraph:  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed appropriate 
for treatment with adjunctive LCM) who have not previously participated in a LCM clinical 
study will be permitted to enroll directly into SP848.  
Subjects who enroll directly into SP848 without previous participation in a LCM clinical study 
will undergo screening. Eligible subjects will initiate treatment with LCM, and the LCM dose 
will be titrated to a level to optimize tolerability and seizure con trol (see Section  4.4.1 ). Subjects 
will be able to receive LCM oral solution or LCM tablets for up to 2  years as determined 
appropriate by the inve stigator.  
Was revised as follows:  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age with partial -onset seizures (deemed appropriate 
for treatment with adjunctive LCM) w ho have not previously participated in a LCM clinical 
study will be permitted to enroll directly into SP848. Beginning with local Protocol Amendment 
5.2 for sites in Japan, approximately 46  eligible pediatric subjects ≥4  years to ≤17  years of age 
with part ial-onset seizures who have not previously received LCM will directly enroll at 
approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 for sites in China, 
approximately 60 additional eligible pediatric subjects with partial -onset seizu res aged ≥4  years 
to ≤17  years, who have not previously participated in a LCM clinical study, will enroll directly 
into SP848.  
Subjects who enroll directly into SP848 without previous participation in a LCM clinical study 
will undergo screening. Eligible s ubjects will initiate treatment with LCM, and the LCM dose 
will be titrated to a level to optimize tolerability and seizure control (see Section  4.4.1 ). Subjects 
will be able to receive LCM oral solution or LCM tablets for up to 2  years as determined 
appropriate by the investigator.  
SP848 includes subjects ≥1 month to ≤18 years of age since subjects who complete SP847 or 
another applicable LCM pediatr ic epilepsy study in subjects <18 years of age may have aged to 
18 years old by the time they complete that study and enroll in SP848.  
 
Clinical Study Protocol, Section 4.2 (Variables to be assessed). Original text, Section 4.2.1 and 
Section 4.2.2:  
4.2 Var iables to be assessed  
4.2.1 Primary variables  
Safety and tolerability will be assessed using the following variables:  
• Adverse events reported spontaneously by the subject and/or caregiver, or observed by the 
investigator  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 302 of 324 
 • Subject withdrawal due to AEs  
• Hemat ology, blood chemistry, endocrinology, and urinalysis parameters  
• 12-lead ECGs  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated BMI  
• Tanner Stage (if applicable)  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
• Achenbach CBCL at Baseline for children 18  months and older (CBCL/1½ -5 and 
CBCL/6 -18) assessing behavior  
• Bayley -III scales at Baseline for children <18  months of age at time of enrollm ent 
(applicable only to subjects enrolled in English -speaking countries)  
• Cognitive function assessments (BRIEF -P/BRIEF) (if applicable)  
4.2.2 Secondary variables  
Secondary variables include:  
• Seizure counts, which will be assessed using seizure diaries in o rder to evaluate preliminary 
evidence of efficacy during long -term exposure in this population  
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• Quality of life assessments (PedsQL) (if applicable)  
• Health care resource use (concomitant AEDs, medical procedures, health care provider 
consultations not related to study, hospitalizations not related to study)  
• LCM palatability and ease of use questionnaire  
Was revised as follows:  
4.2 Variables to be assessed  
4.2.1 Safety variabl es 
4.2.1.1 Primary safety variables  
The primary safety variables are:  
• Incidence of TEAEs  
• Incidence of serious AEs (SAEs)  
• Subject withdrawal from the study due to TEAEs  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 303 of 324 
 4.2.1.2 Other safety variables  
The other safety variables are:  
• Hematology, blood chemist ry, endocrinology, and urinalysis parameters  
• 12-lead electrocardiograms (ECGs)  
• Vital sign measurements (blood pressure and pulse)  
• Physical and neurological examination findings  
• Body weight, height, and calculated body mass index (BMI)  
• Tanner Stage (if appl icable)  
• Achenbach Child Behavior Checklist (CBCL) at Baseline for children 18  months and older 
(CBCL/1½ -5 and CBCL/6 -18) assessing behavior  
• Bayley -III scales at Baseline for children <18  months of age at time of enrollment 
(applicable only to subjects enro lled in English -speaking countries)  
• Cognitive function assessments (Behavior Rating Inventory of Executive Function® 
[BRIEF®]/BRIEF®-Preschool Version [BRIEF®-P]) (if applicable)  
• LCM palatability and ease of use questionnaire  
4.2.2 PK variables  
4.2.2.1 Primary PK variables  
No primary PK variables are defined for this study.  
4.2.2.2 Other PK variables  
The other PK variables are:  
• Plasma concentrations of LCM (for population PK analysis) and concomitant AEDs  
4.2.3 Efficacy variables  
4.2.3.1 Primary efficacy  variables  
No primary efficacy variables are defined for this study.  
4.2.3.2 Secondary efficacy variables  
The secondary efficacy variables, based on daily seizure diaries, are:  
• Percent change from Baseline in 28 -day partial -onset seizure frequency  
• ≥50% re duction in 28 -day partial -onset seizure frequency  
• ≥75% reduction in 28 -day partial -onset seizure frequency  
• Seizure days per 28 days (subjects with generalized seizures only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 304 of 324 
 • Seizure -free status  
4.2.3.3 Other efficacy variables  
The other efficacy variables are: 
• Clinical Global Impression of Change  
• Caregiver Global Impression of Change  
• Quality of life assessments (Pediatric Quality of Life Inventory [PedsQL™]) (if applicable)  
• Health care resource use (concomitant AEDs, medical procedures, health care provider  
consultations not related to study, hospitalizations not related to study)  
• All seizure frequency analyses as described in the secondary efficacy variables (presented for 
the overall Treatment Period only) may be additionally presented by modal daily dose group, 
by seizure type, by seizure classification subgroup, by time interval, by visit or time period, 
or by completer cohort  
 
Clinical Study Protocol, Section 4.3.3.1 (Potential drug -induced liver injury IMP 
discontinuation criteria). Original text, first , second, third, and fourth paragraphs:  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary sh ould also be discontinued.  
The PDILI criteria below require immediate and permanent discontinuation of IMP:  
• Subjects with either of the following:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
The PDILI criterion below requir es immediate discontinuation of IMP:  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivit y symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
investigator.  
• Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, 
fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
Was revised as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 305 of 324 
 Subjects with potential drug -induced liver injur y (PDILI) must be assessed to determine if IMP 
must be immediately and permanently discontinued. In addition, all concomitant medications 
and herbal supplements that are not medically necessary should also be discontinued.  
The PDILI criteria below require  immediate and permanent discontinuation of IMP:  
• Subjects with either of the following:  
− ALT or AST ≥5xULN  
− ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
• Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or h ypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (without clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
The PDILI criterion below requir es discussion with the Medical Monitor to decide whether the 
subject is allowed to continue on IMP.  
• Subjects with ALT or AST ≥3xULN (and ≥2x Baseline) and <5xULN, total bilirubin 
<2xULN, and no eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of he patitis 
(eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness).  
 
Clinical Study Protocol, Section 4.4.1.2 (Subjects enrolling directly into SP848). Original text, 
first paragraph:  
Beginning with Protocol Amendment  4, at selected sites, up  to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. After Screening, eligible subjects 
will initiate treatment with LCM  (oral solution or tablet, as chosen by the investigator and 
subject/caregiver), and the LCM dose will be titrated to a level to optimize tolerability and 
seizure control.  
Was revised as follows:  
Beginning with Protocol Amendment  4, at selected sites, up to approximately 100  eligible 
pediatric subjects ≥4  years to ≤17  years of age who have not previously participated in a LCM 
clinical study will be permitted to enroll directly into SP848. Beginning with local Protocol 
Amendment 5.2 f or sites in Japan, appr oximately 46  eligible pediatric subjects ≥4  years to 
≤17 years of age with partial -onset seizures who have not previously received LCM will directly 
enroll at approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 f or sites 
in China, a pproximately 60 additional eligible pediatric subjects with partial -onset seizures aged 
≥4 years to ≤17  years, who have not previously participated in a LCM clinical study, will enroll 
directly into SP848. After Screening, eligible subjects will initiate t reatment with LCM (oral 
solution or tablet, as chosen by the investigator and subject/caregiver), and the LCM dose will be 
titrated to a level to optimize tolerability and seizure control.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 306 of 324 
 Clinical Study Protocol, Section 4.4.1.4 (Study completion). Origin al text, first paragraph:  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who compl ete the study depending on the treatment option selected 
by the investigator in consultation with the subject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 2 8 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper of LCM.  
Was revised as follows:  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investigator in consultation with the sub ject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper of LCM. The Safety Follow -Up Visit and 
the Safety Follow -Up telephone contact are not required for subjects who participate in EP0151 
or EP0152.  
 
Clinical Study Protocol, Section 4.5 (Expected duration of the study). Original text, first 
paragraph:  
The maximum duration of LCM administration for an individual subject will be approximately 
2 years.  
Was revised as follows:  
The maximum duration of LCM administration for an individual subject will be approximately 
2 years or until approval of the marketing application (for Japan only), whichever comes first.  
 
Clinical Study Protocol, Section 5 (Treatment Procedures By Visit). Original text , first and 
second paragraphs:  
For all scheduled visits and telephone contacts (with t he exception of the Safety Follow -Up 
telephone contact), a visit window of ±7 days relative to Visit  1 is applicable. The Safety 
Follow -Up telephone contact will be performed 28 -35 days after the last dose of LCM. A 
detailed tabular schedule of study proce dures is provided in Section  16.1. For further details of 
the assessments and the required procedures and methods, please refer to Section  6, Section  7, 
and Section  8. 
Were revised as follows:  
For all scheduled visits and telephone contacts (with the exception of the Safety Follow -Up 
telephone contact), a visit window of ±7 days relative to Visit  1 is applicable. The Safety 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 307 of 324 
 Follow -Up telephone contact will be performed 28 -35 days after the last dose of LCM. The 
Safety Follow -Up Visit and the Safety Follow -Up telephone contact are not required for subjects 
who participate in EP0151 or EP0152.  
Assessments will be done during monthly visits for the first 3 months, every 2 months for the 
remainder o f Year 1, and every 3 months for Year 2. A detailed tabular schedule of study 
procedures is provided in Section  16.1. For further details of the ass essments and the required 
procedures and methods, please refer to Section  6, Section  7, and Section  8. 
 
Clinical Study Protocol, Section 5.16 (Visit 13/Termination Visit  [Week 96]). Original text, first 
paragraph:  
At the completion of the study, investigators should discuss treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some  subjects who complete the study depending on the treatment option selected 
by the investigator in consultation with the subject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for subjects 
who complete the study and who do not undergo taper of LCM.  
Was revised as follows:  
At the completion of the study, investigators should discuss  treatment options with the subject 
and/or their parent/legal guardian to best manage the subject’s epilepsy. Taper of LCM may not 
be required for some subjects who complete the study depending on the treatment option selected 
by the investigator in consul tation with the subject and/or parent/legal guardian. These subjects 
should complete Visit  13/Termination Visit and then complete the Safety Follow -Up telephone 
contact 28 to 35  days after Visit  13/Termination Visit. The Final Visit is not required for sub jects 
who complete the study and who do not undergo taper of LCM. The Safety Follow -Up Visit and 
the Safety Follow -Up telephone contact are not required for subjects who participate in EP0151 
or EP0152.  
 
Clinical Study Protocol, Section 5.19 (Final Visit).  Original text, first paragraph:  
Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication.  
Was revised as follows:  
Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication. The Final Visit is not required for subjects who participa te in EP0151 or EP0152.   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 308 of 324 
 Clinical Study Protocol, Section 5.20 (Safety Follow -Up telephone contact). Original text, first 
paragraph:  
The Safety Follow -Up telephone contact is required for all subjects (those who complete the 
study as planned or have withd rawn prematurely from the study). For subjects who complete the 
study, this telephone contact will occur 28 to 35  days after Visit  13/Termination Visit (subjects 
who do not undergo taper of LCM) or 28 to 35  days after the last dose of LCM (subjects who 
discontinue use of LCM [ie, taper]). For subjects who withdraw prematurely from the study, this 
telephone contact will occur 28 to 35  days after the Early Termination Visit (subjects who do not 
undergo taper of LCM) or 28 to 35  days after the last dose of LCM  (subjects who discontinue 
use of LCM [ie, taper]).  
Was revised as follows:  
The Safety Follow -Up telephone contact is required for all subjects (those who complete the 
study as planned or have withdrawn prematurely from the study) who do not participate i n 
EP0151 or EP0152. For subjects who complete the study, this telephone contact will occur 28 to 
35 days after Visit  13/Termination Visit (subjects who do not undergo taper of LCM) or 28 to 
35 days after the last dose of LCM (subjects who discontinue use o f LCM [ie, taper]). For 
subjects who withdraw prematurely from the study, this telephone contact will occur 28 to 
35 days after the Early Termination Visit (subjects who do not undergo taper of LCM) or 28 to 
35 days after the last dose of LCM (subjects who  discontinue use of LCM [ie, taper]). The Safety 
Follow -Up telephone contact is not required for subjects who participate in EP0151 or EP0152.  
 
Clinical Study Protocol, Section  5.21(Study conduct due to coronavirus disease 2019 pandemic) 
was newly added as  follows:  
The protocol -mandated visit schedule should be followed to the extent possible, considering the 
individual benefit -risk assessment by the investigator. If necessary, remote visits may be 
conducted and the subjects or caregivers will be contacted by telephone or videoconference. 
Remote follow -up, at minimum with a telephone call after 3 months, must be done (preferably 
more frequently and as needed to follow -up on participant safety assessments).  
Ad hoc subject contact may be warranted  to underst and the current health status of the subjects, 
to follow up on AEs, and inform them of any protective measures taken by the clinical site as a 
result of the coronavirus disease 2019 (COVID -19) pandemic (eg, any measures that may limit 
access to the site or  may require additional actions by the study participant prior to entry to the 
site).  
If a subject needs to be discontinued and cannot come into the clinic, then appropriate tapering 
instructions will be provided, and a visit will be scheduled to perform s afety assessments as soon 
as possible.  
In situations where a subject is unable to return to the study site, investigators will assess and 
document the subject’s safety via telephone contact. Based on information gathered from the 
telephone contact, investi gators will confirm whether the subject could continue the current 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 309 of 324 
 study treatment based upon the outcome of the safety assessment. Subjects’ agreement to 
implement this procedure should be obtained and documented prior to implementing any 
changes. Changes  in the study treatment supply in this situation are described in Section  9.5.  
If a subject visits another facility for a medical issue (or has to sw itch sites for a COVID -19-
related reason), the investigator should request contact with the physician providing care to 
provide a detailed explanation of the subject’s condition and his/her participation in the clinical 
study. Subjects or caregivers shall be reminded to completely collect and keep records of this 
visit.  
Deviations to data collection including inability to perform some assessments, such as ECG, 
blood collection for safety laboratory assessments and PK, or alternative methods of assessment, 
such as phone calls, should be recorded in the source documentation and notated as “not done” in 
the eCRF.  
In cases where subjects cannot return to the clinic, and it will not be possible to dispense a new 
seizure diary, subjects will be instructed to cont inue recording of seizures in a manner that is 
mutually agreed with the investigator (eg, hand -written notes, recording on a smart device). Any 
recording of seizures in a manner outside of the study seizure diary must be carefully 
documented in the source medical records (copies/print -screen printouts of these recordings will 
be brought to and retained at the site).  
 
Clinical Study Protocol, Section 6.2.1 (Clinical Global Impression of Change). Original text, 
first paragraph:  
The Clinical Global Impression of Change will be completed according to the tabular schedule of 
study procedures, Section  16.1. 
Was revised as follo ws:  
The Clinical Global Impression of Change will be assessed at least once per year and be 
completed according to the tabular schedule of study procedures, Section  16.1. 
 
Clinical Study Protocol, Section 6.2.2 (Caregiver Global Impression of Change). Original text, 
first paragraph:  
The Caregiver Global Impression of Change will be completed according to the tabular schedule 
of study procedures, Section  16.1. 
Was revised as follows:  
The Caregiver Global Impression of Change will be assessed at least once per year and be 
completed according to the tabular schedule of study procedures, Section  16.1. 
 
Clinical Study Protocol, Section 6.3 (Pediatric Quality of Life Inventory). Original te xt, first 
paragraph:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 310 of 324 
 The PedsQL is a validated instrument that consists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions (Varni et al, 2001; 
Varni et al, 2011). The PedsQL will be a dministered according to the tabular schedule of study 
procedures, Section  16.1. 
Was revised as follows:  
The PedsQL is a validated instrument that c onsists of generic core scales suitable for use with 
pediatric populations, including those with acute or chronic health conditions (Varni et al, 2001; 
Varni et al, 2011). The PedsQL will be completed up to two times per year and will be 
administered accor ding to the tabular schedule of study procedures, Section  16.1. 
 
Clinical Study Protocol, Section  8.1.10 (Occurrence of COVID -19) was newly added as  follows:  
Occurrence of COVID -19 in subjects should be reported as either “suspected COVID -19” or 
“confirmed COVID -19” along with all available relevant data including diagnostic and 
laboratory data. For subjects where COVID -19 is still suspected despite a  negative viral test, 
please report as “suspected COVID -19” and provide relevant data to support the diagnosis as 
well as the test results.  
 
Clinical Study Protocol, Section 8.3 (Laboratory measurements). Original text, laboratory test 
table:  
Urinalysis  Hematology  Clinical chemistry  Endocrinology  
Specific gravity  RBC  Total serum 
protein  Cholesterol  FSH 
pH WBC  Albumin  Triglycerides  LH 
Albumin  Differential count  Calcium  Total bilirubin  Testosterone  
Glucose  Platelet count  Phosphorus  Alkaline 
phosphatase  TSH  
Ketone  Hemoglobin  Glucose  Creatinine  T3 (total and 
serum -free)  
Microscopic exam 
for blood cells for 
casts/hpf  Hematocrit  Serum electrolytes 
(sodium, 
potassium, 
chloride, 
bicarbonate)  AST  
ALT  
GGT  T4 (total and 
serum -free)  
  Uric acid  BUN   
Was revised as follows:  
Urinalysis  Hematology  Clinical chemistry  Endocrinology  
Specific gravity  RBC  Total serum 
protein  Cholesterol  FSH 
pH WBC  Albumin  Triglycerides  LH 
Protein  Differential count  Calcium  Total bilirubin  Testosterone  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 311 of 324 
 Urinalysis  Hematology  Clinical chemistry  Endocrinology  
Glucose  Platelet count  Phosphorus  Alkaline 
phosphatase  TSH  
Ketone  Hemoglobin  Glucose  Creatinine  T3 (total and 
serum -free)  
Microscopic exam 
for blood cells for 
casts/hpf  Hematocrit  Serum electrolytes 
(sodium, 
potassium, 
chloride, 
bicarbonate)  AST  
ALT  
GGT  T4 (total and 
serum -free)  
  Uric acid  BUN   
 
Clinical Study Protocol, Section 8.3.2 (Liver function tests and evaluation of PDILI). Original 
text, seventh paragraph:  
When IMP is stopped due to PDILI (as described in Section 4.3.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings.  
Was revised as follows:  
When IMP is stopped due to PDILI (as d escribed in Section 4.3.3.1 ), IMP must be permanently 
discontinued.  
 
Clinical Study Protocol, Section 8.3.2.3 (Testing: identification/exclusion of a lternative 
etiology). Original text, Table 8 -2: 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 312 of 324 
 Table  8‒2: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRa 
Serum pregnancy test  
PK sample  
ALT=alanine aminotransferase; CPK=creatine phosphokinase; HBcAb -IgM=hepatitis B core antibody -IgM;  
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic acid; 
ULN=upper limit of normal  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderne ss; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
Was revised as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 313 of 324 
 Table  8‒2: PDILI laboratory measurements  
Virology -
related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Hematocrit  
Hemoglobin  
Platelet count  
RBC count  
WBC count  
WBC differential count  
Urinalysis  Toxicology screen  
Chemistry  Amylase  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH to evaluate possible muscle injury causing transaminase 
elevation  
ALT  
AST  
ALP  
GGT  
Albumin  
Additional  Prothrombin time/INRa 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 314 of 324 
 Serum pregnancy test  
PK sample  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; CPK=creatine 
phosphokinase;  GGT=gamma -glutamyltransferase; HBcAb -IgM=hepatitis B core antibody -IgM; 
HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; LDH=lactate 
dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RBC=red blood cell; 
RNA=ribonucl eic acid; ULN=upper limit of normal; WBC=white blood cell  
a Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatitis sym ptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
 
Clinical Study Protocol, Section 8.4.5 (Tanner Stage). New final  paragraph added as follows:  
The evaluation of Tanner Stage for applicable subjects will be completed according to the tabular 
schedule of study procedures, Section  16.1. 
 
Clinical Study Protocol, Section 8.4.6 (Assessment of suicidality). New second paragraph added 
as follows:  
Subjects enrolling directly who are ≥6 years of age will complete the “Baseline/Screening” 
version of the C -SSRS at Visit 1 and will complete the “Since Last Visit” version at subsequent 
visits. If a subject becomes 6 years of age during the study, the “Already Enrolled” version of the 
C-SSRS should be used at the first visit at which the subject is 6 years of age and the “Sinc e Last 
Visit” version used at subsequent visits.  
 
Clinical Study Protocol, Section 8.4.7 (Achenbach CBCL). Original text, second, third, and 
fourth paragraphs:  
The same scale will be completed at the Screening Visit (subjects enrolling directly into SP848) , 
Visit  1 (subjects enrolling from SP847 or other pediatric clinical studies in epilepsy), and 
Visit  13/Termination Visit (or Early Termination Visit) (all subjects) by the parent(s)/legal 
representative(s). The completion of the Achenbach CBCL will requir e approximately 
45 minutes.  
In both questionnaires, the occurrence of certain problems and behaviors in the past 6 months 
will be scored on the following scale:  
• 0=not true (as far as known)  
• 1=somewhat or sometimes true  
• 2=very true or often true  
Eight syndrome scores will be calculated from these questions, which will in turn be summarized 
by 2 composite scores. Additionally, for each score on the question, syndrome, and total level, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 315 of 324 
 categorizations based on a normative sample will be used to eval uate normal, borderline, or 
clinically relevant behavior.  
Was revised as follows:  
The Achenbach CBCL will be completed according to the tabular schedule of study procedures, 
Section  16.1. 
In both questionnaires, the occurrence of certain problems and behaviors (in the past 2 months 
for the CBCL/1½ -5 version and in the past 6 months for the CBCL/6 -18 version) will be scored 
on the following scale:  
• 0=not true (as far as known)  
• 1=somewhat or sometimes true  
• 2=very true or often true  
Syndrome scores will be calculated from these questions, which will in turn be summarized by 
2 composite scores. Additionally, for each syndrome and composite scores, categor izations based 
on a normative sample will be used to evaluate normal, borderline, or clinically relevant 
behavior.  
 
Clinical Study Protocol, Section 8.4.8 (Bayley Scales of Infant and Toddler Development, Third 
Edition). Original text, final paragraph:  
The same scale will be completed at the Screening Visit (subjects enrolling directly into SP848), 
Visit  1 (subjects enrolling from SP847 or other pediatric clinical studies in epilepsy), and 
Visit  13/Termination Visit (or Early Termination Visit) (all subject s) for children from 1  month 
to <18 months of age enrolled in English -speaking countries.  
Was revised as follows:  
The Bayley -III scales will be completed according to the tabular schedule of study procedures, 
Section  16.1. 
 
Clinical Study Protocol, Section 8.4.9 (Palatability and ease of use questionnaire for LCM). New 
final paragraph added as follows:  
The questionnaire will be completed according to  the tabular schedule of study procedures, 
Section  16.1. 
 
Clinical Study Protocol, Section 8.4.10 (Behavior Rating Inventory of Executive Function). 
Original text, fourth paragraph:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 316 of 324 
 The BRIEF rating form contains items in nonoverlapping clinical scales. These theoretically and 
statistically derived scales form 2  broader Indexes: Behavioral Regulation (3  scales) and 
Metacognition (5  scales), as well as a Global Executive Composite score.  
Was revised as follows:  
The BRIEF rating form consists of items that measure various aspects of executive functioning: 
Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, Organization of 
materials, and Monitor. These clinical scales form 2  broader Indexes: Behavioral Regulation 
(3 scales) and Metacognition (5  scales), as well as a Global Executive Composite score.  
 
Clinical Study Protocol, Section 9.2 (Supply, handling, and storage). Or iginal text, first 
paragraph:  
Lacosamide (oral solution [syrup] and tablet) is stable at room temperature and is to be stored at 
temperatures not exceeding 25°C (77°F). Lacosamide should not be frozen.  
Was revised as follows:  
Lacosamide (oral solution [sy rup] and tablet) is stable at room temperature and is to be stored at 
temperatures not exceeding 25.4°C (77.7°F) or below 14.5°C (58.1°F). Lacosamide should not 
be frozen or refrigerated.  
 
Clinical Study Protocol, Section  9.5 (Alternative study treatment supply due to COVID -19 
pandemic) was newly added as follows:  
When a subject can no longer return to the study site due to general circumstances but will 
continue in the study, the following methods may be used to provide study treatment:  
• Site to subject: I n instances where site staff can ship study treatment dispensed from the site 
pharmacy supply directly to the subject.  
• Depot to subject: In instances where it is not possible for the site staff to access study 
treatment in the site pharmacy and/or ship stu dy treatment dispensed from the site pharmacy 
supply directly to the subject.  
 
Clinical Study Protocol, Section 12.1.2 (Statistical analysis of safety variables). Original text, 
Section 12.1.2.1 and Section 12.1.2.2:  
12.1.2 Statistical analysis of primary variables  
The primary variables, for assessment of safety and tolerability, are AEs as well as subject 
withdrawals due to AEs; changes in vital signs, ECGs, clinical laboratory tests, body weight, 
height, and calculated BMI; and physical and neurological e xamination findings.  
12.1.2.1 AEs  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 317 of 324 
 Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®), and tabulated by system organ class and preferred term.  
Treatment -emergent AEs will be defined as those events which started on  or after the date of first 
SP848 LCM administration, or whose severity worsened on or after the date of first SP848 LCM 
administration. Adverse events occurring within 30 days after last dose of LCM will be 
considered treatment emergent. The incidence of TEAEs will be presented by system organ class 
and preferred term. Serious AEs will also be tabulated and listed.  
12.1.2.2 Other safety variables  
The other safety variables include changes in laboratory parameters (ie, hematology, clinical 
chemistry, and ur inalysis), ECG measurements, vital sign measurements (blood pressure and 
pulse rate), body weight, height, calculated BMI, and Tanner Stage (if applicable). The actual 
measurement and its change from Baseline (SP847 [or other primary study as applicable] V isit 1) 
or the Screening Visit (for subjects who entered directly into SP848) will be analyzed 
descriptively and presented by visit. In addition, shift tables may be used to evaluate the number 
and percentage of subjects having a different post -Baseline st atus when compared with their 
Baseline status.  
The shift from Baseline to the subject’s last visit at which a physical and/or neurological 
examination was performed post -Baseline will be summarized by category.  
Laboratory, ECG, and vital signs data outside  of the respective reference ranges will be listed 
and highlighted.  
Changes in behavior and development from Baseline as measured using the Achenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
children <18 mon ths of age will be summarized descriptively and presented by visit. Changes in 
cognitive function as measured using the BRIEF -P/BRIEF will be summarized by descriptive 
statistics at each visit. Baseline is defined as Visit  1 for subjects from SP847 or othe r epilepsy 
studies. Baseline values for subjects who enroll directly into SP848 will be taken from the 
Screening Visit.  
Was revised as follows:  
12.1.2 Statistical analysis of safety variables  
12.1.2.1 Primary safety variables  
The primary variables, for as sessment of safety and tolerability, are the incidence of TE AEs and 
the incidence of SAEs.  
12.1.2.1.1 AEs  
Adverse events will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA®), and tabulated by system organ class and preferred term . 
Treatment -emergent AEs will be defined as those events which started on or after the date of first 
SP848 LCM administration, or whose severity worsened on or after the date of first SP848 LCM 
administration. Adverse events occurring within 30 days after last dose of LCM will be 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 318 of 324 
 considered treatment -emergent. The incidence of TEAEs will be presented by system organ class 
and preferred term. Serious AEs will also be tabulated and listed.  
12.1.2.2 Other safety variables  
The other safety variables include cha nges in laboratory parameters (ie, hematology, clinical 
chemistry, endocrinology, and urinalysis), 12 -lead ECG measurements, vital sign measurements 
(blood pressure and pulse rate), physical and neurological exam findings, body weight, height, 
calculated B MI, and Tanner Stage (if applicable). The actual measurement and its change from 
Baseline (SP847 [or other primary study as applicable] Visit 1) or the Screening Visit (for 
subjects who entered directly into SP848) will be analyzed descriptively and presen ted by visit. 
In addition, shift tables may be used to evaluate the number and percentage of subjects having a 
different post -Baseline status when compared with their Baseline status.  
The shift from Baseline to the subject’s last visit at which a physical and/or neurological 
examination was performed post -Baseline will be summarized by category.  
Laboratory, ECG, and vital signs data outside of the respective reference ranges will be listed 
and highlighted.  
Changes in behavior and development from Baseline a s measured using the Achenbach CBCL 
for children 18  months and older (CBCL/1½ -5 and CBCL/6 -18) and Bayley -III scales for 
children <18 months of age will be summarized descriptively and presented by visit. Changes in 
cognitive function as measured using the  BRIEF -P/BRIEF will be summarized by descriptive 
statistics at each visit. Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy 
studies. Baseline values for subjects who enroll directly into SP848 will be taken from the 
Screening Visit.  
12.1.2.2.1 Palatability and ease of use questionnaire  
Data from the palatability and ease of use questionnaire will be summarized descriptively at each 
visit where it is assessed.  
 
Clinical Study Protocol, Section 12.1.4 (Statistical analysis of secondary  variables). Original 
text, Section 12.1.4.1 and Section 12.1.4.2:  
12.1.4 Statistical analysis of secondary variables  
12.1.4.1 Seizure frequency  
Seizure frequency will be assessed using seizure diaries in order to evaluate the preliminary 
efficacy of LCM in this population. Seizure frequency per 28  days will be calculated as ([number 
of seizures over the specified time interval]) divided by [number of days in the interval]) 
multiplied by 28  and summarized descriptively and presented graphically at each vis it and 
grouped by dose.  
12.1.4.2 Clinical Global Impression of Change and Caregiver Global Impression of Change  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 319 of 324 
 The number and percentage of subjects with each Clinical Global Impression of Change and 
Caregiver Global Impression of Change value will be sum marized at each visit in which they are 
assessed and grouped by dose.  
12.1.4.3 Palatability and ease of use questionnaire  
Data from the palatability and ease of use questionnaire will be summarized descriptively at each 
visit where it is assessed.  
12.1.4.4  PedsQL  
The PedsQL score and change from Baseline scores will be analyzed in a descriptive manner. 
Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy studies. Baseline values 
for subjects who enroll directly into SP848 will be taken f rom the Screening Visit.  
12.1.4.5 Health care resource use  
Descriptive statistics will be presented for the number of medical resources used (medications, 
consultations, procedures, hospitalizations, and length of hospital stays).  
Was revised as follows:  
12.1.4 Statistical analysis of efficacy variables  
12.1.4.1 Secondary efficacy variables  
12.1.4.1.1 Percent change from Baseline in 28 -day partial -onset seizure frequency  
Seizure frequency will be assessed using seizure diaries in order to evaluate the pre liminary 
efficacy of LCM in this population. Seizure frequency per 28  days will be calculated as ([number 
of seizures over the specified time interval]) divided by [number of days in the interval]) 
multiplied by 28  and summarized descriptively for the over all Treatment Period.  
12.1.4.1.2 ≥50% reduction in 28 -day partial -onset seizure frequency  
For subjects with POS, the number and percentage with ≥50% reduction in 28 -day partial -onset 
seizure frequency (≥50% responders) will be summarized for the overall Tr eatment Period.  
12.1.4.1.3 ≥75% reduction in 28 -day partial -onset seizure frequency  
For subjects with POS, the number and percentage with ≥75% reduction in 28 -day partial -onset 
seizure frequency (≥75% responders) will be summarized for the overall Treatme nt Period.  
12.1.4.1.4 Seizure days per 28 days (subjects with generalized seizures only)  
For subjects with generalized seizures, the number of seizure days per 28  days will be 
summarized descriptively for the overall Treatment Period . 
12.1.4.1.5 Seizure -free status  
The number and percentage of subjects achieving a seizure -free status for the overall Treatment 
Period will be presented.  
12.1.4.2 Other efficacy variables  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 320 of 324 
 12.1.4.2.1 Clinical Global Impression of Change and Caregiver Global Impression of 
Change  
The number and percentage of subjects with each Clinical Global Impression of Change and 
Caregiver Global Impression of Change value will be summarized at each visit in which they are 
assessed and grouped by dose.  
12.1.4.2.2 PedsQL  
The PedsQL score and ch ange from Baseline scores will be analyzed in a descriptive manner. 
Baseline is defined as Visit  1 for subjects from SP847 or other epilepsy studies. Baseline values 
for subjects who enroll directly into SP848 will be taken from the Screening Visit.  
12.1.4 .2.3 Health care resource use  
Descriptive statistics will be presented for the number of medical resources used (medications, 
consultations, procedures, hospitalizations, and length of hospital stays).  
12.1.4.2.2 Seizure frequency analyses  
All seizure freq uency analyses as described in the secondary efficacy variables (Section  12.1.4.1 ) 
may be additionally presented by modal daily dose group, by seizure  type, by seizure 
classification subgroup, by time interval, by visit or time period, or by completer cohort. 
Additional details will be provided in the Statistical Analysis Plan.  
 
Clinical Study Protocol, Section 12.1.5 (Handling of protocol violators, dr op-outs, and missing 
values). New final paragraph added as follows:  
Protocol deviations (eg, missing assessments or visits) related to COVID -19 will be documented.  
 
Clinical Study Protocol, Section 12.2 (Determination of sample size). Original text, second  and 
third paragraphs:  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age who have not previously participated 
in a LCM clinical study will be permitted to e nroll directly into SP848. The purpose of enrolling 
these subjects directly into SP848 is to obtain additional long -term safety exposures in the age 
range from which adequate PK data have already been obtained in SP847; the additional 
long-term safety data  will be included in planned LCM marketing applications for subjects 
≥4 years of age.  
Beginning with Protocol Amendment 6, up to 75 eligible pediatric subjects ≥4  years to <17  years 
of age who have participated in EP0060 will be permitted to enroll into SP 848. 
Was revised as follows:  
In addition, at selected sites, beginning with Protocol Amendment  4, up to approximately 
100 eligible pediatric subjects ≥4  years to ≤17  years of age who have not previously participated 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 321 of 324 
 in a LCM clinical study will be permitt ed to enroll directly into SP848. Beginning with local 
Protocol Amendment 5.2 for sites in Japan, approximately 46  eligible pediatric subjects ≥4  years 
to ≤17  years of age with partial -onset seizures who have not previously received LCM will 
directly enrol l at approximately 9 sites in Japan. Beginning with local Protocol Amendment 5.4 
for sites in China, approximately 60 additional eligible pediatric subjects with partial -onset 
seizures aged ≥4  years to ≤17 years, who have not previously participated in a L CM clinical 
study, will enroll directly into SP848. The purpose of enrolling these subjects directly into SP848 
is to obtain additional long -term safety exposures in the age range from which adequate PK data 
have already been obtained in SP847; the additio nal long -term safety data will be included in 
planned LCM marketing applications for subjects ≥4  years of age.  
Beginning with Protocol Amendment 6, up to 75 eligible pediatric subjects ≥4  years to <17  years 
of age who have participated in EP0060 will be pe rmitted to enroll into SP848. Protocol 
Amendment 8 allows an enrollment increase from 75 to 100 eligible pediatric subjects ≥1 month 
to ≤17 years of age with epilepsy who participated in EP0060 to enroll in SP848 in order to 
reflect EP0060’s inclusion of s ubjects down to 1 month of age.  
In total, up to approximately 400 subjects may be eligible to participate in SP848.  
 
Clinical Study Protocol, Section 16.1 (Tabular schedule of study procedures). Original text, 
Table 16 -1 (Schedule of study procedures for S P848 [Year 1]), footnotes f and g:  
f  Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication.  
 
g  This TC occurs 28  to 35 days after the last dose of LCM.  
Were revised as follows:  
f  Subjects who complete the study or withdraw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the fi nal dose of study 
medication. The Final Visit is not required for subjects who participate in EP0151 or EP0152.  
 
g  This TC occurs 28  to 35 days after the last dose of LCM. The Safety Follow -Up TC is not 
required for subjects who participate in EP0151 or E P0152.  
 
Clinical Study Protocol, Section 16.1 (Tabular schedule of study procedures). Original text, 
Table 16 -2 (Schedule of study procedures for SP848 [Year 2]), footnotes e and f:  
e  Subjects who complete the study or withdraw prematurely from the study,  and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication.  
f  This TC occurs 28  to 35 days after the last dose of LCM.  
Were revised as follows:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 322 of 324 
 e  Subjects who complete the study or with draw prematurely from the study, and who discontinue 
use of LCM (ie, taper), should complete the Final Visit 2  weeks after the final dose of study 
medication. The Final Visit is not required for subjects who participate in EP0151 or EP0152.  
 
f  This TC occurs 28  to 35 days after the last dose of LCM. The Safety Follow -Up TC is not 
required for subjects who participate in EP0151 or EP0152.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 323 of 324 
 18 DECLARATION AND SIGN ATURE OF INVESTIGATO R 
I confirm that I have carefully read and understood this protocol  and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clinical Practice and local 
laws and requirements.  
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this pro tocol.  
I received and have read all study -related information provided to me.  
The objectives and content of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by UCB 
BIOSCIENCES.  
All rights of publication of the results reside with UCB BIOSCIENCES, unless other agreements 
were made in a separate contract.  
Investigator:  
 
   
Printed name    Date/Signature  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
 CONFIDENTIAL  20 Oct 2020  
   
Clinical Study Protocol                                                   SPM 927  SP848  
   
 
 
Page 324 of 324 
 19 SPONSOR DECLARATION  
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol and according to current Good Clinical Practice.  
 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: SP848-protocol-amend-8
Version: 2 . 0
Document Number: CLIN-000127983
Title: SP848 Protocol Amendment Version 8
Approved Date: 26 Oct 2020
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Subject Matter Expert
Date of Signature: 23-Oct-2020 15:46:49 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Medical
Date of Signature: 26-Oct-2020 08:03:05 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 26-Oct-2020 13:36:05 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 